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Abstract
At the present there are 36 approved antiviral drugs in the UK of which half are 
nucleoside analogues. However, the emergence of drug resistance and of new virus 
strains necessitates new drugs. In particular in this thesis, different nucleoside 
analogues were studied as potential antivirals.
One of the major issues related to nucleoside analogues is the emergence of resistance 
due to a lack of bioactivation to the monophosphate form. To overcome this issue, the 
phosphoramidate ProTide technology can be applied. This strategy allows the 
delivery of the monophosphate form directly inside the cell.
Bicyclic nucleoside analogues are a new class of anti-varicella zoster agents of which 
Cfl743 is the most potent anti-varicella zoster compounds reported to date. Its 5’- 
valyl derivative, FV100, is currently in phase II clinical trials. A series of derivatives 
to increase the activity and to investigate the mechanism of action of this new class of 
compound are reported. Moreover, attempts to improve the scale up synthesis of 
FV100 are described.
Ribavirin is a broad spectrum antiviral drug. The application of the ProTide approach 
to this compound was not successful. Enzymatic and molecular modelling studies 
have been performed in order to understand the lack of activity.
Acyclovir and its esters are currently the treatment of choice for herpes simplex and 
varicella-zoster infections. The application of the ProTide technology gave surprising 
results. In fact, these compounds have been found to be active against HIV, whilst 
ACV itself did not show any activity. Moreover, these compounds retained activity 
versus thymidine kinase deficient strains against which acyclovir lost activity. These 
striking results prompted us to investigate other different nucleoside analogues, 
through a virtual screening using reverse transcriptase, guanylate or adenylate kinase 
and human polymerase y. The selected nucleoside analogues from this study include: 
ganciclovir, penciclovir and their derivatives. ProTides of these are thus pursued.
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1. Introduction
1.1 Virus: classification, structure and replication
Viruses are considered to be the smallest organisms able to infect vertebrates, protists, 
plants, insects, yeasts, fungi, bacteria and other unicellular organisms. At present there 
are over 6000 viruses of which about 200 can infect human beings.1,2 
Viruses can be classified with two different systems: the international committee on 
taxonomy of viruses (ICTV) and the Baltimore classification.3,4
1.1.1 Structure of the virus
Viruses are obligate parasites that need a cell host to reproduce their genome and they 
proliferate by invading the non-infected cells. They consist of a core of nucleic acid, 
DNA or RNA enclosed within a protein shell called a capsid. The capsid can also be 
coated by another glycoprotein layer called an envelope. The process of infection 
starts when viruses enter into contact with the surface of the cell. Firstly, viruses bind 
the receptors present in the cell membrane. These receptors can promote a series of 
functional changes in the membrane with the results of facilitating the permeation of 
the viruses into cells. Moreover, they give the selectivity to the virus to infect specific 
cells.5 A large number of viruses can interact with more than one receptor; for 
example, the capacity of herpes virus to infect different cells is due to its ability to 
interact with different receptors.6
Here, we report as an example the mechanism of replication of human 
immunodeficiency virus (HIV) with the potential targets for antiviral drugs. This 
replication cycle is different from the replication of DNA viruses. In fact, as HIV 
belongs to the retrovirus family and it is a RNA virus, it needs firstly a reverse 
transcription followed by an integration into the host genome whilst in the case of 
DNA viruses, the viral genome is replicated by a viral DNA polymerase.5
1.1.2 Mechanism of replication of HIV
As previously mentioned, viruses have to interact initially with the host cell by 
binding with the receptors situated in the cell membrane. Fig 1.1 reports the 
mechanism of replication for HIV. The glycoprotein gpl20 situated in the viral 
envelope interacts with the CD4 receptors and with a co-receptor, which is CXCR4
1
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for T lymphocytes or CCR5 for macrophages, creating a bond necessary for the 
proceeding fusion step. The inhibition of this interaction might block the entry of the 
virus into the host cell. The interaction of gpl20 with the membrane receptor is 
followed by the interaction of the subunit gp41 with the surface of the cell, which 
gives a series of changes of the external structure of the virus and the host cell 
membrane with the result of the virus-cell fusion and the entry of the capsid core 
inside the host cell. The blockade of this step might prevent the entry of the virus.
Once inside the cell, before the process of the replication begins, HIV has to lose the 
capsid in order to release the genetic material, constituted by two copies of the single­
stranded RNA and the enzymes, reverse transcriptase (RT), integrase (IN) and 
protease (PR), necessary for replication.
In the case of DNA viruses, the replication of the genome is carried out by the viral 
DNA polymerase, which is expressed in the infected cells. The DNA polymerase is a 
well known target for antiviral therapy which will be discussed later in this chapter.
Infected cell
HIV p a r t i d e ^ ^  
budding from cell
Reverse
transcnpl HIV proteins
Integrase
DNA copy  
of HIV RNA
DNA integrates 4 
into host genome
Fig. 1.1 : mechanism of replication of HIV (from ref. 7).
In the case of HIV, its RNA genome needs to be converted to DNA by the RT. RT is 
a RNA-dependent DNA polymerase encoded by the virus. It consists of two catalytic 
sites: a polymerase active site and ribonuclease site. The transcription of a single
2
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stranded RNA into a RNA-DNA hybrid is carried out by the polymerase site. The 
RNA-DNA hybrid is then hydrolysed to a single-stranded DNA by the ribonuclease H 
site. The single-stranded DNA is then converted to a double strand again by the RT in 
the polymerase site. This step is necessary for the proliferation of the virus in the host 
cell and it represents one well-known target for anti-HIV therapy, constituted by 
nucleoside reverse transcriptase inhibitors (NRTIs), as inhibitors of the catalytic 
binding site, and non-nucleoside reverse transcriptase inhibitors (NNRTIs), as 
inhibitors of the allosteric site. Being present only in the virus-infected cells, RT is a 
good target in terms of selectivity and therapeutic index. Once the double DNA strand 
is formed, it needs to be integrated into the host genome. This step requires the 
retroviral enzyme IN. IN works in two steps: in the first, it cleaves the 3’-end of the 
viral DNA. The second step consists of the integration, process called strand transfer, 
of the viral DNA in the cellular genome. IN is another valid target for anti-HIV 
therapy as it is present only in the infected cells.
The integrated viral DNA into the host genome is called proviral DNA and it might 
remain dormant in the cell host or it can be transcribed to viral messenger RNA 
(mRNA) or to viral genome RNA by the cellular enzymes. The viral messenger is 
now translated to polyproteins, structural proteins and enzymes. These polyproteins 
are cleaved by the PR enzyme into two different types of proteins: functional proteins, 
with enzymatic activity, or structural proteins, which will form part of the virion 
structure. The step mediated by the PR is crucial for the viral proliferation as it 
releases all the proteins necessary for the assembly of a new viral particle and it 
presents another target for antiviral therapy. It is not only a target for anti-HIV 
therapy but also has potential for hepatitis C virus (HCV) and herpersvirus for 
instance.
Two single RNA strands and the three enzymes necessary for the replication are now 
enclosed into the new capsid. The last step consist in the release of the capsid through 
the host cell membrane, which forms the envelope of the new viral particle, which 
once matured, can infect another cell. The inhibition of the assembly as well as the 
inhibition of the release of the newly formed viruses might block the progress of the 
infection.
This process happens billions of times per day and HIV is able to destroy the host 
immune system.5,8' 10
3
Marco Derudas Chapter 1
1.2 Antiviral agents
Viral infections can be symptomatic or asymptomatic, and can cause mild to severe 
symptoms and even death. For most of them, the immune system of the host is able to 
react to the virus invasion producing the antibody necessary to fight the infection and 
protecting the organism from further infection by the same virus.
A possibility to prevent the viral infection is the administration of a vaccine, which 
gives the antibody necessary to recognize the virus by the immune system. There are 
several vaccines available such as those for hepatitis A and B, polio, tetanus, seasonal 
influenza, varicella zoster virus (VZV), etc.5
For some infections, for which the immune system is not able to react or vaccines are 
not available, the development of antiviral agents was and is currently necessary. 
Also, for post-exposure treatment an antiviral agent may well be the only alternative. 
As seen in Fig. 1.1, there are several potential targets to which a drug can interact and 
there is at least one drug from most of them. The potential targets are:
- viral attachment and entry;
- viral uncoating;
- viral genome replication;
- viral assembly and maturation;
- viral release.
Currently there are 36 approved antiviral drugs in the UK (British National Formulary 
(BNF) 56, October 2008) and several others are currently under clinical trial. In 
particular, acyclovir (ACV), ganciclovir (GCV), penciclovir (PCV), ribavirin and 
some of the RT inhibitors will be discussed in detail as they are part of the work 
presented in this thesis.
1.2.1 Inhibitors of viral attachment and entry
The inhibition of this early stage allowed the use of compounds that do not need to 
enter inside the cells, as they are preventing the first step of the viral infection.
The first approved drug able to inhibit HIV entry is enfuvirtide, which is a peptide 
containing 36 amino acids (Fig. 1.2).
Ac-Tyr-Thr-Ser-Leu-Ue-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-
Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-
NH2
Fig. 1.2. Amino acids sequence of enfuvirtide.
4
motif) CCR5 coreceptor. This receptor is expressed on T cells and is used by the 
to bind to the cell surface and diffuse inside the cells.5
Fig. 1.3 reports the structure of maraviroc (1). It acts as CCR5 antagonist preve 
the binding o f the virus to the receptor. Moreover, maraviroc is an oral bioavai 
drug.
F. F
NH
1
Fig. 1.3. Structure of maraviroc.
1.2.2 Inhibitors o f viral uncoating
The viral uncoating is the process by which the virus releases the genetic materia] 
the cytoplasm or into the nucleus, consenting the process o f  replication.
Currently there are two drugs approved (Fig. 1.4): amandatine (2), approved h 
1966, and rimantadine (3) approved in 1994. Both drugs are active against influ
13 14virus. ’
2 3
Fig. 4: amantadine and rimantadine structures.
5
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These two adamantane derivatives act by inhibiting the ion channel in the cytoplasm 
leading to a decrease of the pH, which promotes the degeneration of the envelope on 
the virus with consequent release of the ribonucleoprotein into the cytoplasm. After 
its release, the ribonucleoprotein is transported into the nucleus for the transcription 
and replication.15,16
Besides the antiviral activity, amantadine is also used in the treatment of Parkinson 
disease, however the mechanism of action is not fully understood and may involve the 
inhibition of the N-methyl-D-aspartate receptor.17
1.2.3 Inhibitors of the viral genome replication
As already discussed, once inside the cell, viruses start the process of replication of 
their genome. This process is different depending on the type of virus: DNA, RNA or 
retrovirus for instance.
The majority, 17 out of 36, of the current antiviral drugs are nucleoside analogues 
(NAs). These compounds act as analogues of the native nucleosides. Fig. 1.5 reports 
the structures of the native nucleosides: adenosine or deoxyadenosine (4), guanosine 
or deoxyguanosine (5), cytidine or deoxycytidine (6), deoxythymidine (7) and uridine
(8).
R = H or OH
OH R OH R
4 5
O O
OH R 6
Fig. 1.5 : the native nucleosides.
OH ? OH OH 8
6
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1.2.3.1 Viral DNA polymerase inhibitors
Viral DNA polymerase is the enzyme involved in the replication of the viral DNA. 
The compounds clinically approved (Fig. 1.6) in the UK as inhibitors of this 
polymerase are: ACV (9) and its prodrug valacyclovir (12), GCV (10) and its prodrug 
valganciclovir (13), PCV (11) and its prodrug famciclovir (14), the acyclic nucleoside 
phosphonate cidofovir (15) and the non-nucleoside foscarnet (16). Another 
compound, not licensed in the UK and in the USA but commercially available in 
several countries in Europe, is the deoxyuridine analogues brivudin (BVdU, 17). All 
of these compounds inhibit the herpes polymerase.
NH
< ' X x
H O ^^ vl
9
NH ,
NHN ^ A
O *nX a
NH;
H,CT " C H , 12
NH,
O
A
H0 15
N^O
^  N * " S A  
^ Y °v i N 
10
NH;
NHn^ A  
? A
H3C ^ C H 3 OH 13
NH,
HO
S /OH
OH O 
16
H ,C
HO
O
A.
Br
HO
NH,
OH 11
N '^ mAN NH,
O
A
14
c h 3
o
NH 
N^O
A d
OH 17
Fig. 1.6 : Viral DNA-polymerase inhibitors.
1.2.3.1.1 Acyclovir: antiviral activity and mechanism of action
ACV (9) is a guanine analogue with activity against herpes simplex virus (HSV)-l 
and 2 and VZV.18 Due to its poor bioavailability, a series of prodrugs have been 
synthesized. The L-valyl ester derivative, valaciclovir (12), showed the best profile. It 
is metabolised in the gut and in the liver by valacyclovir hydrolase to ACV increasing 
its bioavailability by ca. 4 fold.19
The mechanism of action of ACV (Fig. 1.7) involves activation to the monophosphate 
(MP) form (18) mediated specifically by HSV or VZV thymidine kinase (TK).18 TK- 
deficient strains show resistance to ACV due to the lack on bioactivation as the 
cellular kinases are unable to phosphorylate ACV.20 Guanosine monophosphate
7
Marco Derudas Chapter 1
kinase converts ACV-MP to the diphosphate (DP) form (19),21 followed by 
conversion to the triphosphate (TP) form (20) mediated by nucleoside diphosphate 
kinase.22 In its triphosphate form, ACV is incorporated into the growing viral DNA 
competing with deoxyguanosine triphosphate (dGTP).18,23 Once incorporated into the 
DNA the lack of the 3’-OH does not allow the addition of further deoxynucleoside 
which involves the termination of the DNA elongation.24 25
<' NHX NH;
HSV or VZV 
Thymidine Kinase
OH OH OH 4
20
T .
NH
X NH,
Cellular Kinase
OH
H O '^O ^^0
I^T NHX NH;
18
Cellular Kinase
OH OH
ho'»vo'£ ‘ox's^ '° nJ
NH
XN NH2
19
Vir*l DNA potymeras*
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Fig. 1.7 : mechanism of action of ACV (adapted from ref. 5).
The specific phosphorylation mediated by the viral TK, as well as the ability to inhibit 
the viral polymerase 10-30 times more specifically than cellular polymerase gives 
ACV a good therapeutic index (TI),18 and it remains still the treatment of choice for 
HSV and VZV infections, with sales of over $1.6 billion for Valtrex and $0.16 billion 
for Zovirax topical in 2008.26 However, resistance to this drug has developed. The 
mechanisms of resistance to ACV can involve the TK and/or the viral polymerase.27 
28 With regard to TK, the resistance can be due to a total lack of the enzyme (TK
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deficient strain), a decrease in the production of this enzyme or a decreased activity of
this enzyme (TK low producer) or an alteration of the enzyme for which ACV is not a
*) 0substrate (TK altered). In the case of the viral polymerase, the resistance is due to a 
modification of the active site with consequent poor interaction with ACV-TP.28
1.2.3.1.2 Ganciclovir: biological activity and mechanism of action
The discovery of ACV was quickly followed by the discovery of GCV (10). GCV 
showed improved activity against HSV-1 and 2 compared to ACV, and also showed 
potent activity against human cytomegalovirus (HCMV), another virus belonging to 
the herpesviridae family, against which ACV showed poor activity.30 GCV was the 
first approved drug for the treatment of HCMV infections. GCV is an acyclic 
analogue of 2’-deoxyguanosine and it differs from ACV for the presence of the 3’- 
OH. As for ACV, the mechanism of action of GCV involves phosphorylation to the 
triphosphate form. In HSV-infection, the first step of phosphorylation is specifically 
mediated, as well as for ACV, by HSV-encoded TK.14 In the case of CMV, the 
conversion to the monophosphate is mediated by CMV-encoded protein kinase (PK).
i 1
This protein is expressed by the gene UL97 and it has selectivity for GCV. In fact, 
the mutation of this gene gives resistance to GCV due to lack of phosphorylation.31 
Further phosphorylation to the triphosphate are mediated by cellular kinases.32 The 
triphosphate is the active form of GCV and it acts as an inhibitor of the viral DNA 
polymerase. In contrast with ACV, which acts as chain terminator, GCV, due to the 
presence of the 3’-OH, showed incorporation of one additional nucleotide.33 This 
specific viral polymerase is expressed by the UL54 gene and also in this case,
32mutation of this gene can give resistance to GCV.
GCV showed higher selectivity to the viral polymerase in comparison with the 
cellular polymerase.34 However, this selectivity is not as great as the selectivity 
showed by ACV against HSV. In fact, GCV showed a greater toxicity compared to 
ACV, including bone marrow suppression (neutropenia, anemia and 
trombocy topenia).32
One of the major issues for GCV, as well as for ACV, is its poor bioavailability, 
which is approximately 5%:32 As for ACV, the L-valinyl ester product of GCV, 
valganciclovir (13), has been synthesized showing a huge increase of bioavailability 
up to 60%.32
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GCV and valganciclovir are currently used for the treatment of HCMV infection 
particularly in immunocomprised patients.14
1.2.3.1.3 Penciclovir: antiviral activity and mechanism of action
Another acyclic nucleoside analogue discovered after ACV and strictly related to 
GCV, being its carbo analogue, is PCV (11). This compound showed antiviral activity 
slightly less active than ACV against HSV-1 and 2 and slightly more active than ACV 
against VZV.35 PCV also showed activity against Epstein-Barr virus (EBV) and 
hepatitis B virus (HBV).36 As for both ACV and GCV, the mechanism of action of 
PCV involves phosphorylation to the monophosphate form mediated by HSV or 
VZV-TK and it has been reported to be more specific for PCV than for ACV.37 
Further phosphorylation to PCV-TP gives the active form of PCV, which inhibits the 
viral DNA polymerase showing a similar mechanism of action of ACV.38 In this case, 
ACT-TP is a better inhibitor of the polymerase than PCV-TP.37 PCV is currently used 
topically for HSV infection. Its prodrug, famciclovir (14) is used for the treatment of 
VZV infections.36 This prodrug consists in the diacetyl derivative of 6- 
deoxypenciclovir which has considerably improved oral bioavailability.39 To release 
the parent, it needs a double activation: the hydrolysis of the two acetyl groups and 
the oxidation at the 6-position. The major bioactivation pathway firstly involves the 
hydrolysis of one acetyl group probably in the intestine, followed by the removal of 
the second acetyl in the liver.40 The last step implicates the oxidation of the 6-position 
which is mediated by either the xanthine oxidase36 or aldehyde oxidase.41
1.2.3.1.4 Cidofovir, foscarnet and brivudin: antiviral activity and mechanism of 
action
Cidofovir or (S)-l-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (15) is a 
nucleotide analogue (NtA). In fact, cidofovir bears a phosphonate group, which is 
equivalent to the phosphate group but with the property of being stable to the 
hydrolysis mediated by phosphatase to which normal phosphate NAs are unstable.42 
Contrary to the other NAs previously described in this chapter, cidofovir needs only 
two phosphorylations to be converted in the active form and in this form is able to 
inhibit viral DNA polymerase but also cellular polymerases.42 Cidofovir shows a very 
wide antiviral spectra including all the viruses belonging to the herpesviridae family,
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poxviridae (for example cowpox, vaccinia) etc.42 It is currently approved mainly for 
the treatment of HCMV retinitis in patients with AIDS.36
The only currently approved non-nucleoside inhibitor of viral polymerase is foscarnet 
or phosphonoformic acid (16).43 The principal target of foscarnet is HCMV, but it has 
also activity against others herpesvirus, such as HSV-1 and 2, VZV, EBV, human 
herpes virus 6 (HHV). Foscarnet is also able to inhibit HIV.14 Foscarnet acts by 
blocking the pyrophosphate cleavage of the terminal nucleoside by binding the 
pyrophosphate binding site of the viral polymerase with consequent blockage of the 
DNA polymerization.14
BVdU or (£)-5-(2-bromovinyl)-2’-deoxyuridine (17) is a deoxyuridine analogue that 
is currently approved in some territories mainly for the treatment of VZV infections 
but also against HSV-1 infections.44, 45 In common with the other NAs, BVdU needs 
to be bioactivated to the triphosphate form. In this form, BVdU acts either by 
competing with the natural nucleoside deoxythymidine triphosphate (dTTP) and 
inhibiting the viral polymerase or it can be incorporated into the growing DNA and it 
can affect the stability and the function of the viral DNA.45
An important issue related to BVdU is the interaction with 5-fluorouracil. This 
interaction is related to the metabolism of BVdU to (£)-5-(2-bromovinyl)-uracil 
(BVU) and 2-deoxyribose-1-phosphate mediated by thymidine phosphorylase. BVU 
is a potent inhibitor of the enzyme responsible for the dihydropyrimidine 
dehydrogenase, a key enzyme in pyrimidine metabolism. This enzyme is involved in 
the metabolism of 5-fluorouracil, whose antitumor activity and toxicity is greatly 
enhanced by the inhibition of this enzyme by BVU.45
1.2.3.2 Reverse transcriptase inhibitors
As already described previously in this chapter, RT is a fundamental enzyme for HIV 
replication; it transcribes a single-stranded RNA into a double-stranded DNA. After 
the discovery of HIV and the development of compounds able to inhibit the 
replication of the virus, RT became one of the most studied enzymes and currently 
there are 9 RT inhibitors approved in the UK of which 6 NRTIs, 1 nucleotide-RTIs 
(NtRTI) and 2 NNRTIs. Several others are currently approved in other countries or 
under clinical investigations.46
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1.2.3.2.1 Nucleoside reverse transcriptase inhibitors
The currently approved NRTIs are (Fig. 1.8): 3’-azido-2\3’-dideoxythymidine or 
azidothymidine (AZT) or zidovudine (21), 2 \3 ’-dideoxyinosine or didanosine (ddl) 
(22), 2’,3’-didehydro-2\3’-dideoxythymidine (d4T) or stavudine (23), (-)-P-L-3’-thia- 
2’,3’-dideoxycytidine (3TC) or lamivudine (24), (1S, 4/?)-4-[2-amino-6-
(cyclopropylamino)-9//-purin-9-yl]-2-cyclopentene-l-methanol or abacavir (ABC) 
(25) and (-)-P-L-3’-thia-2,,3’-dideoxy-5-fluoro-cytidine (FTC) or emtricitabine (26).
Fig. 1.8: currently approved NRTIs.
NRTIs, as already seen for the DNA polymerase inhibitors, need to be bioactivated to 
the triphosphate form to be able to inhibit the enzyme by acting as a chain terminator. 
Fig. 1.9 illustrates the mechanism of action of the first approved anti-HIV compound: 
AZT (21), which inhibits HIV replication in the nM range (50-500 nM).47 The first 
step of bioactivation is the conversion of AZT to its monophosphate form (27) 
mediated by cellular TK.48 Contrary to the case of ACV, which is specifically 
phosphorylated by the HHV-TK and it gives the selectivity for ACV, AZT is as good 
a substrate as thymidine for cellular TK and moreover, there is no difference in 
phosphorylation between HIV-infected and non-infected cells.48 The second 
phosphorylation, to obtain the AZT-DP (28), is mediated by cellular thymidylate 
kinase and this is the rate limiting step in the bioactivation of AZT. Nucleotide 
diphosphate kinase (NDK) converts AZT-DP to the triphosphate. AZT-TP (29) 
inhibits RT by acting as a chain terminator due to the absence of the 3’-OH49 at a 
much lower concentration than that required to inhibit cellular polymerases showing a
o o n
A
good TI.48
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In spite of its selectivity, AZT showed toxicity in patients including bone marrow 
suppression, which leads to anemia and neutropenia.5
ddl (22) was the second anti-HIV compound approved followed by d4T (23) in 
1994.50 Their mechanism of action is similar to AZT, however ddl needs first to be 
converted to the inosine monophosphate than to dideoxyadenosine monophosphate 
(ddAMP); in the triphosphate form, they compete with deoxyadenosine triphosphate 
(dATP) and dTTP respectively in the DNA synthesis acting as chain terminators due 
to the lack of the 3’-OH.14
Lamivudine (24) is a particular nucleoside as the 3 ’-carbon is substituted with sulphur 
and it is a L-stereoisomer, not the natural D-stereoisomer. The antiviral activity of 
lamivudine was first reported in 1991 and it was evaluated as a mixture of isomers.51 
The separation of the two stereoisomer showed that both stereoisomers have anti-HIV 
activity but surprisingly the L-enantiomer showed less toxicity than the D-enantiomer. 
Moreover, although less active than AZT, the selectivity index of lamivudine is -100 
times greater than AZT.52 53 The mechanism of action of lamivudine is similar to 
AZT and acts by inhibiting DNA synthesis.14
Lamivudine was found to be active against HBV54 and it is currently approved also 
for the treatment of chronic HBV infections.46
Abacavir (25) was approved in 1998 and it is the only guanosine analogue available 
for the treatment of HIV. ABC is a prodrug of the earlier reported carbovir, which is a 
carbocyclic guanosine analogue. First, carbovir was synthesized and biologically
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evaluated as a mixture of two isomers, (+)-carbovir and (-)-carbovir,55 but further
The poor bioavailability of carbovir prompts the design of a series of different 
prodrugs ending to the cyclopropyl amine derivative, ABC.57 The mechanism of 
activation of ABC involves firstly the phosphorylation to the monophosphate by 
adenosine phosphotransferase followed by conversion to carbovir monophosphate
led to the active form of ABC, which acts as competitive inhibitor of dGTP and as a 
chain terminator in the DNA synthesis.59
Emtricitabine or FTC (26) is the latest NRTI approved. FTC is a cytidine derivative 
with the unusual oxathiolane ring. The (-)-P-isomer of FTC has been found to be 
more active than the other enantiomer by —150 fold in the inhibition of HIV at non­
toxic concentrations.60 As for the others NRTI, the mechanism of action of FTC 
involves phosphorylation to the triphosphate form. FTC showed activity against HBV 
and in this case, as well, the (-)-P-isomer has been found to be more potent, -40 fold, 
than the other enantiomer.61
1.2.3.2.2 Nucleotide reverse transcriptase inhibitors
Currently only one NtRTI has been approved for the treatment of HIV (Fig. 1.10): 
tenofovir disoproxil fumarate (31), which is a prodrug of tenofovir (TNF) (30).
c h 3 o
Fig. 1.10: tenofovir (30) and its disoproxil fumarate prodrug (31).
As already described for cidofovir, the particularity of this class of compounds is the 
by-pass of the first step of phosphorylation needing only two phosphorylation steps to 
the corresponding triphosphate analogue. TNF showed activity against HIV-1 and 2, 
and also against HBV.42 The chirality in TNF is extremely important as the (R)- 
enantiomer is more potent than the (iS)-enantiomer.62 Due to the poor bioavailability
studies showed that the (-)-isomer was the most potent anti-HIV inhibitor.56
mediated by a cytosolic enzyme.58 Further phosphorylation to the di- and triphosphate
COOH
HOOC
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of TNF, for the presence of the negative charges at the phosphate moiety, a series of 
prodrugs has been designed. Amongst these, the bis disoproxil fumarate has been 
selected, showing increased bioavailability but also increased potency probably due to 
the increased uptake inside the cell.63,64
1.2.3.2.3 Anti-hepatitis nucleoside and nucleotide analogues
Three compounds belong to this class of compounds presently approved in the UK 
(Fig. 1.11): adefovir dipivoxil (32), entecavir (33) and telbivudine (34). These 
compounds have been included in this section as their target, HBV-RT, is very similar 
to HIV-RT.
Adefovir dipivoxil is an oral prodrug of adefovir. The prodrug, as noted for TNF, 
increased the bioavailability compared to the parent but also its potency against 
HIV.65 Adefovir is a NtA bearing a phosphonate moiety as described above for 
cidofovir and TNF. After the phosphorylation to the corresponding triphosphate form, 
it acts by targeting the HBV-RT, but also HIV-RT, blocking the DNA synthesis. It 
also has activity against all the HHVs.42,66
Fig. 1.11: anti-HBV drugs.
Entecavir (33) was firstly designed as an anti-HSV agent, but it was found to be active 
against HBV in the nM range.67 The characteristic of this deoxyguanosine analogue is 
the unusual sugar moiety, which is a carbocycle bearing a exocyclic double bond. It is
Telbivudine (34) is the p-L-2’-deoxy-thymidine. It acts, after phosphorylation to the 
triphosphate form, as inhibitor of HBV-RT. It showed only activity against HBV and 
not against HIV.68
o
selectively active against HBV and it acts by inhibiting the RT.67
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1.2.3.2.4 Non-nucleoside reverse transcriptase inhibitors
At present, only two NNRTIs, nevirapine (35) and efavirenz (36), have been licensed 
in the UK (Fig. 1.12), with several others currently under clinical investigation.46 Two 
more compounds have been licensed by the FDA: delavirdine (37), which is rarely 
used, and etravirine (38), which has been recently approved.46
h 3c
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Fig. 1.12: non-nucleosides reverse transcriptase inhibitors.
NNRTIs interact with a binding site of RT, which is different from the active site of 
the enzyme. This interaction leads to a change of the conformation of the active site of 
the enzyme with the result to block the activity of RT. Resistance to the NNRTIs 
occurs very quickly due to the change of conformation of the binding site. NNRTIs 
inhibit only HIV-1 and they showed a very good cytotoxic profile as they do not 
interact with human polymerases.69
The first NNRTI reported was nevirapine (35), which showed activity against HIV-1
7Hwithout competing with dGTP. Moreover, nevirapine has been found to be active 
against AZT-resistant strain and to be synergistic with AZT, confirming the difference
71in the mechanism of action of these two categories of anti-HIV drugs.
The second NNRTI approved in the UK is efavirenz (36). Its mechanism of action 
and activity are similar to nevirapine. It showed also activity against several HIV-1 
mutants strains; these results encourage the use of this compound in case of 
resistance.72
1.2.4 HIV integrase inhibitors
The inhibition of the integrase blocks the integration of the viral DNA into the host 
genome. As this enzyme is only present in the HIV infected cells, it is considered an 
important target for the design of new anti-HIV agents.73 Several integrase inhibitors 
have been synthesized and described,74 but at present, only one has been licensed: 
raltegravir (39, Fig. 1.13).
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Fig. 1.13: currently approved integrase inhibitor raltegravir.
Raltegravir inhibits the strand transfer of integrase, it showed a good antiretroviral 
profile, also against multi-drug resistant strains.75
1.2.5 Protease inhibitors
Another important target in the development of antiviral therapy, especially for HIV 
infections, is the enzyme PR. The catalytic site of PR has been identified and 
crystallized helping the design and synthesis of PR-inhibitors.10
4 8 49
Fig. 1.14: anti-HIV protease inhibitors.
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At this time ten PR inhibitors (Fig. 1.14) have been approved in the UK: saquinavir 
(40), ritonavir (41), indinavir (42), nelfinavir (43), amprenavir (44), lopinavir (45), 
atazanavir (46), fosamprenavir (47), tiprinavir (48) and darunavir (49). I4,46A11 the 
compounds currently approved share the same mechanism of action. These 
compounds bear a stable peptidomimetic moiety (red circle). The stability is due to 
the presence of a hydroxyethylene core that can not be cleaved by the enzyme, with 
the result of blocking its activity.10
1.2.6 Anti-HIV therapy
Having discussed all the classes of compounds used for the treatment of HIV 
infections, it is necessary to briefly report the different therapeutic regimens in use. 
Since the discovery of AZT and its approval for the treatment of HIV almost 20 years 
ago, several improvements have been made in this field. The emergence of resistance 
using only AZT mono therapy has been described.76 However, the discovery of new 
RT inhibitors as well as the discovery of new classes of compounds, such as PR 
inhibitors, changed the way to treat HIV. The current treatment, called highly active 
antiretroviral therapy (HAART), includes the combination of NRTI, NNRTI and/or 
PR inhibitors. This combination has the aim not only to reduce the insurgence of 
resistance, but also acts in terms of synergy and reduction of toxicity.77 There are 
several combination drugs on the market, such as: atripla (efavirenz, emtricitabine, 
TNF), combivir (lamivudine and AZT), trizivir (ABC, lamivudine and AZT), truvada 
(emtricitabine and TNF), etc.26 One of the goals of this combination is also the 
compliance of patients being a longterm therapy.
1.2.7 Ribavirin: a broad antiviral with different potential targets
Ribavirin (50, Fig. 1.15) is a NA with antiviral activity against a number of DNA and
•70
RNA viruses in vitro and in vivo.
o
OH OH 
50
Fig. 1.15: the antiviral drug ribavirin,
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As for the other NAs, ribavirin needs to be converted into its 5’-monophosphate form 
by intracellular phosphorylation mediated by adenosine kinase, followed by further 
phosphorylation to the di- and triphosphate.79 Its mechanism of action is not 
completely understood and, depending on the virus examined, several mechanisms 
have been proposed:
a) it has been found that in the monophosphate form, ribavirin inhibits inosine 
monophosphate dehydrogenase. The inhibition of this cellular enzyme leads to 
a reduction of GTP,80,81 the decrease of GTP may promote the incorporation 
of ribavirin triphosphate into viral RNA;82
b) in the triphosphate form, ribavirin inhibits viral RNA synthesis by inhibition 
of the viral polymerase in influenza virus;83
c) in Dengue virus, ribavirin triphosphate has been found to inhibit viral 2’-0- 
methyltransferase while ribavirin monophosphate inhibits the viral guanylyl 
transferase;84
d) once incorporated in the viral RNA, ribavirin induces an accumulation of 
mutations, which, if lethal, impede viral replication (so called “error 
catastrophy”);85
e) finally, in HBV and HCV affected patients, ribavirin modulates diverse
8 6  87immunomodulatory activities.
Ribavirin is currently in used for the treatment of respiratory syncytial virus (RSV)
and forms part o f the only approved combination therapy for hepatitis C virus (HCV)
88infection in association with interferon-a.
1.2.8 Influenza virus neuraminidase inhibitors
Influenza virus neuraminidase is an important enzyme in the proliferation of the virus. 
The function of this enzyme, which is encoded by the virus, is to cleave the bond 
between the new hemagglutinin virion and the sialic acid of the host cells helping the 
release of the new virions and the consequent spread of infection. The blockade of 
this enzyme stops the proliferation of the virus.5
In the UK, two inhibitors of influenza virus neuraminidase have been approved (Fig 
1.16): zanamivir (51) and oseltamivir (52), which is a prodrug of the free acid parent.
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Fig. 16: neuraminidase inhibitors.
Zanamivir have been discovered through molecular modeling design from the crystal 
structure of the enzyme and it showed potent inhibitory activity against both influenza
• 89A and B virus. Due to the poor bioavailabilty, zanamivir is administrated by 
inhalation.
Modification of the structure of zanamivir, to improve oral bioavailability, led to the 
parent of oseltamivir.90 Oseltamivir is orally bioavailable and effective and safe for 
the treatment of influenza infections.91
1.2.9 Antiviral agents currently under clinical investigations
The need for new antiviral agents is always in continuous process, especially to treat 
HIV and HCV infections. Moreover, the emergence of drug resistance or new virus 
strains, such as swine influenza virus, or the need of new therapy with fewer adverse 
effects, pushes the pharmaceutical companies as well as the research groups to 
continue the fight against viruses.
In 2008, it has been reported by De Clercq and Field the current state of art of the 
current drugs in the market and those ones currently under clinical investigation.36,46, 
88 The major effort has been made for the treatment of HIV infection, for which there 
are 25 compounds currently approved (22 in the UK), other 3 are expected to be 
approved in the near future and another 15 (of which 7 NAs) are under clinical 
investigation. In the case of HCV infection, there are more than 10 compounds in 
clinical trials of which 5 are NAs.
It is clear from this data that NAs occupy a huge part of the antiviral treatment; to 
summarize, 18 out of 36 approved antiviral agents in the UK are NAs.
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1.3 Phosphate Prodrugs
One of the major issues concerning the use of NAs is the innate or acquired resistance 
to the drug. In most of the cases, resistance can be due to: 
poor cell entry; 
transporter deficiency;
poor bioactivation to the active form, usually in the first step of
phosphorylation (TK or other cellular kinases);92,93
poor affinity versus the target, ex. polymerase, or RT, etc.93,94
Mutations of these enzymes change the conformation of the active site and NAs are 
less recognized by the enzyme.
One of the major goals of medicinal chemists and biologists is to overcome this issue 
and in particular the new technologies to overcome the first step of phosphorylation 
will be described.
1.3.1 Phosphate prodrug technologies
The three steps of phosphorylation to the active form of NAs are mediated by kinases.
NAs can be substrates for viral kinases, cellular kinases or both. The specificity for
one or the other as well as the selectivity for the polymerase gives the selectivity of 
the drug. Moreover, some NAs, such as ACV, are selectively phosphorylated by 
HHV-encoded TK and this factor gives selectivity of ACV to these infections28 
In addition, it has been described how the first step of activation is the key-limiting 
step in the process of bioactivation of NAs and the by-pass of this step could 
improve/extend the activity of NAs.93
To overcome this issue several methodologies have been developed.
One of the easiest ways is the use of monophosphate NAs. However, monophosphates 
themselves can not be used to by-pass this step, because of their instability in 
biological media and poor passive diffusion through cellular membranes due to their 
extremely high hydrophilicity.
A second approach has been the use of phosphonates. These are particular analogues 
where the phosphorus-carbon bond is more resistant to degradation by cellular 
enzyme than the phosphorus-oxygen bond present in the phosphates.42 The issue 
related to the poor lipophilicity for these compounds has been solved by synthesising 
phosphanate prodrugs.
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A third approach is the delivery of a monophosphate prodrug. Currently, there are 
different methodologies and they are used in both antiviral and anticancer fields (for
will be discussed:
bis(pivaloyloxymethyl) (POM)- and bis(isopropyloxycarbonyloxymethyl) 
(POC) prodrug;
bis(S-dithioethyl) (SDTE)- and bis(S-acyl-2-thioethyl) (SATE) prodrug;
cycloSdX prodrug;
phosphoramidate diester;
phospholipid conjugates;
hepdirect prodrug;
diamidate prodrug;
arylphosphoramidate.
1.3.1.1 Bis(POM) and bis(POC) approach
This approach was firstly reported by Farquhar and coworkers and it consists of a 
POM phosphate masking group (Fig. 1.17). Once inside the cell, the POM-group is 
enzymatically cleaved by a carboxyesterase to release the monophosphate form of the 
NA.98 This approach has been successfully applied to ddU (53),98 AZT (54),99 and 5- 
fluoro-2’-deoxyuridine (55).100 One of the major successes is the application of this 
approach to TNF (bis-POC) (31) and to adefovir (bis-POM) (32), which are currently 
in the market.46
Fig. 1.17: Bis(POM) and Bis(POC) approach.
1.3.1.2 Bis(SDTE) and bis(SATE) approaches
Fig 1.18 reports the bis(SDTE) (56) and bis(SATE) (57) approaches, which have been 
described by Gosselin and Imbach. Both approaches need enzymatic bioactivation but 
while for bis(SDTE), it is a reductase that mediated the cleavage in the case of
reviews see Jones,93 Meier,95 Wagner,96 and Hecker and Erion97) and the following
o o o
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bis(SATE), it is a carboxyesterase, showing similar bioactivation mechanism 
compared to bis(POM).101
Fig. 1.18: bis(SDTE) and bis(SATE) approach.
These approaches have been successfully applied to AZT, retaining good activity in 
the TK-deficient strain, to d4T, and to ACV, extending its activity to HBV.101
1.3.1.3 CycloSal approach
This approach has been developed by Meier and coworkers and it is completely 
different from the others as it requires chemical activation. The lability of the phenyl 
and the benzyl phosphate moieties controls the hydrolysis of the prodrug.95 This 
method has been applied to several NAs such as d4T (58, Fig. 1.19),102 AZT,103 etc. 
Following these results, a second and a third generations of cycloSal have been 
designed, with the introduction of esterase-cleavable functions (Fig. 1.19, here 
reported applied to d4T, 59 for the second generation, 60 and 61 for the third 
generation).104' 106 Recently Meier and coworkers reported the application of this 
technology to mask NA diphosphates.107
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Fig. 1.19: cycloSal approach.
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1.3.1.4 Phosphoramidate diester approach
This approach has been developed by Wagner et al., and it is a variant of the
technology developed by McGuigan et al. (arylphosphoramidate ProTide approach).
In this strategy, only one negative charge in the phosphate moiety is masked by an
amino acid, whilst the other is free (Fig. 1.20). The unmasked charge gives more
water solubility and stability in human plasma.
o o imh2
H3CV ^ nh fT^N
"  N ^ O  O N ^^O  O N ^ O
NH NH
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4-0H -PhC H 2, Bn. 3-indolyl-C H 2 “ R: Bn. 3-indolyl-CH 2 R: Bn, 3-indolyl-C H 2
Fig. 1.20: phosphoramidate diester approach.
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Notably, in this approach the chirality at the phosphorus is absent, and it differs from 
several other approaches in this regard. The bioactivation of this prodrug involved an 
hydrolysis of the P-N mediated by a phosphoramidase type enzyme. This approach 
has been applied for example to AZT (62),108 5-fluoro-2’-deoxyuridine (63) and 1-|3- 
arabinofuranosylcytosine (64).109
1.3.1.5 Phospholipid conjugates approach
This approach has been developed by Hostetler et al. and it has been applied 
specifically to acyclic nucleoside phosphonates (Fig. 1.21), such as cidofovir (65 and 
66) and (S)-9-(2-phosphono-methoxypropyl)adenine (HPMPA) (67 and 68).110
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Fig. 1.21: phospholipid conjugates approach.
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This strategy involves the masking of one negative charge with a phospholipid 
moiety. In particular, the hexadecyloxypropyl and octadecyloxyethyl esters gave the 
best results. The mechanism of bioactivation involves cleavage of the phospholipid 
part mediated by phospholipase C. The application of this approach to cidofovir gave 
a remarkable increase in the potency of this compound against several viruses, 
enhancing for example the activity against HCMV by 400 fold and against VZV by 
1200 fold. In the case of HPMPA this approach enhanced the antiviral activity against 
HCMV by 270 fold and against HIV-1 by 11000 fold.'10
1.3.1.6 HepDirect approach
Cyclic l-aryl-l,3-propanyl ester (HepDirect) is a strategy developed by Metabasis. 
These prodrugs are specifically bioactivated by the cytochrome P450 with the 
consequent delivery of the monophosphate form within the liver, decreasing the 
toxicity to other organs.97 At present three HepDirect prodrugs are currently under 
clinical evaluation (Fig. 1.22): pradefovir (69), which is a prodrug of adefovir, for the 
treatment of HBV, MB07133 (70), prodrug of cytarabine monophosphate, for the 
treatment of primary liver cancer and the non-nucleoside MB07811 (71) for the 
treatment of hyperlipidemia.97
Fig. 1.22: hepdirect approach.
1.3.1.7 Diamidate prodrug
Firstly reported by McGuigan et al. applying this technology to AZT, it has not been 
greatly developed.97 As already seen for the phosphoramidate diester approach, the 
phosphorus is no longer chiral.
Recently, this approach has been applied to a fructose-1,6-bisphosphatase inhibitor 
(72, Fig. 1.23) and advanced in clinical trial for the treatment of type 2 diabetes.
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Moreover, Gilead has applied this strategy to 9-[2-(phosphonomethoxy)ethoxy]- 
adenine (PMEA) (73) and to phosphonomethoxyethylguanine (PMEG) (74). Further 
studies indicate the delivery of the parent into the cells.97
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Fig. 1.23: phosphonic diamide approach.
1.3.1.8 Arylphosphoramidate ProTide approach
This approach has been developed by McGuigan and co-workers (for review see 
Cahard111 and Mehellou112). Initially designed with the alkyl and haloalkyl phosphate 
triesters (75, Fig. 1.24) followed by the substitution of one of the chains with an 
amino acid giving the alkyloxyphosphoramidate (76) and 
haloalyloxyphosphoramidate (77). Then the bis-aryloxy compounds (78) have been 
introduced and finally the arylophosphoramidate currently used (79).111112
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Fig. 1.24: the history of arylphosphoramidate ProTide approach.
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This technology has been applied to several NAs showing in most of the cases 
improvement/extension of the activity and further activity against TK deficient 
strains, successfully by-passing the first step of phosphorylation. The literature reports 
many examples: d4T,113, 114 ddA,115 abacavir,116 4’-azidouridine,117 N-
aeetylglucosamine,118 etc.
1.3.1.8.1 Mechanism of activation of arylphosphoram idate
Fig. 1.25 reports the putative bioactivation pathway for the arylphosphoramidate.
ArO NA A rO  NA O NA 9  NA
O -P -O  O -P -O  O-F’ -O  O -P -O
NH --------- -----► NH  - -----► o tfdS ^ NH    ^H
" M "  M r "  M r "
0  80  °  81 82  83  8
Fig. 1.25: mechanism of activation of arylphosphoramidate.
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The first step (a) is the hydrolysis of the carboxylic ester moiety (81) hypothesised to 
be mediated by a carboxyesterase-type enzyme.119,120 In particular, evidence indicated 
that this enzyme is cathepsin A, and its mechanism of action will be discussed later in 
this thesis.121
The second step (b) is a spontaneous cyclisation through an internal nucleophilic 
attack of the carboxylate on the phosphorus centre with displacement of the aryl 
moiety (82).
The third step (c) is the opening of the unstable putative cyclic mixed anhydride 
mediated by water (83).
The fourth step (d) is the cleavage of the P-N bond perhaps mediated by a 
phosphoramidase-type enzyme with the release of the monophosphate (84).119 More 
specifically, this final step is supposed to be mediated by human hint enzyme 1, which 
belongs to the HIT superfamily.122 Its mechanism will be discussed later in this thesis.
1.3.1.8.2 SAR of the arylphosphoram idate moiety
The arylphosphoramidate moiety consists of three variable components: the aryl, the 
amino acid and the ester. All these parts contribute to the activity of these prodrugs. In 
particular, the combination of these moieties plays a crucial role in terms of 
lipophilicity and pharmacokinetics.
27
Marco Derudas Chapter 1
1.3.1.8.2.1 Ester moiety
The first part to be considered is the ester, as it is involved in the first step of the 
bioactivation. Several esters have been considered: linear such as methyl, ethyl, n- 
propyl, pentyl, etc; branched such as 2-propyl, tert-butyl, etc; and the benzyl group. In 
particular, in most of the cases, phosphoramidate carrying the benzyl group proved to 
be highly potent, whilst in the case of the tert-butyl, the prodrugs are inactive, and this 
is probably due to a lack of bioactivation as the tert-butyl moiety is loo bulky to be 
processed by the enzyme.11,112
1.3.1.8.2.2 Aryl moiety
The aryl component is the second part to be processed, more specifically released. 
Depending on the aryl group, it can be released faster or slower, being an equilibrium 
step. Several aryl moieties have been considered, especially the phenyl and 1- 
naphthol, and several substitutions to the phenyl ring have been considered in order to 
improve the activity.11 ’’112
1.3.1.8.2.3 Amino acid moiety
The amino acid is probably the most important part of the arylphosphoramidate 
moiety. In this case as well, several amino acids have been considered and L-alanine 
gives, usually, the best results. The unnatural amino acid a,a-dimethylglycine is a 
good substituent of L-alanine in terms of activity. The other amino acids used often 
gave reduced activity compared to L-alanine. Another important asp«ect concerning 
the amino acid is its stereochemistry; in fact, the L-isomer is often more active than 
the D-isomer, and this is probably due to the interaction with the enzymes involved in 
the bioactivation.111 ’112
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1.3.1.9 Summary of phosphate prodrug technologies
To summarize, Table 1.1 reports the different phosphate prodrug approached 
discussed in this section with the enzyme involved in the bioactivation pathway and 
they are progressed to human trials.
Prodrug Class Enzyme(s) involved Taken to human trials
Bis(POM)/Bis(POC) Esterase Yes
Bis(SDTE)/Bis(SATE) Esterase No
CycloSal Chemical No
Phosphoramidate Diester Esterase, amidase No
Phospholipid Conjugate Phosphodiesterase Yes
HepDirect Cytochrome P450 Yes
Phosphonic Diamide Esterase, amidase Yes
Arylphosphoramidate (ProTide) Esterase, amidase Yes
Table 1.1: summary of the phosphate prodrug approaches
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1.4 Objectives
As previously mentioned, new antiviral agents are continuously required, especially 
for the treatment of HIV and HCV, but also against those viruses for which drug 
resistance emerges.
In the present work, the synthesis and the biological evaluation of novel antiviral 
drugs will be reported. In particular, the specific aims are:
synthesis and biological evaluation of novel derivatives of bycyclic nucleoside 
analogues (BCNAs);
attempts to improve the scale up synthesis of FV100, which is the most potent 
anti-VZV agent reported to date and currently in phase II clinical trials; 
the application of the phosphoramidate approach to ribavirin; 
the application of the ProTide approach to acyclovir;
the identification of acyclovir derivatives through a virtual screening using 
RT, adenylate or guanylate kinase, and polymerase y;
synthesis and biological evaluation of acyclovir derivatives and application of 
the phosphoramidate approach.
30
Marco Derudas Chapter 1
1.5 References
1. Fauquet, C. M.; Mayo, M. A.; Maniloff, J.; Desselberger, U.; Ball, L. A. Virus 
taxonomy, Viiith report of the international committee on taxonomy of viruses. 
London, Elsevier, 2005.
2. Woolhouse, M. E. J.; Howey, R.; Gaunt, E.; Reilly, L.; Chase-Topping, M.; 
Savill, N. Temporal trends in the discovery of human viruses. Proc. R. Soc. B 
2008, 275, 2111-2115.
3. Virus taxonomy 2008. International Committee on taxonomy of viruses. 
http://www.ictvonline.org/virusTaxonomv.asp?version=2008&bhcp=:l 
Accessed 28 June 2009.
4. Baltimore, D. Expression of animal virus genomes Bacteriol. Rev. 1971, 35, 
235-241.
5. Knipe, D. M.; Mowley, P. M. Fields Virology, 5 Ed. 2007, Lippincott Williams 
& Wilkins, Philadelphia, USA.
6. Spear, P. G.; Manoj, S.; Yoon, M.; Jogger, C. R.; Zago, A.; Myscofski, D. 
Different receptors binding to distinct interfaces on herpes simplex virus gD can 
trigger events leading to cell fusion and viral entry. Virology 2006, 344, 17-24.
7. Weiss, R. A. Gulliver’s travels in HIVland. Nature, 2001, 410, 963-967.
8. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug. Discov. 
2007, 6, 1001-1018.
9. Stevens, M. De Clercq, E.; Balzarini, J. The regulation of HIV-1 transcription: 
molecular targets for chemotherapeutic intervention. Med. Res. Rev. 2006, 26, 
595-625.
10. Patick, A. K.; Potts, K. E. Protease inhibitors as antiviral agents. Clin. 
Microbiol. Rev. 1998, 11, 614-627.
11. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. 
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 
lymphocytes. Nat. Rev. Drug. Discov. 2006, 3, 215-225.
12. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; 
Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, 
D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a potent, 
orally bioavailable, and selective small-molecule inhibitor of chemokine 
receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 
activity. Antimicrob. Agents Chemother. 2005, 49, 4721-4732.
31
Marco Derudas Chapter 1
13. Davies, W. L.; Grunert, R. R.; Haff, R. F.; McGahen, J. W.; Neumayer, E. M.; 
Paulshock, M.; Watts, J. C.; Wood, T.R.; Hermann, E. C.; Hoffmann, C. E. 
Antiviral activity of 1-adamantanamine (amantadine). Science 1964, 144, 862- 
863.
14. De Clercq, E. Antiviral drugs in current clinical use J. Clin. Virol. 2004, 30, 
115-133.
15. Wang, C.; Takeuchi, K.; Pinto, L. H.; Lamb, R. A. Ion channel activity of 
influenza A virus M2 protein: characterization of the amantadine block. J. Virol.
1993, 67, 5585-5594.
16. Bukrinskaya, A. G.; Vorkunova, N. K.; Kornilayeva, G. V.; Narmanbetova, R. 
A.; Vorkunova, G. K. Influenza virus uncoating in infected cells and effect of 
rimantadine. J. Gen. Virol. 1982, 60, 49-59.
17. Blanpied, T. A.; Clarke, R. J.; Johnson, J. W. Amantadine inhibits NMDA
receptors by accelerating channel closure during channel block. J. Neurosci.
2005, 25, 3312-3322.
18. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; De Miranda, P.; Beauchamp, L.;
Schaeffer, H.L. Selectivity of action of an antiherpetic agent: 9-(2-hydroxy- 
ethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA 1977, 74, 5716-5720.
19. Weller, S.; Blum, M.R.; Doucette, M.; Burnette, T.; Cederberg, D.M.; De 
Miranda P.; Smiley M.L. Pharmacokinetics of the acyclovir pro-drug
valacyclovir after escalating single- and multiple-dose administration to normal 
volunteers. Clin. Pharmacol. Ther. 1993, 54, 595-605.
20. Coen, D. M. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol.
1994, 2, 481-485.
21. Miller, W. H.; Miller, R. L. Phosphorylation of acyclovir monophosphate by 
GMP kinase. J. Biol. Chem. 1980, 255,7204-7207.
22. Miller, W. H.; Miller, R. L. Phosphorylation of acyclovir diphosphate by 
cellular enzyme. Biochem. Phamacol. 1982,31, 3879-3884.
23. Furman, P. A.; St. Clair, M. H.; Fyfe, J. A.; Rideout, J. L.; Keller, P. M.; Elion, 
G. B. Inhibition of herpes simplex virus-induced DNA polymerase activity and 
viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its 
triphosphate. J. Virol. 1979,3 2 ,72-77.
32
Marco Derudas Chapter 1
24. Furman, P. A.; McGuirt, P. V.; Keller, P. M.; Fyfe, J. A.; Elion, G. B. Inhibition 
by acyclovir of cell growth and DNA synthesis of cells biochemically 
transformed with herpesvirus genetic information. Virology 1980,102,420-430.
25. Reardon, J. E.; Spector, T. Herpes simplex virus type 1 DNA polymerase. 
Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 1989, 264, 
7405-7411.
26. Top 200 drugs for 2008, http:/www.drugs.com/top2Q0.html Accessed 18lh 
August 2009.
27. Coen, D. M.; Schaffer, P. A. Two distinct loci confer resistance to 
acycloguanosine in herpes simplex virus type 1. Proc. Natl Acad. Sci. USA 
1980, 77, 2265-2269.
28. Schnipper, L. E.; Crumpacker, C. S. Resistance of herpes simplex virus to 
acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. 
Proc. Natl Acad Sci. USA 1980, 77, 2270-2273.
29. Larder, B. A.; Cheng, Y.-C.; Darby, G. Characterization of abnormal thymidine 
kinases induced by drug-resistant strains of herpes simplex virus type 1. J. Gen. 
Virol. 1983,64,523-532.
30. Cheng, Y.-C.; Huang, E.-S.; Lin, J.-C.; Mar, E.-C.; Pagano, J. S.; Dutschman,
G. E.; Grill, S. P. Unique spectrum of activity of 9-((l,3-dihydroxy-2- 
propoxy)methylJ-guanine against herpesviruses in vitro and its mode of action 
against herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 1983, 80, 2767- 
2270.
31. Sullivan, V.; Talarico, C. L.; Stanat, S. C.; Davis, M.; Coen, D. M. Biron, K. K. 
A protein kinase homologue controls phosphorylation of ganciclovir in human 
cytomegalovirus-infected cells. Nature 1992, 358, 162-164.
32. Biron, K. K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 
71, 154-163.
33. Reid, R.; Mar, E.-C.; Huang, E.-S.; Topal, M. D. Insertion and extension of 
acyclic, dideoxy, and ara nucleotides by herpesviridae, human a  and human |3 
polymerases. J. Biol. Chem. 1988, 263, 3898-3904.
34. Biron, K. K.; Stanat, S. C.; Sorrell, J. B.; Fyfe, J. A.; Keller, P. M.; Lambe, C. 
U.; Nelson, D. J. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-
33
Marco Derudas Chapter 1
l-(hydroxymethyl)ethoxy]methyl}guanine in human diploid fibroblasts infected 
with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 1985, 82, 2473-2477.
35. Boyd, M. R.; Bacon, T. H.; Sutton, D.; Cole, M. Antiherpesvirus activity of 9- 
(4-hydroxy-3-hydroxy-methylbut-l-yl)guanine (BRL 39123) in cell culture. 
Antimicrob. Agents Chemother. 1987, 31, 1238-1242.
36. Field. H. J.; De Clercq, E. Antiviral Chemistry & Chemotherapy’s current 
antiviral agents FactFile (2nd edition): DNA viruses. Antiviral Chem. 
Chemother. 2008, 79, 51-62.
37. Eamshaw, D. L.; Bacon, T. H.; Darlison, S. J.; Edmonds, K.; Perkins, R. M.; 
Vere Hodge, R. A. Mode of antiviral action of penciclovir in MRC-5 cells 
infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster 
virus. Antimicrob. Agents Chemother. 1992, 36, 2747-2757.
38. Vere Hodge, R. A.; Perkins, R. M. Mode of action of 9-(4-hydroxy-3- 
hydroxymethylbut-l-yl)guanine (BRL 39123) against herpes simplex virus in 
MRC-5 cells. Antimicrob. Agents Chemother. 1989, 33, 223-229.
39. Hamden, M. R.; Jarvest, R. L.; Boyd, M. R.; Sutton, D.; Vere Hodge, R. A.
Prodrugs of the selective antiherpesvirus agent 9-(4-hydroxy-3- 
hydroxymethylbut-l-yl)guanine (BRL 39123) with improved gastrointestinal 
absorption properties. J. Med. Chem. 1989, 32, 1738-1743.
40. Vere Hodge, R. A.; Sutton, D.; Boyd, M. R.; Hamden, M. R.; Jarvest, R. L.
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus
agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; 
penciclovir]. Antimicrob. Agents Chemother. 1989, 33, 1765-1773.
41. Rashidi, M. R.; Smith, J. A.; Clarke, S. E.; Beedham, C. In vitro oxidation of 
famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea 
pig, rabbit, and rat liver. Drug Metab. Dispos. 1997, 25, 805-813.
42. DeClercq, E.; Holy, A. Acyclic nucleoside phosphonates: a key class of 
antiviral drugs. Nat. Rev. Drug Discov. 2005, 4, 928-940.
43. Helgstrand, E.; Eriksson, B.; Johansson, N. G.; Lannero, B.; Larsson, A.; 
Misiorny, A.; Noren, J. O.; Sjoberg, B.; Stenberg, K.; Stening, G.; Stridh, S.; 
Oberg, B. Trisodium phosphonoformate, a new antiviral compound. Science, 
1978, 201, 819-821.
34
Marco Derudas Chapter 1
44. DeClercq, E.; Descamps, J.; De Somer, P.; Barr, P. J.; Jones, A. S.; Walker, R. 
T. (E)-5-(2-bromovinyl)-2'-deoxyuridine: A potent and selective anti-herpes 
agent. Proc. Natl. Acad. Sci. USA 1979, 7<5, 2947-2951.
45. De Clercq, E. Discovery and development of BVDU (brivudin) as a therapeutic 
for the treatment of herpes zoster. Biochem. Pharmacol. 2004, 68, 2301-2315.
46. De Clercq, E.; Field, H. J. Antiviral Chemistry & Chemotherapy’s current 
antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses. 
Antiviral Chem. Chemother. 2008, 19, 75-105.
47. Mitsuya, H.; Weinhold, K.; Furman, P. A.; St. Clair, M. H.; Nusinoff Lehrman, 
S.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. 3’-azido-3’- 
deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and 
cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- 
associated virus in vitro. Proc. Natl. Acad. Sci. USA 1985, 82, 7096-7100.
48. Furman, P. A.; Fyfe, J. A.; St. Clair, M. H.; Weinhold, K.; Rideout, J. L.; 
Freeman, G. A.; Nusinoff Lehrman, S.; Bolognesi, D. P.; Broder, S.; Mitsuya,
H.; Barry, D. W. Phosphorylation of 3’-azido-3’-deoxythymidine and selective 
interaction of the 5’-triphosphate with human immunodeficiency virus reverse 
transcriptase. Proc. Natl. Acad. Sci. USA 1986, 83, 8333-8337.
49. St. Clair, M. H.; Richards, C. A.; Spector, T.; Weinhold, K. J.; Miller, W. H.; 
Langlois, A. J.; Furman, P. A. 3’-azido-3’-deoxythymidine triphosphate as an 
inhibitor and substrate of purified human immunodeficiency virus reverse 
transcriptase. Antimicrob. Agents Chemother. 1987, 31, 1972-1977.
50. Mitsuya, H.; Broder, S. Inhibition of the in vitro infectivity and cytopathic effect 
of human T-lymphotrophic virus type III/lymphadenopathy-associated virus 
(HTLV-III/LAV) by 2’,3’-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 
1986, 83, 1911-1915.
51. Soudeyns, H.; Yao, X.-J.; Gao, Q.; Belleau, B.; Kraus, J.-L.; Nguyen-Ba, N.; 
Spira, B.; Wainberg, M. A. Anti-human immunodeficiency virus type 1 activity 
and in vitro toxicity of 2’-deoxy-3’-thiacytidine (BCH-189), a novel 
heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 1991, 35, 1386- 
1390.
52. Coates, J. A.; Cammack, N.; Jenkinson, H. J.; Mutton, I. M.; Pearson, B. A.; 
Storer, R.; Cameron, J. M.; Penn, C. R. The separated enantiomers of 2’-deoxy- 
3’-thiacytidine (BCH-189) both inhibit human immunodeficiency virus
35
Marco Derudas Chapter 1
replication in vitro. Antimicrob. Agents Chemother. 1992, 36, 202-205.
53. Coates, J. A.; Cammack, N.; Jenkinson, H. J.; Jowett, A. J.; Jowett, M. I.; 
Pearson, B. A.; Penn, C. R.; Rouse, P. L.; Viner, K. C.; Cameron, J. M. (-)-2’- 
deoxy-3’-thiacytidine is a potent, highly selective inhibitor of human 
immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. 
Agents Chemother. 1992, 36, 733-739.
54. Doong, S.-L.; Tsai, C.-H.; Schinazi, R. F.; Liotta, D. C.; Cheng, Y.-C. Inhibition 
of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine 
and related analogues. Proc. Natl. Acad. Sci. USA 1991, 88, 8495-8499.
55. Vince, R.; Hua, M.; Brownell, J.; Daluge, S.; Lee, F. C.; MShannon, W.;
Lavelle, G. C.; Qualls, J.; Weislow, O. S.; Kiser, R.; Canonico, P.; Schultz, R.; 
Narayanan, V.; Mayo, J.; Shoemaker, R.; Boyd, M. Potent and selective activity 
of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human 
immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 1988, 156, 
1046-1053.
56. Carter, S. G.; Kessler, J. A.; Rankin, C. D. Activities of (-)-carbovir and 3’- 
azido-3’-deoxythymidine against human immunodeficiency virus in vitro. 
Antimicrob. Agents Chemother. 1990, 34, 1297-1300.
57. Daluge, S. M.; Good, S. S.; Faletto, M. B.; Miller, W. H.; St. Clair, M. H.;
Boone, L. R.; Tisdale, M.; Parry, N. R.; Reardon, J. E.; Domsife, R. E.; Averett,
D. R.; Krenitsky, T. A. 1592U89, a novel carbocyclic nucleoside analog with 
potent, selective anti-human immunodeficiency virus activity. Antimicrob. 
Agents Chemother. 1997, 41, 1082-1093.
58. Faletto, M. B.; Miller, W. H.; Garvey, E. P.; St. Clair, M. H.; Daluge, S. M.; 
Good, S. S. Unique intracellular activation of the potent anti-human 
immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 1997, 
41, 1099-1107.
59. Parker, W. B.; White, E. L.; Shaddix, S. C.; Ross, L. J.; Buckheit, R. W.; 
Germany, J. M.; Secrist, J. A.; Vince, R.; Shannon, W. M. Mechanism of 
inhibition of human immunodeficiency virus type 1 reverse transcriptase and 
human DNA polymerases a, /3 and y by the 5’-triphosphate of carbovir, 3’- 
azido-3’-deoxythymidine, 2’,3’-dideoxyguanosine, and 3’-deoxythymidine. J. 
Biol. Chem. 1991, 266, 1754-1762.
60. Schinazi, R. F.; McMillan, A.; Cannon, D.; Mathis, R.; Lloyd, R. M.; Peck, A.;
36
Marco Derudas Chapter 1
Sommadossi, J.-P.; St. Clair, M.; Wilson, J.; Furman, P. A.; Painter, G.; Choi, 
W.-B.; Liotta, D. C. Selective inhibition of human immunodeficiency viruses by 
racemates and enantiomers of c/.s-5-fluoro-l-[2-(hydroxymethyl)-l,3- 
oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 1992, 36, 2423-2431.
61. Furman, P. A.; Davis, M.; Liotta, D. C.; Paff, M.; Frick, L. W.; Nelson, D. J.; 
Domsife, R. E.; Wurster, J. A.; Wilson, L. J.; Fyfe, J. A.; Tuttle, J. V.; Miller, 
W. H.; Condreay, L.; Averett, D. R.; Schinazi, R. F.; Painter, G. R. The anti­
hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) 
enantiomers of m-5-fluoro-1 -[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. 
Antimicrob. Agents Chemother. 1992, 36, 2686-2692.
62. Balzarini, J.; Holy, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; 
DeClercq, E. Differential antiherpesvirus and antiretrovirus effects of the (S) 
and the (R) enantiomers of acyclic nucleoside phosphonates: potent and 
selective in vitro and in vivo antiretrovirus activities of (R)-9-(2- 
phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 
1993, 37, 332-338.
63. Robbins, B. L.; Srinivas, R. V.; Kim, C.; Bischofberger, N.; Fridland, A. Anti­
human immunodeficiency virus activity and cellular metabolism of a potential 
prodrug of the acyclic nucleoside phosphonate 9-/?-(2-phosphonomethoxy- 
propyl)adenine (PMPA), bis (isopropyloxymethylcarbonyl)PMPA. Antimicrob. 
Agents Chemother. 1998, 42, 612-617.
64. Naesens, L.; Bischofberger, N.; Augustijns, P.; Annaert, P.; Van Den Mooter, 
G.; Arimilli, M. N.; Kim, C. U.; DeClercq, E. Antiretroviral efficacy and 
pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2- 
phosphonomethoxy-propyl)adenine in mice. Antimicrob. Agents Chemother. 
1998, 42, 1568-1573.
65. Naesens, L.; Balzarini, J.; Bischofberger, N.; DeClercq, E. Antiretroviral 
activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2- 
phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 
9-(2-phosphonomethoxyethyl)adenine. Antimicrob. Agents Chemother. 1996, 
40,22-28.
66. Naesens, L.; Balzarini, J.; DeClercq, E. Therapeutic potential of PMEA as an 
antiviral drug. Rev. Med. Virol. 1994, 4, 147-159.
37
Marco Derudas Chapter 1
67. Innaimo, S. F.; Seifer, M.; Bisacchi, G. S.; Standring, D. N.; Zahler, R.; 
Colonno, R. J. Identification of BMS-200475 as a potent and selective inhibitor 
of hepatitis B virus. Antimicrob. Agents Chemother. 1997, 41, 1444-1448.
68. Bryant, M. L.; Bridges, E. G.; Placidi, L.; Faraj, A.; Loi, A.-G.; Pierra, C.; 
Dukhan, D.; Gosselin, G.; Imbach, J.-L.; Hernandez, B.; Juodawlkis, A.; 
Tennant, B.; Korba, B.; Cote, P.; Marion, P.; Cretton-Scott, E.; Schinazi, R. 
Sommadossi, J.-P. Antiviral L-nucleosides specific for hepatitis B virus 
infection. Antimicrob. Agents Chemother. 2001, 45, 229-235.
69. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the 
treatment of human immunodeficiency virus type 1 (HIV-1) infections: 
strategies to overcome drug resistance development. Med. Res. Rev. 1996, 16, 
125-157.
70. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, 
J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosehthal, A. S.; Faanes, 
R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L.. Inhibition of HIV-1 replication by 
a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
71. Richman, D.; Rosenthal, A. S.; Skoog, M.; Eckner, R. J.; Chou, T.-C.; Sabo, J. 
P.; Merluzzi, V. J.; BI-RG-587 is active against zidovudine-resistant human 
immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. 
Agents Chemother. 1991, 35, 305-308.
72. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T.
A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S.; Pettibone, D. J.; 
O’Brien, J. A.; Ball, R. G.; Balani, S. K.; Lin, J. H.; Chen, I-W.; Schleif, W. A.; 
Sardana, V. V.; Long, A. J.; Byrnes, V. W.; Emini, E. A. L-743,726 (DMP- 
266): a novel, highly potent nonnucleoside inhibitor of the human 
immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents 
Chemother. 1995, 39, 2602-2605.
73. DeClercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 
2002, 7, 13-25.
74. Pommier, Y.; Marchand, C.; Neamati, N. Retroviral integrase inhibitors year
2000: update and perspectives. Antiviral Res. 2000, 47, 139-148.
75. Markowitz, M.; Morales-Ramirez, J. O.; Nguyen, B.-Y.; Kovacs, C. M.;
Steigbigel, R. T.; Cooper, D. A.; Liporace, R.; Schwartz, R.; Isaacs, R.; Gilde, 
L. R.; Wenning, L.; Zhao, J.; Teppler, H. Antiretroviral activity,
38
Marco Derudas Chapter 1
pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 
integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected 
individuals. J'. Acquir. Immune Defic. Syndr. 2006, 43, 509-515.
76. Larder, B. A.; Darby, G.; Richman, D. D.; HIV with reduced sensitivity to 
zidovudine (AZT) isolated during prolonged therapy. Science, 1989, 243, 1731- 
1734.
77. De Clercq, E. The history of antiretrovirals: key discoveries over the past 25 
years. Rev. Med. Virol. 2009, 19, 287-299.
78. Sidwell, R. W.; Huffman, J. H.; Khare, G.P.; Allen, L. B.; Witkowski, J. T.; 
Robins, R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D- 
ribofuranosy 1-1,2,4-triazole-3-carboxamide. Science 1972, 177, 705-706.
79. Graci, J. D.; Cameron, C. E. Quasispecies, Error Catastrophe, and the antiviral 
activity of ribavirin. Virology 2002, 298, 175-180.
80. Streeter, D. G.; Witkowski, J. T.; Khare, G. P.; Sidwell, R. W.; Bauer, R. J.; 
Robins, R. K.; Simon, L. N. Mechanism of action of l-P-D-ribofuranosyl-1,2,4- 
triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. 
Natl. Acad. Sci. USA 1973, 70, 1174-1178.
81. Leyssen, P.; Balzarini, J.; De Clercq, E.; Neyts, J. The predominant mechanism 
by which ribavirin exerts its antiviral activity in vitro against flaviviruses and 
paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 
2005, 79, 1943-1947.
82. Crotty, S.; Maag, D.; Arnold, J. J.; Zhong, W.; Lau, J. Y. N.; Hong, Z.; Andino, 
R.; Cameron, C. E. The broad-spectrum antiviral ribonucleoside ribavirin is an 
RNA virus mutagen. Nat. Med. 2000, 6, 1375-1379.
83. Eriksson, B.; Helgstrand, E.; Johansson, N. G.; Larsson, A.; Misiorny, A.; 
Noren, J. O.; Philipson, L.; Stenberg, K.; Stening, G.; Stridh, S.; Oberg, B. 
Inhibition of influenza virus ribonucleic acid polymerase by ribavirin 
triphosphate. Antimicrob. Agents Chemother. 1977, 11, 946-951.
84. Benarroch, D.; Egloff, M. P.; Mulard, L.; Guerreiro, C.; Romette, J. L.; Canard,
B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2’-0- 
methyltransferase domain by ribavirin-5’-triphosphate. J. Biol. Chem. 2004, 
279, 35638-35643.
39
Marco Derudas Chapter 1
85. Crotty, S.; Cameron, C. E.; Andino, R. RNA virus error catastrophe: direct 
molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 2001, 98, 6895- 
6900.
86. Bergamini, A.; Bolacchi, F.; Cepparulo, M.; Demin, F./ Uccella, I.; 
Bongiovanni, B.; Ombres, D.; Angelico, F.; Liuti, A.; Hurtova, M.; Francioso, 
S.; Carvelli, C.; Cerasari, G.; Angelico, M.; Rocchi, G. Treatment with ribavirin 
and interferon-a reduces interferon-y expression in patients with chronic 
hepatitis C. Clin. Exp. Immunol. 2001, 123, 459-464.
87. Hultgren, C.; Milich, D. R.; Weiland, O.; Sallberg, M. The antiviral compound 
ribavirin modulates the T helper (Th)l/Th2 subset balance in hepatitis B and C 
virus-specific immune responses. J. Gen. Virol. 1998, 79, 2381-2391.
88. De Clercq, E.; Field, H. J. Antiviral Chemistry & Chemotherapy’s current 
antiviral agents FactFile 2008 (2nd edition): RNA viruses. Antiviral Chem. 
Chemother. 2008, 19, 63-74.
89. Von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.;
Van Phan, T.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; 
Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.;
Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors 
of influenza virus replication. Nature, 1993, 363, 418-423.
90. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; 
Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; 
Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel 
hydrophobic interaction in the enzyme active site: design, synthesis, and 
structural analysis of carbocyclic sialic analogues with potent anti-influenza 
activity. J. Am. Chem. Soc. 1997, 119, 681-690.
91. Nicholson, K. G.; Aoki, F. Y.; Osterhaus, A. D. M. E.; Trottier, S.; Carewicz,
O.; Mercier, C. H.; Rode, A.; Kinnersley, N.; Wrad, P. Efficacy and safety of
oseltamivir in treatment of acute influenza: a randomized controlled trial. 
Lancet, 2000, 355, 1845-1850.
92. Gilbert, C.; Bestman-Smith, J.; Boivin, G. Resistance of herpesviruses to 
antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. 
Updates 2002, 5, 88-114.
93. Jones, R. J.; Bischofberger, N. Minireview: nucleotide prodrugs. Antiviral. Res., 
1995, 27, 1-17.
40
Marco Derudas Chapter 1
94. Jonckheere, H.; Anne, J.; De Clercq, E. The HIV-1 reverse transcription (RT) 
process as target for RT inhibitors. Med. Res. Rev. 2000, 20y 129-154.
95. Meier, C. Pro-nucleotides -  Recent advances in the design of efficient tools for 
the delivery of biologically active nucleoside monophosphates. Synlett 1998, 
233-242.
96. Wagner, C. R.; Iyer, V. V.; Mclntee, E. J. Pronucleotides: toward the in vivo 
delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 2000, 20, 417- 
451.
97. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates. J. Med. 
Chem. 2008, 5 /, 2328-2345.
98. Sastry, J. K.; Nehete, P. N.; Khan, S.; Nowak, B. J.; Plunkett, W.; Arlinghaus, 
R. B.; Farquhar, D. Membrane-permeable dideoxyuridine 5’-monophosphate 
analogue inhibits human immunodeficiency virus infection. Mol. Pharmacol. 
1992, 41, 441-445.
99. Pompon, A.; Lefebvre, I.; Imbach, J. L.; Khan. S.; Farquhar, D. Decomposition 
pathways of the mono- and bis(pivaloyloxymethyl) esters of azidothymidine 5’- 
monophosphate in cell extract and in tissue culture medium: an application of 
the on-line ISRP-cleaning HPLC technique. Antivir. Chem. Chemother. 1994, 5, 
91-98.
100. Farquhar, D.; Khan, S.; Srivastva, D. N.; Saunders, P. Synthesis and antitumor 
evaluation of bis[(pivaloyloxy)methyl] 2’-deoxy-5-fluorouridine 5’- 
monophosphate (FdUMP): a strategy to introduce nucleotides into cells. J. Med. 
Chem. 1994, 37, 3902-3909.
101. Gosselin, G.; Girardet, J.-L.; Perigaud, C.; Benzaria, S.; Lefebvre, I.; 
Schlienger, N.; Pompon, A.; Imbach, J.-L. New insights regarding the potential 
of the pronucleotide approach in antiviral chemotherapy. Acta Biochim. Pol. 
1996, 43, 196-208.
102. Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. cyc/o-Sal-2’,3’-dideoxy-2,,3’- 
didehydrothymidine monophosphate (cyc/o-Sal-d4TMP); synthesis and antiviral 
evaluation of a new d4TMP delivery system. J. Med. Chem. 1998, 47, 1417- 
1427.
103. Meier, C.; De Clercq, E.; Balzarini, J. Nucleotide delivery from cyc/oSaligenyl- 
3’-azido-3’-deoxythymidine monophosphates (cyc/oSal-AZTMP). Eur. J. Org. 
Chem. 1998, 837-846.
41
Marco Derudas Chapter 1
104. Meier, C.; Ruppel, M .F. H.; Vukadinovi, D.; Balzarini, J. Second generation of 
cycloSal-pronucleotides with esterase-cleavable sites: the “lock-in”-concept. 
Nucleos. Nucleot. Nucl. 2004, 23, 89-115.
105. Meier, C.; Ducho, C.; Jessen, H.; Vukadinovic-Tenter, D.; Balzarini, J. Second- 
generation cyclo-Sal-d4TMP pronucleotides bearing esterase-cleavable sites -  
The “trapping” concept. Eur. J. Org. Chem. 2006, 197-206.
106. Gisch, N.; Balzarini, J.; Meier, C. Enzymatically activated cyc/oSal- 
d4T6monophosphates: the third generation of cyc/o-Sal-pronucleotides. J  Med. 
Chem. 2007, 50, 1658-1667.
107. Jessen, H. J.; Schulz, T.; Balzarini, J.; Meier, C. Bioreversible protection of 
nucleoside diphosphates. Angew. Chem. Int. Ed. 2008, 47, 922-924.
108. Iyer, V. V.; Griesgraber, G. W.; Radmer, M. R.; Mclntee, E. J.; Wagner, C. R. 
Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of 
amino acid methyl ester and alkyl amide phosphoramidate monoesters of 
3’azido-3’-deoxythymidine (AZT). J  Med. Chem. 2000, 43, 2266-2274.
109. Abraham, T. W.; Kalman, T. I.; Mclntee, E. J.; Wagner, C. R. Synthesis and 
biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2’- 
deoxyuridine and l-|3-arabinofuranosylcytosine: evidence of phosphoramidase 
activity. J  Med. Chem. 1996, 39, 4569-4575.
110. Hostetler, K. Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates 
enhance oral antiviral activity and reduce toxicity: current state of the art. 
Antiviral Res. 2009, 82, A84-A98.
111. Cahard, D.; McGuigan, C.; Balzarini, J. Aryloxy phosphoramidate trimesters as 
Pro-Tides. Mini Rev. Med. Chem. 2004, 4, 371-482.
112. Mehellou, Y.; Balzarini, J.; McGuigan, C. Aryloxy phosphoramidate triesters: a 
technology for delivering monophosphorylated nucleosides and sugars into 
cells. Chem. Med. Chem. 2009, 11, 1779-1791.
113. McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. Aryl 
phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue 
culture and may act by the generation of a novel intracellular metabolite. J. 
Med. Chem. 1996, 39, 1748-1753
114. Balzarini, J.; Karlsson, A.; Aquaro, S.; Perno, C.-F.; Cahard, D.; Naesens, L.; 
De Clercq, E.; McGuigan, C. Mechanism of anti-HIV action of masked alaninyl 
d4T-MP derivatives. Proc. Natl. Acad. Sci. USA 1996, 93, 7295-7299.
42
Marco Derudas Chapter 1
115. McGuigan, C.; Wedgwood, O. M. De Clercq, E. Balzarini, J. Phosphoramidate 
derivatives of 2’,3’-didehydro-2’,3,-dideoxyadenosine [d4A] have markedly 
improved anti-HIV potency and selectivity", Bioorg. Med. Chem. Lett. 1996, 6, 
2359-2362.
116. McGuigan, C.; Harris, S.A.; Daluge, S.M.; Gudmundsson, K.S.; McLean, E.W.; 
Burnette, T.C.; Marr, H.; Hazen, R.; Condreay, L.D.; Johnson, L.; De Clercq,
E.; Balzarini, J. Application of phosphoramidate pronucleotide technology to 
abacavir leads to a significant enhancement of antiviral potency. J. Med. Chem. 
2005, 48, 3504-3515.
117. Perrone, P.; Luoni, G. M.; Kelleher, M. R.; Daverio, F.; Angell, A.; Mulready, 
S.; Congiatu, C.; Rajyaguru, S.; Martin, J. A.; Leveque, V.; Le Pogam, S.;
Najera, I.; Klumpp, K.; Smith, D. B.; McGuigan, C. Application of the
phosphoramidate ProTide approach to 4'-Azidouridine confers sub-micro-molar 
potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem. 2007, 
50, 1840-1849.
118. McGuigan, C.; Serpi, M.; Bibbo, R.; Roberts, H.; Hughes, C.; Caterson, B.;
Gibert, A. T.; Verson, C. R. A. Phosphate prodrugs derived from N-
acetylglucosamine have enhanced chondroprotective activity in explant cultures 
and represent a new lead in antiosteoarthritis drug discovery. J. Med. Chem. 
2008, 51, 5807-5812.
119. Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana, R.; Velazquez,
S.; McGuigan, C.; De Clercq, E.; Balzarini, J. Characterization of the activation 
pathway of phosphoramidate triester prodrugs of stavudine (d4T) and 
Zidovudine (AZT). Mol. Pharmacol. 1999, 56, 693-704.
120. Dang, Q.; Kasibhatla, S. R.; Reddy, K. R.; Jiang, T.; Reddy, M. R.; Potter, S.
C.; Fujitaki, J. M.; van Poelje, P. D.; Huang, J.; Lipscomb, W. N.; Erion, M. D. 
Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a 
series of orally-bioavailable phosphoramidase-sensitive prodrugs for the 
treatment of type 2 diabetes. J. Am. Chem. Soc. 2007, 129, 15491-15502.
121. Birkus, G.; Wang, R.; Liu. X.: Kutty, N.; MacArthur, H.; Cihlar, T.; Gibbs, C.; 
Swaminathan, S.; Lee, W.; McDermott. M. Cathepsin A is the major hydrolase 
catalyzing the intracellular hydrolysis of the antiretroviral nucleotide 
phosphonoamidate prodrugs GS-7340 and GS-9131 Antimicrob. Agents 
Chemother. 2007, 51, 543-550.
43
Marco Derudas Chapter 1
122. Brenner, C. Hint, Fhit. and GalT: function, structure, evolution, and mechanism 
of three branches of the histidine triad superfamily of nucleotide hydrolases and 
transferase. Biochemistry 2002, 4L  9003-9014.
44
Marco Derudas Chapter 2
2. Ten years o f BCNAs: from the bench to clinical trials
2.1 BCNAs: a new class of potent and selective anti-VZV agents
In 1999 during the synthesis of novel 5-alkenyl-2’-deoxyuridine, a new class of potent 
and selective anti-VZV compound was discovered.1 This new class of compounds 
bears an unusual fluorescent bicyclic furanopyrimidine base (bicyclic nucleoside 
analogues, BCNAs). It must be reported that BCNAs were previously obtained in 
several laboratories as a side product in the coupling of terminal alkynes to 5-iodo-2’- 
deoxyuridine, but were never identified as biologically active.2,3
&5a R = H
85b R *  C 3 H 7
85c R = C 5 H u
85d r  = c 6 h ,3
85e r  = c 7 h 14
85f R ~ c 8 h 17
85g R 3  C 9 H 19
85 h R * C ioH2 i
85i r  =  c „ h 2 3
85j R = c 12h 2 5
85k R =  C i4 H 2 9
A C V B V dU  H C 3  C 5  C 6  C 7  C 8  C 9  C IO  C l l  C 1 2  C 1 4
Fig. 2.1: SAR of the first series o f BCNAs (data for VZV-OKA)
Fig 2.1 reports the first series o f compounds made (85a-k). A clear structure activity 
relationship (SAR) of these compounds emerges (Table 2.1): with a short chain (< 6) 
little antiviral activity was found, similar to acyclovir (ACV); in the case of C7 (85e), 
C9 and CIO (85g-h) the activity was moderate. The optimal length of the chain was 
with C8 (851) wherein the activity was roughly similar to BVdU and ca. 300 fold 
more than ACV.1
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Antiviral Activity
FX50 (hM)*
Cytotoxicity
(|iM )
TK+ VZV TK VZV
YS OKA 07/1 YS MCCb CC50c
strain strain strain strain
85a H 33 28 >200 >200 >200 >200
85b C3 0.8 0.8 >200 >200 >200 >200
85c C5 1.8 1.8 >50 >50 >50 >50
85d C6 1.3 1.3 >50 >50 200 >200
85e C7 0.12 0.12 >50 >50 >50 >50
85f C8 0.008 0.008 >50 >50 >50 >50
85g C9 0.02 0.02 >200 >200 >200 >200
85h CIO 0.008 0.015 >50 >50 >50 >50
85i C ll 0.3 0.37 >50 >50 200 >200
85j C12 1.2 0.8 >50 >50 50 >200
85k C14 >50 >50 >50 >200 >200 >200
BVdU - 0.005 0.005 >200 >200 >200 >200
ACV - 1 2.9 74 125 >200 >200
a) effective concentration  required  to reduce virus p laque form ation by 50% ;
b) minimum cytotoxic concen tration  that cause a m icroscopically  detectab le  alteration  o f  cell m orphology;
c) cytotoxic concentration  required  to reduce cell grow th by 50%.
Table 2.1: antiviral activity against VZV for the compounds 85a-k including BVdU 
and ACV as control.
The optimization of the lead compound resulted in a series of 6-p-alkylphenyl 
derivatives (86a-i, Fig. 2.2). From Table 2.2 it is possible to extrapolate a SAR of 
these compounds: as previously noted for the parent alkyl derivatives, there is a 
dependence between the length of the chain and the activity. In fact, in the case of 
chain length C4-C6 (86e-g) a subnanomolar activity against VZV has been found. 
The 6-pentylphenyl 86f, called Cfl743, (EC5o= 0.1 nM) is ca 10000 times more active 
than ACV and ca. 20 times more active than BVDU and it is the most active anti- 
VZV compound reported to date.4 All the compounds have been found to be inactive 
against the TK deficient strains; this result suggests the need of phosphorylation for 
these compounds to show antiviral activity.
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a
3500
3000
2500
2000
1500
0 , 1000
500
86a R =* H
86b r - c h 3
86c r  = c 2h 5
86d R -  C3H7
86e R = C4H9
86f r - c 5h „
86g R = C6Hi3
86 h R 31 c 7Hj5
86i r - c 8h 17
ACV BVdU H C l C2 C3 C 4 C5 C6 C7 C8
Fig. 2.2: SAR of compounds 86a-i (data for VZV-OKA).
Antiviral Activity 
EC50 (jiM)*
Cytotoxicity 
(|iM )
TK* VZV TK VZV
YS
strain
OKA
strain
07/1
strain
YS
strain
MCCb c c 50c
86a H 0.28 0.16 >200 >162 >20 >200
86b Cl 0.06 0.06 103 >200 >200 >200
86c C2 0.09 0.07 >50 >50 >20 123
86d C3 0.01 0.008 >50 >20 >50 188
86e C4 0.0008 0.001 >20 >20 >200 >200
86f C5 0.0001 0.0003 >5 >5 >50 >200
86g C6 0.0002 0.0008 >5 >5 >20 18
86h C7 0.0057 0.0074 >5 >5 5 18
86i C8 0.05 0.065 >20 >20 >20 >200
BVdU - 0.005 0.005 >200 >200 >200 >200
ACV - 1 2.9 74 125 >200 >200
a) effective concentration required to reduce virus plaque form ation by 50%;
b) minimum cytotoxic concentration that cause a m icroscopically  detectable alteration o f  cell m orphology;
c) cytotoxic concentration required to reduce cell grow th by 50%.
Table 2.2: antiviral activity against VZV for the compounds 86a-i and BVdU and
ACV as control.
The high selectivity and the lack of toxicity of Cfl 743 promoted its development as a 
potential new anti-VZV drug (to be discussed later in this chapter).
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2.2 Modifications to the structure of BCNAs
After the discovery of the BCNAs, a significant SAR study, both to the alkyl 
derivatives and the phenyl-alkyl derivatives, has been made in order to improve the 
activity but also to investigate the mechanism of action.
2.2.1 Modifications of the side chain
Being fundamental for the activity of BCNAs, several modifications have been made 
in this regard.
The introduction of halogens (87a-d) at the end of the chain in the case of the nonyl 
derivatives gave compounds that did not significantly differ from the parent 85h in 
potency (Table 2.3).5
SfiTft-F '
8 7 b  R -  Cl 
87c R = Br 
87d  R = I 
8 5 h R = CM^
Antiviral Activity 
ECSo (|*M)*
Cytotoxicity
(HM)
TK* VZV TK' VZV
YS OKA 07/1 YS MCCb CC50c
strain strain strain strain
87a F 0.014 0.022 >20 >20 >50 200
87b Cl 0.012 0.007 15 13 >200 200
87c Br 0.031 0.026 >50 50 >200 >50
87d I 0.034 0.061 >50 >50 50 >200
85h c h 3 0.008 0.015 >50 >50 >50 >50
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concen tration  that cause a m icroscop ically  detectab le  alteration  o f  cell m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%.
Table 2.3: antiviral activity against VZV of halogen terminal substituted BCNA.
Terminal insaturation, alkenyl (88a-d) or alkynyl (89a-d) in the chain led to a 
decrease of activity, with a loss of 4-40 fold for the alkenyl and 250-750 fold for the 
alkynyl compared to the parent (Table 2.4).6
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”88an = 5 '
88b n = 6
88c n - 8
.88dn <«
(rl2C)n (H2C)n 189a n*  51 89b n * 6 
89c n = 7 
89d n = 8
Antiviral Activity 
EC50 (jaM)*
Cytotoxicity
(|*M)
t k a VZV TK VZV
MCCb CC50cYS
strain
OKA
strain
07/1
strain
YS
strain
88a C5 >200 >200 >200 >200 >200 >200
88b C6 13 14 >200 >200 >200 >200
88c C8 0.06 0.27 >200 >50 >200 >200
88d CIO 0.1 0.09 >200 >200 >50 >200
89a C5 10 8 >200 >200 >200 >200
89b C6 33 25 >200 >200 >200 >200
89c C l 37 79 >200 >200 >200 >200
89d C8 4 5 >200 >200 >200 >200
85f C8 0.024 0.008 >50 >50 >50 >50
a) effective co ncen tra tion  required  to reduce virus p laque form ation by 50%;
b) m inim um  cy to tox ic  concen tra tion  that cause a m icroscopically  detectable alteration o f  cell m orphology;
c) cytotoxic concen tration  required  to reduce cell grow th by 50%.
Table 2.4: antiviral activity against VZV of alkenyl and alkynyl terminal BCNA.
The introduction of an ether or a glycol chain either with or without the phenyl ring 
was investigated in order to increase the solubility of these compounds. In spite of the 
increase of water solubility, the ether derivatives (90a-g, 91a-d) have been found to 
be slightly less active than the parent, whilst glycols (91 e, f) have been found to be 
considerably less active (Table 2.5).7'9
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9 0 » R  = CH 3
9 0bR  = C 2 H, 
90c R = C 3 H7 
9 0dR  = C4 H9  
9 0 e R  = C ,H ,, 
9 0 f R  = C6 H 13 
9 0 g R  = C 7 His
[91aR = (C H 2 )2 0<CH 2 )6 C H 3
91 bR  = (C H 2 )30 (C H 2 ),C H 3
91c R -  (CM2 )40 (C H 2 )4 C U 3
9 1 d R  = (CH 2 )30 (C H i) 3CH 3
91c  R = (C H 2 )20(C M 2 )2 0 (C H 2 )3C H 3
9 l f  R = (C H 2 )30 (C H 2 )2 0(C M 2 )2C H 3
OH OH
Antiviral Activity 
EC50 (fiM)'
Cytotoxicity
(HM)
TK+ VZV TK VZV
YS OKA 07/1 YS MCCb c c 50c
strain strain strain strain
90a 0.045 0.05 >50 >50 200 >200
90b 0.012 0.009 45 >50 >50 >200
90c 0.002 0.002 11 >50 >200 >200
90d 0.0021 0.0015 - - >200 >200
90e 0.001 0.001 3.2 >20 >20 >200
90f 0.0014 0.0015 >5 >20 >20 >200
90g 0.006 0.006 >50 >20 >20 >200
91a 8.1 5.9 >50 >50 200 >200
91b 22 17 >50 >50 200 >200
91c 0.75 0.5 >50 >50 >200 >200
91d 9.3 7.9 >50 >50 >200 >200
91e >200 >200 >200 >200 >200 >200
91f 97 120 >200 >200 >200 >200
85f 0.024 0.008 >50 >50 >50 >50
a) effective concen tration  required to reduce virus plaque form ation by 50%;
b) m inim um  cyto tox ic  concentration  that cause a m icroscopically  detectable alteration o f  
cell m orphology;
c) cytotoxic concen tration  required to reduce cell grow th by 50%.
Table 2.5: antiviral activity against VZV of ether and glycol BCNA derivatives.
The movement of the phenyl ring at the end of the chain (92a,b), with different 
lengths, as well as the introduction of oxygen (92c,d,g-i) or sulphur (92e,f) led to a 
reduction of activity (Table 2.6) .10
50
Marco Derudas Chapter 2
r92a R = (C H 2 )3C H 2Ph 
92b R = (C H 2 )4 C H 2Ph 
92c R = (C H 2)3OPh 
92dR = (C H 2)4O Ph 
92c R = (C H 2)3SPh 
92f R = (C U 2)4SPh 
92g R = (C H 2 ) 3O Ph(M e) 
92HR = (C H 2 )3OPh(Ht) 
92i R = (C H 2 ),O Ph(Pr)
Antiviral Activity 
EC5o (liM)*
Cytotoxicity
(HM)
TKhVZV TK VZV
MCCb CC50cYS
strain
OKA
strain
07/1
strain
YS
strain
92a 26 28 >200 >200 >200 >200
92b 9.2 9.4 >20 >20 50 84
92c 92 77 >200 >200 >200 >200
92d 13 25 >200 >200 >200 >200
92e 0.67 0.90 >50 >50 200 >200
92f - - - - - -
92g 11 5 >50 >50 200 >200
92h 10.8 8.4 >50 >50 200 165
92i 2.8 3.2 >20 >20 >50 >200
85f 0.024 0.008 >50 >50 >50 >50
86f 0.0001 0.0003 >5 >5 >50 >200
a) effective concen tration  required  to reduce virus plaque form ation by 50%;
b) m inim um  cyto tox ic  concentration  that cause a m icroscopically  detectable alteration o f  
cell m orphology,
c) cytotoxic concen tration  required  to reduce cell grow th by 50%
Table 2.6: antiviral activity against VZV of alkyl-aryl, -phenoxy and -thiophenyl
BCNA derivatives.
Alkenyl chains, with a double bond at the a-position and ^-configuration, led to a 
retention of activity in the case of para substitution (95a-c) with respect to the phenyl 
ring, and poor activity in the case of ortho (93a-c) and meta (94a-c) substitution, with 
the meta slightly more active than the ortho (Table 2.7).1 '•12
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HO.
« r = c h 3
94bR = C2H, 
94c R = C3H7
OH
95a R = CH3 
95bR = C2H, 
95c R = C3H7J
L . . ,  . — ............ f  'J
Antiviral Activity 
EC50 (liM)*
Cytotoxicity
(|*M)
TK+ VZV TK VZV
YS OKA 07/1 YS MCCb CC5oc
strain strain strain strain
93a ortho - 12 >50 >50 400 103
93b ortho - 33 >50 >50 400 102
93c ortho - 8.4 >50 >50 80 41
94a meta 58 13 >50 >50 >200 >200
94b meta 2.3 1.9 >50 >50 >20 68
94c meta 1.3 1.1 >50 >50 >200 >200
95a para 0.004 0.004 >50 >50 >50 >200
95b para 0.0006 0.0007 >50 >50 >5 >200
95c para 0.0003 0.0008 >50 >50 >5 >200
86f para 0.0006 0.0005 >50 >50 >50 >200
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration  that cause a m icroscopically  detectable alteration o f  cell m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%.
Table 2.7: antiviral activity against VZV of alkenyl BCNA derivatives.
The substitution of the linear chain with branched chains (96a-g) as well as the use of 
cyclohexyl (96h) showed lower activity (Table 2.8). This lack of activity can be due 
to steric hindrance of the bulky chain or to a different lipophilicity of these 
compounds compared to that of the linear parent.13
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96« R » CH(CHj),
9 6 b R  = CH2CH(CHj)2 
96c R = C H 2 CM 2 C H (C H j ) 2 
9 6 d R  = CH2CH2CH2eH(CH3)2 
96e R = C (C H 3)j 
9 6 f  R = CH2C(CH3)3 
9 6 g R  = C H 2 C H 2 C (C H 3)j 
96 h  R = C6H , |
Antiviral Activity 
ECso (IaM)-
Cytotoxicity
(HM)
TIC* VZV TK VZV
YS OKA 07/1 YS M CCb CC5oc
strain strain strain strain
96a 7.9 6.9 >20 >50 >50 45
96b 0.051 0.048 >200 >2 >200 >200
96c 0.0011 0.0017 >50 >2 >50 >200
96d - >80 >80 - 400 >200
96e >20 >50 >50 >50 >50 >200
96f - >80 >80 - 400 140
96g 0.31 0.33 >80 - >80 >200
96h 3.1 1.4 >20 >20 >20 >200
86f 0.0001 0.0003 >5 >5 >50 >200
a) effective concen tration  required  to reduce virus p laque form ation by 50%;
b) m inim um  cy to tox ic  concen tration  that cause a m icroscopically  detectable alteration o f  
cell m orphology;
c) cytotoxic concen tration  required  to reduce cell grow th  by 50% .
Table 2.8: antiviral activity against VZV of branched BCNA derivatives.
The substitution in the phenyl ring with fluorine (97a, 98a, 99a), chlorine (97b, 98b, 
99b) and bromine (97c, 98c, 99c) gave different results compared to the unsubstituted 
ring (Table 2.9): the para substitution is tolerated for chlorine and bromine, while 
fluorine has been found to be inactive; the meta is tolerated for all three halogens used 
but they are less active than the parent compound; the ortho substitution led to an 
increase of activity for all the substitutions with a slightly better activity for the 
chlorine and bromine.14
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97a R = F 
97b R = Cl 
97c R = Br
98a R = F 
98b R -  Cl 
98c R -  Br
HO.
OH
HO,
OH
Antiviral Activity 
ECso (jiM)a
Cytotoxicity
0*M)
TK* VZV TK VZV
MCCb CC5ocYS
strain
OKA
strain
07/1
strain
YS
strain
97a ortho 0.031 0.04 >20 >20 >20 >200
97b ortho 0.011 0.016 >20 >20 137 >200
97c ortho 0.022 0.013 >5 >5 >5 >200
98a meta 1.5 1.3 200 >200 >200 200
98b meta 2.9 3.0 >20 >20 >20 >200
98c meta 2.0 1.5 >5 >5 >5 36
99a para >50 >50 >50 >50 200 171
99b para 0.08 0.09 >20 >20 >20 >200
99c para 0.2 0.29 >5 >5 >2 96
86a - 0.16 0.28 >200 162 >200 >200
86f para 0.0003 0.0001 >20 >5 >20 >200
a ; t i i v w u v s  v u i i^ iu ia u u ii  i v ^ u i i v u  i u  ivuuvw » h u j  p i a v f u v  l u i n m u v u  - ' v / w ,
b) m inim um  cy totoxic concen tration  that cause a m icroscop ically  detectable alteration  o f  cell m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%.
Table 2.8: antiviral activity against VZV of phenyl halogen BCNA derivatives.
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2.2.2 Modification of the phenyl ring
The substitution of the phenyl ring with a pyridyl ring (100a,b) gave a loss of activity 
(Table 2.9).15
c h 3 c h 3
(H2C)4 (H2C)4
HO.
OH 100a
HO.
Antiviral Activity 
ECso (pM)a
Cytotoxicity
(HM)
TKhVZV TK VZV
YS OKA 07/1 YS MCCb c c 50c
strain strain strain strain
100a - >80 >80 400 >200
100b - 0.1 >50 80 >200
86f 0.0001 0.0003 >5 >5 >50 >200
a) effective concen tration  required  to reduce virus plaque form ation by 50%;
b) m inim um  cyto tox ic  concen tration  that cause a m icroscopically  detectable alteration o f  cell 
m orphology;
c) cytotoxic concen tration  required to reduce cell grow th by 50%.
Table 2.9: antiviral activity against VZV of pyridyl BCNA derivatives.
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2.2.3 Modifications at 7-position
The logical substitutions at the 7-position were the bioisosters of the furano ring: 
pyrrole and thiophene.
The substitution of the furano ring with pyrrole (lOla-d) and N-alkylated pyrrole 
(102a-d) led to a loss of activity (Table 2.10).16
(HaC)/
C H .
101« n = 5 
101bn = 7 
101c n = 9 
1 0 1 d n = II
102a R = Me 
102b R = lit 
102c R = nPr 
102d R = Bu
OH OH
Antiviral Activity Cytotoxicity
EC5o (pM)* (pM)
t k hVZV TK VZV
YS OKA 07/1 YS MCCb CC5oc
strain strain strain strain
101a >50 >50 >50 >50 >50 >50
101b 0.38 0.15 >50 >20 20 >50
101c >2 >2 >20 >20 >20 >200
lOld 14 3.7 76 31 >200 >200
102a 8 6 >50 >50 >20 >50
102b >5 >5 >80 >5 >5 20
102c >5 >5 >80 >5 >5 20
102d 7.0 7.1 >20 >50 23 200
85f 0.024 0.008 >50 >50 >50 >50
a) effective concen tra tion  required to reduce v irus plaque form ation  by 50%;
b) m inim um  cyto tox ic  concen tration  that cause a m icroscopically  detectab le  alteration o f  
cell m orphology;
c) cytotoxic concen tration  required to reduce cell grow th by 50%.
Table 2.10: antiviral activity against VZV of N-7 BCNA derivatives.
The replacement of the furano ring with a thiophene ring gave retention of activity in 
the case of the alkyl side chain (103a-f),17 while in the case of the alkylphenyl side 
chain (104a-g) it gave reduction of activity (Table 2.11).18
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103* n = 3 
103bn = 5 
103c n = 7 
103dn = 8  
103e n = 9 
103f n = 11
(H2C)n'
CH,
CH.
HO.
OH
104a n = 1 
104bn = 2 
104c n = 3 
104d n = 4 
104en = 5 
104f n = 6 
104g n = 7
Antiviral Activity 
EC5o (liM)a
Cytotoxicity
0*M)
t k hVZV TK VZV
YS OKA 07/1 YS MCCb CC50c
strain strain strain strain
103a 0.15 0.16 >200 157 >100 >200
103b 0.14 0.14 >50 >50 125 >200
103c 0.005 0.002 >5 >5 20 53
103d 0.01 0.01 >20 >20 >20 >20
103e 0.06 0.03 >5 >5 20 54
103f 0.3 0.2 >5 >5 18 49
104a 0.15 0.2 20 - >200 >200
104b 0.06 0.09 >16 - 80 >200
104c 0.02 0.028 >3.2 - 50 >200
104d 0.014 0.025 20 - 50 >200
104 c 0.043 0.08 >50 - 200 >200
104f 0.18 0.27 >20 - 50 >200
104g 3.4 - >20 - >20 >200
85f 0.0003 0.0001 >5 - >20 >200
a) efTective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration  that cause a m icroscopically  detectable alteration o f  cell 
m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%.
Table 2.11: antiviral activity against VZV of S-7 BCNA derivatives.
Chapter 2
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2.2.4 Modification at 5-position
The only substitution at the 5-position has been done with the BCNA bearing the 
alkyl chain (C10H2O. This substitution included a phenyl ring or para-substituted 
phenyl ring (105a-i), which led to a considerably decreased in the anti-VZV activity 
(Table 2.12).19
105a R = H 
105b R = CH,
105c R = CH2CH, 
105d R = CH(CH,)2 
105e R = COCH, 
105f R = CF,
105g R = OCH,
105h R = NHCOCF, 
105i R = NH2
Antiviral Activity 
EC50 (pM)a
Cytotoxicity
(M'M)
TK" VZV TK VZV
YS OKA 07/1 YS MCCb CC50c
strain strain strain strain
105a >5 >5 >5 >5 20 37
105b 9 9 >5 >5 >20 89
105c >20 >20 >20 >20 50 >200
105d >5 >5 >5 >5 20 >200
105e 5 8 >50 >50 200 >200
105f >20 >20 >20 20 50 >200
105g 4.4 6.7 - >20 >20 >200
105h >200 >50 >50 >50 >200 >200
105i 3.7 4.0 - 8.1 >50 67
85h 0.008 0.015 >50 >50 >50 >50
a) effective concen tration  required to reduce virus plaque form ation by 50%;
b) m inim um  cyto tox ic  concentration  that cause a m icroscopically  detectable alteration o f  
cell m orphology;
c) cytotoxic concen tration  required to reduce cell grow th by 50%.
Table 2.12: antiviral activity against VZV of 5-substituted BCNA derivatives.
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2.2.5 Sugar modifications
A major effort in the SAR studies of BCNA has been directed towards the sugar 
moiety. These modifications have been done to improve the activity but also to clarify 
the mechanism of action of this new class of compounds.
2.2.5.1 Modifications at the 2’-position
The introduction of hydroxyl group at the 2’-position, as ribo sugar (106a) or arabino 
sugar (106b), in the octyl derivative, led to a loss of activity (Table 2.13) showing 
that these modifications in this position are not tolerated.7
c h 3
(H2C)7
HO.
O
OH OH
106a 106b
Antiviral Activity 
EC50 (pM)*
Cytotoxicity
0*M)
TK VZV TK VZV
YS OKA 07/1 YS MCCb c c 50c
strain strain strain strain
106a 21 23 >20 >20 50 >50
106b 3.3 3.6 - - - >20
85f 0.024 0.008 >50 >50 >50 >50
a) effective concen tration  required to reduce virus plaque form ation by 50%;
b) m inim um  cy to toxic concentration  that cause a m icroscopically  detectable alteration o f  cell m orphology,
c) cyto toxic concentration  required to reduce cell grow th by 50%.
Table 2.13: antiviral activity against VZV of 2’-modified BCNA derivatives.
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2.2.5.2 Modifications at the 3’-positions
The 3’-modifications made include (Table 2.14):
- the 3’-deoxy derivative (107) which led to a loss of the anti-VZV activity but 
surprisingly these compounds gained anti-HCMV activity;20
- the d4 derivative (108) which was found to be completely inactive;
- the substitution of the alpha hydroxyl at the 3’-position with the beta hydroxyl (109) 
as well as the substitution with fluorine (110a) and chlorine (110b) led to a loss of 
activity.21*23
These results indicate that the 3’-OH plays a crucial role in the anti-VZV activity.
c h 3
(H2C)4
c h 3 
(h 2C)9
HO.
HO 109
110a R = F 
HObR = Cl
Antiviral Activity 
EC50 (\xMy
Cytotoxicity
(M-M)
t k hVZV TK VZV
YS OKA 07/1 YS MCC b CC50c
strain strain strain strain
107 20 40 >200 >50 >200 >200
108 >50 >50 >50 >50 200 16
109 >20 24 >50 >50 >50 >22
110a >2 >2 >2 >2 - 5.2
110b - >20 >5 - >200 >200
86f 0.0001 0.0003 >5 >5 >20 >200
a) effective concen tration  required to reduce virus plaque form ation by 50%;
b) m inim um  cy totoxic concentration  that cause a m icroscopically  detectable alteration o f  cell 
m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%.
Table 2.14: antiviral activity against VZV of 3’-modified BCNA derivatives.
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2.2.5.3 Modifications at the 5’-positions
A series of modifications has been done to the 5’-position (Table 2.15). The 5’-deoxy 
(111) as well as the 5’-Cl (112) led to a loss of activity indicating the fundamental 
role of this position in the antiviral activity of BCNA presumably due to a need for 5’- 
phosphorylation as confirmed by VZV-TK dependency.23,24
c h 3
(H2C)4
c h 3
(H2C)4
H ,c
OH 111 OH 112
Antiviral Activity 
EC5o (M-M)*
Cytotoxicity
0*M)
TKhVZV TK VZV
YS OKA 07/1 YS MCCb c c 50c
strain strain strain strain
111 >5 >5 >5 >5 20 95
112 3.3 >5 >5 20 >50
86f 0.0001 0.0003 >5 >5 >20 >200
a) effective concen tration  required to reduce virus plaque form ation by 50%;
b) m inim um  cy totoxic concentration that cause a m icroscopically  detectable alteration o f  
cell m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%
Table 2.14: antiviral activity against VZV of 5’-modified BCNA derivatives.
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2.2.5.4 Substitution of the sugar moiety
The substitution of the deoxyribose with an acyclic sugar (113) led to a loss of 
activity compared to the parent compound (Table 2.15).25
The substitution of the sugar with a carbocycle (114), which is usually well tolerated, 
led to a loss of activity (Table 2.15).26 From these results it is clear that substitution at 
the sugar moiety is detrimental to the anti-VZV activity.
c h 3
(H2C)4
HO.
1 1 4OH
Antiviral Activity 
EC50 (liM)a
Cytotoxicity
(HM)
TKhVZV TK VZV
YS
strain
OKA
strain
07/1 YS 
strain strain
MCC b c c 50c
113 - 11 >10 >80 >200
114 0.28 0.49 >50 >20 >50
86f 0.0001 0.0003 >5 >5 >20 >50
a) effective concen tration  required  to reduce virus plaque form ation by 50%;
b) m inim um  cy totoxic concen tration  that cause a m icroscopically detectable alteration o f  
cell m orphology;
c) cytotoxic concen tration  required  to reduce cell grow th by 50%.
Table 2.14: antiviral activity against VZV of sugar-modified BCNA derivatives.
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2.2.6 Summary of SAR for BCNAs
Chapter 2
Chain modification:
- terminal halogen substitution = retention o f activity
- terminal unsaturation = poor activity
- ether = lower activity
- glycol = loss o f activity
- terminal phenyl = lower activity
- para double bond 1,2-position = retention
- ortho/meta double bond 1,2-position = lower activity
- branched chain/cyclohesyl = lower activity
- halogen substitution in the ring = lower activity
Ring sustitution:
- ortho = tolerated
- meta = poor activity
- pyridyl ring = poor activity^
V
R
7-modification:
- N = lower activity
- S = lower activity
- S = retention in the absence
of the phenyl ring
r
5-modification:
- phenyl ring = lower activity
f  " 1........ ...
5'-modification:
- 5'-Cl = poor activity Sugar modification:
- acyclo = poor activity
- carbocycle = poor activity ^
f------
- 5'-deoxy = poor activity^
r ;---------
2'-modification:
3'-modification: - ribo and ara sugar = poor activity^
- 3'-F and 3'-Cl = poor activity
- d4 = poor activity
-2',3'- dideoxy = No VZV activity
HCMV activity ^
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2.3 Mechanism of action of BCNAs
The mechanism of action of this new class of compounds is not completely 
understood. The total lack of activity in the TK deficient VZV-strain suggests an 
obligatory phosphorylation mediated by VZV-TK. This step is mediated specifically 
by the VZV-TK; in fact when incubated with either HSV-TK or cellular TK no 
phosphorylated BCNA metabolites, mono- or diphosphate, have been detected.28 The 
lack in activity found for the 5’-deoxy and halogen derivatives indicates the need of 
the 5’-OH for the antiviral activity. Moreover, the 3’-OH is also fundamental for the 
activity as modifications in this position gave loss of activity. With regard to the alkyl 
chain, its length is critical for the activity and its variation led to a consistent variation 
of the anti-VZV activity. The possible mechanism of action so far hypothesized is 
probably the inhibition of the VZV-polymerase by the triphosphate form of BCNA.
2.4 ProTides of the BCNA lead compound
In order to investigate the mechanism of action of the BCNA lead compound 86f a 
series of ProTide has been synthesized. These compounds have been made with the 
aim to understand if the second step of phosphorylation is mediated by VZV-TK or 
by cellular kinases as this technology is able to bypass the first step by delivering the 
monophosphate into the cell.
Initially a series of 5’-phosphoramidate (Table 2.16, 115a-l) of 86f  have been made. 
However, during the synthesis 3’,5’-diphosphoramidate (116a-c) were isolated and 
biologically evaluated.27
Table 2.16 shows the biological activity for compounds 115a-l and 116a-c. 
Although, these compounds have been found to be less active than the parent 86f, 
they still retain a good potency, which is higher than ACV. A possible explanation of 
these results could be that the phosphorylation mediated by VZV-TK is more efficient 
than the activation of the phosphoramidate. Moreover, the lack on activity in TK- 
deficient strain indicates that the second step of phosphorylation is probably still 
mediated by VZV-TK.
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c h 3
(H2C)4
c h 3
(H2C)4
O -P -O .
X OH
O -P -O
NH
:• M f  9 7 e ; R
O 0 = P -N —^
o > Q
116a-c
Cpds R R ’ X
Antiviral Activity 
EC5o (pM)*
Cytotoxicity
(M-M)
TK+
OKA
strain
VZV TK VZV 
YS 07 
strain strain
MCCb CCsoc
115a Me H Me 0.031 0.024 > 16 80 41.5
115b Me H Et 0.010 0.009 > 16 80 21
115c Me H nPr 0.0066 0.0046 >3.2 16 9
115d Me H 'Pr 0.029 0.014 >3.2 16 9.3
115e Me H *Bu 0.473 0.485 >3.2 16 8.6
115f Me H Bn 0.0067 0.0072 >3.2 80 34
115g Me Me Me 0.100 0.230 15 >20 >50
115h Me Me Et 0.036 0.045 > 4 > 4 27
115i Me Me Bn 0.010 0.024 > 4 > 4 26
115j Bn H Me 0.015 0.032 > 4 20 24
115k Bn H Et 0.016 0.036 > 4 20 12
1151 Bn H Bn 0.010 0.020 > 4 20 20
116a Me H Me 0.43 - > 100 > 100 > 100
116b Me H nPr 0.040 0.030 >40 >40 >20
116c Me H 'Pr 0.180 0.118 >40 >40 >50
ACV - - - 2.9 1 74 >200 >200
86f - - - 0.0003 0.0001 >5 >50 >200
a) effective concentration required to reduce virus plaque form ation by 50%;
b) minimum cytotoxic concentration that cause a m icroscopically  detectable alteration o f  cell m orphology;
c) cytotoxic concentration required to reduce cell grow th by 50%.
Table 2.16: biological results o f BCNA ProTides 115a-l and 116a-c.
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Interestingly, the diphosphoramidates 116a-c still showed some antiviral activity and 
these results suggested to synthesize a series of 3’-phosphoramidate (Table 2.17, 
117a-e).27
ch3
(H2C)4
HO.
9 H R
0 = P - N — \
1 1 7 a -c
Antiviral Activity Cytotoxicity
ECso (nM )a 0*M)
TK+ VZV TK VZV
Cpds R X
OKA
strain
YS
strain
07
strain
MCC c c 50c
117a Me Me 0.011 0.0094 >20 >5 >50
117b Me Et 0.015 - >100 - -
117c Me Bn 0.005 0.0059 >20 >20 >50
117d Bn Me 0.0041 0.005 >20 >20 >50
117e Bn Et <0.009 <0.032 >20 >20 >50
ACV - - 2.9 1 74 >200 >200
86f - - 0.0003 0.0001 >5 >50 >200
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration  that cause a m icroscopically detectable alteration o f  cell m orphology;
c) cyto toxic concentration  required to reduce cell grow th by 50%.
Table 2.17: biological results of 3’-phosphoramidates 117a-e and ACV and 86f  as 
control.
The activity showed by the 3’-phosphoramidates 117a-e is comparable with that of 
the 5’-phosphoramidates. This result is not easy to interpret; an explanation could be 
that inside the cell the 3’-phosphoramidate is metabolised to the monophosphate form 
and then converted to 86f and at this point it is phosphorylated at the 5’-position by
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VZV-TK or it is possible that the phosphate moiety migrates from the 3’-position to 
the 5’-position.27
2.5 FV100: the valyl prodrug derivative of the lead compound Cfl743
As mentioned before, the high selectivity and no-toxicity of Cfl743 promote its 
development as potential new anti-VZV drug. However, the lipophilicity of this 
compound, although fundamental for the activity, implies very low water solubility. 
In order to improve the poor bioavailability of this compound, different prodrugs have 
been considered (Fig. 2.3), such as the tripeptide Val-Pro-Val (118), the valyl ester 
(119) and the monophosphate (120).29 
c h 3
(H2C)4
Val-Pro-ValO. H,C,
OH 118
H O -P -O
OH 119
Fig. 2.3: prodrugs of BCNA lead compound Cfl743.
OH 120
Pharmacokinetic studies showed the best results for the tripeptide Val-Pro-Val, for 
which the bioavailability was increased 20 fold more than the parent compound. For 
the valyl ester prodrug was increased 10 fold compare to the parent compound. The 
monophosphate prodrug instead did not show any significant improvement.
In spite of its higher bioavailability, the tripeptide prodrug has been discarded due to 
synthetic cost. The valyl ester has been chosen as prodrug of Cfl743 for its lower 
synthetic cost and for its efficacy showed with acyclovir (as valacyclovir)30 and 
ganciclovir (as valganciclovir).31
In order to increase the water solubility of (119), the hydrochloride salt has been 
made, raising the solubility from 0.02 mg/mL to 0.49 mg/mL with an enhancement of 
490 times. The antiviral activity for this compound, called FV-100, against VZV 
strain was 3 fold higher that the parent compound.
FV-100 has successful conclude phase I of clinical trial and it is currently on phase II.
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3. Understanding the mechanism of action of BCNA
The mechanism of action of BCNA is not, as already mentioned in Chap. 2, fully 
understood. BCNAs probably need to be phosphorylated as previously described in 
the TK-deficient strains completely lose their activity. Moreover, the 3’- and 5’- 
positions play a crucial role in the activity of this compound. In fact, all the 
modifications done at these positions led to a decrease of activity. Interestingly, the 
application of the ProTide technology did not improve the activity of 86f, but the loss 
of activity in the TK-deficient strains, may indicate that VZV-TK mediates also the 
second step of phosphorylation. Furthermore, the activity found for the 3’-ProTide is 
quite unusual and needs to be further investigated.
In this chapter the synthesis of a series of compounds in order to investigate the 
mechanism of action of BCNA will be described.
3.1 5’-modification of the BCNA lead compound
In order to understand the function of the 5’-OH and to obtain a suitable bioisostere 
for the synthesis of 5’-deoxy-3’-phosphoramidate of the lead compound 86f, the 5’- 
iodo derivative was synthesised.
The general synthesis of BCNAs involves coupling of 5-iodo-2’-deoxyuridine with 
the appropriate alkyne using palladium as the coupling agent, copper (I) iodide and a 
base for the further cyclization.1 The problem in this synthetic route is the purification 
by column chromatography which is followed by a trituration with an organic solvent. 
A new synthetic route, removing the column chromatography purification has been 
studied in order to obtain 86f.2
Scheme 3.1 reports the synthesis of 86f. 5-iodo-2’-deoxyuridine 121 was dissolved in 
anhydrous dimethylformamide (DMF), followed by addition of: (4-pentylphenyl) 
acetylene, tetrakis(triphenylphosphine)-palladium(0) (tetrakis Pd(PPh3)4), copper (I) 
iodide (Cul) and anhydrous diisopropylethylamine (DIPEA). The reaction was stirred 
at room temperature overnight. Copper (I) iodide and anhydrous triethylamine (TEA) 
were added and the reaction was strirred at 85 °C for 7 h. After cooling, the solvent 
was removed and the residue was triturated with dichloromethane (DCM). The solid 
was filtered to give compound 86f as pure product without further purification. 
Notably, this procedure is currently used in the scale up synthesis of this compound.
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HO
o
'V ^ nh
.0 
o h "  121
NH
HO.
OH
CH3
(H2C)4
OH 86f, 63%
R eagents an d  C o n d itio n s : (/)  (4 -p e n ty lp h e n y l)a c e ty le n e , T e tra k is  P d (P P h 3)4, C u l, D IP E A , d ry  D M F , rt, o v e rn ig h t, 
then C u l, d ry  T E A , 85  °C , 7 h.
Scheme 3.1: synthesis of the lead compound 86f.
For the synthesis of the desired 5’-iodo derivative different routes have been taken. 
Firstly, the direct iodination at the 5’-position under Mitsunobu condition using iodine 
and triphenylphosphine gave only a trace of the desired compound contaminated with 
triphenylphosphine. A different synthetic pathway was then performed (Scheme 3.2).
c h 3
(H2C)4
c h 3
(H2C)4
,c h 3
(H2C)4
c h 3
(H2C)4
TBDMSO i i  HO
OTBDMS
122, 95%
OTBDMS
1 2 3 ,8 3 %
i n
126,61%
c h 3
(H2C)4
c h 3
(H2C)4
h3c o 2s o /v H3C 0 2SO
OH
125,70%
OTBDMS 
124, 66%
Reagents and  C o n d itio n s : (/') T B D M S C I, im id a z o le , an h y d ro u s  p y rid in e , rt, 2 h; ( //) IF  A /W a te r / l l  IF (1 /1 /8 ) , 0 °C , 
2 h; ( i i i) m e th a n e su lfo n y l c h lo r id e , a n h y d ro u s  p y rid in e , rt, 20  h; (/v ) T FA A T H F /W ater (1 /2 /4 ) , rt, 2 .5  h; (v) N a l, 
acetone, reflux .
Scheme 3.2: synthesis of 5’-iodo derivative of 86f.
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The 3’ and 5’-positions were protected using tetrabutyldimethylsilyl chloride 
(TBDMSC1) in the presence of imidazole to give 122, followed by selective 
deprotection of the 5’-OH using trifluoroacetic acid (TFA) in water and 
tetrahydrofuran (THF), in a ratio of 1/1/8, at 0 °C to get 123 (this synthetic route will 
be described in Chap. 5). Compound 123 was then mesylated using methanesulfonyl 
chloride in anhydrous pyridine giving 124, followed by 3’-deprotection of the 
TBDMS group to provide 125, which has been tested as a prodrug of 86f. Compound 
125 was then treated with sodium iodide in acetone under reflux to give the final 
product 126.
3.2 Biological evaluation of 5’-derivatives of BCNA lead compound
125 and 126 have been evaluated for their ability to inhibit VZV (Table 3.1).
Antiviral Activity Cytotoxicity
EC50 (pM)* (fiM)
TK+ VZV TK' VZV
______________ K ________«
Compounds OKA strain 07/1 strain
MCC c c 50l
125 >20 - >100 >100
126 0.97 6.8 >50 31.2
86f 0.0003 >20 >20 >200
ACV 3.5 74 1778 796
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cyto tox ic  concentration  that cause a m icroscopically detectable alteration o f  
cell m orphology;
c) cytotoxic concentration  required to reduce cell growth by 50%.
Table 3.1: anti-VZV activity for compounds 125 and 126 including 86f and ACV as 
reference.
125 has been found to be inactive, as already seen for the 5’-chloro and 5’-deoxy 
derivatives (Chap. 2). Interestingly, 126 has been found to be active in the sub-pM 
range (0.97 pM VZV-OKA strain) and also it showed some activity against VZV-TK 
deficient strain (6.8 pM VZV-07/1 strain). However, its apparent antiviral activity 
may be simply cytotoxicity (C C 50  = 31 pM).
Due to synthetic problems, the 5’-deoxy derivative of 86f was selected as an 
intermediate for the synthesis of the 3’-ProTides of the 5’-deoxy derivatives of 86f.
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3.3 Synthesis of the 5’-deoxy derivative of the BCNA lead compound
Initially, the procedure already described for the synthesis of 111 was used. The first 
step of the synthesis was the reaction of 86f with 2-mercaptopyrimidine in the 
presence of N,N-dimethylformamide dineopentylacetal followed by reduction with 
Raney-Nickel providing 111.3 However, due to a low overall yield (11%) for this 
route, a different strategy has been considered (Scheme 3.3).
2’-Deoxyuridine 127 was coupled with 2-mercaptopyrimidine in the presence of N,N- 
dimethylformamide dineopentylacetal, giving 128, followed by reduction in ethanol 
using Raney-Nickel as catalyst providing 129.4 Compound 129 was then selectively 
iodinated at the 5-position using iodine and cerium (IV) ammonium nitrate (CAN) in 
acetonitrile at reflux giving 130.5 The last step involved the coupling of the base with 
(4-pentylphenyl)acetylene under standard conditions to give the desired compound
111. The overall yield for this new synthetic route is 26% compared to 11% 
previously described.
ot
HCL
NH 
N^O
OH 127
( X
* N O
U
£
H,C
OH 128,84%
NH 
N^O
OH 129,63%
c h 3
(H2C)4
H,C
OH 111,63% OH 130,83%
R eagents and  C o n d itio n s : (/) 2 -m e c a p to p y rim id in e , N ,N -d im e th y lfo rm a m id e  d in e o p e n ty la c e ta l, a c e to n itr ile , re flu x , 
4 h; (/'/) R a n e y -N ic k e l, e th a n o l, re f lu x , 2 h; (Hi )  I2, C A N , ace to n itr ile , re flu x , 1.5 h; ( i v )  (4 -p e n ty lp h e n y l)a c e ty le n e , 
T etrakis P dfPPh;?)^  C u l, D IP E A , d ry  D M F , rt, o v e rn ig h t, then  C u l, d ry  T E A , 85 °C , 7 h.
Scheme 3.3: synthesis of 5’-deoxy derivative of our lead compound 86f.
3.4 General synthesis of arylphosphorochloridates
The general synthesis of arylphosphorochloridate (Scheme 3.4) involves coupling of 
the appropriate aryldichlorophosphate with the appropriate amino acid ester using 
anhydrous TEA as a base. Phenyldichlorophosphate is commercially available, whilst
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the naphthyl and p-fluorophenyl derivatives were obtained by coupling of 1-naphthol 
or p-fluorophenol with POCI3 using anhydrous TEA as a base.
0 / Ar°  % R ^ r '^ / R//°
Ar'0H + c r ^ 'o i    0-P -C I+  * h , n V ' r-— iJ— Ar s  r \
Cl C l °  Cl X- o  O -P -N H  O -R "
Cl
Reagents and Conditions: (/) anhydrous TEA, anhydrous Et20 , -78 °C, 1 h, then rt, overnight; (//) anhydrous TEA, 
anhydrous DCM , -78 °C, 1 h, then rt, 2h.
Scheme 3.4: general synthesis of phosphorodichloridates and phosphorochloridates.
The arylphosphorodichloridate were obtained as oil and used without further 
purification. The arylphosphorochloridates were usually purified by filtration through 
silica gel column chromatography or used as a crude in the next step and they were 
obtained as pale yellow oil. In the case of chiral amino acids, such as L-alanine, 
phosphorochloridates were obtained as a mixture of two diastereoisomers, which were 
detected in the 3IP-NMR exhibiting the presence of two peaks.
3.5 Synthesis of the 5’-deoxy-3’-phosphoramidate of the BCNA lead 
compound
Coupling between compound 111 and the appropriate phosphorochloridate (131a-c) 
(Scheme 3.5) was performed using 1-methylimidazole (NMI) as the coupling reagent 
following the Van Boom procedure.6
c h 3 
(H2C)4
o
C I - P - 0
NH
OH 111
N O +
H3C
0  131a-c
H3C 132a: R = M e, R1 = M e, 13% 
132b-d: R = M e, R’ = Et, 22%  
O  u  r  132e: R = H , R1 = M e, 3% 
0 = P - N - (  R'
o >-o
O
Reagents and Conditions: (/) anhydrous N M I, anhydrous THF, rt, overnight.
Scheme 3.5: synthesis of phosphoramidates of compound 111.
The desired compounds were obtained as a mixture of the two diastereoisomers 
confirmed by the presence of two signals in 31P NMR (in the range of 2.7 and 4.4
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ppm). In the case of the ethyl ester derivative, the two diastereoisomers, after 
purification using preparative TLC, were isolated (132b,c) and one fraction was 
obtained as a mixture (132d). The structures of these compounds were confirmed by 
NMR spectroscopy (!H, 13C and 31P NMR) and mass spectroscopy; whilst the purity 
was confirmed by elemental analysis.
3.6 Biological evaluation 5’-deoxy-3’-phosphoramidates of BCNA lead 
compound
The synthesised compounds 132a-e were evaluated for their ability to inhibit the 
replication of VZV.
Antiviral Activity 
EC50 (pM)a
Cytotoxicity
(pM)
TK+ VZV TK VZV
MCCb CC50cCompounds OKA
strain 07/1 strain
132a >20 >20 100 52.8
132b >20 >20 100 56.8
132c >20 >20 100 >100
132d >100 >20 >100 >100
132e >20 >20 100 70.3
86f 0.0003 >20 >20 >200
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cyto tox ic  concentration that cause a m icroscopically  detectable alteration o f  
cell m orphology;
c) cytotoxic concentration  required to reduce cell growth by 50%.
Table 3.2: biological results for compounds 132a-e.
The compounds did not show any activity against VZV (Table 3.2). These results 
support the hypothesis that the activity of BCNA involves a 5’-phosphorylation and it 
does not involve a 3’-phosphorylation or could involve phosphorylation of both 
positions. The activity found for the 3’-ProTides compounds 117a-e can be due to a 
migration of the phosphate moiety from the 3’-position to the 5’-position and this 
migration may help during the activation of the ProTide to release the monophosphate 
form. Another hypothesis is that these compounds act as a prodrug releasing the 
parent nucleoside 86f, which will then be phosphorylated by VZV-TK.
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3.7 Attempt to synthesise mono-, di-, tri- and bisphosphate of BCNA lead 
compound
The next step, in order to elucidate the mechanism of action of BCNA, was the 
synthesis of the possible metabolites of 86f and this includes the synthesis of the 
mono-, di-, tri and bisphosphate. These compounds will then be used as a standard 
reference during the characterization of the metabolites obtained in in vivo 
experiments.
3.7.1 Synthesis of the monophosphate of BCNA lead compound
The monophosphate 120 was synthesised by coupling between 86f and POCI3 in 
triethylphosphate (Scheme 3.6) under Yoshikawa conditions following the procedure 
already described for this compound.2
Reagents and Conditions: (/) POCl3, triethylphosphate. 0 °C, 2.5 h, then 0.4 M  aqueous solution of NH4HCO3.
Scheme 3.6: synthesis of the monophosphate.
The poor yield obtained for this compound is probably due to the relative instability 
of BCNA. In fact, the release of hydrochloric acid during the reaction could cleave the 
glycosidic bond of the compound, which is quite acid labile.
3.7.2 Attempt to synthesise the diphosphate of BCNA lead compound 
Scheme 3.7 reports the synthesis of the diphosphate 133 which involves a 
nucleophilic displacement of the 5’-mesyl group of 125 by the tri(tetra-n-
•j
butylammonium) hydrogen pyrophosphate.
(H2C)4 (H2C)4
HO
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c h 3
(h 2C)4
h 3c o 2s o
OH 1 2 5
c h 3
(H2C)4
o o
H O - P - O - P - O  
OH OH
OH 1 3 3
Reagents and Conditions: (/) anydrous acetonitrile, tris-(tetra-n-butylammonium)hydrogen pyrophosphate, rt, 1 day.
Scheme 3.7: attempt to synthesize the diphosphate of 86f.
No desired compound was isolated due to problem during the purification and 
probably to the poor stability of this compound.
3.7.3 Attempt to synthesise the triphosphate of BCNA lead compound
For the synthesis of the triphosphate 135, two different routes have been considered. 
The first route considered (Scheme 3.8) was the activation of the monophosphate 
using l , l ’-carbonyldiimidazole to get compound 134 followed by attack of the 
pyrophosphate to give the desired triphosphate as the ammonium salt after quenching 
the reaction with an aqueous solution of ammonium bicarbonate.8
(H2C)4
o
OH 12 0
y n 3
(H2C)4
OH 134
V n 3
(H2C)4
n h 4+ 0  0  0
O -P -O -P -O -P -O
O- O- O' 1 ^ ° ^
n h 4+ n h 4+ n h 4+ N —
OH 135
Reagents and Conditions: (/) 1 .l'-carbonyldiimidazole, anhydrous DM F, rt, 4 h; (//') MeOH, rt, 30 min; then 
tributylammonium pyrophosphate, rt, 24 h; then 0.4 M NH4HC03 , 10 min.
Scheme 3.8: first attempt to synthesise the triphosphate of 86f.
The second route (Scheme 3.9) used was the “one-pot-three-step” reaction starting 
from the parent 86f, which was converted to the intermediate 137 using 2-chloro-4H- 
l,3,2-benzodioxaphosphorin-4-one 136 as phosphorylating agent. Compound 137 was 
then opened by the attack of the pyrophosphate with the displacement of the carbonyl 
group followed by cyclisation with the release of the phenolic group to obtain the
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cyclic derivative 138. This intermediate is then oxidized by addition of iodine to 
obtain the triphosphate, which is converted to the ammonium salt after the addition of 
concentrated ammonia.9
This procedure did not succeed probably due to a lack of reactivity in the first step as
mainly starting material was observed on TLC. This could be due to a poor reactivity
of BCNA due to the high lipophilicity of this compound compared to other NAs.
c h 3 
(h 2C)4
HO.
1 3 6
-X-
Cl
, P - 0 .
c h 3
(H2c ')4
n h 4+ o  o  
o - p - o - p - o - p - o
oIt
III
O' O- O- 
N H ,+ N H .+ N H ,+ >-------
OH 1 3 8OH 13 5
Reagents and Conditions: (/) anhydrous pyridine, anhydrous dioxane, anhydrous DM F, rt, 20 min; (ii) bis(tri-n- 
butylammonium)pyrophosphate, anhydrous D M F, anhydrous tributylamine, rt, 10 min; (Hi) 1% solution of iodine 
in a mixture of pyridine/water (98/2), then 5% aqueous solution of thiosulphate, water and conc. ammonia.
Scheme 3.9: second attempt to synthesize the triphosphate of 86f
3.7.4 Attempt to synthesise bisphosphate of BCNA lead compound
Another potential metabolite of 86f could be the bisphosphate (139, Scheme 3.10). In 
fact, from an analysis of the metabolism of a radiolabelled sample of 86f incubated 
with cells that are TK deficient but VZV-TK efficient, performed by Prof Jan 
Balzarini at the Rega Institute, Leuven, Belgium an unknown peak on the HPLC was 
observed. From this experiment, the formation of the monophosphate form as well as 
the glycosidic bond cleavage was noted. However, a peak close to the triphosphate 
form was observed indicating a formation of a polar product, which, however, seems
8 0
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not to have a phosphorus-oxygen-phosphorus linkage as it appeared to be insensitive 
to phosphodiesterase. A possible compound could be the 3’,5’-bisphosphate.
Different strategies have been used for the synthesis of this compound.
The first route used (Scheme 3.10) was the same used for the synthesis of the 
monophosphate, starting from the parent 86f using an excess of POCI3 and using 
triethylphosphate as a solvent in one case or anhydrous pyridine. Initially, the 
compound was purified by silica gel column chromatography and the appropriate 
fractions were collected.
0 = P -0 -  n h 4+
O- n h 4+
Reagents and Conditions: (/) P0C13, triethylphosphate or anhydrous pyridine, 0 °C, 3-6 h, 
then 0.4 M aqueous solution o f N H 4H C 0 3.
Scheme 3.10: first attempt to synthesise the 3’,5’-bisphosphate of 86f.
Mass spectrometry (El) data showed two peaks: one corresponding to the free base, 
meaning that the BCNA is not stable under these conditions due to the release of HC1, 
and another peak corresponding to the sugar bisphosphate. This result indicates that 
this compound could be unstable.
The second route (Scheme 3.11) used to synthesised compound 139 was to use of 2- 
cyanoethyl phosphate as the phosphorylating reagent. The presence of an alkyl chain 
in the phosphate moiety could help in the purification step with the derivative being 
more lipophilic and more stable. For the synthesis, 86f was coupled in the presence of 
dicyclohexylcarbodiimide (DCC) with 2-cyanoethylphosphate, which was obtained 
from the commercially available barium salt form which was converted to the free 
form by washing through a column of Dowex 50 [H+] resin.10 The deprotection step 
could be performed by refluxing the ester phosphate derivative in 0.1N NaOH,10 but 
in this condition BCNAs have been found to be unstable. Another method is the use
c h 3
(H2C)4 (H2C)4
o
n h 4+ o
N O
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of l,8-diazabicycloundec-7-ene (DBU). The starting material disappeared from the 
TLC but the compound isolated showed no phosphorus in 31P-NMR.
c h 3
(h 2C)4
c h 3
(H2C)4
c h 3
(H2C)4
H O -P -O
0 = P - 0
n h 4+ - O -P -O  
o
NH
OH 8 6 f
D-
V  S
o  139
0 = P - 0 -  n h 4+
O- n h 4+
Reagents and Conditions: (/) anydrous pyridine, solution of 2-cyanoethylphosphate in anhydrous pyridine, DCC, rt, 
44 h; (//) DBU, anhydrous THF, 1.5 h, rt.
Scheme 3.11: second attempt to synthesise the 3’,5’-bisphosphate of 86f.
The third route used (Scheme 3.12) to synthesise the 3’,5’-bisphosphate was the 
degradation of the 3 \5 ’-diphosphoramidate of 86f. Compound 141 was obtained by 
coupling between the parent 86f and the phenyl-(methoxy-glycinyl)- 
phosphorochloridate using tert-butylmagnesium chloride (‘BuMgCl) as a coupling 
reagent following Uchiyama condition.11 The phosphoramidate obtained was 
degraded using basic and acid conditions and the reaction was followed by 31P- 
NMR.12
CHj
(H2C)4
. C H j
(H2C)4
c h 3
(H2C)4
OH 8 6 f
O -P -O ,
NH O
141
0 = P - N
OCH3
OH
o  1 3 9
0 = P - 0 H
OH
Reagents and Conditions: (/) Phenyl-(methoxy-glycinyl)-phosphorochloridate, anhydrous THF. anhydrous pyridine, 
‘BuMgCl, rt, overnight; (ii) MeOD, 0.1 M NaOH, 4.5 h, 45 °C, then 0.1 M HCI, rt, 30 min.
Scheme 3.12: third attempt to synthesize the 3 \5 ’-bisphosphate of 86f
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The starting material showed peaks (6 = 4) at 3IP-NMR. The basic conditions 
hydrolysed the ester followed by displacement of the phenyl ring and in the 3IP-NMR 
a peak at (6 = 7) was observed. In acidic condition, the cleavage of the phosphorus- 
nitrogen bond was observed with the release of the monophosphate, which was 
observed in the 3IP-NMR (6 = 0). However, during purification by preparative HPLC 
the desired compound was not recovered but only the products of degradation. 
Although promising, this synthetic route was not further investigated due to time 
constraints.
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3.8 Photoaffinity labeling
Another technique used to investigate the mechanism of action of BCNAs is 
photoaffinity labeling. This method allows the determination of the interaction 
between a ligand and an enzyme. To show their properties, these substrates need to be 
activated, through UV irradiation, to an active form, which is able to bind covalently
1 7with the target enzyme.
Various photophores are currently in use,13 and in particular (Fig. 3.1) arylazide (142) 
and benzophenone (143) have been investigated for BCNA.
Fig. 3.1: proposed photoaffinity labeled BCNA derivatives.
These two photophores have been chosen as they have been used in several substrates 
and on the basis of synthetic access. However, the synthesis of the arylazide 
derivative 142 (Scheme 3.13) has been found to be difficult due to the extreme
146 has been observed. It may be that the azide reacts with the triple bond to form a 
triazole ring, which was not isolated.
Reagents and Conditions: (/) N a N 0 2, HC1/H20 , 0 °C Ih; (//) NaN3, H 20 , 0 °C, 1 h; (Hi) 5-iodo-2'-deoxyU, 
Tetrakis Pd(PPh3)4, Cul, DIPEA, dry DMF, rt, overnight; then Cul, dry TEA, 85 °C, 8 h.
Scheme 3.13: attempt to synthesise the arylazide derivative of 86f.
OH 142 OH 143
reactivity of the azide. In fact, no coupling between the 5-iodo-2’-deoxyuridine and
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Another attempt (Scheme 3.14) has been made starting from compound 148, which 
was obtained by coupling between 121 and 147. The substitution of bromine with
described for simple aromatic systems. In the first case, a mixture of copper iodide, L- 
proline sodium salt and sodium azide was used. However, the conditions required for 
the last step, involving the addition of an aqueous solution of NaOH, even if in small 
amount, are not suitable for BCNAs and the nucleoside degraded.14 In the second 
case, a direct substitution of the bromine using sodium azide in water and DMF at 100 
°C was used. However, after three days no reaction occurred and the starting material 
was recovered.15
R e ag en ts  an d  C o n d itio n s : (/) T e tra k is  P d (P P h 3)4, C u l, an h y d ro u s  D IP E A , an h y d ro u s  D M F , rt, o v e rn ig h t; 
th en  C u l, a n h y d ro u s  T E A , 80  °C , 7 h. (/'/') N a N 3, L -p ro lin e  sod ium  sa lt, C u l, E tO H , H 20 ,  90  °C , 1 d ay ; th en  
aq u e o u s  so lu tio n  o f  N a O H  o r  N a N 3, D M F , H 20 ,  100 °C , 3 days.
Scheme 3.14: attempt to synthesise the arylazide derivative of 86f.
As the use of azide resulted in a failure, the benzophenone was then considered.
For the synthesis (Scheme 3.15), the commercially available 4-bromo-benzophenone 
149 was coupled with trimethylsilyl acetylene under Sonogashira conditions to 
provide compound 150, in quantitative yield and it was used without further 
purification in the deprotection step using sodium methoxide to obtain compound 151. 
Coupling with 5-iodo-2’-deoxyuridine and 151 was performed under standard 
conditions to obtain the desired compound 143 in good yield.
azide has been previously performed following two different procedures already
Br N.
85
Marco Derudas Chapter 3
150, quant
HO.
V o^
OH 1 4 3 ,5 9 %
in
1 5 1 ,9 5 %
Reagents and Conditions: (/) ethynyltrimethylsylil chloride, tetrakis Pd(PPh3)4, Cul, anhydrous DIPEA, 
anhydrous DM F, rt, overnight; (ii) MeONa, anhydrous MeOH, rt, Ih; (/'/'/) 5-iodo-2'-deoxyU, tetrakis Pd(PPh3)4, 
Cul, anhydrous DIPEA, anhydrous DM F, rt, overnight; then Cul, anhydrous TEA, 85 °C, 8 h.
Scheme 3.15: synthesize of the compound 143.
Biological evaluation and photoaffinity labeling experiments are currently underway.
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4. Fluoro derivatives of BCNA lead compound
4.1 2’-fluoro derivative of BCNA lead compound
As already mentioned in Chap. 2, all the modifications at the sugar moiety of the 
BCNAs are detrimental to anti-VZV activity of this class of compound. However, the
same size atomic radius of the hydrogen and could be therefore considered a potential 
favorable replacement for the hydrogen.
The literature reports several examples where the introduction of fluorine at the 2’- 
position of the sugar moiety gives enhancement of antiviral or anticancer activity, for 
example (Fig. 4.1): clevudine (152), currently in phase III clinical trial for the 
treatment of HBV infection;1 RT7128 (153), prodrug of 2’-deoxy-2’-fluoro-2,-C- 
methylcytidine, at present in clinical trial as an anti-HCV agent;2 gemcitabine (154), 
which is 2’-difluorocytidine and it is a potent anticancer compound licensed by Lilly.
m3<j um 3
Fig. 4.1: examples of 2’-fluoro NAs.
In the case of compound 86f, all the potential fluorine-substitutions at the T -position 
have been made (Fig. 4.2) obtaining compounds 155 (a-derivative), 156 (13- 
derivative) and 157 (gem-derivative).
introduction of fluorine at the 2’-position was not so far considered. Fluorine has the
(H2C)4 (H2C)4 (H2C)4
OH "F 
155
OH p 
157156
Fig. 4.2: 2’-fluoro derivatives of 86f.
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4.1.1 Synthesis of the 2’-a-fluoro derivative of the BCNA lead compound 
Scheme 4.1 reports the synthesis of compound 155 starting from the commercially 
available 2’-fluoro-2’-deoxyuridine 158 which was selectively iodinated at the 5- 
position using iodine and CAN in acetonitrile at reflux giving 159 in good yield.4 159 
was then coupled with (4-pentylphenyl)acetylene under Sonogashira conditions to 
give the desired compound 155.
OH p OH "F OH p
158 1 5 9 ,7 9 %  15 5 ,4 2 %
Reagents and Conditions: (/) I2, CAN, acetonitrile, reflux, 1 h; (//) (4-pentyIphenyl)acetylene, Tetrakis Pd(PPh3)4, 
Cul, anhydrous DIPEA, anhydrous DM F, rt, overnight, then Cul, anhydrous TEA, 85 °C, 7.5 h.
Scheme 4.1: synthesis of 2’-a-fluoro derivative 155.
4.1.2 Synthesis of the 2,-|$-fluoro derivative of the BCNA lead compound 
Scheme 4.2 reports the synthesis of the 2’-|3-fluoro derivative 156.
BzO. BzO. I 1
.  x .
OSi(CH3)3
OBz p 
160
OBz p 
1 6 1 ,9 5 %
N
A ,N OSi(CH3)3 
163
O
BzO
OBz p 
164,51%
OH p 
1 5 6 ,4 5 %
Reagents and Conditions: (/) HBr in acetic -acid, DCM. rt, 22 h; (//') hexamethyldisilazane, ammonium sulphate, 
anhydrous acetonitrile, 70 °C, 5 h; (Hi) Nal, anhydrous DCM, anhydrous acetonitrile, rt, 1 week; (/v) MeONa, 
anhydrous MeOH, rt, 1 h; (v) 4-pentylphenylacetylene, tetrakis Pd(PPh3)4, Cul, anhydrous DIPEA, anhydrous 
DMF, rt, overnight, then Cul, anhydrous TEA, 85 °C. 8 h.
Scheme 4.2: synthesis of 2’-p-fluoro derivative 156.
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For this route the intermediate 165 needed to be prepared according to the procedure 
already described in the literature.5
The commercially available 2-P-fluoro-2-deoxy-l,3,5-tribenzoylribose 160 was 
converted to the 1-bromo derivative 161 using hydrobromic acid in acetic acid giving 
the pure compound without purification. 161 was then coupled in the presence of 
sodium iodide with the activated base 163, which was obtained by silylation from 5- 
iodouracil 162 using hexamethyldisilazane in the presence of ammonium sulphate. 
The desired p-anomer 164 was obtained by precipitation during the reaction to give a 
white solid. However, from the filtrate another solid was obtained as a mixture of two 
anomers (a  and P). The two anomers were characterised by NMR comparing the 
results with the data in the literature.The deprotection of the benzoyl group was 
performed using sodium methoxide in anhydrous methanol to give 165 which was 
used without further purification in the coupling step with (4-pentylphenyl)acetylene 
under standard conditions to give the desired compound 156.
4.1.3 Synthesis of the 2’-gem-difluoro derivative of the BCNA lead compound 
Scheme 4.3 reports the synthesis of the 2’-gem-difluoro derivative 157 starting from 
166, which was available in our laboratory. It was coupled with (4- 
pentylphenyl)acetylene under Sonogashira conditions to give the desired compound 
157.
c h 3
(H2C)4
NH
N^O
HCL HO.
O
OH p OH p
166 157,60%
Reagents and Conditions: (/') 4-pentylphenylacetylene, tetrakis Pd(PPh3)4, Cul, anhydrous DIPEA, anhydrous 
DMF, rt, overnight, then Cul, anhydrous TEA, 85 °C, 7.5 h.
Scheme 4.3: synthesis of 2’-gem-difluoro derivative 157.
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4.2 Enzymatic and biological evaluation of 2’-fluoro derivatives
The synthesised compounds and the parent 86f were evaluated for their ability to 
inhibit VZV-TK. In addition, these compounds were evaluated for their ability to 
inhibit two different strains of TK-efficient VZV and one strain TK-deficient VZV 
(Table 4.1).
Enzymatic 
Activity 
IC50 (pM)
Antiviral Activity 
EC50 (pM)*
Cytotoxicity
(pM)
TK+ VZV TIC VZV
Cpds F-position
VAV-iK YS
strain
OKA
strain
07/1
strain
MCC CC50c
155 a-fluoro 2.7 - 0.75 >20 >50 >100
156 (3-fluoro 38 0.011 0.007 >50 >50 -
157 Di-fluoro -13 6.7 1.5 >50 >50 -
86f - 3.3 - 0.0097 >20 >50 77
a) effective concentration required to reduce virus plaque form ation by 50%;
b) minimum cytotoxic concentration that cause a m icroscopically  detectable alteration o f  cell m orphology;
c) cytotoxic concentration required to reduce cell grow th by 50%
Table 4.1: enzymatic and biological evaluation of 2’-fluoro derivatives of 86f.
From Table 4.1, it is easy to note the differences for these compounds. In fact, in the 
case of the enzymatic test using VZV-TK, which as already seen plays a crucial role 
in BCNAs phosphorylation,6 the a-fluoro derivative 155 retains low inhibitorial 
activity, comparable to the parent 86f. The P-fluoro derivative 156 showed a loss of 
potency (10 fold) whilst the gem-fluoro derivative 157 showed an inhibitory activity 
midway between the other two compounds being 4 fold less potent than the parent.
The antiviral activity showed interesting results. In fact, both a- and gem- derivatives 
showed a loss of activity, respectively of ~80 fold and -150 fold, compare to the 
parent. By contrast, the p-derivative is highly active, being of anti-VZV activity 
comparable with the parent compound.
All the compounds showed no activity against VZV TK-deficient strain, supporting 
the fact that they need to be phosphorylated to show antiviral activity.
It is interesting to note that in spite of being a good substrate for the VZV-TK, 
compound 155 did not show the same potency in the antiviral assay. This aspect was 
already noticed with other BCNA derivatives.6
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4.3 Molecular modeling studies on VZV-TK
It has been reported that the conformation of the sugar moiety (north or south) is 
fundamental for the interaction with the active site of target enzymes, such as TK or 
polymerase (viral or cellular), and usually one conformation is preferred to the other.7 
Sugars are usually in dynamic equilibrium with both conformations as the energy
o
barrier is quite low. To block the conformation either to the north or to the south 
conformation, locked NAs have been designed and in particular in this experiment the 
methanocarbathymidine has been used with the carbosugar moiety blocked in the 
north (167, Fig. 4.3) and the south conformation (168).8
Fig. 4.3 : locked NAs.
From these studies using HSV-TK, it appears that, for the first step of 
phosphorylation, the NA in the north conformation is a weak substrate for the HSV- 
TK whilst the south one does not bind. However, for the second step of 
phosphorylation mediated by HSV-TK, it has been found that the south conformer is a 
better substrate than the north. In the incorporation of both conformers into the DNA, 
the north was preferred to the south and this is also proved by the antiviral testing as 
the north conformer was found to be active whilst the south conformer was inactive.
In order to understand the differences in the inhibitory activity versus VZV-TK for 
the BCNA fluoro-derivatives, the affinity with the enzyme using docking techniques 
has been performed.
Firstly, stochastic and systematic searches, with the aim to find the lowest energy 
conformation for these compounds, have been performed.
From these studies (Fig. 4.4) it has been found that the north conformation of the 
sugar is more stable for the a-fluoro derivative 155 and for the gem-fluoro derivative 
157 compared to the south conformation by 1.8 and 1.0 kcal, respectively. On the 
contrary, for the (3-fluoro derivative 156 the south conformation was more stable than 
the north by 1.2 kcal.
o o
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155  (n o r th ) 1 5 6  (so u th )  157 (n o r th )
Fig. 4.4 : lowest energy conformation for the BCNA fluoro-derivatives.
The lowest minimised structure of both north and south conformation for these 
compounds have been docked with VZV-TK (protein data bank (PDB) lOSN).
In the case of compound 155 (Fig. 4.5) the north conformation displayed a better 
docking compared to the south, due to the formation of a hydrogen bond between the 
fluorine and the hydroxyl of the tyrosine 59 of the enzyme, which was of 2.78 A in 
the case of the north conformation and 3.87 A for the south conformation.
155 (north ) 155 (sou th)
Fig. 4.5: VZV-TK docking results for the a-fluoro 155.
In the case of the (3-fluoro derivative 156, the south conformation showed a better 
docking compared to the north (Fig. 4.6). However, the fluorine in the (3-position is 
not able to interact with the tyrosine 59 of the enzyme.
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156 (n o r th ) 156 (so u th )
Fig. 4.6: VZV-TK docking results for the p-fluoro 156.
157 (n o r th ) 157 (sou th )
In the case of the gem-fluoro 157, both north and south conformations showed the 
same interaction with the active site of the enzyme (Fig. 4.7).
Fig. 4.7: VZV-TK docking results for the gem-fluoro 157.
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In fact, the formation of the hydrogen bond between the fluorine and the hydroxyl of 
the tyrosine 59, with a distance of 2.82 A for the north conformation and 2.52 A for 
the south was noticed.
These studies support the results of the enzymatic experiment, which showed good 
affinity for 155, poor affinity for compound 156, whilst 157 showed an intermediate 
affinity for the enzyme.
These results are also in agreement with the result obtained using the locked NA, for 
which the north conformation is preferred to the south in the case of the first step of 
phosphorylation, whilst the south is preferred for the second phosphorylation. These 
results are in agreement with both enzymatic and biological results obtained.
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4.4 Application of the phosphoramidate approach to the BCNA 2’-fluoro 
derivatives
In order to investigate the enzymatic activity and the antiviral activity found for these 
compounds, a series of phosphoramidates have been synthesised.
The synthesis of the phosphoramidates (Scheme 4.4) has been performed by coupling 
the appropriate nucleoside (155-157) with the appropriate phosphorochloridate (131a, 
c, d) using NMI as coupling reagent.
ci- p
V ° ^ . n. +x-tV ' R"
OH £, 0R
155 R=F, R’=H
156 R=H, R - F
157 R=F, R =F
x-'V'v' OH h
169a R=F, R - H ,  R"=CH3, X = C H 3 
169b R=F, R = H , R"=CH3, X=Bn  
169c R=F, R’= H . R - H ,  X = C H 3 
170 R =H . R - F ,  R"=H, X = C H 3 
171a R=F, R - F ,  R "= €H 3, X = C H 3 
171b R=F, R - F ,  R"=CH3, X = C H 3 
171c R=F, R’=F . R"=CH3, X=Bn  
17Id  R=F, R '=F, R"=H. X = C H 3
131a R"=CH3, X = C H 3 
131c R"=H, X = C H 3 
131d R"=CH3, X=Bn
Reagents and Conditions: (/') anhydrous N M I, anhydrous THF, anhydrous pyridine, rt, 24-48 h.
Scheme 4.4: synthesis of the BCNA fluoro derivatives ProTides.
The coupling reaction proceeded well in the case of the glycinyl derivatives, for 
which all the compounds have been isolated. In the case of the p-fluoro derivative 
only one compound was isolated, the glycinyl derivative, whilst for the other two 
coupling reactions it was not possible to isolate the desired compounds as the reaction 
seemed not to work properly leaving starting material and only trace amount of final 
product on the TLC. A possible explanation for these results could be the 
conformation of the sugar of the p-fluoro derivative, which could be not very 
accessible for phosphorylation and this aspect is supported by the computational 
studies previously reported, showing the difference in the sugar conformation 
between the P-fluoro and the other two derivatives.
In the case of the gem-fluoro, the single diastereoisomer of the L-alanine methyl ester 
was isolated as well as the mixture of the two.
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Table 4.2 reports the summary of the BCNA fluoro derivative phosphoramidates.
Cpds F-position Amino Acid Ester JiPNM R ,VF NMR Yield
169a a-fluoro L-alanine Me 3.90, 3.83 -203.40, -203.72 5%
169b a-fluoro L-alanine Bn 3.94,3.71 -200.55, -200.94 7%
169c a-fluoro Glycine Me 5.24, 4.95 -203.47, -203.56 15%
170 P-fluoro Glycine Me 5.26, 5.15 -200.08 4%
171a gem-fluoro L-alanine Me 3.98, 3.96 -118.46,-118.83 2%
171b gem-fluoro L-alanine Me 3.89 -118.54 1%
171c gem-fluoro L-alanine Bn 3.99, 3.79 -118.23,-118.44 4%
171d gem-fluoro Glycine Me 5.42, 4.92 -118.13,-118.65 14%
Table 4.2: summary of BCNA fluoro derivatives phosphoramidates.
4.5 Biological evaluation of BCNA 2’-fluoro derivatives ProTides
The synthesised compounds were evaluated for their ability to inhibit VZV-TK 
(Table 4.3). In addition, these compounds were evaluated for their ability to inhibit 
two different strains of VZV TK-efficient and one strain VZV TK-deficient (Table 
4.3). Compound 86f and the parent fluoro derivatives 155, 156 are included as a 
reference. The biological evaluation for the gem-fluoro ProTides is currently 
underway.
Compounds
Antiviral Activity 
EC5o (HM)*
Cytotoxicity
(1*M)
TK f VZV TK VZV
MCCb CC50cYS strain OKA strain 07/1
strain
YS
strain
169a 0.90 0.90 10.05 9.33 50 7.1
169b - 2 10 - 50 11.3
169c 1.06 1.20 7.13 10.47 50 22.2
170 0.03 0.004 10.0 11.5 50 37.9
155 - 0.75 >20 - >50 >100
156 0.011 0.007 >50 - >50 -
86f 0.00031 0.00030 >2 >2 >2 >100
a) effective concentration  required to reduce v irus plaque form ation by 50%;
b) m inim um  cytotoxic concentration  that cause a m icroscopically  detectable alteration o f  cell m orphology;
c) cytotoxic concentration  required to reduce cell grow th by 50%.
Table 4.3: anti-VZV activity of BCNA fluoro derivatives ProTides.
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From Table 4.3 it is clear that the BCNA fluoro-derivatives ProTides retain the same 
activity of the corresponding parent compound. In the case of the TK-deficient strains, 
all the compounds showed some activity, losing, however, in potency compared to the 
TK-efficient strains. Interestingly, all the compounds showed cytotoxity, and probably 
the activity found against the TK-deficient strains may be simply toxicity.
The antiviral evaluation for the gem-fluoro derivative ProTides is currently under 
way.
From these results it is clear that the phosphoramidate technology did not improve the 
activity for these compounds. However, these compounds have been found to be 
cytotoxic, in a range between 7-38 pM. Moreover, the activity found against the 
VZV-TK deficient strains may be toxicity.
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4.6 Investigation of possible biodistribution study of a fluoro derivative of 
BCNA lead compound through MRI studies
Magnetic resonance imaging (MRI) is a common medical technique used in 
radiology. This technique allows the study of the structure and activity of the body; in 
fact using contrast agents is possible to enhance the appearance of specific area of the 
body such as blood vessels or tumors.
Using this technique it is possible to study the distribution of compounds in the body. 
In order to investigate the distribution of BCNA lead compound 86f in mice a fluoro- 
derivative 172 has been designed and synthesised.
Fig. 4.8: the terminal fluoro derivative of BCNA lead compound 86f.
Fluorine has been chosen for several reasons. Its magnetic properties can be detected 
by magnetic resonance and the substitution at the end of the chain with halogens gave 
retention of activity.
4.6.1 Synthesis of the terminal fluoro derivative of the BCNA lead compound
The synthesis of compound 172 (Scheme 4.5) involves a cross coupling reaction of 5- 
iodo-2’-deoxyuridine and l-ethynyl-4-(5-fluoropentyl)benzene 177 under 
Sonogashira conditions. The alkyne derivative was synthesised in 5 steps starting 
from the commercially available 5-phenylpentanol-l-ol 173. The iodination of 173 
proceeded in excellent yield (94%) to give compound 174, which was however, 
slightly contaminated with the ortho-iodo derivative. The cross-coupling of 174 with 
trimethylsilyl acetylene was performed under Sonogashira conditions to obtain 
compound 175, which was deprotected to yield compound 176 using sodium
F
(H2C)4 (H2C)5
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methoxide in methanol. The final synthone 177 was obtained by fluorination of 176 
using diethylamino sulphur trifluoride (DAST).
F
(H2C)5
(H2C)4 o h
(H2C)4 OH (H2C)4 OH
173
(H2C)4 o h
III /v
174,94%
175. 53%
II
176.99%
HO.
177,39% OH 172,50%
Reagents and Conditions: (/) I2, sodium iodate, glacial acetic acid, H 2S 04, 105 °C, 1 h; (//) trimethylsilylacetylene, 
tetrakis Pd(PPh3)4, Cul, anhydrous DIPEA, anhydrous DM F, rt, overnight; (///) MeONa, anhydrous MeOH, rt, lh; 
(/v) DAST. anhydrous DCM , rt, 2 h; (v) 5-iodo-2'-deoxyuridine. tetrakis Pd(PPh3)4, Cul. anhydrous DIPEA. 
anhydrous DM F, rt, overnight; then Cul, anhydrous TEA, 85 °C, 7.5 h.
Scheme 4.5: synthesis of compound 172.
4.6.2 Biological evaluation of the terminal fluoro derivative of the BCNA lead 
compound
The synthesised compound 172 was evaluated for its ability to inhibit the replication 
of VZV (Table 4.3). Data for VZV are given for the activity of these compounds 
versus two VZV-strains of TK-competent and also one strain of TK-deficient cells. 
The data includes 86f, ACV and BVdU as a reference.
Compounds
Antiviral Activity 
ECso (pM)*
Cytotoxicity
(pM)
TK+
YS
strain
VZV
OKA
strain
TK VZV 
07/1 
strain
MCCb CC50c
172 0.004 0.0089 > 5 > 2 > 100
86f 0.0027 0.0014 >0.2 >0.2 -
ACV 4.4 16 61 >1778 1107
BVdU 0.013 0.017 4.2 >1201 1201
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cyto toxic concentration  that cause a m icroscopically detectable alteration o f  cell 
m orphology;
c) cytotoxic concentration required to reduce cell growth by 50%.
Table 4.3: antiviral activity against VZV for the compound 33.
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Compound 172 retains the anti-VZV activity. Unfortunately, preliminary MRI studies 
showed poor sensitivity for this compound probably due to the presence of just only 
one fluorine in the structure, which is not enough to be detected.
Further studies, including the synthesis of a trifluoroderivative and the synthesis of a 
radiolabeled 18F derivative of 86f have been considered.
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5. Improving the synthesis of FV100
FV100 is the valyl ester prodrug of Cfl743, the most active anti-VZV compound 
reported to date. As already mentioned, FV100 successfully completed phase I 
clinical trials and is currently on phase II.
Its development as a new anti-VZV drug involves new synthetic strategies, which will 
cut the cost not only for trials but also for the market in the case this compound 
becomes clinically available.
5.1 C urrent scale up synthesis of FV100
The first step of the synthesis of FV-100 involves a Sonogashira cross-coupling 
reaction between the 5-iodo-2’-deoxyuridine and (4-pentylphenyl)acetylene in the 
same conditions described in Chap. 3, to provide the compound pure without recourse 
to chromatography.1
The current synthetic scale up of 119 as a hydrochloride salt (Scheme 5.1) involves 7 
steps starting from 86f. The first step involves selective protection at the 5’-position 
with 4,4’-dimethoxytrityl chloride to obtain compound 178 followed by protection of 
the 3’-position with chloroacetic chloride to give compound 179 and selective 5’- 
deprotection in acidic conditions to obtain compound 180. The overall yield for these 
three steps is 50%.
The coupling of compound 180 with N-9-fluorenylmethoxycarbonyl (Fmoc)-L-valine 
was performed using DCC and with dimethylaminopyridine (DMAP) as a catalyst to 
obtain compound 181. This compound was treated with thiourea and sodium 
carbonate to deprotect the 3’-position giving 182 followed by deprotection of the 
Fmoc group using piperidine to yield compound 119. The hydrochloride salt 119*HCI 
was obtained by dissolving 119 in DCM and adding 20% HCl/isopropanol (IPA) with 
an overall yield from the coupling step of 74%. The compound was then further 
purified by crystallization to obtain the final compound. The yield for this last step 
was 80%. The overall yield for the synthetic route is 30%, providing 3-5 kg of 
U9'HC1.
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c h 3
(H2C)4
HO. I
OH 8 6 f
NHFmoc
c h 3 o
H aC ^.-k^O
c h 3 o
c h 3 
(h 2C)4
DMTrO.
OH 182
OH 1 1 9
NHFmoc
H3C ^.-k^O
c h 3 o
DMTrO
H,C
NH*HCI
OH 119-H CI
Reagents and Conditions: (/) DM Tr-C l, pyridine, DCM , rt, 30 min, then 0-5 °C, 30 min; (//) chloroacetic anhydride, 
DMAP, DCM , rt; (Hi) acetic acid/water, 25-45 °C, 6 h; (iv) Fmoc-L-valine, DCC, DMAP, THF, rt, 2.5 h; (v) 
thiourea, Na2C03, DCM /EtOH, 40-45 °C, 2 h; (v/) piperidine, DCM , rt, 2.5 h; (v/7) HC1/IPA, DCM , 5-10 °C, 1.5 h.
Scheme 5.1: current scale up synthesis of FV-100.
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5.2 New potential synthetic routes for the synthesis of FV100
In order to improve the overall yield of this synthesis as well as to reduce the number 
of steps different synthetic routes have been considered.
5.2.1 Selective 5’-OTBDMS deprotection
Firstly, consideration is given to the synthesis of the first synthon, the 5’-OH-3’- 
protected derivative of 86f and the synthetic route, already described in Chap. 3, was 
used (Scheme 5.2). This route involves a 3’,5’-protection using TBDMS-C1 followed 
by selective deprotection at the 5’-position. In order to increase the overall yield, 
several conditions have been considered especially for the second step. 
c h 3 c h 3 c h 3
(H2C)4 (H2C )4 (H2C)4
HO. HO.
OTBDMSO,
OH OTBDM S OTBDM S
86 f 122,90-96%  123
R e ag en ts  an d  C o n d itio n s : (/) T B D M S C 1, im id azo le , a n h y d ro u s  p y r id in e  o r  D M F , rt, o v e rn ig h t;
(//) d if fe re n t c o n d itio n s  se e  T a b le  5 .1 .
Scheme 5.2: synthetic route to obtain the first synthon 123.
The first step involves a 3’,5’-protection, to obtain compound 122, using TBDMSC1
9 1in the presence of imidazole using DMF or pyridine. ’ The reaction works with both 
solvent giving a yield of 90-96% in the case of pyridine and 89-94% in the case of 
DMF. Flowever, the work-up using pyridine is easier than using DMF. Notably, the 
compound was obtained pure without need of purification.
For the second step several conditions have been used and they are summarized in 
Table 5.1. The best result has been obtained using a mixture a TFA/water in THF in 
different ratios. However, for this method, several aspects must be considered such as 
volume of solvent, addition of the reagents, temperature and time. The volume of 
solvent used is important in this step as the desired compound 123 precipitates during 
the reaction. It has been noted that in the presence of a large amount of solvent 123 is 
soluble and it can be fully deprotected. Concerning the addition of the reagents, 
optimum results have been obtained adding slowly cold TFA/H2O at 0 °C and stirring
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at this temperature followed by a slow increase to room temperature. As already 
mentioned, the desired compound precipitates during the reaction and it can be 
removed by filtration. The filtrate contains still starting material and the 3’-OH-5’- 
OTBDMS derivative as a side product can be reacted with TFA/H2O to give a second 
portion of 123, which again precipitates during the reaction. The combined fractions 
of 123 were washed with diethyl ether to remove the TFA, starting material and of 3’- 
OH-5’-OTBDMS side product. 123 was then dissolved in DCM leaving in the filter 
the parent compound 86f. The compound was obtained pure without purification.
Reagents Conditions Yield
TFA/H2O/THF = 1/1/84 0 °C, 2 h then slowly rt, 4 h 75-83%
TFA/H2O/THF = 1/1/5 0 °C, 7 h 51%
TFA/H2O/THF = 1/1/6 rt, reagents add in three portions 55%
TFA/H2O/THF = 3/3/10 Addition at -15 °C, then 0 °C, 4 h, 80%
then slowly rt, 3 h
Acetic acid/H20/THF rt, 5 days 65%
= 13/7/35
Acetic acid/H20/THF rt, 5 days 54%
= 6/3/4
90% TFA6 0 °C, 20 min Degradation
95% TFA/DCM = 1/17 - 10 °C, 2 h Degradation
TFA/DCM = l / l 8 rt, 20 min Full deprotection
NH4F, MeOH9 rt, 3 days 48-58%
TBAF silica gel solid rt, 6 h Mixture of different
support, THF10 compounds
Pyridinium-/?-toluene 50 °C, 3 h Mixture of different
sulfonate, EtOH11 compounds
Table 5.1: conditions used for the selective removal of 5’-OTBDMS.
Other methods have been used .in order to increase the yield and to reduce the time. 
The use of more concentrated acid, which reduced the reaction time, gave degradation 
of the starting material, perhaps due to the acid labile glycosidic bond. In these 
conditions, the deprotection of the 3’-position was preferred to the 5’-position and 
moreover full deprotection was observed. Using mild conditions, such diluted acetic
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acid or ammonium fluoride, the desired compound was isolated, but the yield and the 
reaction time were not suitable for a scale up synthesis.
The average overall yield for these steps was 73%, with an increase of more than 20% 
compared to the current synthesis. Furthermore, the number of steps has been 
decreased from three to two.
5.2.2 Synthesis of FV100 from the Boc-L-valine derivative
N-(tert-butoxycarbonyl) (Boc) has been chosen as a protecting group in this particular 
route as it is an acid labile group so its deprotection as well as the deprotection of the 
3’-OTBDMS may be achieved in one reaction (Scheme 5.3). Moreover, the use of 
hydrochloric acid could give directly FV100 as a salt reducing further the number of 
steps.
The coupling with 123 and Boc-L-valine was performed using the same conditions
used in the current scale up synthesis using DCC and a catalytic amount of DMAP.
The desired compound 183 was obtained and used without further purification in the
deprotection step. In order to understand and to investigate the deprotection step,
different conditions have been used (Table 5.2).
CH3 c h 3
(H9C)4 (H2C)4 (H2C)4
R e agen ts an d  C o n d itio n s : (/) B o c -L -v a lin e , D C C . D M A P , rt, o v e rn ig h t; (//) d if fe re n t c o n d itio n s  see  T a b le  5.2 .
Scheme 5.3: synthesis of FV100 through Boc-L-valine derivative 183.
The TBDMS group is quite labile and easy to remove under the majority of the 
conditions used (Table 5.2). By contrast, the Boc-moiety has been found to be 
particularly resistant to the conditions applied and in particular under conditions in 
which it is usually removed, such as 4N HC1 in water, which is used in the synthesis 
of valaciclovir. Due to the poor stability of the glycosidic bond, it was not possible to 
increase either the reaction time or the concentration of the acid. In fact, in some cases
NHBoc
OTBDM S
123
OTBDM S
183
OH
119
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the cleavage of the glycosidic bond has been observed along with the formation of 
degradation products by TLC.
Reagents Conditions Results
t f a / h 2o / t h f = 1/ 1/44 rt, 24 h TBDMS deprotection
TFA/DCM = 1/112 rt, 1.5 h Cleavage of glycosidic bond
TFA/MeOH= 1/112 Sequential addition at TBDMS deprotection and
0 °C rt, 20 h degradation
TFA/dioxane = 1/112 Sequential addition at TBDMS deprotection and
0 °C rt, 20 h degradation
IN HC1/THF = 2/113 rt, 1 day Degradation
4N HC1/ H20  = 1/214 rt, 1 day Partial TBDMS deprotection
12N HCI/H2O = 0.1/214 rt, 1 day No reaction
0.01 N HC1 rt, 1 day Not soluble
20% HC1 in I PA/I PA = Sequential addition, rt, Partial TBDMS deprotection,
1/115 6 h cleavage of glycosidic bond
20% HC1 in IPA/1PA = Sequential addition at Partial TBDMS deprotection,
5/315 0 °C rt, 1 day cleavage of glycosidic bond
4N HCl/Dioxane = 1/2 Addition at 0 °C, rt, 36 Partial TBDMS deprotection,
h degradation
4N HCl/MeOH = 1/6 Addition at 0 °C, rt, 36 Partial TBDMS deprotection,
h degradation
10% H2SC>4/Dioxane = rt, 5h TBDMS deprotection
1/512
/7-Ts0H  H20 , MeOH12 rt, 22h Degradation
p-Ts0H H20 , EtOAc 50 °C, overnight No reaction
TBDMSC1, MeOH12 Reflux, 4.5 h Cleavage of glycosidic bond
TBDMSC1, MeOH rt, 22h Degradation
TBAF solid support, THF10 rt, 40 h TBDMS deprotection
H20 Reflux, 4 days No deprotection of Boc
CAN, acetonitrile16 Reflux, 2 days No reaction
1MBC13 in DCM, DCM Addition at 0 °C, rt 3 h TBDMS deprotection, 
degradation
Table 5.2: conditions used for the deprotection of BOC and 3’-OTBDMS.
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Although promising, in terms of number of steps, unfortunately this synthetic route 
failed.
5.2.3 Synthesis of FV100 from the Fmoc-L-valine derivative
The second route (Scheme 5.4) considered for the synthesis of FV100 used Fmoc as 
the protecting group of the L-valine. For the synthesis of 184, the same procedure 
already described was used. The desired compound was obtained and used as crude, 
however, it was not completely pure and it was contaminated with Fmoc-L-valine.
c h 3
(H2C)4
c h 3
(H2C)4
HO.
OTBDM S
NHFmoc
CH3 O
OTBDMS
NHFmoc
H’°y V
c h 3 o
123 184
i n
c h 3 
/
(H2C)4
H ,C
OTBDMS
(H2C)4
n h 2-h c i
*°yV V o.
c h 3 o
OH
185 119-HC1
o v e ra ll  y ie ld  2 3 %
R eagents an d  C o n d itio n s : (/) F m o c -L -v a lin e , D C C , D M A P , rt, o v e rn ig h t; ( i i )  T F A /H 2 0 /T H F  =  1 /1/4, rt, o v e rn ig h t; 
(Hi)  p ip erid in e , D C M , rt, 10 m in ; ( iv )  p ip e r id in e , D C M , rt, 10 m in , th en  2 0 %  H C 1/IPA , 5 -1 0  °C , 1.5 h; 2 0 %  
HC1/IPA, rt. 2 -4  h, th en  0 -5  °C , o v e rn ig h t.
Scheme 5.4: synthesis of FV100 through Fmoc-L-valine derivative 184.
To obtain compound 119, two different strategies have been followed: the first one 
was the deprotection of the TBDMS group using TFA/H2O/THF (1/1/8) followed by 
deprotection of the Fmoc group using piperidine and then the formation of the 
chloridate using 20% HC1/IPA. The second strategy was the removal of the Fmoc 
group followed by the deprotection of the TBDMS group and formation of the salt in
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one reaction. This last reaction was successful and 119*HC1 was isolated pure without 
purification. The overall yield for this route was 23%. However, it must be said that 
compound 184 was used not completely pure and this could have influenced the 
deprotection step. Due to time constraints, this route has not been further investigated.
5.2.4 Direct esterification of the unprotected nucleoside using lipase
Another attempt to reduce the number of steps has been attempted using an enzymatic 
procedure. In this way, the specificity given by the enzyme in the esterification step 
may allow the use of unprotected nucleoside. Lipase has been used for its selectivity 
in the esterification process, for example, in the selective acyclation of ribavirin with 
L-alanine19 or in the selective 5’-acetylation of 6-methoxy-ara-guanosine.20 Different 
methods and conditions have been used for this route (Scheme 5.5) and Table 5.3 
summarises them.
(H 2 C ) 4
OH 86 f OH 119 R = H
1 8 2  R — Fr
Reagents and  C o n d itio n s : (/) d if fe re n t  c o n d itio n s , see  T a b le  5 .3 .
Scheme 5.5: synthesis of FV100 using unprotected 86f.
Unfortunately, all the different conditions used in this new route were not successful 
for the synthesis of FV100. In fact, only starting material was recovered after the 
reaction.
However, there are several key factors to be considered in getting these lipase 
reactions to work in a synthetic direction. It has been reported that the solvent can 
widely affect the reaction in terms of selectivity and yield, however being purely 
empirical, a number of different solvents need to be tried, especially considering the 
poor solubility of the parent compound 86f.
The type of enzyme used is also critical. The lipase from Candida antarctica in solid
1 fi 90support (novozyme-435) is widely used and reported. ' However, several other 
lipases are available, but not all lipases work well and several attempts using different
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lipases need to be performed. It may be that the enzymes could be used on a more 
soluble and reactive precursor of 86f and this is currently underway at our sponsor.
Reagents Conditions Results
L-valine, lipase from Candida rugosa type VIII, 
DCM/DMF, pH4 acetate buffer17
Reflux, 3 days Negative
Fmoc-L-valine, lipase from Candida rugosa type 
VIII, DCM/DMF, pH4 acetate buffer17
Reflux, 3 days Negative
L-valine, lipase acrylic resin from Candida 
antarctica, THF18
Reflux, 3 days Negative
L-valine ethyl ester, lipase acrylic resin from 
Candida antarctica, THF18
Reflux, 3 days Negative
Fmoc-L-valine, lipase acrylic resin from Candida 
antarctica, THF18
Reflux, 3 days Negative
Fmoc-L-valine-acetoxime, lipase acrylic resin from 
Candida antarctica, THF, DMF19,20
65 °C, 1 week Negative
Fmoc-L-valine-acetoxime, lipase acrylic resin from 65 °C, 1 day, 85 °C Negative
Candida antarctica, DMF 2 days
Table 5.3: conditions used for the synthesis of FV100 using unprotected 86f.
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5.3 Conclusion
The improvement of the synthesis of FV100, plays at this point of its development a 
crucial role in order to reduce the production cost. At present the current scale up 
synthesis involves seven steps: for the first three steps, to obtain the 5’-OH-3’- 
protected derivative of 86f, the overall yield was 50%, for the following four steps, to 
obtain 119HC1 was 74%, whilst the last crystallization step gave 80% yield. The 
corresponding overall yield for this synthetic route is 30%.
In the present work, a consistent improvement for the synthesis of the first synthon 
has been made improving by more than 20% the overall yield, from 50% to 73%, and 
reducing the number of steps from three to two.
For the second part of the synthetic route different strategies have been used.
The use of Boc protected amino acid was particularly fascinating in terms of further 
reduction of number of steps, being that Boc is an acid labile group. However, the 
deprotection step was not successful as the Boc group was extremely stable under the 
conditions in which the glycosidic bond was stable.
The use of Fmoc as the protecting group was more successful than the Boc route and 
the final compound was isolated with an overall yield of 23%, which is less than the 
overall yield obtained from the current scale up synthesis (74%).
The last attempt to reduce the number of steps and to increase the overall yield has 
been made using the direct esterification of the unprotected nucleoside using lipase. 
All the different conditions used resulted in failure. However, due to time constraints, 
this route has not been further investigated.
In conclusion, a new route for the synthesis of 119*HC1 has been preliminary 
developed. This route includes five steps with an overall yield of 17%, whilst the 
current synthesis involves seven steps and an overall yield of 30%.
In spite of having less synthetic yield, the new route needs to be further investigated 
especially in the second part of the synthesis in order to be used for a scale up 
synthesis.
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6. Ribavirin ProTides
6.1 Ribavirin background
As already seen in the introduction, ribavirin 50 is a nucleoside analogue with 
antiviral activity against a number of DNA and RNA viruses in vitro and in vivo} 
Ribavirin is converted by intracellular phosphorylation (Fig. 6.1) mediated by 
adenosine kinase to the monophosphate 186, followed by further phosphorylation 
mediated by cellular kinases to the diphosphate 187 and to the triphosphate 188.2
0  ° \
K nh2 / - nh2
 ^ .N o  S. -N
N 77 N
H O . I H O -P -O . I
A d e n o s in e  K in a s e  q h
OH OH OH OH
50 186
C e llu la r  K in a s e  
O O
^ - n h 2  K n h 2
OH OH OH
^ -N O O ^ -N
N C e llu la r  K in a s e  ■ •• ND _ 0  | «  i v nw a c  H 0 _ p _ 0 _ p _ 0  |
D  1 ^ ° ^  OH OH
OH OH OH OH
188 187
Fig. 6.1 : ribavirin and its subsequent phosphorylation products.
Phosphorylations to the phosphate forms of ribavirin are essential for its activity 
but the exact mechanism of action is unclear and may vary. The phosphorylation 
to monophosphate is the rate limiting step at least in some cases.3 The ProTide 
technology has been applied to ribavirin in order to improve and extend its 
activity against different viruses.
A small series of phosphoramidates with different lipophilicities (CLogP) has 
been synthesised with the aim to study the SAR of these compounds.
6.2 Synthesis of ribavirin
Ribavirin has been synthesized following the procedure reported by Ramasamy et 
al. (Scheme 6.1).4 Condensation of commercially available 1,2,3,5-tetra-O-acetyl- 
|3-D-ribofuranose 189 and l,2,4-triazole-3-carboxylate 190 in the presence of 
bis(p-nitrophenyl)phosphate provided compound 191 as pure |3-anomer corfirmed
117
Marco Derudas Chapter 6
by the chemical shift presented in the literature. Deprotection of 191 using 
methanolic ammonia at room temperature for 12 h gave ribavirin 50.
o
^ och3
/MK ,N N
.  >~OCH3 AcO. I HO. I
V ± r 0Ac + «j T  1 . “ , V ° 7
o
V - n h 2
-NN
OAcOAc Pj OAc OAc o h  o h
189 190 1 9 1 ,5 2 %  5 0 ,8 7 %
R eagents and C onditions: (/) b is(/j-n itrophenyl)phosphate , 170 °C, 25 m in; (/'/) M eO H /N H 3, rt, 20 h.
Scheme 6.1: synthesis of ribavirin.
6.3 Synthesis of ribavirin phosphoramidates
In order to improve the poor solubility of ribavirin and to prevent the formation of 
side products, the 2’ and 3’ positions of the sugar were protected with 
cyclopentanone using perchloric acid as catalyst to give the desired compound 
192 (Scheme 6.2).
Compound 192 was coupled with the appropriate phosphorochloridates 193a-c 
using ‘BuMgCl as the coupling reagent to give the desired compounds 194a-c
(Scheme 6.2).'
OH OH
O
K nh2
/ / “ *.NN
.HV oJ
o
K nh2
.NN
BnO
°^ > < y 1 9 2 ,9 0 %
O
>~NH2
O -P -O  | 111
NH
Bn0Y ^ "
0 f t
C I-P -0
193a: R = M e 
1 93b : R = Bn 
193c: R =  H
O -P -O
vj H 1^-
OH OH
194a: R = M e , 32%
194b : R =  B n , 44%
194c: R = H , 15%
R eagents and C onditions: (/) cyclo p en tan o n e , H C I0 4, rt, overnight; (//') ‘B uM gC l, anhydrous T H F, rt, overnight; 
( i i i ) 60%  form ic acid, rt, overnight.
195a: R = M e , 28%  
195b: R = B n , 28%  
195c: R = H , 17%
Scheme 6.2: Synthesis of ribavirin ProTides.
The protecting group was then removed using 60% formic acid at room 
temperature overnight giving the desired final compounds 195a-c. All of these
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compounds have been obtained as mixtures of two diastereoisomers, confirmed 
by the presence of two peaks on 3IP NMR. Mass spectroscopy, elemental analysis 
and HPLC confirmed the structures and the purity for these compounds.
6.4 Biological evaluation of ribavirin ProTides
The synthesised compounds 195a-c were evaluated for their ability to inhibit the 
replication of different viruses (Table 6.1). All compounds display increased 
ClogP values compared to ribavirin, which, most likely, enhances their cellular 
permeability.
Antiviral Activity 
EC5o (pM)*
Cytotoxicity
(pM)
Cpds CLogP RSV
HCV
Huh-5-2
Influenza A 
H3N2 subtype
Influenza B MCCb
195a 0.96 45 68 18 14 >100
195b 2.38 >20 >70 >100 >100 >100
195c 0.84 58 - >20 >20 >100
50 -2.85 19 87±22 9 9 >100
a) effective concentration required to reduce virus plaque formation by 50%;
b) m inim um  cytotoxic concentration  that cause a microscopically detectable alteration o f  cell m orphology;
Table 6.1: biological evaluation of ribavirin ProTides.
Although active, the ProTides did not show any improvement of activity 
compared to the parent compound, their antiviral concentrations being, at best, in 
the 14-100 pM range. In the case of RSV, for which ribavirin is clinically 
approved, the L-alanine 195a and glycine 195c ProTides were about 3-fold less 
active than the parent nucleoside. Compound 195a proved equipotent to ribavirin 
in inhibiting HCV subgenomic replicon replication. ProTide 195a was active 
against influenza virus (its potency being ~2- fold lower than that of ribavirin). 
For all the viruses tested, the phenylalaninyl ProTide 195b had no or borderline 
activity at the highest concentration tested (100 pM).
No relantionship between lipophilicity and activity has been found for these 
compounds.
All three ProTides were non-toxic to uninfected cells at 100 pM, as was ribavirin. 
No activity (>100 pM) has been found against parainfluenza-3-virus, reovirus-1,
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sindbis virus, coxsackie virus B4, HIV-1, HIV-2, HSV-1, HSV-2, HSV-1 TK- 
deficient strain, CMV, feline corona virus, feline herpes virus (data not shown).
In order to understand the relatively poor activity of these ProTides, which is 
suggestive of ineffective activation, enzymatic and preliminary molecular 
modeling studies were performed.
6.5 Enzymatic studies using carboxypeptidase Y enzyme
The putative mechanism of activation of phosphoramidate prodrugs (Fig. 6.2), as 
mention in Chap. 1, involves an initial hydrolysis of the carboxylic ester by a 
carboxypeptidase type enzyme obtaining compound 196 with subsequent 
spontaneous cyclisation with displacement of the aryloxy group giving compound 
197 followed by opening of the unstable ring mediated by water to get compound 
198. The last step in the bioactivation involves the hydrolysis of the P-N bond by 
a phosphoramidase-type enzyme to obtain the monophosphate form of ribavirin 
186.6 7
O
)^NH2
/ K.N
N
O -P-O P ' P - 0O-P-O
---------- ► NH ► O s = ^ N H
^ X ^ C H a O H  OH ° X x ;H3 OH OH H3C OH OH
196 197
O O
K nh2 ^~nh2
° S j N 9 Sj-n
O -P -O  I d O -P-O  I
° .  ^  -  NH ^
OH OH X ^ C H 3 OH OH
a: esterase o r carboxyp ep tid ase  type en zy m e: 1 * 6  O 19*
b: spon taneous cyclisation ;
c: open ing  o f  the unstab le  pu ta tive  cyc lic  m ixed  anhydride m ediated by w ater; 
d: hydro lysis o f  the P-N  bond  by a phosphoram id ase-ty p e  enzym e.
Fig. 6.2 : putative mechanism of activation of ribavirin ProTide 195a.
An enzymatic study using- carboxypeptidase Y has been performed in order to 
investigate whether ribavirin ProTide can be metabolised, following the procedure
O
already described by Birkus.
195a was incubated with carboxypeptidase Y in ^-acetone and Trizma buffer (pH 
= 7.6) and the enzyme reaction was followed by 31P NMR. The spectra (Fig. 6.3)
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shows fast metabolism of the starting material (5p = 4) to the putative intermediate 
198 (8p = 7), the reaction being completed within 1.5-2 h. The suggestion that the 
reaction product is structure 198 is based on two factors. Firstly, while 195a 
contains a chiral phosphorus and displays two phosphorus signals in the NMR, the 
(8p = 7) product elicits only one signal, suggestive of an achiral phosphorus, as in 
198. Secondly, other reports of amino aryl phosphates such as 198 indicate a 
chemical shift of this magnitude.9 Close examination of the early (3-30 min) 
spectra shows a double peak at 8p < 5, indicative of a chiral phosphorus and 
consistent with the proposed activation pathway. This species is considered to be 
the initial cleavage product 196 on the basis of similar analogues.9 This enzyme 
experiment indicates that the first activation step of Protide 195a is sufficiently 
efficient and comparable in rate to cases where ProTides show good biological 
efficacy.10
___________________________________  12 h
i ____________________________________  6 h
ft? 6 U
1.5 h 
1 h
45 min 
30 min 
15 min
J  A  _  3 min
_i —1_______  Blank
Fig 6.3: enzymatic experiment of compound 195a with carboxypeptidase Y.
6.6 Molecular modelling studies using human hint enzyme
The last step in the bioactivation pathway involves hydrolysis of the P-N bond by 
a phosphoramidase-type enzyme.1 ’’12
Preliminary molecular modelling studies using docking techniques were 
performed in order to understand if ribavirin L-alanine phosphate 198, putative
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intermediate obtained during the enzymatic experiment, could be a good substrate 
for the human hint enzyme.
This enzyme is considered to be responsible for the cleavage of the phosphorus- 
nitrogen bond in the final step of the phosphoramidate activation. It belongs to the 
HIT superfamily.13 The proposed mechianism of action of this enzyme (Fig. 6.4) 
involves an attack of the histidine 112 (red) to the phosphorous followed by the 
release of the amino moiety, which is favoured by the protonation mediated by the 
serine (green). Subsequently, a molecule of water attacks the phosphorous with 
the release of the histidine (red) and the protonation of the serine (green).13
Hint  „ Hint
H --------O — ' ,H O-
RCMHg p
^  * H int.  W p  'Hint. _ --------------------------------------- ^ ----► L J i n .  V O ^ _ . x O
S)NH .......
H2Nt5 /  ....... r  H2t f S NH........?  V ® N H
AdoV _ N^  Ado S '
NH Hint
Hint AMP
Hint. N ^ nh  ____
S>NH HO—  '
Hint
H2N^ /
Fig. 6.4: proposed mechanism of action of Hint.
Docking studies were carried out using a co-crystallised structure of adenosine 
monophosphate (green structure on Fig. 6.5) with the enzyme in order to identify 
the catalytic site. From these studies (Fig. 6.5) it appears that ribavirin L-alanine 
phosphate is not able to interact with the catalytic site of the enzyme; in fact, the 
phosphate moiety is placed just outside the binding pocket, (see Chap.7 as a good 
example of a docking on Hint enzyme).
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Fig 6.5: docking of compound 198 with Hint-enzyme.
These results support that the lack of activity found for this compound could be 
due to the poor deliver of the monophosphate form inside the cells.
6.7 Conclusion
To summarise, a series of novel ribavirin ProTides has been synthesised. No 
improvement/extension of activity has been found. A likely explanation for this 
aspect is the relatively poor activation of the ProTide to the free monophosphate. 
Enzyme assays indicate that the first step of activation is efficient and that the 
blockade may be at the final P-N cleavage step by HINT. This is consistent with 
our preliminary molecular modeling data with the HINT enzyme.
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7. Acyclovir ProTides
7.1 Acyclovir background
ACV (Fig 7.1, 9) (2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin- 
6-one), as already seen in Chap. 1, is a guanine analogue antiviral drug. ACV and 
its prodrug are the current treatment of choice for HSV and VZV infections.1
o
w ,
h3c^ ch3 12 
Fig. 7.1 : ACV and its prodrug valacyclovir.
The mechanism of action involves phosphorylation to give the monophosphate, 
which is selective in the infected cells and is mediated by a herpes virus-specified 
TK.2 The monophosphate is subsequently converted to the di- and triphosphate by 
cellular kinases. In the active triphosphate form, ACV inhibits the HSV 
polymerases 10-30 times more than cellular DNA polymerases.2 
To overcome the major problem of ACV, its poor oral bioavailability, a series of 
prodrugs have been synthesised. The L-valyl ester of ACV (valacyclovir, 12) is 
metabolised in the gut and in the liver by valacyclovir hydrolase to ACV,3 
increasing its bioavailability by ca. 4 fold.4
HHV encoded TK specifically phosphorylates ACV to the monophosphate form. 
This step of phosphorylation gives the selectivity of this compound for certain 
viruses, especially HSV and VZV. However, due to the large use of ACV and 
valacyclovir, resistance to these drugs is increasing. The resistance is due to a lack 
of phosphorylation by a loss of viral TK activity or by an alteration of the viral 
polymerase for which ACV-TP is not a good substrate. The by-pass of the first 
step of phosphorylation may be achieved by applying the ProTide technology to 
ACV. The intracellular delivery of the monophosphate may lead to a reduced 
antiviral selectivity, but the activity against TK-deficient ACV resistant HSV can 
be enhanced. Moreover, activity may also be broadened to other viruses.
«nA h
ho^ ° ^ N N NHa
9
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7.2 Design of acyclovir phosphoramidates
Previously, we reported the synthesis of a masked phosphate (199a, Fig. 7.2), 
using the phosphoramidate technology, with the purpose to obtain a nucleoside 
kinase-independent antiviral.5 The data on 199a shows that the activity is similar 
to ACV against HCMV and VZV, whilst surprisingly the compound was totally 
inactive against HSV-2, while ACV is active.5
In order to improve the activity of 199a, a new series of ACV phosphoramidates 
has been synthesised (199b-m, Fig. 7.2).
o
o
Compounds Ar R R’ X CLogP
199a Ph Me H Me -0.82
199b Ph Me H Bn 0.89
199c Ph Me H 'Pr 0.02
199d Ph H Me Bn 0.89
199e p-F-Ph Me H Bn 1.11
199f Naph Me H Me 0.35
199g Naph Me H nPr 1.41
199h Naph Me H Bn 2.06
199i Ph Bn H Bn 2.31
199j Naph Me Me Bn 2.37
199k6 Naph Me H Et 0.88
19916 Naph Me H 'Pr 1.19
199m6 Naph Me H lBu 1.59
Fig. 7.2 : ACV phosphoramidates.
As already seen in Chap. 1, the ProTide moiety has three different changeable 
parts: the aryl moiety, the amino acid and the ester. In the first part of this study 
L-alanine was chosen as the amino acid, as it has shown an optimal biological 
profile,7 whilst varying the other two components. For the aryl moiety were 
considered: phenol, 1-naphthol and /7-fluoro-phenol and as ester moiety: methyl,
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ethyl, rt-propyl, /50-propyl, rm-butyl and benzyl and combinations thereof. All 
these combinations allowed us to extensively vary the CLogP for these 
compounds and to study how this variation can influence the antiviral activity. For 
example, 1-naphthol was chosen to improve the lipophilicity and for its leaving 
group ability, fundamental in the activation of phosphoramidates. Moreover, an 
enhancement of activity against a panel of cancer cell lines for naphthol 
phosphoramidates of other nucleosides has been reported.8 9 In addition, L- 
phenylalanine and the non-natural amino acids D-alanine and dimethylglycine 
have been considered.
7.3 Synthesis of acyclovir ProTides
In order to improve the poor solubility of ACV in the optimal solvent (THF), 
usually used for the preparation of phosphoramidates, the guanine base was 
protected using V,V-dimethylformamide dimethyl acetal (Scheme 7.1).10
o o
i'-fV ‘ . ('Til
N ^ N ^ N H ;  _  O  n ^ n ^ n ^ n - ^ 3
H O ^ 0 ^  CH,
9  2 0 0 ,9 7 %
R eagents and C onditions: (/) N ,N -d im ethy lfo rm am ide d im ethyl ace ta l, D M F, rt, 1 day.
Scheme 7.1: protection of ACV with DMF.
The solubility was improved sufficiently and compound 200 was coupled 
(Scheme 7.2) with the appropriate phosphorochloridate (131a, d-h, 193a, d, e) 
using ‘BuMgCl as a hydroxyl activator,11 in anhydrous THF giving the desired 
compounds (201 a-j). The deprotection step was initially carried out by refluxing 
the N2-DMF-protected ProTides in ^-propanol. However, due to a transesteri- 
fication during the synthesis of 199h, obtaining compound 199g, the solvent was 
changed to 2-propanol obtaining the desired compounds (199a-f, h, i).
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O  Ar 
C I - P - 0
HO
200
N ^A NH
x.oJ T r
CH* 11 R'
• T o ^ 0^  N n^ n'°Hj
NH
x V > R 2#li" io
CH,
13 1 a  A r= P h , R = C H 3, R ’= H , X = M e 
131d  A r= P h , R = C H 3 . R '= H , X = B n  
131e A r= P h , R = C H 3 , R '= H , X = jPr 
1 3 1 f A r= P h , R = H , R '= C H 3, X = B n  
131g  A r= P h , R = B n , R '= H , X = B n  
131h  A r= p -F -P h , R = C H 3, R '= H , X = B n  
19 3 a  A r= N a p h , R = C H 3 , R '= H , X = B n  
1 9 3 d  A r= N a p h , R = C H 3, R '= H , X = M e 
193e A r= N a p h , R = C H 3, R '= C H 3 , X = B n
NH
O
u xArO ^
O-P-O^^ ^
NH
x.O ^ X r
o R
NH,
R eagents and C onditions: (/') ‘B uM gC l, anhydrous TH F, rt, overn igh t, (//') 1-propanol or 2-propanol, reflux , 18-96 h.
Scheme 7.2: synthesis of ACV ProTides.
All the compounds have been obtained as mixtures of two diastereoisomers 
confirmed by the presence of two peaks in the 31P-NMR, with the exception of the 
dimethylglycine derivative 199j, due to the absence of a second chiral center. 
Table 7.1 summarises the ACV ProTides made.
Compounds Ar R R’ X J,P NMR Yield
199a Ph Me H Me 3.72,3.55 13%
199b Ph Me H Bn 3.80,3.50 14%
199c Ph Me H 'Pr 3.80,3.65 7%
199d Ph H Me Bn 3.80,3.50 25%
199e /7-F-Ph Me H Bn 4.02,3.78 16%
199f Naph Me H Me 4.07, 4.05 7%
199g Naph Me H nPr 4.09, 4.01 4%
199h Naph Me H Bn 4.13,3.96 35%
199i Ph Bn H Bn 3.41,3.31 14%
199j Naph Me Me Bn 2.52 23%
Table 7.1: summary of ACV ProTides
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7.4 Biological evaluation of acyclovir ProTides
The synthesised compounds 199a-j and the previously reported 199k-m6 were 
evaluated for their ability to inhibit the replication of different viruses.
7.4.1 Anti-HSV activity of acyclovir ProTides
Table 7.2 reports the antiviral activity of ACV ProTides versus HSV-1 (TK 
efficient and TK deficient strains) and HSV-2.
Antiviral Activity 
ECso (pM)a
Cytotoxicity
(1AM)
Compounds CLogP HSV-1 HSV-2 HSV-1 TK MCCb i c 50c
199a -0.82 20±0 16±5.7 79±29 >100 -
199b 0.89 8±5.7 4±0 15±7.1 >50 91
199c 0.02 10±0 8.5±0.7 27±25 >50 >100
199d 0.89 2±0 1.4±0.8 23±16 >100 -
199e 1.11 0.9±0.1 0.5±0 1.5±0.7 >100 -
199f 0.35 16±5.7 10±2.1 79±29 >50 >100
199g 1.41 5.5±2.1 1.9±1.6 16±5.7 >50 68
199h 2.06 2±0 1.4±0.8 10±2.1 >20 20
199i 2.31 17±4.2 8±5.7 >100 >50 87
199j 2.37 2.4±0 1.6±1.1 3.2±1.1 >50 >100
199k6 0.88 32±25 9.5±0.7 32±18 >150 >100
19916 1.19 15±7.1 10±0 >45 >50 >100
199m6 1.59 >100 50 >100 >50 >100
ACV -2.42 0.4 0.2 50 >100 -
a) effective concentration required to reduce virus plaque formation by 50%;
b) m inim um  cytotoxic concentration  that cause a microscopically detectable alteration o f  cell m orphology;
c) inhibitory concentration required to inhibit cell proliferation by 50%.
Table 7.2: antiviral activity against HSV-1 and 2 for ACV ProTides including 
ACV as a control.
The antiviral activity of ACV was in the sub-micromolar range versus HSV-TK 
efficient strain, whilst it lost activity versus the HSV-1 TK-deficient strain (50 
p,M). Interestingly, almost all the ACV ProTides showed activity against all the 
strains with some exceptions. The majority of the compounds showed activity in 
the range 1-30 p,M and notably retaining a good activity against the TK-deficient
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strain. Only one compound 199m, bearing the ‘butyl group as an ester did not 
show any activity. The lack on activity for this compound will be discussed later 
in this chapter. No relation between the lipophilicity and activity has been found 
for these compounds. The activity of several ACV ProTides versus the HSV-1 
TK-deficient strain demonstrates a successful kinase bypass for these compounds. 
Moreover, in spite of being less selective due to the viral kinase bypass, these 
compounds did not show appreciable cytotoxicity.
7.4.2 Anti-VZV activity of ACV ProTides
Table 7.3 reports the antiviral activity of ACV ProTides versus VZV (two strains 
of TK efficient and two strains of TK deficient).
Antiviral Activity 
EC50 (pM)a
Cytotoxicity
(pM)
Cpds CLogP -
TK f VZV TK VZV
MCCb c c 50cYS
strain
OKA
strain
07/1
strain
YS
strain
199a -0.82 20 19 24 16 >100 162
199b 0.89 1.0 0.72 1.8 0.59 >50 >100
199f 0.35 10.9 7.6 22 6.1 >50 >100
199g 1.41 2.8 1.4 2.5 - >50 -
199h 2.06 3.3 7.2 6.9 - >50 20
199i 2.31 6.6 5.2 8.4 10.0 >50 86.9
199j 2.37 1.7 5.5 6.0 3.33 >100 >100
ACV -2.42 2.9 2.5 61 43 >500 1350
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration  that cause a m icroscopically detectable alteration o f  cell m orphology;
c) cytotoxic concentration  required to reduce cell growth by 50%.
Table 7.3: antiviral activity against VZV for ACV ProTides including ACV as a 
control.
Most of the compounds showed good potency in these assays, showing retention 
of activity compared to ACV. Notably, several of the agents retain activity versus 
TK deficient strains, whilst ACV showed a loss of activity. Interestingly, 
compound 199b showed submicromolar activity and it retained activity versus TK 
deficient strains. Moreover, the compounds tested did not show cytotoxicity while 
compound 199h did show some toxicity (20 pM).
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In this case as well no clear relation between lipophilicity and activity has been 
found for these compounds. However, compound 199a, which has the lowest 
CLogP, showed the lowest antiviral activity and it may be due to a poor 
intracellular uptake.
7.4.3 Anti-HCMV activity of ACV ProTides
Table 7.4 reports the antiviral activity of ACV ProTides versus HCMV.
Cpds CLogP
Antiviral Activity 
EC50 (pM)8
Cytotoxicity
(1AM)
AD-169
strain
Davis
strain MCCb c c 50c
199a -0.82 >50 31.6 >100 162
199b 0.89 12.6 2.9 >50 >100
199f 0.35 39.8 10 >50 >100
199g 1.41 13.4 0.8 >100 67.5
199h 2.06 2.1 1.8 >100 59.4
199i 2.31 20 10 >50 86.9
199j 2.37 6.0 2.1 >100 >100
199k 20 2.5 > >50 >100
1991 1.19 31.6 5.0 >50 >100
199m 1.59 >50 >50 >50 >100
GCV -2.54 3.60 5.7 >200 857
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration that cause a m icroscopically detectable 
alteration o f  cell m orphology;
c) cytotoxic concentration  required to reduce cell growth by 50%.
Table 7.4: antiviral activity against HCMV for ACV ProTides including GCV as 
a control.
The activity of ACV ProTides against HCMV again confirmed the success of the 
phosphoramidate technology when applied to ACV. In fact, some of the 
compounds showed inhibitory activity against HCMV comparable to GCV, which 
is currently the treatment of choice of this type of infection.
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7.4.4 Biological activity versus osteosarcoma of ACV ProTides
Table 7.5 reports the activity against osteosarcoma (OST) cells; both a TK
deficient strain and TK deficient/HSV-1 TK-competent strain.
Compounds CLogP
Antiviral Activity 
C C 5 0  (pM)
OST TK OST TK /HSV-1 TK+
199a -0.82 6.6±4.1 2.7±0.5
199b 0.89 2.4±1.8 0.52±0.33
199f 0.35 0.85±0.30 0.40±0.24
199i 2.31 149±76 1.0±0.9
1991 2.37 0.65±0.30 0.14±0.04
199m 1.59 205±85 3.8±1.8
ACV -2.42 102±64 0 .14±0.06
Table 7.5. Antiviral activity against OST for ACV ProTides including ACV as a 
control.
The results from Table 7.5 prove the successful by-pass of the first step of 
phosphorylation delivering the monophosphate form inside the cells. In fact, in 
the TK deficient strain, ACV is inactive, while most of its prodrugs are active. In 
the strain with HSV-1 TK, ACV becomes active and the ProTides retain activity. 
Interesting results are from two of these prodrugs: 199i and 199m. In fact, they 
did not show any activity against the TK deficient strain, this is due to the poor 
bioactivation of this prodrug to the deliver the monophosphate. Compound 199* 
bears the L-phenylalanine as amino acid, which is not the ideal amino acid and it
I ^
showed loss of activity compared to the L-alanine derivatives for instance. 
Compound 199m bears the tert-buiy\ as amino acid ester, which is not process by 
the carboxypeptidase esterase as the tert-butyl moiety is too bulky and is not able
1 9to interact with the active site of the enzyme. The activity found for these 
compounds against TK competent strain can be due to the cleavage of the prodrug 
to deliver ACV followed by phosphorylation to the monophosphate form 
mediated by the HSV-1 TK.
133
Marco Derudas Chapter 7
No activity (> 100 pM) for these compounds has been found against: 
parainfluenza-3-virus, reovirus-1, sindbis virus, coxsackie virus B4, vesicular 
stomatitis, respiratory syncytial virus, punta toro virus, influenza A virus, 
influenza B virus, feline corona virus, feline herpes virus (data not shown).
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7.5 Acyclovir ProTides as anti-HIV reverse transcriptase inhibitor
ACV is, as already described at the beginning of the chapter, the current treatment 
of choice for VZV and HSV infection. Its mechanism of action is well understood 
involving inhibition of the viral DNA polymerase and causing the termination of 
the nascent viral DNA chain. Due to the specificity of the phosphorylation 
mediated by specific HHV kinase, ACV shows activity only against HHVs. 
However, clinical study indicates the possible inhibition of HIV-1 by ACV in 
patients coinfected with HHV.13 The reduction of HIV-1 load in these patients has 
been recently reported.14 The mechanism of this suppression was not very clear. 
Further studies demonstrate that ACV is an anti-HIV agent only in the presence of 
HHV co-infections. In fact, in the presence of HHV kinase, ACV can be 
phosphorylated to the monophosphate form and then further is converted to the 
triphosphate form and inhibit the HIV-1 RT.
Since the first phosphorylation step of ACV is specifically carried out by HHV- 
TK, it was clear to test the anti-HIV activity of the ACV ProTides.
7.5.1 Biological evaluation versus HIV of acyclovir ProTides
The ACV ProTides were evaluated for their ability to inhibit the replication of 
HIV-1 and HIV-2 (CEM) and HIV-1 (MT-4) (Table 7.6).
ACV did not show any activity against HIV-1 and 2, whilst almost all of its 
ProTides showed activity. In particular, all the L-alanine derivatives with the 
exception of 199c, e, m, showed inhibitorial activity against HIV in a range of 
6.2-17 \xM against HIV-1 (CEM), in a range of 0.8-15 |uM against HIV-1 (MT-4) 
and in a range of 8.9-42 p,M against HIV-2 (CEM). No clear SAR could be 
observed for these compounds in terms of lipophilicity, and also regarding the 
aryl and ester moieties. The lack of activity obtained for compound 199m, bearing 
the ‘butyl group as an ester, is in agreement with the literature.12 The lack of 
activity found for compound 199c is quite surprising, as the naphthyl derivative 
1991 was active. The substitution of L-alanine with L-phenylalanine 199i led to a 
decrease of activity, whilst the substitution with the non-natural amino acid D- 
alanine 199d and dimethylglycine 199j led to a loss of activity. In the case of the 
dimethylglycine derivative, this lack on activity is quite surprising as from 
previous studies this type of substitution is usually well tolerated. The lack of
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activity found for the D-alanine derivative is in agreement with the literature.12 
Thus L-alanine seems strongly preferred here.
Antiviral Activity 
ECso (pM)a
Cytotoxicity
(pM)
Cpds CLogP
HIV-1
CEM
HIV-2
CEM
HIV-1
MT-4
i c 50b
CEM
CC50c
MT-4
IC50b
MT-4
199a -0.82 17±4.6 26±8.5 15 67±7.8 - -
199b 0.89 16±14 11 ±4.9 5.7±1.6 42±11 >150 33.8±10.6
199c 0.02 >100 >100 >150 >100 >150 >150
199d 0.89 >250 >250 - >250 - -
199e 1.11 >20 >20 - 76±13 - -
199f 0.35 10±7.9 13±6.4 4.7±2.1 57 >150 18.7±3.2
199g 1.41 6.6±5.6 24±30 10 22 - -
199h 2.06 15±14 8.9±6.3 0.8 17 - >150
199i 2.31 26±11 34±24 16 42 - -
199j 2.37 >100 79±30 - >100 - -
199k6 0.88 12±9.8 42± 13 1.7±0.8 32±7.8 >150 18.7±3.2
19916 1.19 6.2±5.4 12±0.71 5.4 36±15 >150 72.5
199m6 1.59 >100 >100 >150 >100 >150 >150
ACV -2.42 >250 >250 >250 >250 >250 >250
a) effective concentration  required to reduce virus plaque formation by 50%;
b) cytotoxic concentration required to decrease the viability o f  the cell cultures by 50%;
c) inhibitory concentration required to inhibit cell proliferation by 50%.
Table 7.6: anti-HIV activity for ACV ProTides.
One of the major issues for this new class of anti-HIV compounds is their 
cytotoxicity. In fact, all of these compounds showed an antiproliferative effect in 
the range 17-76 pM in the case of CEM and 12-34 pM in the case of MT-4. Thus, 
by-passing HHV-TK does have a potential toxicity penalty.
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7.6 Acyclovir ProTides as anti-HCV inhibitors
After the discovery of the anti-HIV activity for the ACV ProTides, these 
compounds have been tested against HCV, with interesting results (Table 7.7).
Cpds Aryl
Amino
Acid
Ester CLogP
Antiviral 
Activity 
EC5o (pM)a
HCV
Huh-5-2
Cytotoxicity
(M-M)
CC50b
199b Ph L-Ala Bn 0.89 12 >66
199c Ph L-Ala ipr 0.02 32 >33
199d Ph D-Ala Bn 0.89 >33 >33
199e /7-F-Ph L-Ala Bn 1.11 22 >33
199f Naph L-Ala Me 0.35 19 >33
199g Naph L-Ala nPr 1.41 10 >33
199h Naph L-Ala Bn 2.06 8.7 >33
199i Ph L-Phe Bn 2.31 25 >66
199j Naph DMG Bn 2.37 11 >33
199k6 Naph L-Ala Et 0.88 17 >66
199m6 Naph L-Ala lBu 1.59 33 >33
ACV - - - -2.42 30 >33
a) effective concentration required to reduce virus plaque formation by 50%;
b) cytotoxic concentration required to decrease the viability o f  the cell cultures by 50%;
Table 7.7: anti-HCV activity for ACV ProTides.
ACV showed activity (30 pM) against HCV. All the compounds tested showed 
activity versus HCV in the range 8.7-33 pM, with the best result achieved with 
compound 199h, which is 3 times more active than the parent. The D-alanine 
derivative 199d did not show any activity. Also in this experiment, no clear-cut 
SAR could be observed with regard to the nature of the aryl moiety, the alaninyl 
ester moiety or lipophilicity. Notably, none of the compounds tested showed any 
cytotoxicity in this test.
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7.7 Summary of ACV ProTides activity
The application of the phosphoramidate ProTide technology to ACV has been a 
success. In fact, in different tests this technology allowed us to extend and in 
some cases to improve the antiviral activity of ACV. In the case of the HSV, ACV 
ProTides showed a successful by-pass of the first step of phosphorylation, 
showing activity versus TK-deficient strains, for which ACV showed a loss of 
activity. These results have been confirmed also against VZV, with retention of 
activity against TK-deficient strains.
The extention of activity versus HCMV and HCV, but more importantly versus 
HIV, showed the success of this technology applied to ACV.
Analysing all the results, it is possible to summarise that the L-alanine is optimal 
for the antiviral activity, especially against HIV for which the substitution with 
other amino acids led to a decrease of activity. The anti-HSV and anti-VZV 
activity seems to tolerate some amino acid substitutions. This aspect may be due 
to a different bioactivation of the ACV ProTides in these two tests, due for 
example to different specificities and/or different intracellular levels of the 
necessary activating enzymes.
In order to investigate the differences in activity found for these compounds, 
enzymatic and molecular modelling studies have been performed.
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7.8 Enzymatic studies using carboxypeptidase Y on ACV ProTides
The supposed mechanism of activation of ProTides has been already described in 
Chap. 1 and 6.To investigate the difference in activity found for some of the ACV 
ProTides enzymatic studies using carboxypeptidase Y, as already seen with the 
ribavirin ProTide, have been performed. For these experiments compounds 199b, 
c and m were chosen because 199b was active against all HSV, VZV, HIV, HCV; 
199c was against HSV, VZV and HCV but not versus HIV, whilst 199m was 
inactive in all the biological assays.
The same procedure used in Chap.6 was followed, dissolving the compound in 
acetone-^ and trizma buffer (pH = 7.6) and recording a blank before the addition 
of the enzyme.
o __ o
NH 204
-o. 'CH.
<'N/ x
o l o — ° "  N NHi
0=^NH 
H3C
203
—r- 
5.5
—r-
7.5
—|— 
7.0
—r— 
6.0
—r~
5.0
—I—
4.5
“ I—
3.06.5 4.0 3.5 2J
15h
11.30b
lOh
6b
4h
2.30h
1.20h
lh
TlSmin
lOmin
3m in
S ta rtin g
M ateria l
Fig. 7.3: carboxypeptidase-mediated cleavage of compound 199b, monitored by
3Ip n m r .
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Compound 199b (Fig. 7.3, Sp= 3.65 and 3.60) was fast hydrolised to the 
intermediate 202 (5p= 4.85 and 4.70), which is then further processed to the final 
compound 204 (Sp= 7.10). Notably, the intermediate 203 is detected by the 31P 
NMR. The half-life of compound 199b is 17 min.
1 week
72h
63h
47h
45h
12h
S ta rtin g
M aterial
7.5 7.0 6.5 6.0 55 5.0 4J 3.0
Fig. 7.4: carboxypeptidase-mediated cleavage of compound 199c, monitored by
3Ip n m r .
In the case of the isopropyl derivative 199c, the experiment (Fig. 7.4) shows a 
slow conversion of the starting material to the desired compound 203 (6p= 7.10) 
showing an half-life of 46 h and the need of more enzyme to complete the 
hydrolysis. Notably, it seems from the spectra that one of the two 
diastereoisomers is faster metabolised than the other.
■v*- 15h
Uh
3m in
T "
7.3
”T“
7.0
“ 7“
6.3
“ T”
6.0
T”
5.5
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5.0
_r-
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“ I
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"T“
3.5
Fig. 7.5: carboxypeptidase-mediated cleavage of compound 199m, monitored by
3ip n m r .
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The experiment (Fig. 7.5) of the tert-bu\y\ derivative 199m showed no conversion 
at all, and this result is in accordance with the lack of antiviral activity for this 
compound and it is probably due to the presence of the /er/-butyl moiety which is 
too bulky to be processed by the enzyme.
These experiments show that ACV ProTides need to be bioactivated in order to 
show the antiviral activity. The results found for these experiments are in 
agreement with the results found in the anti-HIV assay and the assay may be 
regarded as partially predictive of antiviral efficacy.
The different results obtained for these three compounds have been investigated 
using molecular modelling techniques.
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7.9 Molecular modelling-1: carboxypeptidase Y enzyme
Carboxypeptidase Y is considered to be one putative enzyme responsible for the 
cleavage of the amino acid ester moiety. In order to understand the results 
obtained in the enzymatic experiments, molecular modelling studies using 
docking techniques have been performed on the crystal structure of the enzyme 
(PDB 1YSC).15 The mechanism of action of this enzyme involves firstly the 
attack of the Seri 46 to the carbonyl of the ester, which is coordinated with the NH 
from Gly52 and Gly53.16 Fig. 7.6 reports the catalytic site of the enzyme with the 
docking of compound 199b.
Fig. 7.6: catalytic site of carboxypeptidase Y.
The catalytic site consists of two different pockets. In the pocket on the left is 
placed the ester of the amino acid (red in the picture), whilst in the pocket on the 
right is placed the aryl moiety of the phosphoramidate (blue). The nucleoside base 
(yellow) is placed outside the pocket.
Compound 199b showed a positive interaction, for both phosphate 
diastereoisomers, with the active site of the enzyme (Fig. 7.7, shown RP 
diastereoisomer). In fact, the carbonyl group is in a favourable position for the 
coordination with the NH of both Gly52 and Gly53, and it is able to interact with 
the catalytic Seri46. This result supports the enzymatic result obtained for this 
compound.
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,V_5J
Fig. 7.7: docking of compounds 199b (Rp) within the catalytic site of 
carboxypeptidase Y.
In the case of compound 199c (Fig. 7.8, shown Rp diastereoisomer) different 
results have been obtained in the case of the Rp diastereoisomer and the Sp 
diastereoisomer.
4 33
Fig. 7.8: docking of compounds 199c (RP) within the catalytic site of 
carboxypeptidase Y.
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In fact, while for the Rp the carbonyl group is in a positive orientation for the 
attack of the Seri46, the carbonyl of the Sp diastereoisomer is situated in a 
different orientation and it is not able to coordinate properly with Gly52 and 
Gly53. This result support the difference in the metabolism found for this 
compound in the enzymatic assay, which showed a faster metabolism for one 
diastereoisomer compared to the other. It is striking that the docking predict an 
isomeric difference here, where observed in the assay, but not for compound 199b 
earlier, where no difference was observed in rate.
The carbonyl of compound 199m (Fig. 7.9, shown Sp diastereoisomer) is not in a 
favourable position due to the presence of the bulky tert-butyl ester. In fact, the 
carbonyl group is not able to interact with the two glycines with a consequent 
poor activation for this compound, in agreement with the enzymatic result.
■V_53
-V_52
560
550
Fig. 7.9: docking of compounds 199m ( S p)  within the catalytic site of 
carboxypeptidase Y.
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7.10 Molecular modelling-2: human Hint enzyme
As already mentioned in Chap.6, human Hint enzyme is considered to be 
responsabile for the cleavage of the phosphorus-nitrogen bond with consequent 
release of the monophosphate form (Fig. 7.10).
o
Fig. 7.10: cleavage of the phosphorus-nitrogen bond mediated by human Hint 
enzyme.
A molecular modelling study using docking techniques has been performed for 
compound 204. (Fig. 7.11 and Fig. 7.12).
Fig. 7.11 reports the interaction of compound 204 with the amino acid involved in 
the cleavage of the phosphorous-nitrogen bond.
Fig. 7.11: interaction of compound 204 within the catalytic site of human HINT 
(I) enzyme
o n
©
145
Marco Derudas Chapter 7
Fig. 7.12: docking of compound 204 within the catalytic site of human HINT (I) 
enzyme
The results from this experiment are quite clear. The compound binds in the 
active site of the enzyme. The phosphate moiety (pink) is in a suitable position for 
the cleavage of the P-N bond. The guanosine base positively interacts with the 
enzyme.
This experiment suggests that the last of the bioactivation of the ACV ProTides, 
in particular L-alanine derivatives, may proceed well, supporting the antiviral 
activity found for this compound.
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8. Virtual Screening on Acyclovir as an anti-HIV agent
The anti-HIV activity found for the ACV ProTides was extremely interesting and 
surprising as these compounds were never previously recognised as anti-HIV 
agents. However, these compounds have been found to be somewhat cytotoxic. In 
order to reduce the cytotoxicity and to boost the potency for these compounds, a 
virtual screening has been performed using docking techniques and using HIV- 
RT, adenylate or guanylate kinase and DNA polymerase y. The goal is to increase 
the specificity for HIV-RT while retaining substrate action of adenylate or 
guanylate kinases.
8.1 Building the acyclovir derivatives database
A compound database has been built considering modifications at the nucleoside 
base and at the acyclic sugar moieties. Fig. 8.1 reports the modifications 
considered and their possible combinations, including:
- simple and branched acyclic sugars;
- oxygen, methylene or sulphur at the 2’-position;
- substitution at the 8-position of the base including: hydrogen, methyl, fluorine, 
bromine or chlorine;
- substitution at the 7-position of the base including: nitrogen or carbon (hydrogen 
or methyl substituted);
- substitution at the 6-position of the base including: carbonyl, amine, chlorine, 
methoxide, ethoxide, phenoxy, methylamine, or cyclopropylamine;
- substitution at the 2-NH position of the base including: hydrogen, methyl, ethyl, 
phenyl or benzyl.
Q = H o r  c h 2o h  
= O, CH2 or S 
Q = H ,C H 3,F , Br or Cl 
Q = N ,C H o rC C H 3
O = c=o, n h 2, a , o c h 3, o c h 2c h 3,
OPh, NHCH3 or NH-cyclopropyl 
Q = H ,  CH3, CH2CH3, Ph or Bn
Fig. 8.1 : ACV derivatives database.
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The combination of all these substitutions gives a total of 3600 compounds. The 
database was divided in two different groups considering the modification at the 
6-position of the base. The first group (3150 compounds) bears the substitution at 
the 6-position compared to ACV. The second group (450 compounds) bears the 
carbonyl moiety at the 6-position. The splitting in two different groups is due to a 
difference in the base pairing. In fact, while the 6-carbonyl compounds, being a 
guanosine analogues, have a base pairing with the cytidine, with the three 
hydrogen bonds, for the 6-modified derivatives, preliminary docking study, 
showed a better base pairing with the thymine (Fig. 8.2). In fact, in the case of the 
6-O-modified derivatives two hydrogen bonds are observed, whilst in the 6-N- 
modified derivatives three hydrogen bonds between the bases are detected.
Fig. 8.2 : base pairing of the 6-carbonyl and 6-modified ACV derivative.
Moreover, the stereochemistry of all the compounds bearing the substitution at the 
acyclic sugar moiety has been considered.
8.2 First screening: docking using HIV-RT enzyme
The first screening considered was using HIV-RT. For these experiments a crystal 
structure of HIV-RT co-crystalized with TNF diphosphate was used (PNB: 
1T05).1
The original structure was used for the docking of the 6-modified ACV 
derivatives, whilst for the 6-carbonyl derivatives the thymine of the enzyme was 
substituted with cytidine. All the compounds were docked in the triphosphate 
form, as they should interact with the catalytic site of RT and act as a chain 
terminator.
Fig. 8.3 reports the catalytic site of HIV-RT including TNF diphosphate.
R H
6-carbonyl-ACV - cytidine 6-O-modified-ACV - thymidine 6-N-modified-ACV - thymidine
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Fig. 8.3 : the catalytic site of RT co-crystalized with TNF diphosphate.
For the first screening, a root mean square deviation (RMSD) < 1 A, which results 
in a good base pairing, was considered. The RMSD measures the difference 
between the prediction and the compound crystallized, in this case respectively 
the compounds docked and TNF diphosphate. In particular, for this experiment 
the deviation from the base of the compounds docked and the base of TNF 
diphosphate has been considered. This allowed us to reduce the number of 
compounds to 782 for the 6-modified group and to 202 for the 6-carbonyl group, 
giving a total of 984 compounds.
Fig. 8.4 reports the best five results for the 6-modified derivatives.
OH
R M S D  = 0.1778 RM SD = 0.3016
R M S D  =  0.3097 RM SD = 0.3190
OH
RM SD = 0.3292
Fig. 8.4 : best HIV-RT 6-modified docked compounds.
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From this first screening, it has been observed that the branched sugar compounds 
are preferred. In fact, in the catalytic site of the enzyme the Tyr 115 and Phe 116 
form a pocket (Fig. 8.5), which is able to accommodate a substitution in the sugar 
moiety. Moreover, another pocket can accommodate a potential substitution at the 
2-amino position. In addition, the substitutions at the 8-position of the base are 
permitted, especially halogen substituents.
Fig. 8.5 reports the docking of the 6-modified derivative with the lowest RMSD. 
Notably, the position of the OH of the branched sugar and of the ethyl at the 2- 
amino position are observed.
Fig. 8.5: docking of the 6-modified derivative with the lowest RMSD.
Fig. 8.6 reports the best five results for the 6-carbonyl derivatives. Also in this 
case, the substitution at the 8-position, the branched sugar and the substitution at 
the 2-amino position are preferred. Notably, the best result for this docking has 
been achieved with GCV.
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o* o- 9- 
0 o o o
Cr Cr O'
N ^ M  MW ' 1 1 N
Q>™ N NH2 ^ P w k ~ . P w ^ ^ " s J  N NH2
OH
R M S D  =  0.1778
9- 9- 9- 
O O O
H’cv 1
® - o c
NH
A .N - CH3 
RM SD =  0.3097
• ° > 6 0 ' 6 ' o ^
?• 9- 9- 
v.p__p___p>
RM SD = 0.3016
NH
N^N^N^CH3 
H
OH
RM SD = 0.3190
O
7 7  7  CI_0 Co d  d  _ r\ . N9
-o '^ o '^ o '^ o ^ VO O O ^
R M SD  =
Fig. 8.6 : best HIV-RT 6-carbonyl docked compounds.
NH
O.J " ^ f p C H a
wOH
 0.3292
Fig 8.7 reports the docking of GCV triphosphate within the active site of the RT.
Fig 8.7: docking of the 6-carbonyl derivative with the lowest RMSD.
The branched sugar of (/?)-GCV is accommodated in the pocket formed by the 
two residues Tyrl 15 and Phel 16.
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8.3 Second screening: docking using adenylate kinase or guanylate kinase
For the second docking adenylate kinase or guanylate kinase were considered. For 
these docking experiments the monophosphate form of the compounds were used 
as these two enzymes catalysed the second step of phosphorylation. The docking 
using kinases that catalysed the phosphorylation to the monophosphate were not 
considered as the phosphoramidate ProTides approach will be applied to the 
selected compounds.
8.3.1 Adenylate kinase docking
The first group of compounds, which bear the 6-modified base, was docked with 
adenylate kinase, as from preliminary docking they showed better results. The 
enzyme used was a crystal structure in complex with PI, P4- 
di(adenosine)tetraphosphate (PDB: 2C95).2
Fig. 8.8 reports the structure of the enzyme with adenosine diphosphate.
Fig. 8.8: crystal structure of adenylate kinase with adenosine diphosphate.
From Fig. 8.8, it is possible to see a pocket close to the sugar moiety and more 
specific to the 3’-position of the sugar. This pocket could allow substitution on the 
acyclic sugar moiety of the ACV derivatives. For these docking experiments, two
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different RMSDs have been considered: the first regarding the position of the base 
(<1 A) and the second considering the position of the phosphate moiety (<3 A). 
These two values allowed a good position of the base and a reasonable position 
for the phosphate moiety, which, however, in same cases, was slightly moved 
compared to the crystallized compound.
Fig. 8.9 reports the best five results for the 6-modified derivatives considering the 
position of the base. In most of the cases, the branched sugar is still preferred. 
Notable from Fig. 8.9 is the presence of the chlorine at the 6-position.
ci ci a
a  a  <T X  CH a* -  n * A N^NH, v | ; 0 ^ " ^P ^  O l   N H 2  A _  /-) Y N N A ^  S N 'N T 'N H 2
0' 6 ° ^ '  H ■O s'o 'V  ^
"OH "OH
RMSD-1 = 0 .18 59  RMSD-1 =  0.2206 RMSD-1 =  0.2341
RM SD -2 = 2.7566 RM SD-2 =  1.5952 RM SD-2 = 1.0007
a
O-
NH,
OH
RM SD-1 = 0 .2 4 1 2  RMSD-1 =0.2415
RM SD -2 =  1.9541 RM SD-2 = 2.4873
Fig. 8.9: best adenylate kinase 6-modified docked compounds.
In Fig. 8.10 is reported the compound within the catalytic site of the enzyme with 
lowest RMSD for the base.
Fig. 8.10: adenylate kinase docking of the 6-modified ACV derivative.
4
155
Marco Derudas Chapter 8
The compound showed a good position of the base, whilst the monophosphate 
moiety was found to be slightly in a different position compared to the 
crystallized compound.
8.3.2 Guanylate kinase docking
The second group of compounds, the 6-carbonyl ACV derivatives, has been 
docked using guanylate kinase. For this experiment the mouse enzyme co­
crystallized with guanosine monophosphate GMP (PDB: 1LVG)3 was used 
showing a similarity with the human enzyme of 88%.
Fig. 8.11 reports the crystal structure of the catalytic site of the enzyme with 
GMP.
Fig. 8.11: catalytic site of guanylate kinase co-crystallized with GMP.
Notable is the presence of a pocket in the proximity of the 3’-position of the 
sugar.
Fig 8.12 reports the best results found for the 6-carbonyl derivatives considering 
the position of the base. Also in this case, RMSD < 1 and < 3 compared 
respectively to the position of the base and to the position of the phosphate of the 
crystallized compound were considered. From these results, the branched sugar is
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still well tolerated and also the substitution at the 8-position with a preference to 
the halogens, whilst the substitutions at the 2-amino position are less tolerated.
o o o
O- K NK  a  O u T
N NHj - o - e w 3-? "2 N NH’
OH OH OH
R M S D - 1 =  0 .2 1 1 9  R M S D -1 =  0 .2 2 0 4  R M S D -1 =  0 .2 2 2 1
R M S D -2  =  0 .8 2 9 8  R M S D -2  =  1 .8 5 7 8  R M S D -2  =  1 .8 7 4 6
O O
0. H O - O C V  a
A _  o p NA NH2 a .  .  n ^ n^ nh,O'“' 0 ^  ^ n'Ur ■2'■v yvwv' ^O
^OH O^H
R M S D - 1 =  0 .2 3 6 5  R M S D -1 =  0 .2 5 6 2
R M S D -2  =  1 .9 9 2 8  R M S D -2  =  1 .5 7 4 0
Fig. 8.12: best guanylate kinase 6-carbonyl docked compounds.
Fig 8.13 reports the docking of the compound with the lowest RMSD compared 
to the position of the base and also showing a good RMSD of the phosphate 
moiety position. In addition, the OH of the branched acyclic sugar is well 
positioned.
Fig. 8.13: guanylate kinase docking of the 6-carbonyl ACV derivative.
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From the virtual screening using either the adenylate or the guanylate kinases the 
number of compounds drops to 218 compounds, of which 63 compounds belong 
to the 6-modified ACV derivative and 155 compounds belong to the 6-carbonyl 
derivatives.
From these first two results seems that the 6-carbonyl group is preferred to the 
modifications in this position. Moreover, good results have been obtained with the 
modification at the sugar moiety and also the substitution at the 8-position with 
halogens.
8.4 Third screening: docking using human polymerase y
The last part of the virtual screening includes the use of the human polymerases. It 
is known that the toxicity of the NAs, especially RT inhibitors, is due to 
interactions with these enzymes.4'7 The subtypes of human polymerase mainly 
involved in the cytotoxicity are: a  and y. Unfortunately, the crystal structures for 
both human polymerases have not yet been identified. However, a model for the 
human polymerase y is available.8 DNA polymerase y is able to incorporate the 
antiviral NtAs, which act as a chain terminators and consequently show 
cytotoxicity.9' 12
The two databases obtained after the first two screening were converted to the 
triphosphate form, as in this form NAs are able to interact with the polymerase. In 
this case, the results were analyzed visually, excluding all the compounds that 
showed good interactions with the catalytic site of the enzyme. From this last 
screening a total of 25 compounds were obtained. The last step of the screening 
was to choose the compounds with the best results with the other two screenings 
and finally those that were accessible from a synthetic point of view. The selected 
compounds are reported in Fig. 8.14.
o o o
Fig. 8.14: selected compounds from the virtual screening.
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Fig. 8.15 reports the virtual screening of ACV derivatives. The initial 3600 
compounds were reduced to 984 after the screening using RT. The screening 
using either guanylate kinase or adenylate kinase reduced the number to 218 
compounds. The final screening using human polymerase y reduced the number to 
25 compounds. Finally, the compounds were analysed for the best docking results 
with RT and guanylate or adenylate kinase and from a synthetic point of view.
3600 compounds
J ReverseTranscriptase
984 compounds
J Guanylate kinase Adenylate kinase
218 compounds
JS h " ’
25 compounds
Best docking results 
Synthetic feasible
5 compounds
Fig. 8.15: summary of the ACV derivatives virtual screening.
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8.5 Chemistry
8.5.1 Synthesis of ganciclovir ProTides
The first compound to be selected was GCV as it showed the best results in the 
RT docking, but also good results with guanylate kinase and polymerase y 
docking. Moreover, GCV is commercially available. For the synthesis of the 
ProTides the same procedure used for the ACV ProTides synthesis was followed 
(Scheme 8.1). The 2-amino functionality of the guanine base was protected using 
V,V-dimethylformamide dimethyl acetal followed by coupling with the 
appropriate phosphorochloridates 131 d, 193a, f using lBuMgCl as a hydroxyl 
activator.13 However, the protected GCV was less soluble than the corresponding 
ACV derivatives; in fact, the addition of pyridine to dissolve the compound was 
necessary. The deprotection step was carried out by refluxing compounds 209a-d 
in 2-propanol to obtain the final compounds 210a-d.
R eagents and  C onditions: (/) N ,N -d im ethy lfo rm am ide dim ethyl acetal, D M F, rt, 29 h; (//) ‘B uM gC l, anhydrous 
T H F, anhydrous pyrid ine , rt, 20 -84  h; ( i i i )  2 -propanol, reflux, 24-80 h.
Scheme 8.1: synthesis of GCV ProTides.
Due to the presence of two hydroxyl groups the compounds were obtained as bis- 
ProTides. Only in the case of the 1-naphthyl-L-alaninyl-isopropyl derivative the 
mono-ProTide 210d was isolated.
Scheme 8.2 reports the synthesis of a cyclic GCV derivative 213, which does not 
have the aryl moiety.
OH 1® OH 208,84%
O Ar 
C I-P -0  
NH
131d A r= P h , X = B n  
193a A r= N a p h ,X = B n  
193f A r= N a p h , X = 'P r
u
O O
ArO
O -P -O ^
NH
' ° Y ^ CH3O
O-FT O-FT
210a R: A r= P h , X = B n , R ’= R  
210b R: A r= N a p h , X = B n , R - R  
210c R: A r= N a p h , X = ‘P r, R ’= R  
210d R: A r= N a p h , X ^ P r ,  R ’= H
209a R: A r= P h , X = B n , R ’= R , 8 0 %
209b R: A r= N ap h , X = B n , R ’= R ,4 6 %  
209c R: A r= N a p h , X = jP r, R '= R ,4 4 %  
209d R: A r= N ap h , X = jP r, R '= H , 14%
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HO
CH a - £ o
V , , *>n*) CH,
211
NH
u
— 0<N'®-N*1' N^ N-CH3
0 9 ^ ° ^  ch3
~ ? 'C T  212, 9 3 %
Nl-T
213
O'^V'Oep J
riP
Et°Y^CH3
O
R eagents and C ond itions: (/) 'B u M g C I, an h y d ro u s T H F , anhydrous py rid ine , rt, 40  h; (//) 2 -p ropano l, reflux , 9 h
Scheme 8.2: synthesis of GCV cyclic ProTide.
Table 8.1 reports the summary of the GCV ProTides with the yield and the 3IP- 
NMR data.
Cpds ProTide Ar Ester CLogP Yield "P-NMR
210a Di Ph Bn 3.42 7% 3.86,3.85,3.80,3.73,
3.52,3.49,3.41
210b Di Naph Bn 5.77 3% 4.23,4.08,3.96,3.93
210c Di Naph 'Pr 4.03 8% 4.29, 4.25, 4.23,4.17
210d Mono Naph ipr 0.41 33% 4.40, 4.36, 4.34, 4.27
213 Cyclic - Et -0.69 11% 3.73,2.89
Table 8.1: summary of GCV ProTides
161
Marco Derudas Chapter 8
8.5.1.1 Biological evaluation of ganciclovir ProTides
GCV ProTides have been evaluated for their ability to inhibit HIV-1 and HIV-2 
and the results are shown in Table 8.2.
Cpds ProTide Ar Ester CLogP
Antiviral 
Activity EC5o 
(pM)
HIV-1 HIV-2
Cytotoxicity
c c 50b
210a Di Ph Bn 3.42 >50 >50 159±82
210c Di Naph ‘Pr 4.03 >100 >100 >100
210d Mono Naph ’Pr 0.41 >20 >20 35±4.2
GCV - - - -2.54 >250 >250 >250
a) effective concentration required to reduce virus plaque form ation by 50%;
b) inhibitory concentration required to inhibit cell proliferation by 50%.
Table 8.2: anti-HIV activity for GCV ProTides.
Unfortunately, none of these compounds showed any anti-HIV activity. This 
could be due to a poor bioactivation of these ProTides with the consequent poor 
delivery of the monosphosphate.
An enzymatic study using carboxypeptidase Y (Fig. 8.16) has been performed 
using compound 210d following the same procedure already described in Chap. 6 
and 7.
rVT^ vwtww
M .tiling
U S  UO X <  XI)  '/• S 7 1) f> '  M l  S S
Fig. 8.16: carboxypeptidase-mediated cleavage of compound 210d, monitored by
31PNMR.
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The experiment shows a slow and partial conversion of the starting material (6p= 
~4) to the metabolised compound (6p= ~7). The result from this experiment may 
support the fact that the poor activity found for these compounds may be due to a 
poor bioactivation.
8.5.2 Synthesis of penciclovir ProTides
The second derivative selected was PCV. For the synthesis of these ProTides the 
same synthetic procedure used for GCV was used. Firstly, PCV was protected 
with V,V-dimethylformamide dimethyl acetal giving compound 214 (Scheme 
8.2). The coupling with the appropriate phosphorochloridate (131d or 193a) was 
performed using ‘BuMgCl as a hydroxyl activator.13 The deprotection step was 
carried out by re fluxing compounds 215a, b in 2-propanol to obtain the final 
compounds 216a, b.
O O O Ar
C l-P -O
HO ^  ^  H O ' > T  ^  CH
'OH 11 OH 214.95%
O
NH
CH,
°  1 3 1 d  A r= P h
1 9 3 a  A r= N ap h
O
‘NH
BnO
</ Y%H <" YY
ArO N ^ N ^ N H 2 ArO N ^ N ^ N ^ N ' CH=
O - P - O ' ^ V ^ J  ^  J i i  o - p - o ^ r ^ J  c h 3
NH L q J _ H  ,CH3 NH O -P -N —P
' Y > CH3 O >-OBn ] [ ^ C H 3 O ^-OBn
O Ar 0  O Ar 0
2 1 6 a  R: A r= P h ,4 %  2 1 5 a  R: A r= P h , 54%
2 1 6 b  R: A r= N a p h , 7 %  2 1 5 b  R: A r= N a p h , 8 4%
R eagents and C onditions: (/) N ,N -d im ethy lform am ide dim ethyl ace ta l, D M F, rt, 6  h; (//) ’B uM gC l, anhydrous T H F,
rt, 8  h; ( i i i )  2 -propanol, reflux , 39-72  h.
Scheme 8.2: synthesis of PCV ProTides.
The coupling reaction seems to work better compared to the GCV ProTides 
synthesis probably due to a' slightly better solubility of PCV compared to GCV. 
However, poor yields have been obtained in the deprotection step due to 
degradation of the products. In this case, the protected PCV ProTides have also 
been biologically evaluated.
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8.5.2.1 Biological evaluation of penciclovir ProTides
The biological evaluation of these compounds against HIV is currently underway. 
The compounds have been evaluated for their ability to inhibit VZV and HSV-1 
and 2.
Table 8.3 reports the anti-VZV activity for PCV ProTides.
o
Ar O 
O -P-O  
NH
BnOY ^ CH3
</nV S h
n^ n^ n^ n'CH3
9 H
O -P -N —f 
o  V-O Bn  
Ar O
CH,
ArO 
O -P-O  
NH
Bn0r ^ cH3
N ^N *Sh2 
9 H £ H3
O -P -N —f
O -^OBn 
Ar ®
215 216
Antiviral Activity 
ECso (M-M)8
Cytotoxicity
(pM)
TK+VZV TK VZV
Cpds Aryl CLogP YS
strain
OKA
strain
07-1
strain
YS/R MCCb CC50c
215a Ph 4.04 6.9 32.2 29.3 28.5 >50 44.5
215b Naph 6.38 8.1 10.9 8.6 11.5 50 20
216a Ph 3.83 8.9 23.7 33 >50 >50 >100
216b Naph 6.18 14.9 17.1 >50 >50 >50 >100
PCV - -2.72 2.2 0.99 12.2 24.5 >100 >100
a) effective concentration required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration that cause a m icroscopically detectable alteration o f  cell m orphology;
c) cytotoxic concentration required to reduce cell growth by 50%.
Table 8.3. Antiviral activity against VZV for PCV ProTides including PCV as a
control.
From these results, the phosphoramidate technology did not improve the activity 
versus VZV compared to the parent nucleoside. Interestingly, a loss of activity in 
TK-deficient strains has been found for the phosphoramidates compared to PCV, 
and this is could be due to a poor activation for these compounds. Moreover, all 
the compounds have been obtained as a di-ProTide and this aspect may infuence 
the activity especially in terms of bioactivation. Notably, the toxicity found for the 
protected compounds is in the range between 20-44.5 i^M.
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Table 8.4 reports the activity versus HSV-1 and 2. Unfortunately, the biological 
results show a total loss of activity against HSV for the ProTides compared to the 
parent compound. This lack of activity can be due to a poor activation of the 
ProTides in this specific assay, which could be due to the fact that the di-ProTide 
is not a good substrate for the enzymes involved in the bioactivation pathway.
Antiviral Activity 
EC50 (pM)a
Cytotoxicity
(pM)
Cpds Aryl CLogP HSV-1 HSV-2 HSV-1 TK MCCb
215a Ph 4.04 >100 >100 >100 >100
215b Naph 6.38 >100 >100 >100 >100
216a Ph 3.83 >100 >100 >100 >100
216b Naph 6.18 >100 >100 >100 >100
PCV - -2.72 0.6 0.8 4 >100
a) effective concentration  required to reduce virus plaque form ation by 50%;
b) m inim um  cytotoxic concentration that cause a m icroscopically detectable alteration o f  cell m orphology;
Table 8.4. Antiviral activity against HSV-1 and 2 for PCV ProTides including 
PCV as a control.
No activity (> 100 pM) for these compounds has been found against: vaccinia 
virus, vesicular stomatitis virus, feline corona virus, feline herpes virus (data not 
shown).
8.5.3 Synthesis of thio-gancyclovir derivative
The third compound selected from the modelling was the thio-derivative of GCV. 
The synthesis of this compound involves 9 steps following the procedure reported 
in the literature.14 The commercially available compound 217 is converted to the 
tosyl derivative 218 in quantitative yield, which is then converted to the thioacetyl 
derivative 219. The deprotection of the acetyl group has been carried out using 
methanolic ammonia or sodium methoxide in methanol obtaining the first synthon 
220 in 72% in both cases. The second synthon 222 was obtained by acetylation 
from the commercially available guanine 221 in acetic anhydride and 
dimethylacetamide.15 The coupling between the two synthons is a “one-pot-three- 
step” reaction involving firstly the attachment of the hydroxyl methylene group to 
the thio-group followed by acetylation of the primary alcohol and then coupling
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with the base to obtain a mixture of N-7 and N-9 isomers. The desired compound 
223 was obtained as a pure N-9 isomer after trituration using DCM and diethyl 
ether. The structure of the compound was confirmed by 'H-NMR comparing the 
result with that reported in the literature.14
o o
° Bn ‘ .T «n-^°Bn « ■ . .gV~0Bn / ‘Won ; / “ Ubn i« /-\Jon |»» /"Ubri in ^ x ^ m u  jy /  t  NhH O -\  TsO-<  iL _ ^ A c S -( Ul HS—\  + < " 1  i -  <' T  1
'-OBn '-OBn ^-OBn \-O B n  N ^ n ^ " n h Ac fj N
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R eagents and C onditions: (/) /j-Ts-C1, anhydrous pyridine, rt, overnight; (//) potassium  thioacetate , anhydrous 
D M F, 90  °C, 2 h; (Hi )  M e O H /N H 3, rt, 16 h or M eO N a, M eO H , rt, 1.5 h; ( i v )  acetic  anhydride, dim ethylacetam ide, 
160 °C, 7 h; (v) p arafo rm aldehyde, HC1 gas, 1 ,2-dichloroethane, 0 °C, 2 h; (v/) sod ium  acetate, anhydrous D M F, rt,
2 h; (v/7) d iacety lguan ine, b is(4 -n itropheny l)phosphate , su lfo lane, 100 °C, 6 h then  rt, 17 h; ( v i i i )  acetic anhydride, 
B F3-Et20 ,  rt, 2.5 h; (ix) M e O H /N H 3, rt, 18 h.
Scheme 8.3: synthesis of the thio-GCV derivative.
The benzyl groups of 223 were converted to acetyl groups using acetic anhydride 
and borontrifluoride etherate to yield compound 224 which was then fully 
deprotected using methanolic ammonia to obtain the desired compound 205 in 
good yield.
An attempt to prepare the phosphoramidates of 205 was made starting from the 
unprotected nucleoside (Scheme 8.4).
o
0 9 //N"Ti nh
<-NI a  c,-p-o ^9 sX nAnH2
B n 0 Y V  O- - ° ^ C oH
L OH 205 B" ° y V
Scheme 8.4: attempt to obtain thio-GCV derivative phosphoramidates.
193a A r= N ap h  
( / ) 1 B uM gC l, anhydrous T H F, anhydrous pyridine, rt, 40 h;
Unfortunately, the direct coupling did not succeed, probably due to the poor 
solubility of the starting material. Due to time constraints, the synthesis of these 
derivatives using protected 205 was not investigated. However, compound 205 
was biologically evaluated and it will be discussed later in this chapter.
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8.5.4 Synthesis of 6-methoxy and 6-chIoro penciclovir derivatives
For the synthesis of these two derivatives a procedure reported in the literature
catalyst to obtain compound 225 in good yield. The chlorination at the 6-position 
was achieved using POCI3 in the presence of benzyltriethylammonium chloride 
and N,N-dimethylaniline to yield compound 226. The deprotection of the acetyl 
group using sodium methoxide in methanol at 40 °C led also to the displacement 
of the 6-chloro obtaining compound 206, whilst the use of methanolic ammonia at 
room temperature led only to the deprotection of the acetyl group obtaining 
compound 207.
R eagents and C onditions: (/') ace tic  an h y d rid e . D M A P , D M F, 45 °C, 1.5 h; (//') PO C I3, benzy ltrie thy lam m onium  
chloride, N ,N -d im eth y lan ilin e , ace ton itrile , 70 °C, lh ; (7/7) M eO N a, M eO H , 4 0  °C , 6 h; (/v) M eO H /N H 3, rt, 6 h.
Scheme 8.4: synthesis of the 6-methoxy and 6-chloro PCV derivatives.
8.5.4.1 Synthesis of 6-methoxy penciclovir ProTides
The synthesis of 6-methoxy PCV ProTides was achieved without the need of the 
2-amino protection as this compound was soluble in THF. Also in this case the 
coupling was performed using ‘BuMgCl as a hydroxyl activator (Scheme 8.5).13
was followed.16 PCV was acetylated using acetic anhydride and DMAP as a
o o Cl
HO
OH 11 OAc 225,83%
NH.
u
AcO
OAc 226,46%
131d A r= P h  
193a A r= N a p h
227a R: A r= P h , R '= R ,2 %  
227b R: A r= P h , R '= H , 3%  
227c R: A r= N a p h , R '= H , 3%
(/) ‘B uM gC l, anhydrous T H F, rt, 40  h.
Scheme 8.5: synthesis of 6-methoxy PCV ProTides.
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In the case of the phenyl derivative the mono- and the di- ProTides were isolated, 
whilst for the 1-naphthyl derivative only the mono-ProTide was isolated.
In spite of being soluble in THF, compound 206 did not show a good reactivity. 
However, the desired compounds were isolated and the structure confirmed by 
NMR and mass spectroscopy.
Due to time constraints, it was not possible to synthesise a ProTide of compound 
207, however, the nucleoside was biologically evaluated (Table 8.5).
8.5.4.2 Biological evaluation
The biological evaluation of these compounds against HIV is currently underway. 
The compounds have been evaluated for their ability to inhibit HSV-1 and 2. 
Table 8.5 reports the biological evaluation against HSV-1 and 2 TK-efficient, and 
versus HSV-1 TK-deficient strain.
Antiviral Activity 
EC5o (m-M)*
Cytotoxicity
(pM)
Cpds ProTide Aryl CLogP HSV-1 HSV-2 HSV-1 TK MCCb
205 - - -2.38 0.5 0.6 2.4 >100
206 - - -0.76 100 >100 >100 >100
207 - - - 1.01 >100 >100 >100 >100
227a Di Ph 5.79 100 >100 100 >100
227b Mono Ph 2.51 58 45 58 >100
227c Mono Naph 3.39 38 20 20 >100
GCV - - -2.54 0.03 0.03 0.03 >100
ACV - - -2.42 0.4 0.4 10 >250
a) effective concentration required to reduce virus plaque formation by 50%;
b) m inim um  cytotoxic concentration  that cause a m icroscopically detectable alteration o fce ll m orphology;
Table 8.5: anti-HSV activity of thio-GCV derivatives, 6-chloro-PCV, 6-methoxy- 
PCV and its ProTides.
The biological results show some activity of the 6-methoxy-PCV Protides. In fact, 
whilst the parent nucleoside 206 did not show any anti-HSV activity the 
monoProTide derivatives 227b and 227c showed some activity, which is fully 
retained versus the TK-deficient strain. Interestingly, compound 205 showed a
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good activity in submicromolar range confirming the results reported in the 
literature.14
8.6 Conclusion
A series of compounds have been designed and synthesised as potential anti-HIV 
agents. Unfortunately, in the case of GCV, although it was found one of the best 
RT-docked compounds, no activity against HIV has been observed. This lack of 
activity may be due to a lack in the bioactivation pathway, which is supported by 
the carboxypeptidase study.
For the other designed compounds, the anti-HIV evaluation is currently 
underway. Other antiviral assays have been performed for these compounds 
showing poor activity versus VZV and HSV in the case of PCV ProTides and 
slight improvement of activity for the 206 ProTides. It must be said that in the 
case of PCV, only the di-Protides were isolated and this aspect may influence the 
activity in terms of bioactivation and the delivery of the monophosphate.
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9. Experimental Part
9.1 General Experimental Details 
Solvents and reagents
The following anhydrous solvents were bought from Aldrich with subaseal 
stopper:
Chloroform (CHCI3), dichloromethane (DCM), diethyl ether (Et20), N,N- 
dimethylformamide (DMF), N-methylimidazole (NMI), pyridine, tetra- 
hydrofuran (THF), triethylamine (TEA). All reagents commercially available 
were used without further purification.
Thin Layer Chromatography (TLC)
Precoated, aluminium backed plates (60 F254, 0.2 mm thickness, Merck) were 
visualized under both short and long wave ultraviolet light (254 nm and 366 nm). 
Preparative TLC plates (20x20 cm, 500-2000 pm) were purchased from Merck.
Column Chromatography (CC)
Column chromatography processes were carried out using silica gel supplied by 
Fisher (60A, 35-70 pm). Glass columns were slurry packed using the appropriate 
eluent and samples were applied either as a concentrated solution in the same 
eluent or pre-adsorbed on silica gel.
High Performance Liquid Chromatography (HPLC)
Analytical and semi-preparative HPLC were conducted by Varian Prostar (LC 
Work Station- Varian prostar 335 LC detector, Varian fraction collector (model 
701), pro-star 210 solvent delivery system, using Varian Polaris C l8-A (10 pm) 
as an analytic column and Varian Polaris C18-A (10 pm) as a semi-preparative 
column. The software used was Galaxie Chromatography Data System.
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Nuclear Magnetic Resonance (NMR)
'H-NMR (500 MHz), l3C-NMR (125 MHz), 3IP- NMR (202 MHz) were recorded 
on a Bruker Avance 500MHz spectrometer at 25 °C. Spectra were calibrated to 
the residual signal of the deuterated solvent used. Chemical shifts are given in 
parts per million (ppm) and coupling constants (J) in Hertz.
The following abbreviations are used in the assignment of NMR signals: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad singlet), dd 
(doublet of doublet), dt (doublet of triplet).
Mass Spectroscopy (MS)
High resolution mass spectroscopy was performed as a service by Birmingham 
University, using fast atom bombardment (FAB) and by Cardiff University, using 
electrospray (ES).
Elemental Analysis (CHN)
CHN microanalysis were performed as a service by the School of Pharmacy at the 
University of London and by MEDAC Ltd, Surrey.
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9.2 Standard procedures
Standard procedure A: synthesis of dichlorophosphates
To a solution of phosphorus oxychloride (1.00 mol/eq) and the appropriate 
substituted phenol or naphthol (1.00 mol/eq) in anhydrous diethyl ether stirred 
under an argon atmosphere and was added dropwise at -78 °C anhydrous TEA 
(1.00 mol/eq). Following the addition, the reaction mixture was stirred at - 78 °C 
for 30 min, then at room temperature overnight. The formation of the desired 
compound was monitored by 31P NMR. The mixture was filtered under nitrogen 
and the corresponding filtrate reduced to dryness to give the crude product as an
oil.
Standard Procedure B: synthesis of phosphorochloridates
To a stirred solution of the appropriate aryl dichlorophosphate (1.00 mol/eq) and 
the appropriate amino acid ester salt (1.00 mol/eq) in anhydrous DCM was added, 
dropwise at -78 °C under an argon atmosphere, anhydrous TEA (2.00 mol/eq). 
Following the addition the reaction mixture was stirred at -78 °C for 1 h, then at 
room temperature for 2 h. Formation of the desired compound was monitored by 
3IP NMR. After this period the solvent was removed under reduced pressure and 
the residue triturated with dry diethyl ether. The precipitate was filtered under 
nitrogen and the solution was concentrated to give an oil. Most of the aryl 
phosphorochloridates synthesised were purified by flash column chromatography 
(eluting with ethyl acetate/petroleum ether = 60/40).
Standard Procedure C: synthesis of phosphoramidates ^BuMgCl method)
To a stirring suspension/solution of the appropriate nucleoside (1.00 mol/eq) in 
anhydrous THF was added dropwise under an argon atmosphere ‘BuMgCl (1.10 
to 2.00 mol/eq) and the reaction mixture was stirred at room temperature for 30 
min. Then was added dropwise a solution of the appropriate phosphorochloridate 
(1.10 to 4.00 mol/eq) in anhydrous THF. The reaction mixture was stirred at room 
temperature overnight. The solvent was removed under reduced pressure and the 
residue was purified by column chromatography eluting with DCM/MeOH in 
different proportions.
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Standard Procedure D: synthesis of phosphoramidates (NMI method)
To a stirring solution of the appropriate nucleoside (1.00 mol/eq) and the 
appropriate phosphorochloridate (3.00 -  4.00 mol/eq) in anhydrous THF was 
added dropwise NMI (5-10 mol/eq) and the reaction was stirred at room 
temperature overnight. After this period the solvent was removed under reduced 
pressure. The residue was dissolved in DCM, washed with water (twice) and 0.5 
N HC1 (twice). The organic phase was dried over MgSC>4, filtered, reduced to 
dryness and the crude purified by column chromatography eluting with 
DCM/MeOH in different proportions.
Standard enzymatic procedure using carboxypeptidase Y
An appropriate phosphoramidate (~5 mg) was dissolved in ^-acetone (0.15 mL)
11
and trizma buffer (pH = 7.6) (0.30 mL) and a P-NMR experiment was recorded
(starting material). Then a solution of carboxypeptidase Y (~0.1 mg) in trizma
*> 1
buffer (0.15 mL) was added and a P-NMR experiment was performed recording 
the experiment every 7 or 15 min.
Molecular modelling
All molecular modelling studies were performed on a MacPro dual 2.66GHz 
Xeon running Ubuntu 8 using Molecular Operating Environment (MOE) 2008.10 
and Plants 1.0. Hydrogen atoms were added to the crystal structure of proteins and 
minimised with MOE until a gradient of 0.05 Kcal mol-1 A-l was reached, using 
the MMFF94x forcefield. The partial charges were automatically calculated. 
Docking experiments were carried out using Plants with the default parameters. 
The results were examined with MOE.
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9.3 Synthesis of phosphorodichloridates 
Synthesis of 1-naphthyl dichlorophosphate [228]
C,oH 7C 1202P
2 Mol Wt.: 261.0411
11 °11 n
O -P -C I
Cl To a stirred solution of 1-naphthol (4.00 g, 27.74 mmol) in dry
diethyl ether (60 mL), under an Argon atmosphere, were added POCI3 (2.59 mL, 
27.74 mmol) and dry TEA (3.87 mL, 27.74 mmol) was then added dropwise, at - 
78 °C. Following the addition, after 30 min at -78 °C, the reaction mixture was 
stirred at room temperature overnight. After 31P NMR, the solvent was removed 
under reduced pressure and the residue was triturated with dry diethyl ether. The 
precipitate was filtered, and the organic phase was removed under reduced 
pressure to give an oil (95%, 6.91 g).
3IP-NMR (CDCI3, 202 MHz): 6 3.72.
'H-NMR (CDCI3, 500 MHz): 5 8.02-8.00 (1H, m, H-8), 7.81-7.80 (1H, m, H-5), 
7.72-7.70 (1H, m, H-4), 7.54-7.45 (4H, m, H-2, H-3, H-6, H-7).
Synthesis of 4-fluorophenyldichIorophosphate [229]
F C6H4CI2FO2P
Mol Wt.: 228.9729
O—P—Cl1 To a stirred solution of 4-fluorophenol (1.83 g, 16.34 mmol) in dry 
Cl
diethyl ether (30 mL), under an Argon atmosphere, were added 
POCI3 (16.34 mL, 16.34 mmol) and dry TEA (2.28 mL, 16.34 mmol) was then 
added dropwise, at -78 °C. Following the addition, after 30 min at -78 °C, the 
reaction mixture was stirred at room temperature overnight. After 3IP NMR, the 
solvent was removed under reduced pressure and the residue was triturated with 
dry diethyl ether. The precipitate was filtered, and the organic phase was removed 
under reduced pressure to give an oil (79%, 2.94 g).
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3IP-NMR (CDCIj, 202 MHz): 6 4.18.
I9F-NMR (CDCIj, 471 MHz): 6 -114.28, -114.29.
'H-NMR (CDCIj , 500 MHz): 5 7.33-7.27 (2H, m, Ph), 7.17-7.11 (2H, m, Ph).
O - P - C I
9.4 Synthesis of phosphorochloridates
Synthesis of phenyl-(methoxy-L-alaninyl)-phosphorochIoridate. [131a]
C10H 13CINO4P 
Mol Wt.: 277.6413
NH
MeO JL. Prepared according to Standard Procedure B, from
CH3
^  phenyldichlorophosphate (2.24 mL, 15.00 mmol), L-alanine
methyl ester HC1 (2.09 g, 15.00 mmol), anhydrous TEA (4.20 mL, 30.00 mmol) 
and anhydrous DCM (80 mL). The reaction mixture was stirred at -78 °C for 30 
min, then at room temperature for 2.5 h. The crude was purified by column 
chromatography eluting with ethyl acetate/hexane = 6/4 to give an oil (81%, 3.35
g)-
3,P-NMR (CDCIj, 202 MHz): 6 7.95, 7.66.
'H-NMR (CDCIj, 500 MHz): 6 7.32-7.15 (5H, m, PhO), 4.42-4.34 (1H, m, NH), 
4.17-4.08 (H, m, CtfNH), 3.72, 3.70 (3H, 2s, CtfjO), 1.45-1.43 (3H, m, CHCT/j).
Synthesis of phenyI-(ethoxy-L-a!aninyl)-phosphorochloridate. [131b]
CiiH ,5C1N04P 
Mol Wt.: 291.6679
Prepared according to Standard Procedure B, from 
phenyldichlorophosphate (2.24 mL, 15.00 mmol), L-alanine ethyl 
ester -HC1 (2.30 g, 15.00 mmol), anhydrous TEA (4.20 mL, 30 mmol) and 
anhydrous DCM (80 mL). The reaction mixture was stirred at -78 °C for 30 min, 
then at room temperature for 3 h. The crude was purified by column
O - P - C I
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O - P - C I
chromatography eluting with ethyl acetate/hexane = 6/4 to give an oil (75%, 3.29 
g)-
3IP-NMR (CDCI3, 202 MHz): 6 8.03, 7.75, 7.71.
'H-NMR (CDCIj, 500 MHz): 5 7.31-7.15 (5H, m, Ph), 4.20-4.02 (3H, m, 
OC//2CH3. NHC/7), 1.44 (3H, t, OCH2C//3), 1.25-1.16 (3H, m, CHC7/3).
Synthesis of phenyl-(methoxy-glycinyI)-phosphorochloridate. [131c]
c 9h ,,c in o 4p
Mol Wt.: 263.6147
Prepared according to Standard Procedure B, from
phenyldichlorophosphate (2.24 mL, 15.00 mmol), glycine methyl 
ester ’HC1 (1.88 g, 15.00 mmol), anhydrous TEA (4.20 mL, 30.00 mmol) and 
anhydrous DCM (80 mL). The reaction mixture was stirred at -78 °C for 30 min, 
then at room temperature for 2 h. The crude was obtained as an oil (93%, 3.70 g).
3IP-NMR (CDC13, 202 MHz): 5 9.03.
'H-NMR (CDCI3, 500 MHz): 6 7.28-7.12 (5H, m, PhO), 4.43 (1H, bs, N//CH2),
3.84 (2H, d, NHC//2), 3.72 (3H, s, OCH}).
Synthesis of phenyl-(benzoxy-L-alaninyl)-phosphorochloridate. [131 d]
C,6H,7C1N04P 
Mol Wt.: 353.7372
Prepared according to Standard Procedure B, using
phenyldichlorophosphate (0.30 mL, 2.00 mmol), L-alanine 
benzyl ester tosylate (0.43 g, 2.00 mmol), anhydrous TEA (0.56 mL, 4.00 mmol) 
in anhydrous DCM (15 mL). The reaction mixture was stirred at -78 °C for 1 h,
then at room temperature for 3.5 h. The crude was obtained as an oil (87%, 0.62
g)-
O - P - C I
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3IP-NMR (CDCI3, 202 MHz): 6 7.86, 7.52.
'H-NMR (CDC13, 500 MHz): 5 7.33-7.28 (10H, m, PhO, OCH2P/i), 5.15-5.13 
(2H, m, OC//2Ph), 4.18-4.13 (1H, m, CWNH), 1.46-1.44 (3H, m, CH3).
O -P - C I
Synthesis of phenyl-(isopropoxy-L-alaninyl)-phosphorochIoridate. [O le]
C i2H ,7C 1N 0 4P 
Mol Wt.: 305.6944
H C O JL . Prepared according to Standard Procedure B, from 
Ti C Ho
phenyldichlorophosphate (2.00 mL, 13.85 mmol), L-alanine 
isopropyl ester -HC1 (2.24 g, 13.85 mmol), anhydrous TEA 
(3.73 mL, 26.77 mmol) and anhydrous DCM (50 mL). The reaction mixture was 
stirred at -78 °C for 30 min, then at room temperature for 2 h. The crude was 
obtained as an oil (96%, 3.94 g).
3IP-NMR (CDCI3, 202 MHz): 6 8.13, 7.75.
'H-NMR (CDCb, 500 MHz): 6 7.47-7.16 (5H, m, PhO), 5.18-4.98 (1H, m, 
COOCH), 4.41, 4.33 (1H, 2bs, NtfCH), 4.21-4.09 (1H, m, NHC/7), 1.53, 1.51 
(3H, 2d, J = 2.3, CHC//3), 1.35 -  1.27 (6H, m, COOCH(C//3)2).
Synthesis of phenyl-(benzoxy-D-alaninyl)-phosphorochloridate. [ 131f]
C,6Hi7ClN04P 
Mol Wt.: 353.7372
Prepared according to Standard Procedure B, using 
phenyldichlorophosphate (1.06 mL, 7.11 mmol), D-alanine 
benzyl ester tosylate (2.50 g, 7.11 mmol), anhydrous TEA (1.98 mL, 14.23 mmol) 
in anhydrous DCM (50 mL). The reaction mixture was stirred at -78 °C for 1 h, 
then at room temperature for 3.5 h. The crude was purified by column
O -P -C I
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chromatography eluting with ethyl acetate/hexane = 7/3 to give an oil (84%, 2.11 
g).
3IP-NMR (CDCI3, 202 MHz): 6 7.86, 7.49.
'H-NMR (CDC13j 500 MHz): 6 7.47-7.22 (10H, m, PhO, OCH2P/i), 5.25-5.23 
(2H, 2s, OC//2Ph), 4.32-4.20 (1H, m, C/7NH), 1.56, 1.54 (3H, 2d, J = 3.3, J = 2.9 
CH3).
Synthesis of 1 -pheny l-(benzoxy-L-pheny lalaniny l)-phosphorochloridate.
H31g]
c 22h 2,c in o 4p
^ f o  Mol Wt.: 429.8332
O -P - C I
NH
Prepared according to Standard Procedure B, from 
phenyldichlorophosphate (1.81 g, 8.57 mmol), L-phenylalanine 
benzyl ester -HC1 (2.50 g, 8.57 mmol), anhydrous TEA (2.40 mL, 17.13 mmol) 
and anhydrous DCM (80 mL). The reaction mixture was stirred at -78 °C for 30 
min, then at room temperature for 2 h. The crude was purified by column 
chromatography eluting with ethyl acetate/hexane = 6/4 to give an oil (58%, 2.15 
g).
31P-NMR (CDC13, 202 MHz): 6 7.80, 7.77.
'H-NMR (CDC13, 500 MHz): 6 7.32-6.91 (15H, m, PhO, CUCU2Ph, OCU2Ph),
5.08-5.07 (2H, m, OC//2Ph), 4.46-4.33 (1H, m, C//NH), 3.12-3.01 (2H, m, 
CHC//2Ph).
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Synthesis of 4-fluoro-phenyl>(benzoxy-L-alaninyl)-phosphorochloridate. 
(131h]
F C,6H,6C1FN04P
Mol Wt.: 371.7277
Prepared according to Standard Procedure B, using 229 (1.50 
mL, 6.55 mmol), L-alanine benzyl ester tosylate (2.30 g, 6.55
CH3
O mmol), anhydrous TEA (1.82 mL, 13.10 mmol) in anhydrous
DCM (40 mL). The reaction mixture was stirred at -78 °C for 30 min, then at 
room temperature for 3 h. The crude was purified by column chromatography 
eluting with ethyl acetate/petroleum ether = 7/3 to give an oil (72%, 1.75 g).
3iP-NMR (CDCI3, 202 MHz): 6 8.34, 8.02.
I9F-NMR (CDCb, 471 MHz): 6 -116.29 (d, J = 3.1), -116.33 (d, J = 2.9).
'H-NMR (CDCb, 500 MHz): 6 7.43-7.33 (5H, m, Ph), 7.26-7.20 (2H, m, Ph),
7.09-7.04 (2H, m, Ph), 5.24, 5.23 (2H, 2s, OC//2Ph), 4.37 (1H, bs, CHN//), 4.32-
4.20 (1H, m, C//NH), 1.55, 1.54 (3H, 2d, J = 5.0, J = 4.6, CHCft).
Synthesis of l-NaphthyI(benzoxy-L-alaninyl)-phosphorochloridate. [193a]
C2oH,9C1N04P 
Mol Wt.: 403.7959
Prepared according to Standard Procedure B, 228 (6.91 g, 
26.48 mmol), L-alanine benzyl ester tosylate (9.30 g, 26.48 
mmol), anhydrous TEA (7.40 mL, 52.96 mmol) in anhydrous DCM (100 mL). 
The reaction mixture was stirred at -78 °C for 1 h, then at room temperature for 2 
h. The crude was purified by column chromatography eluting with ethyl 
acetate/hexane = 5/5 to give an oil (72%, 7.68 g).
O - P - C I
3IP-NMR (CDCb, 202 MHz): 6 8.14, 7.88.
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'H-NMR (CDCIj, 500 MHz): 6 7.99-7.25 (12H, m, Naph, OCH2P/i), 5.15-5.07 
(2H, m, C//2Ph), 4.30-4.23 (1H, m, C/ZCHj), 1.49-1.46 (3H, m, CHC//3).
Synthesis of 1 -Naphthy l(benzoxy-L-pheny lalaninyl)-phosphorochloridate. 
[193b]
C26H23CINO4P 
Mol Wt.: 479.8919
O - P -C I  
NH
Prepared according to Standard Procedure B, from 228 (0.78 g,
Bn
3.00 mmol), L-phenylalanine benzyl ester -HC1 (0.87 g, 3.00 
mmol), anhydrous TEA (0.84 mL, 6.00 mmol) and anhydrous DCM (20 mL). The 
reaction mixture was stirred at -78 °C for 30 min, then at room temperature for 2 
h. The crude was purified by column chromatography eluting with ethyl 
acetate/hexane = 6/4 to give an oil (40%, 0.57 g).
3IP-NMR (CDCIj, 202 MHz): 6 8.32, 8.19.
'H-NMR (CDCIj, 500 MHz): 6 8.04-6.96 (17H, m, Naph, CHCH2Ph, OCH2Ph), 
5.20-5.11 (2H, m, OC//2Ph), 4.64-4.52 (1H, m, C«NH), 3.22-3.08 (2H, m, 
CHCtf2Ph).
Synthesis of l-Naphthyl(benzoxy-glycinyl)-phosphorochloridate. [193c]
C |9H ,7C 1N 0 4P 
Mol Wt.: 389.7693
Prepared according to Standard Procedure B, 228 (0.78 g, 3.00 
mmol), glycine benzyl ester -HC1 (1.01 g, 3.00 mmol), 
anhydrous TEA (0.84 mL, 6.00 mmol) and anhydrous DCM (20 mL). The 
reaction mixture was stirred at -78 °C for 30 min, then at room temperature for
2.5 h. The crude was purified by column chromatography eluting with ethyl 
acetate/hexane = 6/4 to give an oil (73%, 0.85 g).
O -P -C I
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3IP-NMR (CDC13, 202 MHz): 5 8.90.
'H-NMR (CDCI3, 500 MHz): 5 8.02-7.30 (12H, m, Naph, OCH2P6), 5.17 (2H, s, 
OCtf2Ph), 4.24-4.19 (1H, m, N//CH2), 4.00-3.96 (2H, m, NHC//2).
Synthesis of l-Naphthyl-(methoxy-L-alaninyl)-phosphorochloridate. [193d]
C14H15CINO4P 
Mol Wt.: 327.7000
O -P -C I
NH
MeO J L  Prepared according to Standard Procedure B, 228 (2.00 g, 7.66
PI CH3
^  mmol), L-alanine methyl ester HC1 (1.07 g, 7.66 mmol),
anhydrous TEA (2.14 mL, 15.32 mmol) in anhydrous DCM (45 mL). The 
reaction mixture was stirred at -78 °C for 1 h, then at room temperature for 2 h. 
The crude was purified by column chromatography eluting with ethyl 
acetate/hexane = 6/4 to give an oil (61%, 1.54 g).
3IP-NMR (CDCIj, 202 MHz): 6 8.14, 7.88.
'H-NMR (CDCIj, 500 MHz): 5 8.01-7.35 (7H, m, Naph), 4.33-4.27 (1H, m, NH),
4.26-4.20 (1H, m, CtfNH), 3.74, 3.69 (3H, 2s, C//jO), 1.50-1.46 (3H, m, 
CHC/Zj).
Synthesis of l-Naphthyl(benzoxy-dimethylglycinyl)-phosphorochIoridate. 
[193e]
C21H21CINO4P 
Mol Wt.: 417.8225
Prepared according to the Standard Procedure B, using 228 
(1.53 g, 5.88 mmol) and dimethylglycine benzyl ester tosylate 
(2.15 g, 5.88 mmol), anhydrous TEA (4.59 mL, 32.94 mmol) and anhydrous 
DCM (50 mL). The reaction was stirred at room temperature for 2 h. The crude 
product was obtained as an oil (33%, 0.80 g).
O -P -C I
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3IP-NMR (CDCIj, 202 MHz): 6 5.78.
'H-NMR (CDCIj, 500 MHz): 8 8.03-7.28 (12H, m, Naph, OCH2P/i), 5.16 (2H, s, 
OCtf2Ph), 1.76, 1.70 (6H, 2s, C(CH3)2).
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9.5 Synthesis of 5’-derivatives of BCNA lead compound
Synthesis of 3-(2’-deoxy-P-D-ribofuranosyl)-6-(4-/f-pentylphenyl)-2,3-dihy- 
drofuro [2,3-</lpyrimidin-2-one. [86f]
C 2 2 H 2 6 N 2 O 5  
Mol Wt.: 398.4522
To a stirred solution of 121 (3.18 g, 9.00 mmol) in 
anhydrous DMF (46 mL), were added: 4-n-
pentylphenylacetylene (5.26 mL, 27.00 mmol), tetrakis- 
(triphenylphosphine) palladium(O) (1.04 g, 0.90 mmol), 
copper (I) iodide (0.34 g, 1.80 mmol) and DIPEA (3.14 mL,
18.00 mmol) and the reaction mixture was stirred at room
temperature, under an Argon atmosphere overnight. After
this period were added copper (I) iodide (0.34 g, 1.80 mmol) 
and anhydrous TEA (46 mL) and the reaction mixture was stirred at 85 °C for 6 h. 
The solvent was then removed in vacuo, and the resulting residue was dissolved 
in DCM and the solution was stirred at room temperature overnight. The
precipitate obtained was filtered and washed with DCM, to give a white solid
(63%, 2.25 g).
1 H-NMR (DMSO, 500 MHz): 6 8.84 (1H, s, H-4), 7.74 (2H, d, J = 8.2, Ha), 7.33 
(2H, d, J = 8.2, Hb), 7.21 (1H, s, H-5), 6.20 (1H, t, H -l’), 5.29 (1H, d, 3’-OH), 
5.16 (1H, t, 5’-OH), 4.26 (1H, m, H-3’), 3.94 (1H, m, H-4’), 3.72 (1H, m, H-5’), 
3.64 (1H, m, H-5’), 2.63 (2H, t, a-CH2), 2.42 and 2.11 (2H, 2m, H-2’), 1.60 (2H, 
m, P-CH2), 1.36-1.25 (4H, m, Y-CH2, 6-CH2), 0.87 (3H, t, CH3).
13C-NMR (DMSO, 126 MHz): 6 13.87 (CH3), 21.89, 30.35, 30.80, 34.88 (C4EW,
41.23 (C-2’), 60.68 (C-5’), 69.53 (C-3’), 87.56 (C -l’), 88.14 (C-4’), 98.67 (C-5),
106.88 (C-4a), 124.54 (C-Hb), 125.87 (ipso-C), 128.99 (C-Ha), 137.82 (C-4),
144.07 (para-C), 153.75 (C-6), 153.90 (C-2), 171.03 (C-7a).
a)
i ra
H-B
IpsoH-A
,7a
4a
HO.
OH
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Synthesis of 3-(2-deoxy-3,5-di-tert-butyldimethylsilyI-P-D-ribofuranosyl)-6- 
(4-«-pentylphenyl)-2,3-dihydrofuro[2,3-</]pyrimidin-2-one. [122]
CH3 C34H54N205Si2
(H2C)4
Mol Wt.: 626.9740
To a solution of 86f (1.15 g, 2.90 mmol) in dry
pyridine (30 mL) were added TBDMSC1 (0.96 g, 6.38
mmol) and imidazole (0.43 g, 6.38 mmol) and the
reaction mixture was stirred at room temperature for
 . ^  2h. After this period the solvent was removed in vacuo
OTBDMS ^
and the residue was dissolved in DCM. The organic phase was washed with 0.5 M 
aqueous solution of citric acid. The organic phase was dried over MgSC>4, 
concentrated to give a pale yellow solid (95%, 1.72 g).
TBDMSO
'H-NMR (CDC13, 500 MHz): 6 8.58 (1H, s, H-4), 7.60 (2H, d, Ha), 7.18 (2H, d, 
Hb), 6.52 (1H, s, H-5), 6.28-6.26 (1H, m, H -l’), 4.34-4.31 (1H, m, H-3’), 3.97- 
3.94 (2H, m, H-4’, H-5’), 3.77-3.74 (1H, m, H-5’), 2.60-2.55 (3H, m, Ha-2’, a- 
CH2), 2.14-2.09 (1H, m, Hb-2’), 1.59-1.53 (2H, m, CH2), 1.29-1.23 (4H, m, 
2xCH2), 0.88 (9H, s, C(C//3)3), 0.82-0.81 (12H, m, CH3, C(C//3)3), 0.10 (3H, s, 
Si-CH3), 0.07 (3H, s, Si-CH3), 0.01 (3H, s, Si-CH3), 0.00 (3H, s, Si-CH3). 
13C-NMR (CDC13, 126 MHz): 6 -5.40, -5.35, -4.92, -4.50 (Si-CH3), 13.98 (co- 
CH3), 17.94, 18.42 (C(CH3)3), 22.49 (y-CH2), 25.71, 26.00 (C(CH3)3), 30.91,
31.41 (P-CH2, 6-CH2), 35.81 (a-CH2), 42.64 (C-2’), 61.89 (C-5’), 70.18 (C-3’),
88.06, 88.09 (C -l’, C-4’), 96.71 (C-5), 107.83 (C-4a), 124.92 (C-Hb), 125.96 
(ipso-C), 128.98 (C-Ha), 135.81 (C-4), 144.97 (para-C), 154.64 (C-6), 155.78 (C- 
2), 171.65 (C-7a).
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Synthesis of 3-(2-deoxy-3-tert-butyIdimethylsilyl-p-D-ribofuranosyl)-6-(4-rt- 
pentylphenyl)-2,3-dihydrofuro[2,3-</]pyrimidin-2-one. [123]
HO.
P^3 C28H4oN205S i
(H2C)4
Mol Wt.: 512.7131
To a solution of 122 (1.65 g, 2.64 mmol) in THF (40 mL)
and cold water (5 mL) was added, dropwise at 0 °C, cold
trifluoroacetic acid (5 mL) and the reaction mixture was
stirred at 0 °C for 2 h. After this period the reaction mixture
 __. was neutralised with NaHC03, concentrated and the residue
OTBDMS
triturated with diethyl ether. The suspension was filtered and the solid washed 
with diethyl ether to give a white solid (83%, 1.12 g).
'H-NMR (CDC13, 500 MHz): 6 8.54 (1H, s, H-4), 7.57 (2H, d. Ha), 7.15 (2H, d, 
Hb), 6.60 (1H, s, H-5), 6.23 (1H, t, H -l’), 4.42-4.38 (1H, m, H-3’), 4.01-3.96 (2H, 
m, H-4’, H-5’), 3.81-3.78 (1H, m, H-5’), 2.56-2.49 (3H, m, Ha-2 \ a-CH2), 2.28-
2.23 (1H, m, Hb-2’), 1.60-1.52 (2H, m, P-CH2), 1.29-1.23 (4H, m, 6-CH2, y-CH2), 
0.83-0.81 (12H, m, CH3, C(C//3)3), 0.00 (6H, s, Si-(CH3)2).
Synthesis of 3-(2-deoxy-3-tert-butyldimethylsiIyl-5-mesyl-p-D-ribofurano-
syl)-6-(4-/i-pentylphenyI)-2,3-dihydrofuro[2,3-</]pyrim idin-2-one. [124]
c h 3
(H2C)4
h 3c o 2s o
OTBDMS
C29H42N20 7SSi 
Mol Wt.: 590.2482
To a solution of 123 (1.02 g, 2.00 mmol) in dry 
N pyridine (20 mL) was added dropwise, at 0 °C, 
" ^ O  methanesulfonyl chloride (0.23 mL, 3.00 mmol) and 
the reaction mixture was stirred at room temperature 
overnight, then methanesulfonyl chloride (0.23 mL,
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3.00 mmol) was added and the reaction mixture was stirred for 7 h at room 
temperature. The mixture was quenched with water and the precipitate was 
filtered to give a yellow solid (66%, 0.78 g).
'H-NMR (CDC13 500 MHz): 6 8.34 (1H, s, H-4), 7.58 (2H, d, J = 6.9, Ha), 7.16 
(2H, d, J = 6.9, Hb), 6.60 (1H, s, H-5), 6.23 (1H, dd, J = 6.6, H -l’), 4.53 (1H, m, 
H-3’), 4.33-4.28 (2H, m, H-5’), 4.09 (1H, m, H-4’), 3.02 (3H, s, CH3), 2.59 (1H, 
m, H-2’), 2.55 (2H, t, J = 7.5, a-CH2), 2.17 (1H, m, H-2’), 1.55 (2H, m, (3-CH2), 
1.27-1.22 (4H, m, 6-CH2, y-CH2), 0.82 (9H, s, C(C//3)3), 0.80 (3H, t, CH3), 0.00 
(6H, s, Si(CH3)2).
Synthesis of 3-(2-deoxy-5-mesyl-P-D-ribofuranosyl)-6-(4-/i-pentylphenyl)-2,3-
dihydrofuro[2,3-rf]pyrimidin-2-one. [125]
pH3 C23H28N20 7S
(H2C)4
Mol Wt.: 476.1617
To a solution of 124 (0.93 g, 1.58 mmol) in THF (12
N mL) and water (12 mL) was added trifluoroacetic acid
(3 mL), and the reaction mixture was stirred at room 
temperature for 2h, then trifluoroacetic acid (1 mL) 
was added. After 30 minutes trifluoroacetic acid (1 
mL) was added and the reaction mixture was stirred for further lh. After this 
period the solvent was removed under reduced pressure and the crude was 
purified by column chromatography (gradient elution of DCM/MeOH = 97/3 then 
95/5) to give a pale yellow solid (70%, 0.60 g).
h 3c o 2s o
’H-NMR (DMSO, 500 MHz): 6 8.55 (1H, s, H-4), 7.75 (2H, d, J = 8.2, Ha), 7.34 
(2H, d, J = 8.2, Hb), 7.16 (1H, s, H-5), 6.26 (1H, t, J = 6.4, H -l’), 5.56 (1H, d, J = 
4.4, 3’-OH), 4.54-4.42 (2H, m, H-5’), 4.30-4.26 (1H, m, H-3’), 4.18-4.16 (1H, m, 
H-4’) 3.31 (3H, s, CH3), 2.62 (2H, t, J = 7.6, a-CH2), 2.49-2.41 (1H, m, Ha-2’),
2.26-2.17 (1H, m, Hb-2’), 1.64-1.56 (2H, m, P-CH2), 1.36-1.23 (4H, m, 6-CH2, y- 
CH2), 0.87 (3H, t, J = 7.0, co-CH3).
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l5C-NMR (DMSO, 126 MHz): 613.86 (co-CH3), 21.88 (C-y), 30.33 (C-|3), 30.79 
(C-6), 34.88 (C-a), 36.87 (S02CH3), 40.27 (C-2’), 69.17 (C-5’), 69.80 (C-3’), 
84.38 (C-4’), 87.86 (C -l’), 98.52 (C-5), 107.20 (C-4a), 124.59 (C-Hb), 125.77 
(ipso-C), 128.99 (C-Ha), 137.57 (C-4), 144.16 (para-C), 153.68 (C-6), 154.11 (C- 
2), 171.14 (C-7a).
El MS= 499.1520 (M+Na).
Anal. Calcd for C23H28N20 7S: C, 57.97; H, 5.92; N, 5.88. Found: C, 57.98; H, 
5.90; N, 5.79.
Synthesis of 3-(2,5-dideoxy-5-iodo-p-D-ribofuranosyl)-6-(4-/i-pentylphenyl)- 
2,3-dihydrofuro(2,3-r/]pyrimidin-2-one. [126]
C22H25IN2O4 
Mol Wt.: 508.0859
To a solution of 125 (0.10 g, 0.21 mmol), in acetone (3 mL) 
was added sodium iodide (0.25 g, 1.68 mmol) and the 
reaction mixture was stirred at 65 °C for 3.5 h, then at room 
temperature overnight, then at 70 °C for 7h. The solvent 
was removed and the residue purified by column 
chromatography eluting DCM/MeOH = 93/7, to give a pale yellow solid. (61%, 
0.065g).
'H-NMR (DMSO 500 MHz): 6 8.60 (1H, s, H-4), 7.75 (2H, d, J = 8.3, Ha), 7.34 
(2H, d, J = 8.3, Hb), 7.22 (1H, s, H-5), 6.26 (1H, t, H -l’), 5.57 (1H, 3’-OH), 4.21 
(1H, bs. H-3’), 4.06-4.03 (1H, m, H-4’), 3.57-3.55 (2H, m, H-5’) 2.63 (2H, t, J =
7.6, c x -C H 2), 2.47-2.43 (1H, m, H-2’), 2.30-2.24 (1H, m, H-2’), 1.63-1.57 (2H, m, 
P-CH2), 1.35-1.25 (4H, m, 6-CH2, y-CH2), 0.87 (3H, t, CH3).
13C-NMR (DMSO, 126 MHz): 6 7.27 (C-5’), 13.87 (CH3), 21.89, 30.34, 30.79,
34.88 (C4H8), 40.06 (C-2’), 72.93 (C-3’), 86.73 (C -l’). 87.88 (C-4’), 98.63 (C-5),
107.23 (C-4a), 124.58 (C-Hb), 125.78 (ipso-C), 129.03 (C-Ha), 137.38 (C-4),
144.07 (para-C), 153.70 (C-6), 154.11 (C-2), 171.15 (C-7a).
CH3
(H2C)4
OH
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Synthesis of SXpyrimidin-l-ylthioVl’-deoxyuridine. [128]
o  C ,3H 14N 404S
5f l 7 H3 Mol Wt.: 322.3397
O k . ' N ^ °
To a solution of 127 (3.00 g, 13.46 mmol) in dryN ' -O .4'
3qh  acetonitrile (60 mL) were added 2-mercapto-
pyrimidine (1.84 g, 16.43 mmol) and N,N-dimethylformamide dineopentylacetal 
(8 mL) and the reaction mixture was stirred under reflux for 4 h. The solvent was 
then removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH = 9/1, to give a yellow solid (84%, 
3.56 g).
‘H-NMR (DMSO 500 MHz): 6 11.32 (1H, s, NH), 8.65 (2H, d, J = 5.1, 
pyrimidine), 7.67 (1H, d, J = 8.1, H-6), 7.24 (1H, t, J = 5.0, pyrimidine), 6.17 (1H, 
t, H - l’), 5.66 (1H, d, J = 8.1, H-5), 5.41 (1H, d, 3’-OH), 4.24-4.23 (1H, m, H-3’), 
4.01-3.98 (1H, m, H-4’), 3.46-3.43 (2H, m, H-5’), 2.28-2.23 (1H, m, H-2’a), 2.14- 
2.10 (1H, m, H-2’b).
Synthesis of 2 \5 ’-dideoxyuridine. [129]
C9H,2N204 
NH Mol Wt.: 212.2026
A ,N
-O-H3c ^ y To a solution of 128 (2.32 g, 7.21 mmol) in ethanol (110 
^  mL) was added raney-nickel (13 g) and the reaction
mixture was stirred at 80 °C for 1 h. After this period the suspension was filtered 
through celite and the catalyst was washed with hot ethanol. The clear solution 
was concentrated under reduced pressure to give a yellow solid (63%, 1.50 g).
‘H-NMR (DMSO 500 MHz): 5 11.28 (1H, bs, NH), 7.59 (1H, d, J = 8.0, H-6), 
6.09 (1H, t, H - l’), 5.64 (1H, d, J = 8.0, H-5), 5.26 (1H, bs, OH), 3.96-3.95 (1H, 
m, H-3’), 3.83-3.78 (1H, m, H-4’), 2.19-2.14 (1H, m, Ha-2’), 2.12-2.07 (1H, m, 
Hb-2’), 1.24 (3H, d, H-5’).
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Synthesis of 5-iodo-2’,5’-dideoxyuridine. [130]
O C9HMIN2O4 
'> |  NH Mol Wt.: 338.0991
H3c To a solution of 129 (0.42 g, 1.96 mmol) in acetonitrile (20
OH mL) were added iodine (0.30 g, 1.18 mmol) and cerium
(IV) ammonium nitrate (CAN) (0.54 g, 0.98 mmol) and the reaction mixture was 
stirred at reflux for 1.5 h. After this period the reaction was quenched with 
saturated solution of NaHSC>3 then concentrated. The residue was dissolved in 
ethyl acetate and washed with brine (twice), dried under MgSC>4 and concentrated 
under reduced pressure to give a pale yellow solid (83%, 0.55 g).
'H-NMR (DMSO 500 MHz): 6 11.74 (1H, bs, NH), 7.98 (1H, d, H-6), 6.07 (1H, 
t, H -l’), 5.29 (1H, d, OH), 4.04-4.00 (1H, m, H-3’), 3.90-3.86 (1H, m, H-4’), 
2.37-2.31 (1H, m, H.-2’), 2.16-2.11 (1H, m, Hb-2’), 1.31 (3H, d, H-5’).
Synthesis of 3-(2\5’-dideoxy-P-D-ribofiiranosyl)-6-(4-/i-pentylphenyl)-2,3-di- 
hydrofuro [2,3-</]pyrimidin-2-one. [I ll]
CH3
(H2C)4
C 2 2 H 2 6 N 2 0 4  
Mol Wt.: 382.4528
To a stirred solution of 130 (1.36 g, 4.04 mmol) in dry 
DMF (25 mL), were added: 4-«-pentylphenylacetylene
palladium(O) (0.47 g, 0.40 mmol), copper (I) iodide (0.15 
g, 0.81 mmol) and DIPEA (1.41 mL, 8.08 mmol) and the 
reaction mixture was stirred at room temperature, under an Argon atmosphere, 
overnight. After this period, were added copper (I) iodide (0.15 g, 0.81 mmol) and 
anhydrous TEA (25 mL) and the reaction mixture was stirred at 85 °C for 7 h. 
After cooling the reaction mixture was concentrated under reduced pressure and 
the residue purified by column chromatography eluting with DCM/MeOH = 94/6, 
to give a brown solid (63%, 0.93 g).
O
OH
191
Marco Derudas Chapter 9
‘H-NMR (DMSO, 500 MHz): 6 8.57 (1H, s, H-4), 7.78 (2H, d, J = 8.2, Ha), 7.38 
(2H, d, J = 8.2, Hb), 7.24 (1H, s, H-5), 6.19 (1H, t, H -l’), 5.36 (1H, d, 3’-OH), 
4.07-4.02 (2H, m, H-3’, H-4’), 2.68 (2H, t, <x-CH2), 2.47-2.45 (1H, m, Ha-2’), 
2.24-2.20 (1H, m, Hb-2’), 1.67-1.64 (2H, m, P-CH2), 1.41 (3H, d, H-5’), 1.38-1.32 
(4H, m, 6-CH2, y-CH2), 0.92 (3H, t, CH3).
I3C-NMR (DMSO, 126 MHz): 6 13.86 (CH3), 18.71 (C-5’), 21.89, 30.34, 30.79,
34.88 (C4H8), 40.39 (C-2’), 74.03 (C-3’), 83.09 (C -l’), 87.51 (C-4’), 98.83 (C-5), 
107.11 (C-4a), 124.51 (C-Hb), 125.85 {ipso-C), 129.01 (C-Ha), 137.60 (C-4),
144.08 {para-C), 153.74 (C-6), 153.81 (C-2), 171.08 (C-7a).
,3C-NMR(CDC13, 126 MHz): 6 13.99 (cd-CH3), 19.34 (C-5’), 22.49, 30.89,31.42,
35.81 (C4H8), 41.23, 43.05 (C-2’), 75.13 (C-3’), 83.68 (C-4’), 88.63 (C -l’), 97.06 
(C-5), 108.49 (C-4a), 124.94 (C-Hb), 125.77 (ipso-C), 128.76, 129.02 (C-Ha), 
135.17 (C-4), 145.13 (para-C), 154.97 (C-6), 156.10 (C-2), 171.59 (C-7a).
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9.6 Synthesis of 5’-deoxy-3’-phosphoramidate of BCNA lead compound
Synthesis of 3-(2’,5’-dideoxy-p-D-ribofuranosyl-3-|phenyl-(methoxy-L-ala- 
ninyl)] phosphate)-6-(4-/f-pentylphenyl)-2,3-dihydrofuro [2,3-<flpynmidin-2- 
one. (132a]
C32H38N30 8P 
Mol Wt.: 623.6332
Prepared according to Standard Procedure D, from 21 
(0.20 g, 0.52 mmol) in anhydrous THF (5 mL), 49a
(0.58 g, 2.09 mmol) in anhydrous THF (2 mL), NMI
(0.42 mL, 5.23 mmol) and the reaction mixture was 
stirred at room temperature overnight. The residue was 
purified by column chromatography gradient elution of 
DCM/MeOH = 98/2 then 97/3. The product was purified 
by preparative TLC (gradient elution of DCM/MeOH = 
99/1 then 98/2) to give a white solid (13%, 0.041 g).
3,P-NMR (MeOD, 202 MHz): 6 3.40, 2.66.
'H-NMR (MeOD, 500 MHz): 6 8.42, 8.41 (1H, 2s, H-4), 7.57 (2H, d, Ph), 7.28
(2H, t, OPh), 7.17-7.08 (5H, m, Ph, OPh), 6.89, 6.88 (1H, 2s, H-5), 6.11, 6.07 
(1H, 2t, H -l’), 4.80-4.78, 4.75-4.73 (2H, 2m, H-3’), 4.35-4.33, 4.30-4.28 (2H, 2m, 
H-4’), 3.90-3.87 (1H, m, C//CH3), 3.60, 3.57 (3H, 2s, COOC//3), 2.89-2.85, 2.81- 
2.76 (1H, 2m, Ha-2’), 2.53 (2H, t, a-CH2), 2.36-2.30, 2.27-2.21 (1H, 2m, Hb-2’), 
1.56-1.50 (2H, m, P-CH2), 1.37, 1.34 (3H, 2d, H-5’), 1.27-1.19 (7H, m, y-CH2, 6- 
CH2, CHC//3), 0.80 (3H, t, (d-CH3).
,3C-NMR (MeOD, 126 MHz): 6 14.39, 15.46 (2s, a)-CH3), 19.15, 19.33 (2s, C- 
5’), 20.16 (d, 5C P = 7.4, CHCH3), 20.35 (d, JC-p = 7.0, CHCH3), 23.57, 32.12, 
32.61, 36.76 (C4H8), 40.34, 40.37 (2s, C-2’), 51.55, 51.74 (2s, CHCH3), 52.77,
52.81 (2s, COOCH3), 81.78 (d, JC-p = 5.0, C-3’), 82.24 (d, JC-p = 5.5, C-3’), 83.85 
(d, 5C-p= 5.7, C-4’), 83.94 (d, JC-p = 6.6, C-4’), 90.00 (C -l’), 98.93, 98.95 (2s, C- 
5), 110.27 (C-4a), 121.41, 121.45, 121.59, 121.63, 125.94, 126.27, 126.33,
CH3
(H2C)4
O
?  H P H: 
0 = P - N —(
OCH
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127.23, 130.16, 130.85, 130.89 (C-Ha, C-Hb, ‘ipso’-C, PhO), 138.06 (C-4), 146.37 
(para-C), 152.18 (‘ipso’ PhO), 156.32 (C-6), 157.38 (C-2), 173.08 (C-7a), 175.62 
(COOCH3).
El MS= 646.23 (M+Na).
Anal. Calcd for C32H38N3O8P: C, 61.63; H, 6.14; N, 6.74. Found: C, 61.38; H, 
6.31; N, 6.45.
Synthesis of 3 -(2 \5 ’-dideoxy-P-D-ribofuranosyI-3-[phenyI-(ethoxy-L-alani- 
nyl)] phosphate)-6-(4-/t-pentylphenyl)-2,3-dihydro-furo-[2,3 </]pyrimidin-2-
C 3 3 H 4 0 N 3 O 8 P  
Mol Wt.: 637.6598
Prepared according to Standard Procedure D, from 21 (0.20 
g, 0.52 mmol) in anhydrous THF (5 mL), 50b (0.61 g, 2.09 
mmol) in anhydrous THF (2 mL), NMI (0.42 mL, 5.23 
mmol) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column 
chromatography, gradient elution of DCM/MeOH = 98/2 
then 97/3. The product was purified by preparative TLC 
(gradient elution of DCM/MeOH = 99/1 then 98/2) to give a 
white solid (total yield 22%, 0.072 g). 132b (9.6%, 0.032 g), 
132c (6%, 0.020 g), 132d (6%, 0.020 g).
132b:
31P-NMR (MeOD, 202 MHz): 6 3.47, 2.73.
'H-NMR (MeOD, 500 MHz): 6 8.43, 8.42 (1H, 2s, H-4), 7.59-7.58 (2H, m, Ph), 
7.27 (2H, t, OPh), 7.17-7.08 (5H, m, Ph, OPh), 6.89, 6.88 (1H, 2s, H-5), 6.12,
6.08 (1H, 2t, H -l’), 4.80-4.77, 4.75-4.73 (1H, 2m, H-3’), 4.36-4.34, 4.30-4.28 
(1H, 2m, H-4’), 4.06, 4.00 (2H, 2q, COOC//2CH3), 3.88-3.84 (1H, m, C//CH3), 
2.88-2.84, 2.81-2.77 ( 1H, 2m, Ha-2’), 2.53 (2H, t, a-CH2), 2.37-2.32, 2.27-2.22 
(1H, 2m, Hb-2’), 1.56-1.50 (2H, m, |3-CH2), 1.37, 1.34 (3H, 2d, H-5’), 1.28-1.23
one. [132b-d]
c h 3
(H2C)4
o
?  H , CH 3 
0 = P —N— C
O > ~ O E t
O
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(7H, m, y-CH2, 6-C H 2, C H C //3), 1.15, 1.11 (3H, 2t, COOCH2C//3), 0.80 (3H, t, 
00-CH3).
13C-NMR (MeOD, 126 MHz): 6 14.34, 14.49 (co-CH3, OCH2CH3), 19.05, 19.29 
(2s, C-5’), 20.18 (d, Jc p = 7.4, CHCH3), 20.41 (d, JC-P = 7.0, CHCH3), 23.56,
32.15, 32.58, 36.74 (C4H8), 40.32, 40.35 (2s, C-2’), 51.64, 51.84 (2s, CHCH3), 
62.34, 62.38 (2s, OCH2CH3), 81.63 (d, JC-p = 5.0, C-3’), 82.22 (d, JC- p  = 5.6, C- 
3’), 83.78 (d, J c-p = 5.7, C-4’), 83.94 (d, J C-p = 6.6, C-4’), 90.01, 90.06 (2s, C -l’), 
98.92, 98.96 (2s, C-5), 110.30 (C-4a), 121.39, 121.43, 121.58, 121.61, 125.96, 
126.25, 126.31, 127.29, 130.19, 130.83, 130.87 (C-Ha, C-Hb, ‘ipso’-C, PhO), 
138.13 (C-4), 146.43 (para-C), 152.15, 152.20 (‘ipso’ PhO), 156.76, 156.80 (2s, 
C-6), 157.47 (C-2), 173.15 (C-7a), 174.87, 175.62 (2s, COOCH2CH3).
El MS= 660.25 (M+Na).
Anal. Calcd for CjsH^NjOgP-HzO: C, 60.45; H, 6.46; N, 6.41. Found: C, 60.76;
H, 6.67; N, 6.10.
132c:
31P-NMR (MeOD, 202 MHz): 6 3.48.
'H-NMR (MeOD, 500 MHz): 6 8.45 (1H, s, H-4), 7.61 (2H, d, Ph), 7.28 (2H, t, 
OPh), 7.19 (2H, d, Ph), 7.14-7.09 (3H, m, OPh), 6.92 (1H, s, H-5), 6.13 (1H, t, H- 
1’), 4.80-4.75 (1H, m, H-3’), 4.31-4.29 (1H, m, H-4’), 4.01 (2H, q, 
COOC//2CH3), 3.88-3.84 (1H, m, C//CH3), 2.90-2.85 (1H, m, Ha-2’), 2.55 (2H, t, 
a-CH2), 2.38-2.33 (1H, m, Hb-2’), 1.58-1.52 (2H, m, p-CH2), 1.35 (3H, d, H-5’),
I.29-1.22 (7H, m, y-C H 2, 6-C H 2, CHC//3), 1.11 (3H, t, COOCH2C //3), 0.81 (3H, 
t, (0-CH3).
13C-NMR (MeOD, 126 MHz): 6 14.34, 14.48 (00-CH3, OCH2CH3), 19.04 (C-5’), 
20.18 (d, J c-p = 7.4, CHCH3), 23.56, 32.15, 32.58, 36.74 (C4H8), 40.34 (d, J C-p = 
4.3, C-2’), 51.84 (CHCH3), 62.34 (OCH2CH3), 81.63 (d, JC-p = 5.0, C-3’), 83.77 
(d, J C-p = 5.7, C-4’), 90.02 (C -l’), 98.97 (C-5), 110.30 (C-4a), 121.58, 121.61,
125.96, 126.31, 127.30, 130.20, 130.83 (C-Ha, C-Hb, ‘ipso’-C, PhO), 138.14 (C- 
4), 146.44 (para-C), 152.15 (‘ipso’ PhO), 156.80 (C-6), 157.46 (C-2), 173.16 (C- 
7a), 175.23 (COOCH2CH3).
El MS= 660.25 (M+Na).
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Anal. Calcd for CjsFUoNsOsP ^H zO: C, 58.83; H, 6.58; N, 6.24. Found: C, 58.62;
H, 6.82; N, 5.13.
132d:
31P-NMR (MeOD, 202 MHz): 6 2.74.
'H-NMR (MeOD, 500 MHz): 6 8.44 (1H, s, H-4), 7.61 (2H, d, Ph), 7.20-7.16 
(4H, m, Ph, OPh), 7.12-7.09 (1H, m, OPh), 7.14-7.0 (1H, m, H-4’), 4.06 (2H, q, 
COOC//2CH3), 3.88-3.85 (1H, m, C//CH3), 2.82-2.77 (1H, m, Ha-2’), 2.55 (2H, t, 
a-CH2), 2.28-2.22 (1H, m, Hb-2’), 1.56-1.52 (2H, m, P-CH2), 1.38 (3H, d, H-5’),
I.29-1.22 (7H, m, y-CH2, 5-CH2, CHCT/j), 1.16 (3H, t, COOCH2C/73), 0.81 (3H, 
t, (JO-CH3).
I3C-NMR (MeOD, 126 MHz): 5 14.34, 14.49 (co-CHj, OCH2CH3), 19.29 (C-5’),
20.41 (d, J c-p = 7.0, CHCHj), 23.56, 32.15, 32.58, 36.74 (C4H8), 40.34 (d, Jc_/> =
3.9, C-2 ’), 51.64 (CHCHj), 62.38 (OCH2CH3), 82.22 (d, JC-r = 5.6, C-3’), 83.94 
(d, J c - p  = 6.6, C-4’), 90.06 (C -l’), 98.92 (C-5), 110.30 (C-4a), 121.39, 121.43,
125.97, 126.25, 127.30, 130.19, 130.87 (C-Ha, C-Hb, ‘ipso’-C, PhO), 138.12 (C- 
4), 146.42 (para-C), 152.15 (‘ipso’ PhO), 156.77 (C-6), 157.47 (C-2), 173.17 (C- 
7a), 174.91 (COOCH2CH3).
El MS= 660.24 (M+Na).
Anal. Calcd for C33H40N3O8P-H2O: C, 60.45; H, 6.46; N, 6.41. Found: C, 60.96; 
H, 6.69; N, 5.71.
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Synthesis of 3-(2’,5’-dideoxy-P-D-ribofuranosyI-3-[phenyl-(methoxy-glyni- 
nyl)] phosphate)-6-(4-rt-pentyIphenyl)-2,3-dihydro-furo [2,3-d \pyrimidin-2-
one. [132e]
c h 3
(H2C)4
o
C31H36N308P 
Mol Wt.: 609.6066
Prepared according to Standard Procedure D, from 21 
(0.20 g, 0.52 mmol) in anhydrous THF (5 mL), 50c 
(0.55 g, 2.09 mmol) in anhydrous THF (2 mL), NMI 
(0.42 mL, 5.23 mmol) and the reaction mixture was 
stirred at room temperature overnight. The residue was 
purified by column chromatography gradient elution of 
DCM/MeOH = 98/2 then 97/3. The product was purified 
by preparative TLC (eluting gradient DCM/MeOH = 
99/1 then 98/2), then by preparative reverse phase HPLC 
(gradient elution of H20/CH3CN= from 100/0 to 0/100 in 30 min) to give a white
solid (3%, 0.010 g).
0 = P - N
OCH<
3IP-NMR (MeOD, 202 MHz): 6 4.42, 4.21.
'H-NMR (MeOD, 500 MHz): 6 8.45, 8.45 (1H, 2s, H-4), 7.61 (2H, d, Ph), 7.28 
(2H, t, OPh), 7.19 (2H, d, Ph), 7.17-7.09 (3H, m, OPh), 6.92, 6.92 (1H, 2s, H-5), 
6.13-6.09 (1H, m, H -l’), 4.85-4.80 (1H, m, H-3’), 4.42-4.37, 4.32-4.28 (1H, 2m, 
H-4’), 3.70-3.65 (2H, m, NHC//2), 3.61-3.60 (3H, 2s, COOC//3), 2.87-2.77 (1H, 
m, H,-2’), 2.55 (2H, t, a-CH2), 2.35-2.24 (1H, 2m, Hb-2’), 1.58-1.52 (2H, m, |3- 
CH2), 1.40, 1.35 (3H, 2d, H-5’), 1.31-1.20 (4H, m, y-CH2, 6-CH2), 0.81 (3H, t, co- 
CH3).
n C-NMR (MeOD, 126 MHz): 6 14.35 (00-CH3), 19.11, 19.26 (2s, C-5’), 23.56,
32.15, 32.59, 36.75 (C4H8), 40.35 (C-2’), 43.65 (NHCH2), 52.62 (COOCHj),
81.84 (d, Jc-p = 6.0, C-3’), 82.09 (d, JC-p = 5.4, C-3’), 83.86 (d, }C-P = 4.7, C-4’), 
83.92 (d, J c-p = 6.9, C-4’), 89.99, 90.04 (C -l’), 98.93 (C-5), 121.44, 121.48,
121.54, 121.58,125.96, 126.33, 127.28, 130.18, 130.86, 130.89 (PhO, Ph), 138.11
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(C-4), 146.41 (para-C), 152.15 (‘ipso’ PhO), 156.77 (C-6), 157.43 (C-2), 173.14 
(C-7a), 174.09 (COOCH3).
El MS= 660.24 (M+Na).
HPLC (H2O/CH3CN from 100/0 to 0/100 in 30 min): Rt 22.67, 22.97 min.
9.7 Synthesis of benzophenone derivative of BCNA
Synthesis of 4-(trimethylsilyI)ethynyl-benzophenone [ISO]
O CigHigOSi 
Mol Wt.: 278.4204
To a solution of 4-bromo-benzophenone 149 (2.50 
g, 9.57 mmol) in anhydrous DMF (30 mL) were 
added: ethynyltrimethylsilane (4.00 mL, 28.72 mmol), tetrakis-
(triphenylphosphine) palladium(O) (1.11 g, 0.96 mmol), Cu(I)I (0.37 g, 1.91 
mmol), anhydrous DIPEA (3.33 mL, 19.15 mmol) and the reaction mixture was 
stirred at room temperature overnight. After this period, the solvent was removed 
and the residue triturated with acetone and methanol and the filtered. The organic 
phase was concentrated and further triturated with methanol and filtered. The 
filtrate was concentrated to give the desired compound, which was used without 
any further purification, (quantitative, 2.66 g).
'H-NMR (DMSO, 500 MHz): 5 7.75-7.56 (9H, m, Ph), 0.26 (9H, s, 3xCH3).
Synthesis of 4-ethynyl-benzophenone [151]
c ,5h 10o
Mol Wt.: 206.2393
To a suspension of 150 (2.65 g, 9.57 mmol) in anhydrous methanol (50 mL) was 
added MeONa (0.62 g, 11.49 mmol) and the reaction mixture was stirred at room 
temperature for 1 h. Then the reaction mixture was neutralized with amberlite, 
filtered and concentrated to give a black oil (95%, 1.97 g).
'H-NMR (DMSO, 500 MHz): 6 7.75-7.55 (9H, m, Ph), 4.48 (1H, s, CH).
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Synthesis of 3-(2’-deoxy-p-D-ribofuraiiosyI)-6-(4-/i-benzoyIphenyl)-2,3- 
dihydrofuro [2,3-</]pyrimidin-2-one. [143]
C24H20N2O6 
Mol Wt.: 432.4254
To a stirred solution of 121 (1.06 g, 3.00 mmol) in 
anhydrous DMF (15 mL), were added: 151 (1.81 g, 8.80 
O mmol), tetrakis-(triphenylphosphine) palladium(O) (0.35 
g, 0.30 mmol), Cu(I)I (0.11 g, 0.60 mmol) and anhydrous 
DIPEA (1.04 mL, 6.00 mmol) and the reaction mixture 
was stirred at room temperature, under an argon 
atmosphere overnight. After this period were added Cu(I)I (0.11 g, 0.60 mmol) 
and anhydrous TEA (15 mL) and the reaction mixture was stirred at 85 °C for 8 h. 
The solvent was then removed and the residue was triturated with DCM and the 
solution was stirred at room temperature overnight. The precipitate obtained was 
filtered and washed with DCM, to give a white solid as pure compound which 
was filtered through silica gel eluting with DCM/MeOH = 90/10 (59%, 0.77 g).
'H-NMR (DMSO, 500 MHz): 6 8.96 (1H, s, H-4), 8.01 (2H, d, J = 8.3, Ph), 7.86 
(2H, d, J = 8.3, Ph), 7.77 (2H, d, J = 7.2, Ph), 7.71 (1H, t, J = 7.4, Ph), 7.59 (2H, t, 
J = 7.6, Ph), 7.50 (1H, s, H-5), 6.19 (1H, t, J = 6.0, H -l’), 5.30 (1H, d, J = 4.3, 3’- 
OH), 5.18 (1H, t, J = 5.2, 5’-OH), 4.27 (1H, dd, J = 9.5, 4.3, H-3’), 3.97-3.95 (1H, 
m, H-4’), 3.77-3.69 (1H, m, H-5’), 3.69-3.60 (1H, m, H-5’), 2.48-2.39 (1H, m, H- 
2’), 2.20-2.07 (1H, m, H-2’).
13C-NMR (DMSO, 126 MHz): 6 41.24 (C-2’), 60.61 (C-5’), 69.44 (C-3’), 87.78 
(C -l’), 88.22 (C-4’), 102.27 (C-5), 106.52 (C-4a), 124.44, 128.60, 129.55, 130.46,
131.97, 132.75 (Ph), 136.90, 136.92 (ipso-carbonyl), 139.27 (C-4), 152.33 (C-6), 
153.70 (C-2), 171.05 (C-7a), 194.92 (C=0).
El MS= 433.1414 (M+H) and 496.1508 (M+MeCNNa+).
Anal. Calcd for C24H20N2O6: C, 66.66; H, 4.66; N, 6.48. Found: C, 66.26; H, 4.43; 
N, 6.28.
HO.
OH
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9.8 Synthesis of 2’-fluoro derivative of BCNA lead compound 
Synthesis of 5-iodo-2’-deoxy-2’-a-fluoro-uridine [159]
NH
HO.
O
OH
C9H 10FIN 2O5 
Mol Wt.: 372.0890
To a solution of 2,-a-fluoro-2’deoxy-uridine 158 (2.00 g, 8.12 
mmol) in anhydrous acetonitrile (50 mL) were added iodine (1.24 
g, 4.87 mmol) and CAN (2.23 g, 4.06 mmol) and the reaction mixture was stirred under 
reflux for lh. After this period, the reaction mixture was quenched with a saturated 
solution of Na2S203 and then concentrated. The residue was dissolved in ethyl acetate 
and washed with brine (twice). The organic phase was dried over MgSC>4, concentrated to 
give a pale yellow solid (79%, 2.40 g).
,9F-NMR (DMSO, 471 MHz): 6 -202.14.
'H-NMR (DMSO, 500 MHz): 6 11.71 (1H, s, NH), 8.52 (1H, s, H-6), 5.86 (1H, d, J =
16.9, H -l’), 5.58 (1H, d, J = 6.3, 3’-OH), 5.36 (1H, s, 5’-OH), 5.08 (0.5H, s, H-2’), 4.98 
(0.5H, s, H-2’), 4.17 (1H, d, H-3’), 3.89 (1H, d, J = 7.5, H-4’), 3.81 (1H, d, J = 10.5, H- 
5’), 3.60 (1H, d, J=  10.5, H-5’).
13C-NMR (DMSO, 126 MHz): 6 58.50 (C-5’), 66.73 (d, JC- f  = 16.3, C-3’), 69.04 (C-5), 
83.00 (C-4’), 87.39 (d, JC- f  = 34.1, C -l’), 95.12 (d, JC- f  = 184.3, C-2’), 144.66 (C-6),
149.94 (C-2), 160.53 (C-4).
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HO.
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Synthesis of 3-(2’-a-fluoro-2,-deoxy-p-D-ribofuranosyl)-6-(4-/i-pentyIphenyl)-2,3-
dihydrofuro [2,3-^]pyrimidin-2-one [155]
c h 3
(H2C)4 C22H25FN2O5
Mol Wt.: 416.4427
To a solution of 159 (1.50 g, 4.03 mmol) in anhydrous DMF (20 
mL) were added: 4-«-pentylphenylacetylene (2.36 mL, 12.09 
mmol), tetrakis (0.47 g, 0.40 mmol), copper (I) iodide (0.15 g, 0.81 
mmol) and DIPEA (1.40 mL, 8.06 mmol) and the reaction mixture 
was stirred at room temperature, under an Argon atmosphere 
overnight. After this period were added copper (I) iodide (0.15 g, 0.81 mmol) and 
anhydrous TEA (20 mL) and the reaction mixture was stirred at 85 °C for 7.5 h. The 
solvent was then removed in vacuo, and the resulting residue was triturated with 
methanol, filtered and washed with methanol and DCM to obtain a black solid (pure by 
NMR). The organic phase was concentrated and the residue purified by column 
chromatography, eluting with DCM/MeOH = 96/4. The compound was obtained as a 
dark solid which was combined with the previous precipitate and filtered through a silica 
gel column, eluting with DCM/MeOH = 96/4 to give a black solid. The solid obtained 
was washed with acetone, filtered and the solid was further washed with petroleum ether 
to give a white-grey solid (42%, 0.70 g).
I9F-NMR (DMSO, 471 MHz): 6-201.19.
‘H-NMR (DMSO, 500 MHz): 6 8.94 (1H, s, H-4), 7.75 (2H, d, J = 8.1, Ha), 7.32 (2H, d, J 
= 8.1, Hb), 7.22 (1H, s, H-5), 6.02 (1H, d, J = 17.0, H -l’), 5.60 (1H, d, J = 6.6, 3’-OH), 
5.42 (1H, t ,  J = 4.9, 5’-OH), 5.00 (1H, dd, J = 3.7, Jh-f = 52.6, H-2’), 4.26-4.20 (1H, m, 
H-3’), 3.95 (1H, dd, J = 12.4, 2.9, H-4’), 3.77-3.67 (2H, m, H-5’), 2.61 (2H, t, J = 7.6, a - 
CH2), 1.65-1.61 (2H, m, P-CH2), 1.42-1.18 (4H, m, Y-CH2, 6-CH2), 0.86 (3H, t, J = 6.9, 
co-CHj).
I3C-NMR (DMSO, 126 MHz): 6 13.84 (CH3), 21.88, 30.33, 30.79, 34.88 (C4H8), 58.42 
(C-5’), 66.31 (d, Jc..f= 16.3, C-3’), 83.04 (C-4’), 89.54 (d, ic f  = 34.0, C -l’), 94.16 (d,
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JC-f = 185.7, C-2’), 98.56 (C-5), 107.19 (C-4a), 124.58 (C-Hb), 125.77 (ipso-C), 128.96
(C-Ha), 137.77 (C-4), 144.14 {para-C), 153.69 (C-6), 154.12 (C-2), 171.27 (C-7a). 
El MS= 416.1738 (M+).
To a solution of 160 (2.00 g, 4.31 mmol) in anhydrous DCM (9 mL) was added dropwise 
under Ar atmosphere a 33%wt solution of HBr in acetic acid (1.54 mL, 9.04 mmol) and 
the reaction mixture was stirred at rt overnight. After this period, 33%wt solution of HBr 
in acetic acid (0.77 mL, 4.50 mmol) was added and the reaction mixture was stirred at rt 
for further 7h. Then the reaction mixture was quenched with saturated solution of 
NaHCC>3. The organic phase was washed with saturated solution of NaHCC>3 (twice) and 
then dried over MgS04, then concentrated to give a colourless oil (95%, 1.73g).
Anal. Calcd for Czz^sFNzOs-O.SHzO: C, 62.11; H, 6.16; N, 6.58. Found: C, 61.73; H, 
6.15; N, 6.41.
Synthesis of 2-deoxy-l-aIpha-bromo-2-beta-f1uoro-3,5-di-0-benzoyl-d-ribofi]ranose 
[161]
OBz p
Ci9Hi6BrFC>5 
Br Mol Wt.: 423.2297
l9F-NMR (CDC13, 471 MHz): 6 -165.93.
'H-NMR (CDClj, 500 MHz): 6 8.18-8.04 (4H, m, Bz), 7.69-7.43 (6H, m, Bz), 6.66 (1H, 
d, J = 12.2, H -l’), 5.57 (1H, dd, J = 3.2, JH.F= 22.0, H-2’), 4.87-4.72 (4H, m, H-3’, H-4’, 
H-5’).
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Synthesis of 2,4-bis-0-(trimethylsilyl)-5-iodouracil [163]
OSi(CH3)3 C ,o H ,9 lN 20 2 S i2  
Mol Wt.: 382.3455
N OSi(CH3)3
To a suspension of 162 (0.49 g, 2.04 mmol) in anhydrous acetonitrile (10 mL) were 
added ammonium sulphate (0.027 g, 0.2 mmol) and hexamethyldisilazane (0.48 mL, 2.30 
mmol) and the reaction mixture was stirred at reflux for 22h. After this period, 
hexamethyldisilazane (0.96 mL, 4.08 mmol) was added and the reaction mixture was 
stirred at reflux for further 4h and then concentrated. The crude was used in the next step 
without purification.
Synthesis of l-(2-deoxy-2-fluoro-3,5-di-0-benzoyI-D-arabino-furanosyl)-5-iodouracil
mmol) and the reaction mixture was stirred at rt for 6 days. After this period the 
suspension was filtered and the solid was washed with water and DCM to give the 
desired compound as a white solid (51%, 2.45 g).
[164]
C23H 18FIN207 
NH Mol Wt.: 580.3011
BzO
To a solution of 161 (3.50 g, 8.27 mmol) in DCM (65 mL) and 163 
(8.27 mmol) in acetonitrile (15 mL) was added Nal (0.99 g, 6.62
19F-NMR (DMSO, 471 MHz): 5-199.13.
'H-NMR (DMSO, 500 MHz): 6 8.08-7.99 (5H, m, H-6, Bz), 7.74-7.66 (2H, m, Bz), 7.60- 
7.52 (4H, m, Bz), 6.31 (1H, dd, J = 3.7, JH-f =  19.4, H -l’), 5.71 (1H, ddd, J = 4.8, 1.3, JH- 
F= 20.3, H-3’), 5.54 (1H, ddd, J = 3.8, 1.4, J„.F = 50.7, H-2’), 4.81-4.71 (2H, m, H-5’), 
4.63 (1H, dd, J = 8.3, 4.3, H-4’).
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Synthesis of 5-iodo-2’-p-f1uoro-2’-deoxyuridine [165)
O C9H,oFIN205 
,NvT| NH Mol Wt.: 372.0890 
N O
HO^
To a stirring solution of 164 (2.40 g, 4.14 mmol) in anhydrous
OH p methanol (60 mL) was added NaOMe (0.49 g, 9.70 mmol) and the
reaction mixture was stirred at room temperature for 1 h. After this period, the reaction 
was neutralized with amberlite, filtered and concentrated to give the desired product, 
which was used in the following step without further purification.
,9F-NMR (DMSO, 471 MHz): 6 -198.65.
‘H-NMR (DMSO, 500 MHz): 6 8.21 (1H, s, H-6), 6.08 (1H, dd, J = 4.5, JH-f  = 13.9, H- 
1’), 5.93 (1H, bs, 3’-OH), 5.27-5.25 (1H, m, 5’-OH), 5.14-5.11 (1H, m, H-2’), 5.04-4.99 
(1H, m, H-2’), 4.29-4.19 (1H, m, H-3’), 3.81-3.78 (1H, m, H-4’), 3.71-3.65 (1H, m, H- 
5’), 3.61-3.56 (1H, m, H-5’).
Synthesis of 3-(2’-a-fluoro-2’-deoxy-P-D-ribofuranosyl)-6-(4-/f-pentylphenyl)-2,3- 
dihydrofuro [2,3-<f)pyrimidin-2-one [156]
C22H25FN2O5 
Mol Wt.: 416.4427
To a solution of 165 (1.54 g, 4.14 mmol) in anhydrous DMF (20 
mL) were added: 4-«-pentylphenylacetylene (2.40 mL, 12.41 
mmol), tetrakis (0.48 g, 0.41 mmol), copper (I) iodide (0.16 g, 0.83 
mmol) and anhydrous DIPEA (1.44 mL, 8.27 mmol) and the 
reaction mixture was stirred at room temperature, under an argon 
atmosphere overnight. After this period were added copper (I) 
iodide (0.16 g, 0.83 mmol) and anhydrous TEA (20 mL) and the reaction mixture was 
stirred at 85 °C for 8 h. The solvent was then removed in vacuo and the residue was
(H2C)4
HO.
OH
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triturated with DCM and stirred at room temperature for 2h and then filtered and washed 
with DCM to give a white solid (45%, 0.77 g). A sample was filtered through silica gel 
for biological testing.
19F-NMR (DMSO, 471 MHz): (5-197.85.
'H-NMR (DMSO, 500 MHz): 8 8.73 (1H, s, H-4), 7.74 (2H, d, J = 8.3, Ph), 7.33 (2H, d, 
J = 8.3, Ph), 7.22 (1H, s, H-5), 6.25, 6.22 (1H, 2d, J = 3.7, }h.f = 17.1, H -l’), 6.07 (1H, d, 
J = 4.6, 3’-OH), 5.28 (1H, t, J = 5.8, 5’-OH), 5.24, 5.14 (1H, 2dd, J = 3.6, 2.3, W  = 52.0, 
H-2’), 4.29, 4.26 (1H, 2dd, J = 6.1, 4.3, JH.F = 18.2, H-3’), 3.99 (1H, q, H-4’), 3.71-3.63 
(2H, m, H-5’), 2.62 (2H, t, a-CH2), 1.59 (2H, quintet, (3-CH2), 1.35-1.24 (4H, m, y-CH2, 
6-CH2), 0.86 (3H, t, CH3).
,3C-NMR (DMSO, 126 MHz): 6 13.85 (CH3), 21.87 (CH2), 30.32 (|3-CH2), 30.78 (CH2), 
34.87 (a-CH2), 60.13 (C-5’), 73.08 (d, J C-f  = 24.5 Hz, C-3’), 85.22 (C-4’), 86.15 (d, JC-f  
= 16.6 Hz, C -l’), 94.66 (d, JC-f = 191.5 Hz, C-2’) 98.60 (C-5), 107.14 (C-4a), 124.61 
(Ph), 125.70 (ipso-C), 128.99 (Ph), 138.70 (C-4), 144.20 (para-C), 153.47 (C-6), 154.20 
(C-2), 171.30 (C-7a).
El MS= 416.1749 (M+).
HPLC = H20/A cCN from 100/0 to 0/100 in 30 min = retention time 23.81 min.
Synthesis of 3-(2’-di-fluoro-2,-deoxy-p-D-ribofuranosyI)-6-(4-/f-pentylphenyl)-2,3- 
dihydrofuro [2,3-^pyrimidin-2-one [157]
c 22h 24f 2n 2o 5
Mol Wt.: 434.4332
To a solution of 166 (0.18g, 0.47 mmol) in anhydrous DMF (5 mL) 
were added: 4-«-pentylphenylacetylene (0.27 mL, 1.41 mmol), 
tetrakis (0.055 g, 0.047 mmol), copper (I) iodide (0.018 g, 0.047 
mmol) and DIPEA (0.16 mL, 0.94 mmol) and the reaction mixture 
was stirred at room temperature, under an Argon atmosphere
(H2C)4
HO.
OH
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overnight. After this period were added copper (I) iodide (0.018 g, 0.047 mmol) and 
anhydrous TEA (5 mL) and the reaction mixture was stirred at 85 °C for 7.5 h. The 
solvent was then removed in vacuo and the residue was purified by column 
chromatography, eluting gradient of DCM, then DCM/MeOH = 98/2, then 96/4. The 
compound was obtained as a brown-dark solid, which was triturated with acetone and 
petroleum ether then filtered, and the solid was washed with acetone and petroleum ether 
to give a white-pale yellow solid (60%, 0.075 g).
19F-NMR (DMSO, 471 MHz): 6-116.84.
‘H-NMR (DMSO, 500 MHz): 6 8.75 (1H, s, H-4), 7.76 (2H, d, J = 8.2, Ha), 7.34 (2H, d, J 
= 8.2, Hb), 7.23 (1H, s, H-5), 6.35 (1H, d, J = 6.5, H -l’), 6.33-6.30 (1H, m, 3’-OH), 5.43 
(1H, t, J = 5.3, 5’-OH), 4.36-4.18 (1H, m, H-3’), 3.99-3.95 (1H, m, H-4’), 3.91-3.85 (1H, 
m, H-5’), 3.75-3.69 (1H, m, H-5’), 2.63 (2H, t, J = 7.6, a-CH2), 1.68-1.52 (2H, m, |3- 
CH2), 1.40-1.21 (4H, m, y-CH2, S-CH2), 0.87 (3H, t, J = 7.0, CH3).
,3C-NMR (DMSO, 126 MHz): 6 13.85 (CH3), 21.88, 30.32, 30.79, 34.90 (C4H8), 58.62 
(C-5’), 68.14 (t, Jc-F=  22.4, C-3’), 81.11 (C-4’), 85.14 (t, Jc~f = 31.2, C -l’), 98.37 (C-5),
107.94 (C-4a), 120.84, 122.91 (C-2’), 124.75 (C-Hb), 125.56 (ipso-C), 129.01 (C-Ha), 
137.26 (C-4), 144.44 (para-C), 153.68 (C-6), 154.87 (C-2), 171.53 (C-7a).
El MS= 435.1731 (M+H).
Anal. Calcd for C22H24F2N2O5*0.5H2O: C, 59.59; H, 5.68; N, 6.32. Found: C, 59.38; H, 
5.59; N, 6.25.
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9.9 Synthesis of 2’-fluoro derivatives on BCNA lead compound ProTides
Synthesis of 3-(2’-a-fluoro-2’-deoxy-p-D-ribofuranosyI-5-[phenyl-(methoxy-L- 
alaniny 1)] phosphate)-6-(4-/i-pentylphenyl)-2,3-dihydrofuro [2,3-d]pyrimidin-2-one 
[169a]
C32H37FN3O9P 
Mol Wt.: 657.6230
Prepared according to Standard Procedure D, from 155
(0.20 g, 0.48 mmol) in anhydrous THF (5 mL) and
anhydrous pyridine (5 mL), O la  (0.67 g, 2.40 mmol) in 
anhydrous THF (2 mL), NMI (0.19 mL, 2.40 mmol) and 
the reaction mixture was stirred at room temperature 
overnight. After this period were added O la  (0.40 g,
1.44 mmol) in anhydrous THF (2 mL) and NMI (0.11 mL, 1.44 mmol) and the reaction 
mixture was stirred at room temperature for further 7 h. After this period the solvent was 
removed and the residue dissolved in DCM. The organic phase was washed with a 0.5 M
aqueous solution of citric acid (twice) and water (twice), dried over MgS04 and
concentrated. The residue was purified by column chromatography gradient elution of 
DCM/MeOH = 98/2 then 97/3 to give a white solid which was further purified by 
preparative TLC (gradient elution of DCM/MeOH = 99/1, then 98/2, then 96/4) to give a 
white solid (5%, 0.015 g).
3IP-NMR (MeOD, 202 MHz): 6 3.90, 3.83.
19F-NMR (DMSO, 471 MHz): (5-203.40, -203.72.
‘H-NMR (MeOD, 500 MHz): 6 8.72, 8.71 (1H, 2s, H-4), 7.66-7.59 (2H, m, Ph), 7.43-
7.17 (7H, m, Ph), 6.87, 6.75 (1H, 2s, H-5), 6.16 (0.5H, d, J = 8.3, H -l’), 6.13 (0.5H, d, J 
= 8.5, H -l’), 5.09 (1H, dd, J = 3.1, J H- f =  52.1, H-2’), 4.79-4.64 (1H, m, H-5’), 4.57-4.42 
(1H, m, H-4’), 4.40-4.27 (2H, m, H-3’, H-5’), 4.08-3.99 (1H, m, C //C H 3), 3.68 (3H, s,
CH3
(H2C)4
O - P - O
NH
O
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OCH3), 2.66 (2H, t, J = 7.7, cx-CH2), 1.73-1.60 (2H, m, P-CH2), 1.44-1.28 (7H, m, y- 
CH2, 6-CH2, CHC//3), 0.93 (3H, t, J = 7.0, CH3).
13C-NMR (MeOD, 126 MHz): 6 14.35 (CH3), 20.34 (d, JC-p = 7.4, CHCH3), 20.53 (d, JC- 
P = 6.4, CHCH3), 23.56, 32.14, 32.59, 36.74 (C4H8), 51.55, 51.77 (CHCH3), 52.81, 52.85 
(2s, OCH3), 65.64 (d, Jc P = 2.8, C-5’), 65.68 (d, JC-p = 2.0, C-5’), 68.80 (d, JC-p = 16.5, 
C-4’), 68.93 (d, Jc- p = 16.2, C-4’), 82.56, (d, JC-p = 8.3, C-3’) 82.63 (d, JC-p = 8.3, C-3’), 
92.26, 92.54 (2d, JC F = 34.8, C -l’), 94.30, 95.80 (2d, JC-F = 187.7, C-2’), 98.96, 98.99 
(2s, C-5), 110.45 (C-4a), 121.42, 121.50, 121.51, 121.53, 121.55, 123.94, 125.90, 126.02, 
126.40, 127.12, 127.14, 130.09, 130.17, 130.20, 130.59, 130.72, 130.93, 131.00, (PhO, 
Ph), 138.52, 138.54 (C-4), 146.49, 146.50 (2s, para-C), 152.00, 152.05 (2s, ‘ipso’ PhO),
156.59 (C-6), 157.45, 157.49 (C-2), 173.36 (C-7a), 175.31 (d, JC-p = 5.2, COOCH3),
175.58 (d, Jc-p = 4.5, COOCH3).
El MS= 658.2330 (M+H).
HPLC = H20/AcCN from 100/0 to 0/100 in 30 min = retention time 20.43 min.
Synthesis of 3-(2’-a-fluoro-2’-deoxy-p-D-ribofuranosyl-5-[phenyl-(benzoxy-L- 
alaninyl)] phosphate)-6-(4-/i-pentylphenyl)-2,3-dihydrofuro [2,3-d \pyrimidin-2-one 
[169b]
CH3
(H2C)4
C 3 8 H 4 1 F N 3 0 9 P  
Mol Wt.: 733.7190
Prepared according to Standard Procedure D, from 155 
(0.17 g, 0.40 mmol) in anhydrous THF (5 mL) and
anhydrous THF (2 mL), NMI (0.16 mL, 2.00 mmol) and 
the reaction mixture was stirred at room temperature 
O overnight. After this period were added 131d (0.42 g, 1.20
mmol) in anhydrous THF (2 mL) and NMI (0.09 mL, 1.20 mmol) and the reaction 
mixture was stirred at room temperature for further 24 h. Then NMI (0.09 mL, 1.20 
mmol) was added and the reaction mixture stirred at room temperature for further 7 h.
fo1 n
O - P - O .
NH
BnO
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After this period the solvent was removed and the residue dissolved in DCM. The organic 
phase was washed with a 0.5 M aqueous solution of citric acid (twice) and water (twice), 
dried over MgS04 and concentrated. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 97/3 to give a white solid 
which was further purified by preparative TLC (gradient elution of DCM/MeOH = 99/1, 
then 98/2, then 96/4) to give a white solid (7%, 0.020 g).
3IP-NMR (MeOD, 202 MHz): 6 3.94, 3.71.
19F-NMR (DMSO, 471 MHz): <5-200.55, -200.94.
'H-NMR (MeOD, 500 MHz): 6 8.70, 8.67 (1H, 2s, H-4), 7.70-7.60 (2H, m, Ph), 7.47-
7.18 (12H, m, Ph, PhO, CH2Ph), 6.86, 6.79 (1H, 2s, H-5), 6.14 (0.5H, d, J = 9.3, H -l’), 
6.11 (0.5H, d, J = 10.0, H -l’), 5.18-5.06 (2H, m, CH2Ph), 5.00-4.93 (1H, m, H-2’), 4.71- 
4.51 (1H, m, H-5’), 4.50-4.41 (1H, m, H-5’), 4.36-4.23 (2H, m, H-3’, H-4’), 4.16-4.02 
(1H, m, C//CH3), 2.68 (2H, t, J = 7.4, a-CH2), 1.73-1.55 (2H, m, |3-CH2), 1.48-1.27 (7H, 
m, y-CH2, §-CH2, CHC//3), 0.93 (3H, t, J = 6.6, CH3).
13C-NMR (MeOD, 126 MHz): 6 14.35 (CH3), 20.28 (d, JC-p = 7.7, CHCH3), 20.51 (d, JC- 
P = 6.3, CHCH3), 23.56, 32.15, 32.58, 36.74 (C4H8), 51.68, 51.94 (CHCH3), 65.59 (d, JC- 
P = 5.0, C-5’), 65.80 (d, J c-p = 5.4, C-5’), 68.03 (CH2Ph), 68.71, 68.85 (C-4’), 82.52,
82.58 (2s, C-3’), 92.23, 92.51 (2d, JC-f = 24.4, C -l’), 95.27, 95.77 (2d, JC F = 188.7, C- 
2’), 99.00, 99.02 (2s, C-5), 110.46 (C-4a), 121.45, 121.49, 121.53, 121.56, 125.93, 
126.37, 126.42, 127.14, 129.14, 129.18, 129.32, 129.57, 130.19, 130.93, 130.98, (PhO, 
CU2Ph, Ph), 137.17 (‘ipso’ OCU2?h), 138.53 (C-4), 146.50 (para-C), 152.03 (‘ipso’ 
PhO), 156.58 (C-6), 157.45 (C-2), 173.34 (C-7a), 174.95 (COOCH3).
El MS= 734.2616 (M+H) 756.2448 (M+Na).
HPLC = H20/MeOH 20/80 isocratic = retention time 28.08, 30.03 min.
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fo
I n
O -P -O .
NH
OH
Synthesis of 3-(2’-a-fluoro-2’-deoxy-P-D-ribofuranosyI-5-[phenyl-(methoxy- 
glycinyl)] phosphate)-6-(4-«-pentylphenyl)-2,3-dihydrofuro [2,3-(/]pyrimidin-2-one 
[169c]
pH3 C31H35FN3O9P
(H2C)4
Mol Wt.: 643.5965
Prepared according to Standard Procedure D, from 155 
(0.20 g, 0.48 mmol) in anhydrous THF (10 mL), 131c
(0.25 g, 0.96 mmol) in anhydrous THF (2 mL), NMI
(0.08 mL, 0.96 mmol) and the reaction mixture was 
stirred at room temperature overnight. After this period 
O were added anhydrous pyridine (2 mL), 131c (0.25 g,
0.96 mmol) in anhydrous THF (2 mL) and NMI (0.08 mL, 0.96 mmol) and the reaction
mixture was stirred at room temperature for further 7 h. Then were added 131c (0.38 g,
1.44 mmol) in anhydrous THF (2 mL) and NMI (0.11 mL, 1.44 mmol) and the reaction 
mixture was stirred at room temperature for 16 h. After this period the solvent was 
removed and the residue dissolved in DCM. The organic phase was washed with a 0.5 M 
aqueous solution of citric acid (twice) and water (twice), dried over MgS04 and 
concentrated. The residue was purified by column chromatography gradient elution of 
DCM/MeOH = 98/2 then 97/3 to give a white solid (15%, 0.046 g).
31P-NMR (MeOD, 202 MHz): 6 5.24, 4.95.
,9F-NMR (MeOD, 471 MHz): (5-203.47, -203.56.
'H-NMR (MeOD, 500 MHz): 6 8.71, 8.69 (1H, 2s, H-4), 7.61-7.56 (2H, m, Ph), 7.49-
7.34 (2H, m, Ph), 7.34-7.17 (5H, m, Ph), 6.84, 6.73 (1H, 2s, H-5), 6.13 (1H, d, J = 17.0, 
H -l’), 5.14, 5.04 (1H, 2t, J = 3.8, W  = 52.0, H-2’), 4.78-4.68 (1H, m, H-5’), 4.59-4.47 
(1H, m, H-4’), 4.41-4.28 (2H, m, H-3’, H-5’), 3.89-3.80 (2H, m, NHC//2), 3.68 (3H, 2s, 
OCH3), 2.64 (2H, t, J = 7.7, a-CH2), 1.71-1.59 (2H, m, P-CH2), 1.46-1.28 (4H, m, y-CH2, 
6-CH2), 0.93 (3H, t, J = 7.0, CH3).
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l3C-NMR (MeOD, 126 MHz): 6 14.38 (CH3), 23.57, 32.11, 32.62, 36.75 (C4H8), 43.76 
(CH2NH), 52.69, 52.71 (2s, OCH3), 65.63 (d, JC-r = 5.0, C-5’), 65.72 (d, JC-r = 4.8, C- 
5’), 68.75 (d, Jc-p = 11.7, C-4’), 68.89 (d, JC-p = 11.7, C-4’), 82.57, 82.64 (2s, C-3’), 
92.17, 92.44 (2d, JC- f  = 34.8, C -l’), 95.09 (d, JC- f  = 187.8, C-2’), 98.98 (C-5), 110.42 
(C-4a), 121.51, 121.55, 125.87, 125.90, 126.43, 127.08, 130.14, 130.97, 131.02 (PhO, 
Ph), 138.50, 138.56 (C-4), 146.41 (para-C), 152.00, 152.06 (2s, ‘ipso’ PhO), 156.77 (C- 
6), 157.35, 157.42 (C-2), 172.97 (d, JC-r = 4.5, COOCH3), 173.03 (C-7a), 173.27 (d, JC-r 
= 1.8, COOCH3).
El MS= 644.2202 (M+H) and 667.2043 (M+Na).
HPLC = H2O/ACCN from 100/0 to 0/100 in 30 min = retention time 27.59 min.
= H20/MeOH 20/80 isocratic = retention time 5.88 min.
Synthesis of 3-(2’-p-2’-deoxy-p-D-ribofuranosyI-5-[phenyl-(methoxy-glycinyl)] 
phosphate)-6-(4-/f-pentylphenyl)-2,3-dihydrofuro [2,3-</]pyrimidin-2-one [170]
CH3
(H2c ')4
fo
I II
O - P - O .
NH
OH
C31H35FN3O9P 
Mol Wt.: 643.5965
O
Prepared according to Standard Procedure D, from 156 
(0.20 g, 0.48 mmol) in anhydrous THF (10 mL) and 
anhydrous pyridine (2 mL), 131c (0.63 g, 2.40 mmol) in 
anhydrous THF (5 mL), NMI (0.20 mL, 2.40 mmol) and 
the reaction mixture was stirred at room temperature 
overnight. After this period were added 131c (0.63 g, 
2.40 mmol) in anhydrous THF (5 mL) and NMI (0.20 mL, 2.40 mmol) and the reaction 
mixture was stirred at room temperature for further 24 h. After this period the solvent was 
removed and the residue dissolved in DCM. The organic phase was washed with a 0.5 M 
aqueous solution of HC1 (twice) and water (twice), dried over MgS04 and concentrated. 
The residue was purified by column chromatography gradient elution of DCM/MeOH = 
98/2 then 97/3 to give a white solid which was further purified by preparative TLC
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(gradient elution of DCM/MeOH = 99/1, then 98/2, then 96/4) to give a white solid (4%,
0.012 g).
31P-NMR (MeOD, 202 MHz): 6 5.26, 5.15.
19F-NMR (DMSO, 471 MHz): (5-200.08.
’H-NMR (MeOD, 500 MHz): 6 8.66, 8.64 (1H, 2s, H-4), 7.70-7.16 (9H, m, Ph, PhO), 
6.88, 6.86 (1H, 2s, H-5), 6.41, 6.37 (1H, 2t, J = 3.5, 5H-f = 18.5, H -l’), 5.31-5.30 (0.5H, 
m, H-2’), 5.21-5.20 (0.5H, m, H-2’), 4.49-4.32 (4H, m, H-3\ H-4’, H-5’), 3.86-3.81 (2H, 
m, NHC//2), 3.68 (3H, 2s, OCH3), 2.67 (2H, t, J = 8.3, a-CH2), 1.70-1.64 (2H, m, p- 
CH2), 1.42-1.28 (4H, m, y-CH2, 6-CH2), 0.93 (3H, t, J = 7.3, CH3).
13C-NMR (MeOD, 126 MHz): 6 14.36 (CH3), 23.56, 32.14, 32.59, 36.75 (C4H8), 43.70 
(CH2NH), 52.57, 52.66 (2s, OCH3), 66.92 (C-5’), 75.25 (d, JC-p = 10.9, C-4’), 75.46 (d, 
Jc-p = 10.6, C-4’), 85.24, 85.31 (2s, C-3’), 89.06 (d, JC-f= 13.7, C -l’), 89.16 (d, JC- f  =  
14.3, C -l’), 96.16 (d, Jc-F = 194.4, C-2’), 98.89, 98.91 (C-5), 110.12 (C-4a), 121.56, 
121.60, 121.64, 121.67, 121.70, 121.74, 125.78, 125.96, 126.21, 126.35, 127.17, 130.19,
130.66, 130.89, 130.90 (PhO, Ph), 139.75, 139.78 (C-4), 146.47 (para -C ), 152.18 (2s, 
‘ipso’ PhO), 156.46 (C-6), 157.46 (C-2), 172.94 (COOCH3), 173.26 (C-7a), 173.28 
(COOCH3).
El MS= 666.2001 (M+Na).
HPLC = H20/A cCN from 95/5 to 0/100 in 30 min = retention time 28.60 min.
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Synthesis of 3-(2’-di-fluoro-2,-deoxy-p-D-ribofuranosyl-5-(phenyl-(methoxy-L- 
alaninyl)] phosphate)-6-(4-«-pentylphenyI)-2,3-dihydrofuro [2,3-<flpyrimidin-2-one 
[171a] and [171b]
CH3
(H2C)4
o - p - o
c h 3 o h
C32H36F2N309P 
Mol Wt.: 675.6135
Prepared according to Standard Procedure D, from 157 
(0.20 g, 0.46 mmol) in anhydrous THF (10 mL), O la  
‘1ST (0.64 g, 2.30 mmol) in anhydrous THF (5 mL), NMI
(0.18 mL, 2.30 mmol) and the reaction mixture was 
F stirred at room temperature overnight. After this period
O were added O la  (0.64 g, 2.30 mmol) in anhydrous THF
(5 mL) and NMI (0.18 mL, 2.30 mmol) and the reaction mixture was stirred at room 
temperature for further 8 h. Then NMI (0.09 mL, 1.20 mmol) was added and the reaction 
mixture stirred at room temperature for further 24 h. After this period the solvent was 
removed and the residue dissolved in DCM. The organic phase was washed with a 0.5 M 
aqueous solution of HC1 (twice) and water (twice), dried over MgSCL and concentrated. 
The residue was purified by column chromatography gradient elution of DCM/MeOH = 
100/0 then 98/2 then 97/3 to give a white solid which was further purified by preparative 
TLC (gradient elution of DCM/MeOH = 99/1, then 98/2, then 96/4) to give a white solid 
as a mix of two diasteroisomer (0.005 g) and as a single diastereoisomer (0.004 g).
171a
31P-NMR (MeOD, 202 MHz): 5 3.98, 3.96.
I9F-NMR (DMSO, 471 MHz): <5-118.46, -118.83, -118.93, -119.44, -120.23.
'H-NMR (MeOD, 500 MHz): 5 8.55, 8.51 (1H, 2s, H-4), 7.81-7.65 (2H, m, Ph), 7.48-
7.16 (7H, m, Ph), 6.96, 6.88 (1H, 2s, H-5), 6.48-6.44 (1H, m, H -l’), 4.68-4.46 (2H, m, H- 
5’), 4.43-4.31 (1H, m, H-4’), 4.31-4.24 (1H, m, H-3’), 4.04-3.92 (1H, m, C/7CH3), 3.68, 
3.67 (3H, 2s, OCHj), 2.69 (2H, t, J = 7.6, a-CH2), 1.71-1.65 (2H, m, P-CH2), 1.43-1.30 
(7H, m, y-CH2, 6-CH2, CHC//3), 0.94 (3H, t, J = 6.9, CH3).
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13C-NMR (MeOD, 126 MHz): 6 14.35 (CH3), 21.00 (d, J C- p  = 7.8, CHCH3), 21.06 (d, JC- 
P = 7.0, CHCH3), 23.55, 32.15, 32.57, 36.76 (C4H8), 50.04 (CHCH3), 52.79 (OCH3), 
65.76 (C-5’), 69.82, 70.04 (2s, C-4’), 82.86, 82.92 (2s, C-3’), 94.47 (C -l’), 98.86, 98.89 
(2s, C-5), 110.87 (C-4a), 121.32, 121.52, 121.56, 126.06, 126.09, 126.22, 126.44, 126.48,
127.01, 129.59, 129.83, 130.23, 130.40, 130.94, 131.03, 132.51, 132.64 (C-2’, PhO, Ph),
138.38 (C-4), 145.11, 146.70 (2s, para-C), 150.97 (‘ipso’ PhO), 156.66 (C-6), 158.01 (C- 
2), 173.56 (C-7a), 174.50 (COOCH3).
HPLC = H2O/ACCN from 95/5 to 0/100 in 40 min = retention time 29.72, 33.48 min.
171b
31P-NMR (MeOD, 202 MHz): 6 3.89.
19F-NMR (DMSO, 471 MHz): 6-118.54.
'H-NMR (MeOD, 500 MHz): 6 8.54 (1H, s, H-4), 7.71-7.69 (2H, m, Ph), 7.45-7.19 (7H, 
m, Ph), 6.83 (1H, 2s, H-5), 6.56-6.38 (1H, m, H -l’), 4.66-4.51 (1H, m, H-5’), 4.50-4.41 
(1H, m, H-5’), 4.40-4.29 (1H, m, H-4’), 4.29-4.20 (1H, m, H-3’), 4.08-3.98 (1H, m, 
C//CH3), 3.69 (3H, s, OCH3), 2.69 (2H, t, J = 7.7, a-CH2), 1.73-1.58 (2H, m, P-CH2), 
1.46-1.26 (7H, m, y-CH2, 6-CH2, CHC//3), 0.94 (3H, t, J = 7.0, CH3).
13C-NMR (MeOD, 126 MHz): 6 14.35 (CH3), 20.45 (d, JC- p  = 6.6, CHCH3), 23.56,
32.15, 32.58, 36.75 (C4H8), 50.04 (CHCH3), 52.78 (OCH3), 65.56 (C-5’), 68.87 (C-4’), 
81.04 (C-3’), 94.47 (C -l’), 98.72 (C-5), 110.81 (C-4a), 121.44, 121.48, 121.53, 121.57,
126.05, 126.24, 127.00, 129.55, 129.83, 130.23, 130.82, 130.98, 132.63 (C-2’, PhO, Ph),
138.38 (C-4), 146.72 (para-C), 156.66 (C-6), 158.02 (C-2), 173.56 (C-7a), 174.50 
(COOCH3).
HPLC = H20/A cCN from 95/5 to 0/100 in 40 min = retention time 34.41 min.
= H20/MeOH 20/80 isocratic = 23.53.
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O-P-O
Synthesis of 3-(2’-di-fluoro-2’-deoxy-p-D-ribofuranosyl-5-[phenyl-(benzoxy-L- 
alaninyl)] phosphate)-6-(4-«-pentylphenyl)-2,3-dihydrofuro [2,3-d]pyrimidin-2-one 
[171c]
CH3 C38H40F2N3O9P
(H2C)4
Mol Wt.: 751.7095
Prepared according to Standard Procedure D, from 157 
(0.20 g, 0.46 mmol) in anhydrous THF (12 mL), 131d
'O (0.81 g, 2.30 mmol) in anhydrous THF (5 mL), NMI (0.18
mL, 2.30 mmol) and the reaction mixture was stirred at 
B nV W H f" f  room temperature overnight. After this period were added
O 131d (0.81 g, 2.30 mmol) in anhydrous THF (5 mL) and
NMI (0.18 mL, 2.30 mmol) and the reaction mixture was stirred at room temperature for 
further 8 h. Then NMI (0.09 mL, 1.20 mmol) was added and the reaction mixture stirred 
at room temperature overnight. After this period the solvent was removed and the residue 
dissolved in DCM. The organic phase was washed with a 0.5 M aqueous solution of citric 
acid (twice) and water (twice), dried over MgS04 and concentrated. The residue was 
purified by column chromatography gradient elution of DCM/MeOH = 100/0 then 98/2 
then 96/4 to give a white solid which was further purified by preparative HPLC (isocratic 
MeOH/H20 = 80/20) to give a white solid (4%, 0.012 g).
31P-NMR (MeOD, 202 MHz): 6 3.99, 3.79.
,9F-NMR (DMSO, 471 MHz): <5-117.93, -118.23,-118.44,-118.74, -119.61.
'H-NMR (MeOD, 500 MHz): 6 8.52, 8.49 (1H, 2s, H-4), 7.66 (2H, d, J = 7.9, Ph), 7.40-
7.17 (12H, m, Ph, PhO, CU2?h), 6.85, 6.79 (1H, 2s, H-5), 6.44 (1H, dd, J = 14.8, 7.4, H- 
1’), 5.21-5.10 (2H, m, CH2Ph), 4.65-4.52 (1H, m, H-5’), 4.51-4.38 (1H, m, H-5’), 4.39- 
4.29 (1H, m, H-4’), 4.27-4.16 (1H, m, H-3’), 4.16-4.04 (1H, m, C//CH3), 2.67 (2H, t, J =
7.5, <x-CH2), 1.72-1.60 (2H, m, P-CH2), 1.47-1.28 (7H, m, y-CH2, 6-CH2, CHC//3), 0.93 
(3H, t, J = 7.0, CH3).
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13C-NMR (MeOD, 126 MHz): 6 14.36 (CH3), 20.26 (d, JC-p = 7.7, CHCH3), 20.43 (d, Jc_ 
P = 6.9, CHCH3), 23.56, 32.14, 32.58, 36.75 (C4H8), 51.71, 51.93 (CHCH3), 65.55 (d, Jc_ 
P = 6.1, C-5’), 65.62 (d, Jc_/> = 5.8, C-5’), 68.02, 68.05 (2s, CH2Ph), 70.75, 70.91 (2s, C- 
4’), 81.03 (C-3’), 87.68 (C -l’), 98.75, 98.78 (2s, C-5), 110.80 (C-4a), 121.51, 121.54,
121.55, 121.59, 126.05, 126.41, 126.98, 129.12, 129.20, 129.35, 129.58, 130.21, 130.91,
130.97, (C-2’, PhO, CH2/>h, Ph), 137.17 (‘ipso’ OCH2P/z), 138.25, 138.35 (2s, C-4), 
146.68 (para-C), 152.07 (‘ipso’ PhO), 156.62 (C-6), 157.94 (C-2), 173.49 (C-7a),
174.66, 174.96 (COOCH2Ph).
El MS= 752.2555 (M+H), 774.2372 (M+Na).
HPLC = H20/A cCN from 95/5 to 0/100 in 40 min = retention time 38.96 min.
H20/MeOH 20/80 isocratic = retention time 33.48, 35.43 min.
Synthesis of 3-(2’-di-fluoro-2’-deoxy-P-D-ribofuranosyl-5-[phenyl-(methoxy- 
glycinyl)] phosphate)-6-(4-/i-pentylphenyl)-2,3-dihydrofuro [2,3-<flpyrimidin-2-one 
[171d]
c h 3
(H2C)4
h 3c o
o - p - o
c 3,h 34f 2n 3o 9p
Mol Wt.: 661.5869
Prepared according to Standard Procedure D, from 157 
(0.20 g, 0.46 mmol) in anhydrous THF (10 mL), 131c 
NT (0.61 g, 2.30 mmol) in anhydrous THF (5 mL), NMI
(0.18 mL, 2.30 mmol) and the reaction mixture was 
F stirred at room temperature overnight. After this period
O were added 131c (0.61 g, 2.30 mmol) in anhydrous THF
(5 mL) and NMI (0.18 mL, 2.30 mmol) and the reaction mixture was stirred at room 
temperature for further 8 h. Then NMI (0.09 mL, 1.20 mmol) was added and the reaction 
mixture stirred at room temperature for further 24 h. After this period the solvent was 
removed and the residue dissolved in DCM. The organic phase was washed with a 0.5 M 
aqueous solution of HC1 (twice)' and water (twice), dried over MgS04 and concentrated. 
The residue was purified by column chromatography gradient elution of DCM/MeOH =
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98/2 then 97/3 to give a white solid which was further purified by preparative TLC 
(gradient elution of DCM/MeOH = 99/1, then 98/2, then 96/4) to give a white solid 
(14%, 0.042 g).
31P-NMR (MeOD, 202 MHz): 6 5.42, 4.92.
,9F-NMR (DMSO, 471 MHz): 5-118.13, -118.65.
'H-NMR (MeOD, 500 MHz): 6 8.55, 8.52 (1H, 2s, H-4), 7.70-7.59 (2H, m, Ph), 7.48-
7.17 (7H, m, Ph, PhO), 6.88, 6.79 (1H, 2s, H-5), 6.45 (1H, d, J = 7.0, H -l’), 4.73-4.63 
(1H, m, H-5’), 4.60-4.48 (1H, m, H-5’), 4.47-4.30 (1H, m, H-4’), 4.30-4.23 (1H, m, H- 
3’), 3.89-3.82 (2H, m, NHC//2), 3.70 (3H, 2s, OCH3), 2.64 (2H, t, J = 7.6, a-CH2), 1.69-
1.59 (2H, m, (3-CH2), 1.45-1.26 (4H, m, y-CH2, 6-CH2), 0.92 (3H, t, J = 7.0, CH3). 
,3C-NMR (MeOD, 126 MHz): 6 14.39 (CH3), 23.57, 32.10, 32.61, 36.76 (C4H8), 43.72 
(CH2NH), 52.72 (OCH3), 65.55 (C-5’), 70.90 (C-4’), 80.97 (C-3’), 87.40, 87.52 (C -l’), 
98.76, 98.79 (2s, C-5), 110.80, 110.83 (2s, C-4a), 121.53, 121.56, 121.60, 123.49,
126.01, 126.03, 126.44, 126.47, 126.92, 126.94, 129.57, 130.18, 130.86, 130.96, 131.00, 
132.61 (C-2’, PhO, Ph), 138.32, 138.44 (C-4), 146.63 (para-C), 152.03, 152.09 (2s, 
‘ipso’ PhO), 156.64 (C-6), 157.88, 157.94 (2s, C-2), 173.04, 173.08 (2s, C-7a), 173.47 
(COOCH3).
El MS= 662.2073 (M+H), 684.1885 (M+Na).
HPLC = H20/A cCN from 100/0 to 0/100 in 40 min = retention time 35.12 min.
= H20/MeOH 20/80 isocratic = retention time 21.44 min.
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9.10 Synthesis of the terminal fluoro derivative of BCNA lead compound
Synthesis of 5-(4-iodophenyl)pentan-l-ol [174]
(H2C)5OH c " h ” 1 0
Mol Wt.: 290.1407
I A solution of glacial acetic acid (13.5 mL) and iodine (2.50 g, 8.81 mmol) 
was heated at 100 °C then were added conc. H2SO4 (1.4 mL) and 173 (3.37 mL, 20 
mmol). After was added dropwise a suspension of sodium iodate (0.99g, 5.0 mmol) in 
water (3 mL) in 30 minutes and the reaction mixture was stirred at 105 °C for lh 
(monitored by TLC). The reaction was poured in ice/water and quenched with a saturated 
solution ofN aH C03. The aqueous solution was extracted with DCM. The organic phase 
was then dried over MgSC>4, concentrated. The crude of reaction was dissolved in a 
solution of NaOH (2.0 g) in methanol (20mL) and water (20 mL) and the reaction 
mixture was stirred at 75 °C for 1.5 h. After cooling, the reaction mixture was extracted 
with DCM, the organic phase was dried over MgSC>4, concentrated to give a brown oil as 
a mixture of ortho and para desired compound (94%, 5.45 g).
'H-NMR (DMSO, 500 MHz): 6 7.63-7.61 (2H, s, Ph), 7.02 (1H, d, Ph), 4.35-4.31 (1H, 
m, OH), 3.42-3.36 (2H, m, cd-CH2), 2.54-2.50 (2H, m, a-CH2), 1.57-1.49 (2H, m, (3- 
CH2), 1.47-1.23 (4H, m, y-CH2, 6-CH2).
Synthesis of 5-(4-((trimethylsilyl)ethynyl)phenyl)pentan-l-ol. [175]
(H2c)5OH C,6H24OSi
Mol Wt.: 260.4467
To a solution of 1*74 (2.50 g, 8.62 mmol) in anhydrous DMF (30 mL) were 
added ethynyl trimethylsilyl (3.58 mL, 25.85 mmol), tetrakis- 
HsC CH°"* (triphenylphosphine) palladium(O) (0.99g, 0.86 mmol), copper (I) iodide
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(0.33 g, 1.72 mmol) and DIPEA (3.00 mL, 17.23 mmol) and the reaction mixture was 
stirred at room temperature overnight. After this period the solvent was removed and the 
residue purified by column chromatography eluting petroleum ether/ ethyl acetate = 8/2, 
to give a brown oil (53%, 1.18 g).
'H-NMR (CDC13, 500 MHz): 6 7.26-7.24 (2H, d, J = 8.2, Ph), 6.97 (2H, d, J = 8.2, Ph), 
3.52-3.48 (2H, m, oo-CH2), 2.51-2.44 (2H, m, a-CH2), 1.56-1.41 (4H, m, 2xCH2), 1.28- 
1.22 (1H, m, y-CH2), 0.12 (9H, s, 3xCH3).
Synthesis of 5-(4-ethynylphenyl)pentan-l-ol. [176]
(H2C)5OH c ” h >‘°
Mol Wt.: 188.2655
To a solution of 175 (1.08 g, 4.16 mmol) in anhydrous MeOH (20 mL) was 
added dropwise under an argon atmosphere a solution of sodium methoxide 
(0.27 g, 5.0 mmol) in anhydrous MeOH (5 mL) and the reaction mixture was stirred at 
room temperature for lh. After this period the solution was neutralised with amberlite 
120, filtered and then concentrated to give a brown oil. (99%, 0.77 g).
'H-NMR (CDCIj, 500 MHz): 6 7.34 (2H, d, J = 8.1, Ph), 7.07 (2H, d, J = 8.1, Ph), 3.59- 
3.56 (2H, m, co-CH2), 2.97 (1H, s, CH), 2.56 (2H, t, J = 7.7, a-CH2), 1.62-1.51 (4H, m, 
2xCH2), 1.37-1.30 (2H, m, y-CH2).
Synthesis of l-ethynyl-4-(5-fluoropentyl)benzene. [177]
(H2C)5F c i3H i5F
Mol Wt.: 190.2566
To a solution of 176 (0.71 g, 3.76 mmol) in anhydrous DCM (10 mL) was 
added dropwise at 0 °C under an argon atmosphere (diethylamino)sulfur
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trifluoride (DAST) (1.5 mL, 11.28 mmol). After the addition the solution was stirred at 0 
°C for 5 min then at room temperature for 2h. After this period, the reaction mixture was 
placed in an ice bath and quenched with a saturated solution of NaHCCh. The solution 
was then extracted with DCM and the organic phase washed with water (twice) and 
saturated solution of NaHCCL (once). The organic phase was dried over MgSCL, 
concentrated and the residue purified by column chromatography eluting petroleum ether/ 
ethyl acetate = 9/1, to give a brown oil (39%, 0.28 g).
I9F-NMR (CDCIj, 471 MHz): 5 -218.20.
'H-NMR (CDClj, 500 MHz): 5 7.33 (2H, d, J = 8.1, Ph), 7.05 (2H, d, J = 8.1, Ph), 4.42- 
4.39 (1H, m, co-CHa), 4.32-4.30 (1H, m, o>CHb), 2.95 (1H, s, CH), 2.55 (2H, t, <x-CH2), 
1.67-1.57 (4H, m, 2xCH2), 1.40-1.35 (2H, m,Y-CH2).
Synthesis of 3-(2’-deoxy-p-D-ribofuranosyI)-6-(4-/i-xn-F-pentylphenyI)-2,3- 
dihydrofuro [2,3-</]pyrimidin-2-one. [172]
C22H25FN2O5 
Mol Wt.: 416.4427
To a stirred solution of 121 (0.25 g, 0.69 mmol) in anhydrous DMF 
(5 mL), were added: 177 (0.26 g, 1.39 mmol), tetrakis- 
(triphenylphosphine) palladium(O) (0.08 g, 0.069 mmol), copper (I) 
iodide (0.026 g, 0.14 mmol) and DIPEA (0.24 mL, 1.39 mmol) and 
the reaction mixture was stirred at room temperature, under an 
argon atmosphere overnight. After this period were added copper (I) iodide (0.026 g, 0.14 
mmol) and anhydrous TEA (5 mL) and the reaction mixture was stirred at 85 °C for 7.5 
h. The solvent was then removed in vacuo and the residue purified by column 
chromatography (gradient elution of DCM/MeOH = 98/2 then 96/4 then 90/10, to give a 
pale yellow solid (50%, 0.29 g). .
I9F-NMR (DMSO, 471 MHz): 5 -216.66.
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‘H-NMR (DMSO, 500 MHz): 6 8.84 (1H, s, H-4), 7.75 (2H, d, J = 8.2, Ha), 7.34 (2H, d, J 
= 8.3, Hb), 7.21 (1H, s, H-5), 6.20 (1H, t, J = 6.1, H -l’), 5.29 (1H, d, J = 4.4, 3’-OH), 5.16 
(1H, t, J = 5.2, 5’-OH), 4.48 (1H, t, J = 6.1, co-Ha), 4.39 (1H, t, J = 6.1, co-Hb), 4.28-4.25 
(1H, m, H-3’), 3.95-3.93 (1H, m, H-4’), 3.75-3.69 (1H, m, Ha-5’), 3.67-3.62 (1H, m, Hb- 
5’), 2.65 (2H, t, J = 7.6, a-CH2), 2.44-2.39 (1H, m, H.-2’), 2.14-2.07 (1H, m, Hb-2’), 
1.73-1.59 (4H, m, P-CH2, 6-CH2), 1.41-1.35 (2H, m, y-CH2).
,3C-NMR (DMSO, 126 MHz): 6 24.26, 24.30 (C-y), 29.52, 29.67 (C-P), 30.22 (C-6), 
34.79 (C-a), 41.23 (C-2’), 60.67 (C-5’), 69.54 (C-3’), 83.06, 84.35 (C-co), 87.56 (C-4’), 
88.14 (C -l’), 98.69 (C-5), 106.87 (C-4a), 124.55 (C-Hb), 125.93 {ipso-C), 129.02 (C-Ha), 
137.83 (C-4), 143.84 (para-C), 153.75 (C-6), 153.87 (C-2), 171.02 (C-7a).
El MS= 439.164 (M+Na).
Anal. Calcd for C22H25FN20 5 • '/2H20: C, 62.11; H, 6.16; N, 6.58. Found: C, 61.91; H, 
6.18; N, 6.93.
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9.11 Synthesis of FVI00
Synthesis of 3-(2-deoxy-3-tert-butyldimethylsilyl-p-D-ribofuranosyl)-6-(4-«- 
pentylphenyl)-2,3-dihy-drofuro [2,3-</]pyrimidin-2-one 5’-boc-L-valyl ester
[183]
, . ~ CH3 O
ch3
(H2C)4 C 3 8 H 5 7 N 3 0 8 S i
Mol Wt.: 711.9600
OTBDMS
To a solution of 123 (0.98 g, 1.92 mmol)
in anhydrous DCM (25 mL) were added
at room temperature under an argon 
atmosphere boc-L-valine (0.83 g, 3.83 
mmol), DCC (0.98 g, 4.80 mmol) and 
DMAP (0.05 g, 0.38 mmol) and the reaction mixture was stirred at room 
temperature overnight. After this period the suspension was filtered and the 
organic phase was concentrated. The residue was triturated with DCM and
filtered. The organic phase was concentrated to give a white solid contaminated
with boc-L-valine and used as a crude in the next step.
'H-NMR (DMSO, 500 MHz): 6 8,55 (1H, s, H-4), 7.71 (2H, d, J = 8.1, Ph), 7,33 
(2H, d, J = 8.3, Ph), 7.27 (1H, d, J = 8.0, N//CH), 7.20 (1H, s, H-5), 6.20 (1H, t, J 
= 6.1, H -l’), 4.46-4.35 (2H, m, H-3\ H-4’), 4.32-4.25, 4.18-4.12 (2H, 2m, H-5’), 
3.98-3.92 (1H, m, NHCft), 2.63 (2H, J = 7.6, a-CH2), 2.47-2.40, 2.36-2.28 (2H, 
2m, H-2’), 2.06-1.96 (1H, m, C//(CH3)2), 1.65-1.55 (2H, m, |3-CH2), 1.39 (9H, 
COO(CH3)3), 1.36-1.24 (4H, m, y-CH2, 6-CH2), 0.91-0.83 (18H, m, co-CH3, 
C(CH,h, CH(CH3)2), 0.09 (6H, 2s, Si(C//3)2).
222
Marco Derudas Chapter 9
Synthesis of 3-(2-deoxy-p-D-ribofuranosyl)-6-(4-ji-pentylphenyl)-2,3-dihy- 
drofuro [2,3-</]pyrimidin-2-one 5’-Boc-L-valyl ester
CH3
(H2C)4
C32H43N308 
Mol Wt.: 597.6991
To a solution of 183 (0.25 g, 0.35 mmol) 
in THF (4 mL) and water (1 mL> was
reaction mixture was stirred at room 
temperature for 7 h. After this period the 
reaction mixture was quenched with 
saturated solution of sodium bicarbonate and concentrated. The residue was 
purified by column chromatography eluting with DCM/MeOH = 97/3 to gdve a 
white solid (55%, 0.11 g).
O.
OH
'H-NMR (DMSO, 500 MHz): 6 8.54 (1H, s, H-4), 7.71 (2H, d, J = 8.1, Ph), 7.33 
(2H, d, J = 8.2, Ph), 7.26 (1H, d, J = 7.8, N//CH), 7.18 (1H, s, H-5), 6.23 (1H, t, J 
= 6.3, H -l’), 5.47 (1H, d, J = 4.0, 3’-OH), 4.39-4.28 (H, m, H-5’), 4.27-4.21 (1H, 
m, H-3’), 4.18-4.14 (1H, m, H-4’), 3.96-3.92 (1H, m, NHC//), 2.62 (2H, J = 7.6 
Hz, cx-CH2), 2.49-2.41, 2.27-2.12 (2H, 2m, H-2’), 2.06-1.92 (1H, m, C//(CH3)2), 
1.66-1.54 (2H, m, P-CH2), 1.39 (9H, COO(CH3)3), 1.36-1.22 (4H, m, y-CH2, 6- 
CH2), 0.94-0.82 (9H, m, co-CH3, CH(C//3)2).
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Synthesis of 3-(2-deoxy-3-tert-butyldimethylsiIyl-P-D-ribofuranosyl)-6-(4-/i- 
pentyIphenyl)-2,3-dihy-drofuro [2,3-d]pyrimidin-2-one 5’-Boc-L-valyl ester
[184]
C48H59N308Si 
Mol Wt.: 834.0829
To a solution of 123 (1.46 g, 2.85 
mmol) in anhydrous DCM (35 mL) 
were added at room temperature 
under an argon atmosphere Fmoc-L- 
valine (1.93 g, 5.70 mmol), DCC 
(1.47 g, 7.13 mmol) and DMAP (0.07 g, 0.57 mmol) and the reaction mixture was 
stirred at room temperature overnight. After this period the suspension was 
filtered and the organic phase was concentrated. The residue was triturated with 
DCM and filtered. The organic phase was concentrated to give a white solid 
contaminated with Fmoc-L-valine and used as a crude in the next step.
'H-NMR (DMSO, 500 MHz): 6 8.50 (1H, s, H-4), 7.93-7.82 (4H, m, Ph, N//CH), 
7.81-7.59 (4H, m, Ph), 7.45-7.21 (5H, m, Ph), 7.13 (1H, s, H-5), 6.18 (1H, t, J = 
6.2, H -l’), 4.45-4.13 (8H, m, H-3\ H-4’, H-5’, Fmoc-C//C//2, NHCH), 2.60 (2H, 
J = 7.5, cx-CH2), 2.45-2.37, 2.33-2.24 (2H, 2m, H-2’), 2.18-1.93 (1H, m, 
C//(CH3)2), 1.65-1.53 (2H, m, P-CH2), 1.38-1.19 (4H, m, y-CH2, 6-CH2), 0.96- 
0.81 (18H, m, co-CH3, C(C//3)3, CH(C//3)2), 0.07 (6H, s, Si(C//3)2).
(H2C)4
OTBDMS
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Synthesis of 3-(2-deoxy-P-D-ribofuranosyl)-6-(4-/i-pentylphenyl)-2,3-dihy- 
drofuro [2,3-<flpynmidin-2-one 5’-L-valyl ester HC1 salt; FV-100 [119*HC1]
CH3
(H2C)4
C27H36C1N306 
Mol Wt.: 534.0442
To a solution of 184 (1.02 g, 1.23 mmol) in
h3c^ ch3 U L
T  N O anhydrous DCM (10 mL) was added piperidine
HCI H2N i f  (0.61 mL, 6.15 mmol) and the reaction mixture
XT. was stirred at room temperature for 3.5 h. AfterOH
this period, was added at 0 °C 20% HC1/IPA to pH = 2-3, and the reaction mixture 
was stirred at room temperature for 1 day. A precipitate, corresponding to the 
desired compound, was formed and it was filtered. The organic phase was 
concentrated and the residue triturated with MeOH and diethyl ether to give the 
desired compound as a white solid (23%, 0.13 g).
'H-NMR (DMSO, 500 MHz): 6 8.57 (1H, s, H-4), 8.50 (3H, bs, NH3+), 7.75 (2H, 
d, J = 8.2, Ph), 7.34 (2H, d, J = 8.3, Ph), 7.22 (1H, s, H-5), 6.25 (1H, t, J = 6.2, H- 
1’), 5.57 (1H, d, J = 4.4, 3’-OH), 4.52-4.44 (2H, m, H-5’), 4.33-4.23 (1H, m, H- 
3’), 4.17-4.10 (1H, m, H-4’), 3.93 (1H, d, J = 4.9, NH3C//), 2.63 (2H, J = 7.6, a- 
CH2), 2.48-2.39, 2.32-2.22 (2H, 2m, H-2’), 2.22-2.13 (1H, m, C//(CH3)2), 1.63- 
1.55 (2H, m, P-CH2), 1.41-1.23 (4H, m, y-CH2, S-CH2), 0.99 (3H, t, J = 6.5, 
CH(C//3)2), 0.96 (3H, t, J = 6.9, CH(C//3)2), 0.87 (3H, t, J = 6.9, ca-CH3).
225
AcO
A round bottom flask containing a mixture o f 189 
(5.00 g, 15.73 mmol), 190 (2.00 g, 15.73 mmol) andOAc OAc
bis(p-nitrophenyl)phosphate (0.10 g) was placed in a preheated oil bath at 170 °C 
under vacuum for 25 minutes. After cooling, to 70 °C, ethyl acetate and saturated 
solution o f  NaHCC>3 were added and the aqueous layer was extracted with ethyl 
acetate. The combined ethyl acetate extracts were washed with a saturated 
solution o f  NaHCC>3 , water and brine. The organic phase was dried over MgSC>4 
and concentrated. The residue was dissolved in ethanol (15 mL) and methanol (8 
mL), heated until dissolved, then filtered over cotton and cooled at 0 °C for 4 h. 
The suspension was filtered to give a white solid (52%, 3.15 g).
Synthesis of ribavirin (l-(P-D-ribofuranosyl)-lH-l,2,4-triazole-3-carboxami- 
de). [50]
this period the solution was concentrated and the residue dissolved in ethanol and 
water. The volume o f  the ethanol solution was reduced by heating and the hot
H-NMR (CDC13 500 MHz): 6 8.95 (1H, s, H-5), 6.37 (1H, d, H - l’), 5.70-5.68 
(1H, m, H -2’), 5.55-5.53 (1H, m, H-3’), 4.44-4.35 (2H, m, H-4’, H-5’), 4.12-4.08 
(1H, m, H-5’), 3.88 (3H, s, OCH3), 2.09 (6H, 2s, Ac), 2.03 (3H, s, Ac).
O C 8H 12N 4 0 5  
Mol Wt.: 244.2047
191 (3.10 g, 8.04 mmol) was dissolved in freshly 
prepared methanolic ammonia (20 mL). The reaction 
mixture was stirred at room temperature for 20 h. After
OH OH
2 2 6
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ethanol solution on cooling provided colourless crystals which was filtered, the
filtrate washed with acetone, dried under vacuum to give a white solid (87%, 1.70
g)-
'H-NMR (DMSO 500 MHz): 6 8.89 (1H, s, H-5), 7.85 (1H, s, NH), 7.64 (1H, s, 
NH), 5.81 (1H, d, H -l’), 5.59 (1H, d, 2’-OH), 5.21 (1H, d, 3’-OH), 4.94 (1H, t, 
5’-OH), 4.37-4.34 (1H, m, H-2’), 4.16-4.12 (1H, m, H-3’), 3.96-3.94 (1H, m, H- 
4’), 3.65-3.61 (1H, m, H-5’), 3.52-3.48 (1H, m, H-5’).
Synthesis of 2 \3 ’-0,0-cyclopentylidene ribavirin. [192]
O C 13H 18N 4 O 5
NH2 Mol Wt.: 310.3058
To a solution of 50 (0.25 g, 1.03 mmol) in dry
cyclopentanone (15 mL) was added 70% perchloric acid
(0.10 mL) and the reaction mixture was stirred at room 
temperature for 1.5 h. Then the reaction was quenched 
with NaHCOs and the solution concentrated. The residue was purified by column 
chromatography gradient elution of DCM/MeOH = 9/1 then 8/2, to give a white 
solid (90%, 0.30 g).
'H-NMR (DMSO 500 MHz): 6 8.80 (1H, s, H-5), 7.84 (1H, s, NH), 7.64 (1H, s, 
NH), 6.22 (1H, d, H -l’), 5.15-5.14 (1H, m, H-2’), 4.97-4.95 (1H, t, 5’-OH), 4.87-
4.86 (1H, m, H-3’), 4.27-4.24 (1H, m, H-4’), 3.51-3.46 (1H, m, H-5’), 3.43-3.37 
(1H, m, H-5’), 1.95-1.92 (2H, t, CH2), 1.76-1.73 (2H, m, CH2), 1.66-1.61 (4H, m, 
2xCH2).
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Synthesis of 2 \3 ’-0,0-cyclopentylidene-ribavirin-5’-[l-naphthyl(benzoxy-L- 
alaninyl)] phosphate. 1194a]
1.30 mmol), 193a (0.29 g, 0.71 mmol) in anhydrous THF (6 mL), and the reaction 
mixture was stirred at room temperature overnight. After this period the solution 
was concentrated and the residue purified by column chromatography eluting with 
DCM/MeOH = 98/2, to give a white solid (32%, 0.14 g).
31P-NMR (CDCI3, 202 MHz): 5 3.44, 3.17.
'H-NMR (CDC13, 500 MHz): 6 8.20, 8.19 (1H, 2s, H-5), 7.97-7.18 (12H, m, 
Naph, OCH2P/i), 5.94 and 5.85 (1H, 2d, H -l’), 5.03-5.00 (2.5H, m, OC//2Ph, H-2’ 
of one diastereoisomer), 4.78-4.76 (0.5H, m, H-3’ of one diastereoisomer), 4.69- 
4.67 (0.5H, m, H-2’ of one diastereoisomer), 4.51-4.49 (0.5H, m, H-3’ of one 
diastereoisomer), 4.47-4.44 (1H, m, H-4’), 4.25-4.20 (1H, m, H-5’), 4.19-4.11 
(1H, m, H-5’), 4.07-4.02, 4.00-3.90 (1H, 2m, C7/CH3), 1.92-1.87 (2H, m, CH2), 
1.67-1.52 (6H, m, 3xCH2), 1.30, 1.27 (3H, 2d, CHCH3).
Synthesis of ribavirin-5’-[l-naphthyl(benzoxy-L-alaninyl)] phosphate. [195a]
> C33H36N5O9P
■3 NH2 Mol Wt.: 677.6408
Prepared according to Standard 
Procedure C, from 192 (0.20 g, 0.64 
mmol) in anhydrous THF (6 mL), 
‘BuMgCl (1.0 M THF solution, 1.30 mL,
O C28H3oN509P 
NH2 Mol Wt.: 611.5397
OII
O -P -O . A solution of 194a (0.14 g, 0.20 mmol) in 
60% formic acid (8 mL) was stirred at room 
temperature overnight. After this period the
NH
BnO.
'CH3 OH OH
O
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solution was concentrated and the residue purified by column chromatography 
gradient elution of DCM/MeOH = 96/4 then 95/5, to give a white solid (28%, 
0.035 g).
3,P-NMR (MeOD, 202 MHz): 6 4.21, 4.07.
'H-NMR (MeOD, 500 MHz): 6 8.56, 8.54 (1H, 2s, H-5), 8.01-7.99 (1H, m, H-8 
Naph), 7.77-7.75 (1H, m, H-6 Naph), 7.64-7.62 (1H, m, H-2 Naph), 7.43-7.15 
(9H, m, Naph, OCH2P/z), 5.84, 5.82 (1H, 2d, H -l’), 4.97-4.89 (2H, m, PhC//2),
4.40-4.38 (1H, m, H-2’), 4.35-4.17 (4H, m, H-3’, H-4’, H-5’), 3.98-3.89 (1H, m, 
C//CH3), 1.19-1.16 (3H, m, CHCH3).
13C-NMR (MeOD, 126 MHz): 6 20.23 (d, JC-p = 7.4, CH3), 20.40 (d, JC-p = 6.4, 
CH3), 51.72, 51.82 (CHCH3), 67.67 (d, JC-p = 5.3, C-5’), 67.91, 67.93 (2s, 
OCH2Ph), 68.06 (d, JC-p = 5.6, C-5’) 71.68, 71.80 (2s, C-3’), 76.18, 76.22 (2s, C- 
2’), 84.61 (d, J c- p = 8.0, C-4’), 84.69 (d, J C-/> = 9.6, C-4’), 93.79, 93.83 (2s, C -l’), 
116.17 (d, Jc-p = 3.2, C-2 Naph), 116.35 (d, JC-p = 3.3, C-2 Naph) 122.68, 122.81,
125.92, 125.98, 126.50, 127.48, 127.50, 127.75, 127.88, 128.80, 128.83, 129.24, 
129.26, 129.52, 129.54 (C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-l Naph, C- 
8 Naph, C-8a Naph, OCH2Ph), 136.27, 137.20 (C-4a Naph, ‘ipso’ OCH2Ph),
146.64, 146.68 (2s, C-5), 147.90, 147.96 (2s, ‘ipso’ Naph), 158.62 (C-3), 163.22 
(CONH2), 174.59 (d, J C- p  = 5.2, COOCH2Ph), 174.87 (d, JC - p  = 5.1, COOCH2Ph). 
El MS= 634.17 (M+Na).
Anal. Calcd for C28H3oN50 9P: C, 54.99; H, 4.94; N, 11.45. Found: C, 54.74; H, 
5.41; N, 10.40.
Synthesis of 2 ’,3’-0,0-cyclopentylidene-ribavirin-5’-[l-naphthyl(benzoxy-L- 
phenylalaninyl)] phosphate. [194b]
C39H4oN50 9P 
Mol Wt.: 753.7368
Prepared according to Standard Procedure C, 
from 192 (0.20 g, 0.64 mmol) in anhydrous 
THF (6 mL), ‘BuMgCl (1.0 M THF solution,
O - P - O .
NH
BnO.
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1.30 mL, 1.30 mmol), 193b (0.34 g, 0.71 mmol) in anhydrous THF (7 mL), and 
the reaction mixture was stirred at room temperature overnight. After this period 
the solution was concentrated and the residue purified by column chromatography 
eluting DCM/MeOH = 98/2, to give a white solid (44%, 0.22 g).
3IP-NMR (CDC13, 202 MHz): 6 3.30, 3.22.
'H-NMR (CDC13, 500 MHz): 6 8.17, 8.13 (1H, 2s, H-5), 7.90-6.83 (17H, m, 
Naph, OCH2P/7, CHCH2P/1), 5.91, 5.86 (1H, 2d, H -l’), 4.96-4.94 (2H, m, 
OC//2Ph,), 4.92-4.90, 4.73-4.71 (1H, 2m, H-2’), 4.64-4.63, 4.51-4.49 (1H, 2m, H- 
3’), 4.41-4.38 (1H, m, H-4’), 4.30-4.23 (1H, m, C//CH2Ph) 4.08-4.01, 3.90-3.83 
(1H, 2m, H-5’), 3.81-3.76, 3.67-3.63 (1H, m, H-5’), 2.90-2.82 (2H, m, C//2Ph), 
1.95-1.87 (2H, m, CH2), 1.72-1.55 (6H, m, 3xCH2).
Synthesis of ribavirin-5’-[l-naphthyl(benzoxy-L-phenylalaninyl)] phosphate. 
[195b]
C34H34N5O9P 
Mol Wt.: 687.6356
A solution of 194b (0.14 g, 0.203 mmol) in 
60% formic acid (8 mL) was stirred at room 
temperature overnight. After this period the 
residue purified by column chromatography 
96/4 then 95/5, to give a white solid (28%,
31P-NMR (MeOD, 202 MHz): 6 3.97, 3.83.
'H-NMR (MeOD, 500 MHz): 5 8.64, 8.63 (1H, 2s, H-5), 8.04, 8.00 (1H, 2d, H-8 
Naph), 7.88-7.85 (1H, m, H-6 Naph), 7.68-7.65 (1H, m, H-2 Naph), 7.54-7.46 
(2H, m, H-5, H-7 Naph), 7.34-7.07 (12H, m, Naph, OCH2Ph, CHCH2P/0, 5.93-
5.92 (1H, m, H -l’), 5.04-4.96 (2H, m, OC//2Ph), 4.58-4.55 (1H, m, H-2’), 4.34-
4.29 (1H, m, H-3’), 4.25-4.17 (2H, m, H-4’, NHCH), 4.14-3.97 (2H, m, H-5’), 
3.05-3.02, 2.89-2.80 (2H, 2m, CHC//2Ph).
NH.
O - P - O .
NH
BnO.
Bn OH OH
O
solution was concentrated and the
gradient elution of DCM/MeOH = 
0.035 g).
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l3C-NMR (MeOD, 126 MHz): 6 40.88 (d, JC-p = 10.3, CHCH2Ph), 40.95 (d, i C p 
= 7.4, CHCHjPh), 57.91, 58.06 (2s, NHCH), 67.53 (d, ic-p  = 5.5, C-5’), 67.85 (d, 
3 c - p =  5.5, C-5’), 67.94, 68.00 (2s, OCH2Ph), 71.70, 71.79 (2s, C-3’), 76.17, 76.24 
(2s, C-2’), 84.57 (d, JC-p = 8.1, C-4’), 84.70 (d, i C-p = 8.4, C-4’), 93.80, 93.86 (2s, 
C -l’), 116.06 (d, ic -p  = 3.2, C-2 Naph), 116.10 (d, JC-p = 3.2, C-2 Naph), 122.77, 
122.80, 125.86, 125.89, 126.48, 126.51, 127.46, 127.72, 127.80, 127.84, 127.89,
127.92, 128.75, 128.81, 129.26, 129.28, 129.40, 129.46, 129.49, 129.52, 130.52,
130.57 (C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a 
Naph, OCH27Vt, CHCH2P/i), 136.21, 136.25, 136.94, 137.95, 138.00 (‘ipso’ 
CHCH2P/i, ‘ipso’ OCH2Ph), 146.58 (C-5), 147.82, 147.87 (‘ipso’ Naph), 158.59 
(C-3), 163.22 (CONH2), 173.68 (d, JC-p = 3.2, COOCH2Ph), 173.86 (d, i C-p = 3.6, 
COOCHjPh).
El MS= 710.20 (M+Na).
Anal. Calcd for C34H34N5O9P: C, 59.39; H, 4.98; N, 10.18. Found: C, 59.38; H, 
5.03; N, 9.98.
Synthesis of Z’^ ’-C^O-cyclopentylidene-ribavirin-S’-ll-naphthy^benzoxy- 
glycinyl)] phosphate. [194c]
O C32H34N5O9P
r -  NHo2 Mol Wt.: 663.6142
Prepared according to Standard Procedure C, 
from 192 (0.20 g, 0.64 mmol) in anhydrous 
THF (6 mL), ‘BuMgCl (1.0 M THF solution,
1.30 mL, 1.30 mmol), 193c (0.28 g, 0.71 
mmol) in anhydrous THF (6 mL), and the reaction mixture was stirred at room 
temperature overnight. After this period the solution was concentrated and the 
residue purified by column chromatography eluting with DCM/MeOH = 98/2, to 
give a white solid (15%, 0.066 g).
O - P - O
3IP-NMR (CDCI3, 202 MHz): 6 4.39, 4.22.
'H-NMR (CDC13, 500 MHz): 6 8.20, 8.17 (1H, 2s, H-5), 7.99-7.19 (12H, m, 
Naph, OCH2P/!), 5.94, 5.82 (1H, 2d, H -l’), 5.14-5.11 (0.5H, m, H-2’ of one
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diastereoisomer), 5.04-5.00 (2H, m, OC//2Ph) 4.84-4.83 (0.5 H, m, H-3’ of one 
diastereoisomer), 4.58-4.56 (0.5 H, m, H-2’ of one diastereoisomer), 4.52-4.15 
(3.5 H, m, H-3’ of one diastereoisomer, H-4’, H-5’), 3.86, 3.65 (2H, m, NHC//2), 
1.93-1.56 (8H, m, 4xCH2).
Synthesis of ribavirin-5’-[l-naphthyl(benzoxy-glycinyl)] phosphate. [195c]
o  C27H28N509P
NH
2 Mol Wt.: 597.5131
A solution of 194c (0.065 g, 0.098 mmol) in
  ^ ,  60% formic acid (6 mL) was stirred at room
OH OH
O temperature overnight. After this period the
solution was concentrated and the residue purified by column chromatography 
eluting with DCM/MeOH = 95/5, to give a white solid (17%, 0.010 g).
3IP-NMR (MeOD, 202 MHz): 6 5.34, 5.27.
'H-NMR (MeOD, 500 MHz): 8 8.55, 8.52 (1H, 2s, H-5), 8.03-7.95 (1H, m, H-8 
Naph), 7.77-7.74 (1H, m, H-6 Naph), 7.57-7.56 (1H, m, H-2 Naph) 7.42-7.13 
(8H, m, Naph, OCH2P/?), 5.85, 5.80 (1H, 2d, H -l’), 4.99-4.97 (2H, m, OC//2Ph), 
4.45-4.44 (0.5 H, m, H-2’ of one diastereoisomer), 4.39-4.16 (4.5 H, m, H-2’ of 
one diastereoisomer, H-3’, H-4’, H-5’), 3.73-3.65 (2H, m, NHC//2).
I3C-NMR (MeOD, 126 MHz): 6 44.01, 44.05 (2s, NHCH2), 67.76 (d, JC P = 5.1, 
C-5’), 67.92 (COOCH2Ph), 68.06 (d, JC-p = 5.4, C-5’), 71.74, 71.91 (2s, C-2’),
76.22 (C-3’), 84.80, 84.84 (2s, C-4’), 93.78 (C -l’), 116.24, 116.39, 122.69, 
122.75, 125.99, 126.04, 126.51, 127.46, 127.54, 127.76, 128.82, 129.32, 129.36,
129.55 (C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 
Naph, C-8a Naph, OCH2Ph), 136.27, 137.15 (C-4a Naph, ‘ipso’ OCH2/>h),
146.70, 146.78 (C-5), 147.88, 147.97 (‘ipso’ Naph), 158.62 (C-3), 163.22 
(CONH2), 172.34 (COOCH2Ph).
El MS= 620.15 (M+Na).
N
N
O - P - O .
NH
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9.13 Synthesis of acyclovir ProTides
Synthesis of N2-DMF acyclovir (/V-(9-((2-hydroxyethoxy)methyl)-6-oxo-6,9- 
dihydro-l//-purin-2-yl)-AVV-dimethylformimidamide). [200]
dry DMF (20 mL) was added N,/V-dimethylformamide dimethyl acetal (2.96 mL, 
22.2 mmol) and the reaction mixture was stirred at room temperature for 1 day. 
After this period the suspension was filtered, and the solid was washed with 
diethyl ether to give a white solid (97%, 1.20 g).
'H-NMR (DMSO 500 MHz): 6 11.30 (1H, s, NH), 8.58 (1H, s, C//N(CH3)2), 7.94 
(1H, s, H-8), 5.45 (2H, s, H -l’), 4.65 (1H, t, OH), 3.52-3.49 (4H, m, H-4’, H-5’), 
3.17,3.04 (6H, 2s, N(CH3)2).
Synthesis of N2-DMF acyclovir-[l-phenyI-(methoxy-L-alaninyl)] phosphate.
mL), ‘BuMgCl (1.0 M THF solution, 2.88 mL, 2.88 mmol), 131a (1.20 g, 4.32 
mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 96/4 then 94/6, to give a white solid (36%, 
0.27 g).
3,P-NMR (MeOD, 202 MHz): 6 3.76, 3.53.
O C,,H,6N60 3 
Mol Wt.: 280.2831
To a suspension of 9 (1.00 g, 4.44 mmol) in
[201a]
O c 2,h 28n 7o 7p
Mol Wt.: 521.4635
Prepared according to Standard 
Procedure C, from 200 (0.40 g,
1.44 mmol) in anhydrous THF (15
NH
O
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'H-NMR (MeOD, 500 MHz): 8 8.60 (1H, s, NC//N(CH3h), 7-88, 7.86 ( 1H, 2s, H-
4.15-4.12 (1H, m, H-5’ of one diastereoisomer), 4.10-4.07 (1H, m, H-5’ of one
Synthesis of acyclovir-[l-phenyl-(methoxy-L-alaninyl)J phosphate. [199a]
removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH = 95/5. The product was purified by 
preparative TLC (gradient elution of DCM/MeOH = 95/5 then 94/6 then 92/8) to 
give a white solid (13%, 0.032 g).
31P-NMR (MeOD, 202 MHz): 6 3.72, 3.55.
'H-NMR (MeOD, 500 MHz): 6 7.87-7.85 (1H, 2s, H-8), 7.36-7.33 (2H, m, PhO),
7.20-7.16 (3H, m, PhO), 5.50, 5.47 (2H, 2s, H -l’), 4.27-417 (2H, m, H-5’), 3.97-
3.90 (1H, m, C//CH3), 3.84-3.78 (2H, m, H-4’), 3.69, 3.67 (3H, 2s, COOC//3),
1.35-1.31 (3H, m, CHC//3).
,3C-NMR (MeOD, 125 MHz): 6 20.36 (d, JC-p = 7.0, CH3) 20.44 (d, JC-p = 6.4, 
CH3), 51.45, 51.52 (CHCH3), 52.72, 52.77 (COOCH3), 67.01 (d, JC- p  = 5.3, C-5’), 
67.11 (d, J c-p = 5.3, C-5’), 69.43 (d, J C-p = 5.3, C-4’), 69.48 (d, J C-p = 5.3, C-4’), 
73.68 (C -l’), 117.52, 121.10, 121.14, 121.32, 121.40, 121.42, 121.44, 121.45, 
121.54, 121.58, 123.89, 126.07, 130.10, 130.25, 130.71 (C-5, PhO), 139.79 (C-8),
152.17, 152.22, 152.24 (C-4), 155.69 (C-2), 159.41 (C-6), 175.46 (d, JC - p  = 5.4, 
COOCH3), 175.58 (d, J C - p  = 4.9, COOCH3).
El MS = 489.1267 (M+Na).
HPLC = H2 O/ACCN from 100/0 to 0/100 in 20 min = retention time 9.71 min.
= H20/MeOH 40/60 isocratic = retention time 5.56 min, 5.72 min.
8), 7.27-7.04 (3H, m, PhO), 6.97-6.90 (2H, m, PhO), 5.47, 5.45 (2H, 2s, H -l’),
diastereoisomer), 3.85-3.78 (1H, m, C//CH3), 3.74-3.66 (2H, m, H-4’), 3.58, 3.57 
(3H, 2s, COOCH3), 3.05, 3.01 (6H, 2s,N(C//3)2), 1.15-1.14 (3H, s, CHC//3).
O C,8H23N60 7P 
Mol Wt.: 466.3850
O
NH
1 A solution of 201a (0.27 g, 0.52 mmol) in 
2-propanol (10 mL) was stirred under 
reflux for 40 h. The solvent was then
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Synthesis of N2-DMF acyclovir-|l-phenyl-(benzoxy-L-alaninyl)J phosphate. 
[201b]
C27H32N7O7P 
Mol Wt.: 597.5594
Prepared according to Standard 
Procedure C, from 200 (0.40 g, 1.44 
mmol) in anhydrous THF (15 mL), 
‘BuMgCl (1.0 M THF solution, 2.88 mL, 2.88 mmol), 131d (1.53 g, 4.32 mmol) 
in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography 
eluting with DCM/MeOH = 95/5, to give a white solid (44 %, 0.38 g).
31P-NMR (MeOD, 202 MHz): 6 3.84, 3.47.
!H-NMR (MeOD, 500 MHz): 6 8.54 (1H, s, NC//N(CH3)2), 7.80, 7.77 (1H, 2s, H- 
8), 7.26-7.14 (7H, m, PhO, OCH2P/z), 7.05-7.00 (3H, m, PhO, OCH2PA), 5.41, 
5.38 (2H, 2s, H -l’), 5.01, 4.99 (2H, 2s, OC//2Ph), 4.08-4.05 (1H, m, H-5’ of one 
diastereoisomer), 4.04-4.00 (1H, m, H-5’ of one diastereoisomer), 3.86-3.81 (1H, 
m, C//CH3), 3.66-3.61 (2H, m, H-4’), 3.03, 3.02 (3H, 2s, N(C//3)2), 2.97 (3H, s, 
N(C//3)2), 1.22-1.18 (3H, m, CHC//3).
Synthesis of acydovir-[l-phenyl-(benzoxy-L-alaninyl)] phosphate. [199b]
C 2 4 H 2 7 N 6 O 7 P  
Mol Wt.: 542.4809
A solution of 201b (0.379 g, 0.63 mmol) in 
2-propanol (15 mL) was stirred under 
reflux for 40 h. The solvent was then 
removed under reduced pressure and the residue was purified by column 
chromatography gradient elution of DCM/MeOH = 95/5 then 90/10. The product 
was purified by preparative TLC (gradient elution of DCM/MeOH = 96/4 then 
94/6) to give a white solid (14%, 0.048 g).
0 - p - o ‘x's^  ^
235
Marco Derudas Chapter 9
31P-NMR (MeOD, 202 MHz): 6 3.80, 3.50.
*H-NMR (MeOD, 500 MHz): 6 7.74-7.71 (1H, 2s, H-8), 7.23-7.14 (7H, m, PhO,
OCH2P/0, 7.06-7.01 (3H, m, PhO, OCH2Ph \  5.32, 5.29 (2H, 2s, H-l*), 5.00-4.99 
(2H, 2s, OC//2Ph), 4.04-3.99 (2H, m, H-5’), 3.89-3.82 (1H, m, CHCH3), 3.62-
3.59 (2H, m, H-4’), 1.22, 1.21 (3H, 2d, CHC//3).
13C-NMR (MeOD, 125 MHz): 6 20.34 (d, JC-p = 7.6, CH3) 20.43 (d, JC-p = 6.3, 
CH3), 51.61, 51.73 (2s, CHCH3), 67.01 (d, JC-p = 5.3, C-5’), 67.10 (d, JC- p  = 5.5, 
C-5’), 67.97, 67.98 (2s, OCH2Ph), 69.39 (d, J C- p  = 3.9, C-4’), 69.45 (d, JC-p = 3.9, 
C-4’), 73.76 (C-H), 117.30, 121.39, 121.43, 121.47, 121.51, 126.08, 126.10,
129.19, 129.33, 129.36, 129.53, 129.58, 129.61, 130.19, 130.73 (C-5, PhO, 
OCW2P h \  137.27 (‘ipso’ OCH2P/z), 139.75 (C-8), 152.11, 152.17 (C-4), 155.73 
(C-2), 159.32 (C-6), 174.77 (d, JC-p = 5.2, COOCH2Ph), 174.91 (d, JC-/> = 4.6, 
COOCH2Ph).
El MS= 565.1581 (M+Na).
Anal. Calcd for C ^ H ^ C L P : C, 53.14; H, 5.02; N, 15.49. Found: C, 53.01; H, 
4.90; N, 15.10.
Synthesis of N2-DMF acycIovir-[l-phenyl-(isopropoxy-L-aIaninyI)] 
phosphate. [201c]
O C23H32N7O7P
/ J'T| l)IH Mol Wt.: 549.5166
O N ^ nA N ^ N 'CH*
O - P - O " ^ ^  ^  C H „
l^ l_j 3 Prepared according to Standard
- y V ^ c  Procedure C, from 200 (0.40 g,
CH3 O 1.43 mmol) in anhydrous THF
(15 mL), ‘BuMgCl (1.0 M THF solution, 2.86 mL, 2.86 mmol), 131e (1.31 g, 4.28
mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 97/3 then 96/4, to give a white solid 
(59 %, 0.54 g).
3IP-NMR (MeOD, 202 MHz): 6 3.88, 3.65.
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’H-NMR (MeOD, 500 MHz): 6 8.72 (1H, s, NC//N(CH3)2), 7.96, 7.94 (1H, 2s, H- 
8), 7.36-7.32 (2H, m, PhO), 7.20-7.17 (3H, m, PhO), 5.59, 5.57 (2H, 2s, H -l’), 
5.08-4.92 (1H, m, COOC//(CH3)2), 4.29-4.19 (2H, m, H-5’), 3.91-3.80 (3H, m, 
C//CH3, H-4’), 3.21, 3.14 (6H, 2s, N(C//3)2,), 1.41-1.01 (9H, m, COOCH(C//3)2, 
CHC//3).
Synthesis of acyclovir-[l-phenyl-(isopropoxy-L-alaniny))] phosphate. [199c]
O C20H27N6O7P
>N" r f ^ H  Mol Wt.: 494.4381
O n  N ^ m^ nh
NH A solution of 201c (0.53 g, 0.98 mmol)
in 2-propanol (18 mL) was stirredT T 3
CH3 O under reflux for 72 h. The solvent was
then removed under reduced pressure and the residue was purified by column 
chromatography with DCM/MeOH = 95/5. The appropriate fractions were 
collected, the solvent removed under reduced pressure and the residue was 
tritured with water and the precipitate filtered to give a white solid (7%, 0.035 g).
3,P-NMR (MeOD, 202 MHz): 6 3.80, 3.65.
‘H-NMR (MeOD, 500 MHz): 6 7.86-7.84 (1H, 2s, H-8), 7.36-7.33 (2H, m, PhO),
7.20-7.17 (3H, m, PhO), 5.50, 5.47 (2H, 2s, H -l’), 5.00-4.94 (1H, m, 
COOC//(CH3)2), 4.29-4.16 (2H, m, H-5’), 3.92-3.86 (1H, m, C//CH3), 3.84-3.79 
(2H, m, H-4’), 1.34, 1.31 (3H, 2d, J = 7.1, J = 6.7, CHC//3), 1.25-1.22 (6H, m, 
COOCH(C//3)2).
13C-NMR (MeOD, 125 MHz): 6 20.39 (d, JC-p = 7.0, CHCH3) 20.52 (d, JC-p = 
6.4, CHCH3), 21.89 (CH(CH3)2), 21.96 (d, JC-p = 3.0, CH(CH3)2), 51.68, 51.77 
(CHCH3), 67.01 (d, J c-p = 5.6, C-5’), 67.08 (d, JC- p = 5.5, C-5’), 69.40 (d, J C-p =
6.1, C-4’), 69.46 (d, JC-p = 6.2, C-4’), 70.13, 70.17 (COOCH(CH3)2), 73.67 (C- 
1’), 117.54 (C-5), 121.42 (d, JC-/> = 4.9, PhO), 121.47 (d, JC-p = 4.8, PhO), 126.07 
(d, J c-p = 2.4, PhO), 130.72 (C-5, PhO), 139.75 (C-8), 152.20 (d, h-p = 4.3, C-4), 
152.26 (d, J c - p  = 4.2, C-4), 153.44 (‘ipso’ Ph), 155.71 (C-2), 159.41 (C-6), 174.55 
(d, J c-p = 5.5, COOCH(CH3)2), 174.69 (d, J C-p = 5.0, COOCH(CH3)2).
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El MS= 517.1588 (M+Na)
HPLC = H2O/ACCN from 100/0 to 0/100 in 20 min = retention time 11.27 min.
= EbO/MeOH 40/60 isocratic = retention time 7.40 min.
Synthesis of N2-DMF acyclovir-[l-phenyl-(benzoxy-D-alaninyl)] phosphate. 
[201d]
N
O C27H32N 7O7P
CH0  ^  N ^ m ^ N^ N' CH3
NH Mol Wt.: 597.5594
O - P - O ^ ^ ^ 0 ^  
NH
CH, Prepared according to Standard
Procedure C, from 200 (0.40 g, 1.44 
O mmol) in anhydrous THF (15 mL),
lBuMgCl (1.0 M THF solution, 2.86 mL, 2.86 mmol), 131f (1.51 g, 4.32 mmol) in 
anhydrous THF (10 mL) and the reaction mixture was stirred at room temperature 
overnight. The residue was purified by column chromatography eluting with 
DCM/MeOH = 95/5, to give a white solid (57 %, 0.49 g).
3,P-NMR (MeOD, 202 MHz): 6 3.84, 3.46.
'H-NMR (MeOD, 500 MHz): 6 8.70 (1H, s, NCtfN(CH3)2), 7.95, 7.92 (1H, 2s, H- 
8), 7.43-7.09 (10H, m, PhO, OCH2P/i), 5.55, 5.52 (2H, 2s, H - l’), 5.18-5.06 (2H, 
m, OC//2Ph), 4.22-4.09 (2H, m, H-5’), 4.03-3.94 (1H, m, C//CH 3), 3.82-3.74 (2H, 
m, H-4’), 3.18-3.11 (3H, m, N (C //3)2), 1.36-1.26 (3H, m, CHC//3).
Synthesis of acycIovir-[l-phenyl-(benzoxy-D-alaninyI)] phosphate. [199d]
C24H27N60 7P 
Mol Wt.: 542.4809
A solution o f 201d (0.48 g, 0.80 mmol) in 
2-propanol (20 mL) was stirred under 
reflux for 48 h. The solvent was then 
removed under reduced pressure and the residue was purified by column 
chromatography gradient elution of DCM/MeOH = 96/4 then 94/6 (25%, 0.11 g).
0 - p - o '^ s-^ ^
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3IP-NMR (MeOD, 202 MHz): 6 3.80, 3.50.
'H-NMR (MeOD, 500 MHz): 6 7.83, 7.80 (1H, 2s, H-8), 7.38-7.25 (7H, m, PhO,
OCH2Ph), 7.19-7.11 (3H, m, PhO, OCH2P/*), 5.44, 5.41 (2H, 2s, H -l’), 5.13, 5.12 
(2H, 2s, OC//2Ph), 4.20-4.10 (2H, m, H-5’), 4.02-3.95 (1H, m, C//CH3), 3.76-
3.69 (2H, m, H-4’), 1.35, 1.32 (3H, 2d, J = 7.2, CHC//3).
13C-NMR (MeOD, 125 MHz): 6 20.34 (d, JC-p = 6.8, CH3) 20.43 (d, JC-p = 6.6, 
CH3), 51.60, 51.73 (2s, CHCH3), 67.01 (d, JC-p = 5.5, C-5’), 67.10 (d, iC-p = 5.4, 
C-5’), 67.97, 67.98 (2s, OCH2Ph), 69.34 (d, JC-p = 3.7, C-4’), 69.40 (d, JC-p = 3.7, 
C-4’), 73.69 (C-1’), 117.55, 121.39, 121.43, 121.48, 121.51, 126.10, 126.23, 
129.33, 129.36, 129.57, 129.60, 130.29, 130.59, 130.73 (C-5, PhO, OCU2Ph), 
137.29, 137.59 (‘ipso’ OCH2P/z), 139.75 (C-8), 152.13, 152.17 (C-4), 155.68 (C- 
2), 159.46(C-6), 174.76 (d, JC- p  = 5.0, COOCH2Ph), 174.91 (d, JC-p  = 4.6, 
COOCH2Ph).
El MS= 565.1571 (M+Na)
Anal. Calcd for C24H27N60 7P-H20: C, 51.43; H, 5.22; N, 14.99. Found: C, 51.90; 
H, 5.03; N, 14.67.
Synthesis of N2-DMF acyclovir-[l-p-fluoro-phenyl-(benzoxy-L-alaninyI)] 
phosphate. [201 e]
o  c 27h 3,f n 7o 7p
N ^ A nh Mol Wt.: 615.5499
</ [I |
o  n  N ^ n  N N
0 - P - 0 ~ ° ^  CH
NH
Prepared according to Standard
Procedure C, from 200 (0.40 g, 1.43
VT| CH3
O mmol) in anhydrous THF (15 mL),
lBuMgCl (1.0 M THF solution, 2.86 mL, 2.86 mmol), 131h (1.60 g, 4.28 mmol) 
in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 95/5, to give a white solid (52 %,
0.88 g).
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3IP-NMR (MeOD, 202 MHz): 5 4.08, 3.76.
I9F-NMR (CDC13, 471 MHz): 5 -120.16 (d, J = 2.3), -120.18 (d, J = 2.3).
'H-NMR (MeOD, 500 MHz): 6 8.71 (1H, s, NC//N(CH3)2), 7.97, 7.94 (1H, 2s, H- 
8), 7.40-7.28 (6H, m, Ph), 7.22-7.11 (3H, m, PhO), 5.60-5.50 (2H, m, H -l’),
5.19-5.06 (2H, m, OC//2Ph), 4.20-4.15 (2H, m, H-5’), 3.99-3.95 (1H, m, C//CH3), 
3.80-3.75 (2H, m, H-4’), 3.19, 3.71 (3H, 2s, N(C7/3)2), 3.12 (3H, s, N(C//3)2),
1.36-1.28 (3H, m, CHC//3).
_p— ^
Synthesis of acyclovir-[l-p-fluoro-phenyl-(benzoxy-L-alaninyl)] phosphate. 
[199eJ
C24H26FN6O7P 
Mol Wt.; 560.4714
A solution of 201e (0.458 g, 0.73 mmol) in 
2-propanol (20 mL) was stirred under 
reflux for 24 h. The solvent was then 
removed under reduced pressure and the residue was purified by column 
chromatography with DCM/MeOH = 95/5 to give a white solid (16%, 0.068 g).
3,P-NMR (MeOD, 202 MHz): 6 4.02, 3.78.
19F-NMR (CDC13, 471 MHz): 6 -120.20, -120.22.
'H-NMR (MeOD, 500 MHz): 6 7.84, 7.81 (1H, 2s, H-8), 7.39-7.29 (5H, m, Ph),
7.19-7.11 (2H, m, Ph), 7.06-7.02 (2H, m, Ph), 5.47, 5.44 (2H, 2s, H -l’), 5.15, 5.14
(2H, 2s, OC//2Ph), 4.21-4.11 (2H, m, H-5’), 4.01-3.96 (1H, m, C//CH3), 3.79- 
3.71 (2H, m, H-4’), 1.37, 1.34 (3H, 2d, J = 7.1, J = 7.2, CHC//3).
13C-NMR (MeOD, 125 MHz): 6 20.30 (d, JC-p = 7.1, CH3) 20.40 (d, JC-/> = 6.5, 
CH3), 51.60, 51.72 (2s, CHCH3), 67.04 (d, JC-p = 5.5, C-5’), 67.12 (d, J c~p  = 5.5, 
C-5’), 67.97 (OCH2Ph), 69.32 (d, JC-p = 4.0, C-4’), 69.38 (d, JC-p = 4.1, C-4’), 
73.76 (C-1’), 116.96, 117.15, 117.55, 122.99, 123.04, 123.06, 123.07, 123.10, 
123.14, 128.00, 128.27, 129.35, 129.36, 129.38, 129.57, 129.60, (C-5, PhO, 
OCH2P/0, 137.28 (‘ipso’ OCH2P/7), 139.74 (C-8), 153.41 (C-4), 155.71 (C-2),
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159.42 (C-6), 160.15, 162.09 (F-Ph), 174.71 (d, JC-p = 5.2, COOCH2Ph), 174.83 
(d, J c-p = 4.6, COOCH2Ph).
El MS= 583.1479 (M+Na).
Anal. Calcd for C24H26FN60 7P H 20 : C, 49.83; H, 4.88; N, 14.53. Found: C, 
49.96; H, 4.57; N, 14.38.
Synthesis of N2-DMF acyclovir-[l-naphthyI(methoxy-L-alaninyI)] phosphate. 
[201f]
(15 mL), 'BuMgCl (1.0 M THF solution, 2.88 mL, 2.88 mmol), 193d (1.41 g, 4.32 
mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 96/4 then 94/6, to give a white solid (36%, 
0.43 g).
31P-NMR (MeOD, 202 MHz): 6 4.09, 3.99.
*H-NMR (MeOD, 500 MHz): 6 8.41 (1H, s, NC//N(CH3)2), 8.01-7.95 (1H, m, H- 
8 Naph), 7.79-7.78 (1H, m, H-6 Naph), 7.73-7.71 (1H, m, H-2 Naph), 7.55, 7.53 
(1H, 2s, H-8), 7.43-7.39 (2H, m, Naph), 7.33-7.18 (2H, m, Naph), 5.38, 5.36 (2H, 
2s, H -l’), 4.20-4.13 (2H, m, H-5’), 3.89-3.82 (1H, m, C//CH3), 3.72-3.66 (2H, m, 
H), 3.48, 3.45 (3H, 2s, COOCH3), 2.94, 2.90 (6H, 2s, N(C//3)2) 1.18-1.14 (3H, m,
O C25H3oN70 7P 
Mol Wt.: 571.5222
O
Prepared according to Standard 
Procedure C, from 200 (0.40 g,
1.44 mmol) in anhydrous THF
CHCH3).
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Synthesis of acyclovir-[l-naphthyl(methoxy-L-alaninyI)] phosphate. [199f]
H3CO
C22H25N6O7P 
Mol Wt.: 516.4437
A solution of 201f (0.41 g, 0.72 mmol) in 
2-propanol (15 mL) was stirred under 
reflux for 72 h. The solvent was then 
removed under reduced pressure and the residue was purified by column 
chromatography gradient elution of DCM/MeOH = 98/2 then 96/4 then 92/8. The 
product was purified by preparative TLC (gradient elution of DCM/MeOH = 98/2 
then 96/4 then 95/5) then by preparative reverse phase HPLC (gradient elution of 
H20 /CH3CN= from 100/0 to 0/100 in 45 min) to give a white solid (7%, 0.028 g).
3iP-NMR (MeOD, 202 MHz): 6 4.07, 4.05.
'H-NMR (MeOD, 500 MHz): 6 8.14-8.12 (1H, m, H-8 Naph), 7.88-7.87 (1H, m, 
H-6 Naph), 7.82, 7.81 (1H, 2s, H-8), 7.71-7.70 (1H, m, H-2 Naph), 7.56-7.51 (2H, 
m, H-5 Naph, H-7 Naph), 7.45-7.39 (2H, m, H-3 Naph, H-4 Naph), 5.44, 5.42 
(2H, 2s, H -l’), 4.30-4.28 (1H, m, H-5’ of one diastereoisomer), 4.27-4.24 (1H, m, 
H-5’ of one diastereoisomer), 4.06-3.98 (1H, m, C//CH3), 3.84-3.82 (1H, m, H-4’ 
of one diastereoisomer), 3.80-3.79 (1H, m, H-4’ of one diastereoisomer), 3.63,
3.59 (3H, 2s, COOC//3), 1.34-1.30 (3H, m, CHC//3).
I3C-NMR (MeOD, 125 MHz): 6 20.38 (d, ] C- p  = 7.3, CH3), 20.50 (d, Jc ~ p  = 6.5, 
CH3), 51.59 (C H C H 3), 52.67, 52.76 (COOCH3), 67.24 (d, JC- p  = 5.6, C-5’), 67.31 
(d, J c - p  = 5.1, C-5’), 69.39 (d, J C- p  = 7.4, C-4’), 69.47 (d, J C- p  = 7.6, C-4’), 73.68 
(C -l’), 116.23, 116.25, 116.28, 117.56, 122.69, 122.74, 125.90, 126.51, 127.42, 
127.44, 127.75, 127.89, 127.94, 128.81, 128.83 (C-5, C-2 Naph, C-3 Naph, C-4 
Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph), 136.26 (C-4a 
Naph), 139.69 (C-8), 148.00, 148.06 (‘ipso’ Naph), 153.38 (C-4), 155.80 (C-2),
159.57 (C-6), 175.47 (d, J d - p  = 5.2, COOCH3), 175.60 (d, JC-p = 4.4, COOCH3).
El MS = 539.1410 (M+Na).
Anal. Calcd for C22H25N607P-H20: C, 50.29; H, 4.99; N, 15.99. Found: C, 50.18; 
H, 4.37; N, 13.34.
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Synthesis of N2-DMF acyclovir-[l-naphthyl(benzoxy-L-alaninyl)] phosphate.
(10 mL), ‘BuMgCl (1.0 M THF solution, 2.16 mL, 2.16 mmol), 193a (1.31 g, 3.25 
mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography, 
eluting with DCM/MeOH = 95/5, to give a white solid (17 %, 0.12 g).
31P-NMR (MeOD, 202 MHz): 6 4.18, 3.92.
'H-NMR (MeOD, 500 MHz): 6 8.47, 8.46 (1H, 2s, NC//N(CH3)2), 8.01-7.98 (1H, 
m, H-8 Naph), 7.78-7.74 (2H, m, H-8, H-6 Naph), 7.56, 7.55 (1H, m, H-2 Naph),
7.41-7.12 (9H, m, Naph, OCH2P/z), 5.37-5.36 (2H, 2s, H -l’), 5.00-4.93 (2H, m, 
OC//2Ph), 4.14-4.06 (2H, m, H-5’), 3.96-3.88 (1H, m, C//CH3), 3.88-3.59 (2H, m, 
H-4’), 2.95-2.93 (6H, m, N(C//3)2), 1.20-1.17 (3H, m, CHC//3).
Synthesis of acyclovir-[l-naphthyl(benzoxy-L-a!aninyl)] phosphate. [199h]
removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH = 96/4. The product was purified by 
preparative TLC (gradient elution of DCM/MeOH = 99/1, then 98/2, then 96/4) to 
give a white solid (35%, 0.032 g).
[201 h ]
O C3IH34N 707P 
Mol Wt.: 647.6181
0 _p_0 '^ N^ °i Prepared according to Standard 
Procedure C, from 200 (0.30 g, 
1.08 mmol) in anhydrous THF
NH
O
O C28H29N607P 
Mol Wt.: 592.5396
A solution of 201h (0.10 g, 0.16 mmol) 
in 2-propanol (5 mL) was stirred under 
reflux for 2 days. The solvent was then
NH
O
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3,P-NMR (MeOD, 202 MHz): 6 4.13, 3.96.
‘H-NMR (MeOD, 500 MHz): 6 8.01-7.99 (1H, m, H-8 Naph), 7.77-7.75 (1H, m, 
H-6 Naph), 7.67, 7.64 (1H, 2s, H-8), 7.58-7.13 (10H, m, Naph, OCU2?h), 5.28,
5.25 (2H, 2s, H -l’), 4.99-4.94 (2H, m, OC//2Ph), 4.12-4.06 (2H, m, H-5’), 3.97-
3.93 (1H, m, C//CH3), 3.64-3.59 (2H, m, H-4’), 1.24-1.20 (3H, m, CHC//3). 
13C-NMR (MeOD, 125 MHz): 6 20.32 (d, JC-p = 7.6, CH3), 20.43 (d, JC-p = 6.6, 
CH3), 51.76, 51.81 (2s, CHCH3), 67.20 (d, JC-p = 5.6, C-5’), 67.28 (d, JC-p = 4.9, 
C-5’), 67.95, 67.98 (2s, OCH2Ph), 69.34 (d, JC-p = 7.7, C-4’), 69.40 (d, JC-p = 8.1, 
C-4’), 73.65 (C -l’), 116.26, 116.29, 116.35, 122.69, 122.80, 125.92, 126.51,
127.20, 127.42, 127.46, 127.74, 128.81, 128.83, 129.27, 129.33, 129.52, 129.57 
(C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, 
C-8a Naph, OCU2P h \  136.26, 137.23 (C-4aNaph, ‘ipso’ OCH2P/i), 139.69 (C-8), 
147.98, 148.04 (‘ipso’ Naph, C-4), 152.44 (C-2), 159.39 (C-6), 174.61, 174.88 
(2s, COOCH2Ph).
El MS= 615.17 (M+Na).
Anal. Calcd for C28H 29N 60 7P-H20 : C, 55.08; H, 5.12; N , 13.76. Found: C, 55.81; 
H, 4.91; N , 12.78.
Synthesis of acyclovir-[l-naphthyl(n-propoxy-L-alaninyl)] phosphate. [199g]
O - P - O
NH
C24H29N607P 
Mol Wt.: 544.4968
A solution of 201h (0.78 g, 1.20 mmol) 
in n-propanol (28 mL) was stirred under 
reflux for 18 h. The solvent was then 
removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH = 95/5, to give a white solid (3%,
0.020g).
PrO CHc
O
3iP-NMR (DMSO, 202 MHz): 6 4.09,4.01.
'H-NMR (DMSO, 500 MHz): 6 10.68 (1H, bs, NH), 8.16-8.12 (1H, m, H-8 
Naph), 8.01-7.99 (1H, m, H-6 Naph), 7.86, 7.85 (1H, 2s, H-8), 7.79-7.50 (5H, m,
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Naph), 6.55 (2H, bs, NH2), 6.20-6.14 (1H, m, N//CH), 5.41, 5.40 (2H, 2s, H -l’), 
4.22-4.17 (2H, m, H-5’), 4.00-3.93 (3H, m, C//CH3, OC//2CH2CH3), 3.77-3.74 
(2H, m, H-4’), 1.61-1.50 (2H, m, OCH2C//2CH3), 1.31-1.27 (3H, m, CHC//3), 
0.90-0.84 (3H, m, OCH2CH2C//3).
13C-NMR (DMSO, 125 MHz): b 10.07 (CH3CH2CH2), 19.65, 19.72, 19.77 
(CHCH3), 21.36, 21.39 (2s, CH3CH2CH2), 49.81, 49.89 (2s, CHCH3), 64.87, 
65.11, 65.14 (C-5’), 65.86, 65.90 (2s, OCH2CH2CH3), 67.57, 67.63 (2, C-4’), 
71.84 (C-P), 114.76, 116.48, 121.45, 121.51, 124.08, 125.64, 125.99, 126.04,
126.17, 126.24, 126.61, 127.64, 127.96, 128.32 (C-5, C-2 Naph, C-3 Naph, C-4 
Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph), 134.21 (C-4a 
Naph), 137.57 (C-8), 146.46, 146.51 (‘ipso’ Naph), 151.36 (C-4), 153.88 (C-2), 
156.73 (C-6), 173.13, 173.17, 173.32 (COOCH2CH2CH3).
El MS= 567.17 (M+Na).
Anal. Calcd for C24H29N60 7P-H20: C, 51.25; H, 5.55; N, 14.94. Found: C, 51.40; 
H, 5.40; N, 14.37.
Synthesis of N2-DMF acyclovir-[l-phenyl-(benzoxy-L-phenylalaninyl)] 
phosphate. [201i]
c 33h 36n 7o 7p
Mol Wt.: 673.6554
Prepared according to Standard 
Procedure C, from 200 (0.40 g, 1.44 
mmol) in anhydrous THF (15 mL), 
‘BuMgCl (1.0 M THF solution, 2.88 mL, 2.88 mmol), 131g (1.25 g, 2.88 mmol) 
in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. The residue was purified by column chromatography 
gradient elution of DCM/MeOH = 98/2 then 95/5, to give a white solid (59 %, 
0.58 g).
O - P - O
31P-NMR (MeOD, 202 MHz): 6 3.39, 3.36.
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O-P-O
'H-NMR (MeOD, 500 MHz): 6 8.48, 8.47 (1H, 2s, NC//N(CH3)2), 7.74, 7.73 
(1H, 2s, H-8), 7.19-6.86 (15H, m, PhO, COOCH2P/*, CUCH2Ph), 5.33, 5.32 (2H, 
2s, H -l’), 4.95-4.90 (2H, m, COOC//2Ph), 4.03-3.96 (1H, m, C//CH2Ph), 3.91-
3.86 (0.5H, m, H-5’ of one diastereoisomer), 3.81-3.67 (1.5H, m, H-5’), 3.54-3.48 
(2H, m, H-4’), 2.96-2.87 (7H, m, N(C//3)2, CHC//2Ph of one diastereoisomer), 
2.76-2.71 (1H, m, CHC//2Ph of one diastereoisomer).
Synthesis of acyclovir- [l-phenyl-(benzoxy-L-phenylalaninyl)] phosphate. 
[199iJ
c 30h 31n 6o 7p
Mol Wt.: 618.5769
A solution of 201i (0.49 g, 0.73 mmol) in 2- 
propanol (20 mL) was stirred under reflux 
for 64 h. The solvent was then removed 
under reduced pressure and the residue was purified by column chromatography 
with DCM/MeOH = 95/5. The product was purified by preparative TLC (gradient 
elution of DCM/MeOH = 98/2 then 96/4) to give a white solid (14%, 0.054 g).
31P-NMR (MeOD, 202 MHz): 6 3.41, 3.31.
1 H-NMR (MeOD, 500 MHz): 6 7.65-7.64 (1H, 2s, H-8), 7.19-6.87 (15H, m, PhO, 
COOCH2P/z, CUCU2Ph), 5.25, 5.24 (2H, 2s, H -l’), 4.98-4.95 (2H, m, 
COOC//2Ph), 4.06-3.97 (1H, m, C//CH3), 3.89-3.84 (0.5H, m, H-5’ of one 
diastereoisomer), 3.80-3.64 (1.5H, m, H-5’), 3.48 (2H, bs, H-4’), 2.97-2.90 (1H, 
m, CHC//2Ph of one diastereoisomer), 2.78-2.73 (1H, m, CHC//2Ph of one 
diastereoisomer).
I3C-NMR (MeOD, 125 MHz): 6 40.91 (d, JC-p = 7.2, CHCH2Ph), 40.96 (d, JC-p = 
6.8, CHCH2Ph), 57.77, 57.91 (2s, CHCH2Ph), 66.87 (C-5’), 68.02, 68.03 (2s, 
COOCH2Ph), 69.25, 69.32 (C-4’), 73.64 (C -l’), 117.55, 121.30, 121.34, 121.37, 
121.41, 126.00, 127.93, 129.37, 129.52, 129.54, 129.57, 130.62, 130.65, 130.68 
(C-5, PhO, OCH2Ph, CHCHz/tt), 137.03, 138.02, 138.08 (‘ipso’ CHCH2P/z,
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‘ipso’ OCH2Ph), 139.73 (C-8), 152.08 (C-4), 155.65 (C-2), 159.41 (C-6), 173.85 
(COOCHzPh).
El MS= 641.1886 (M+Na).
HPLC = H2O/ACCN from 100/0 to 0/100 in 20 min = retention time 14.56 min.
= H20/MeOH 40/60 isocratic = retention time 22.52, 24.61 min.
Synthesis of N2-DMF acyclovir-[l-naphthyl(benzoxy-dimethylgIycinyI)] 
phosphate. [20lj]
(10 mL), ‘BuMgCl (1.0 M THF solution, 0.86 mL, 0.86 mmol), 193e (0.80 g, 1.92 
mmol) and the mixture reaction was stirred at room temperature overnight. Then 
'BuMgCl (1.0 M THF solution, 0.58 mL, 0.58 mmol), was added, and after 3 h the 
solution was concentrated. The residue was purified by column chromatography 
eluting with DCM/MeOH = 93/7, to give a white solid (35%, 0.17 g).
31P-NMR (MeOD, 202 MHz): 6 2.55.
'H-NMR (MeOD, 500 MHz): 6 8.59 (1H, s, NC//N(CH3)2), 8.15 (1H, d, J = 7.9 
Hz, H-8 Naph), 7.88 (1H, s, H-6 Naph), 7.86 (1H, s, H-8), 7.67 (1H, d, J = 8.2 
Hz, H-2 Naph), 7.55-7.26 (9H, m, Naph, OCH2P/i), 5.48 (2H, s, H -l’), 5.17-5.08 
(2H, m, OC//2Ph), 4.28-4.17 (2H, m, H-5’), 3.79-3.70 (2H, m, H-4’), 3.09, 3.07 
(6H, 2s, CHN(C//3)2), 1.51, 1.49 (6H, 2s, NHC(C//3)2).
I3C-NMR (MeOD, 125 MHz): 6 27.46 (d, JC-p = 4.8, CH3), 27.71 (d, JC-p = 6.9, 
CH3), 35.30, 41.41 (2s, N(CH3)2), 58.08 (C(CH3)2), 67.20 (d, JC-p = 5.7, C-5’),
68.23 (OCH2Ph), 69.43 (d, J C- p  = 7.3, C-4’), 73.67 (C -l’), 116.31, 117.37 120.33, 
122.95 125.77, 126.47, 127.30, 127.70, 127.89, 128.48, 128.82, 129.29, 129.55, 
130.89 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C- 
8 Naph, C-8a Naph, OCU2Ph), 136.25, 137.33 (C-4a Naph, ‘ipso’ OCH2P/0,
O C32H36N707P 
Mol Wt.: 661.6447
NH Prepared according to Standard 
Procedure C, from 200 (0.20 g, 
0.72 mmol) in anhydrous THFO
247
Marco Derudas Chapter 9
140.61 (C-8), 148.08, 148.14 (‘ipso’ Naph, C-4), 152.45 (C-2), 159.37 (C-6),
159.85 (CH-N(CH3)2) 176.56 (d, JC-p = 3.3, COOCH2Ph).
El MS= 662.2499 (M+H).
Anal. Calcd for CazF^NyOvP-HzO: C, 56.55; H, 5.64; N, 14.43. Found: C, 56.86; 
H, 5.05; N, 13.93.
Synthesis of acyclovir-[l-naphthyl(benzoxy-dimethyiglycinyI)j phosphate. 
[199j]
o C29H3,N60 7 P
NH Mol Wt.: 606.5662
"  NH2
A solution of 201 j (0.17 g, 0.26 mmol) in 
2-propanol (10 mL) was stirred under 
reflux for 96 h. The solvent was then 
removed under reduced pressure and the residue was purified by column 
chromatography eluting with DCM/MeOH = 96/4. The product was purified by 
preparative TLC (gradient elution of DCM/MeOH = 98/2 then 96/4) to give a 
white solid (23%, 0.037 g).
3IP-NMR (MeOD, 202 MHz): 6 2.52.
‘H-NMR (MeOD, 500 MHz): 6 8.20-8.13 (1H, m, H-8 Naph), 7.87 (1H, dd, J =
6.2, 3.2 Hz, H-6 Naph), 7.76 (1H, s, H-8), 7.68 (1H, d, J = 8.2 Hz, H-2 Naph), 
7.55-7.49 (2H, m, Naph, OCH2Pfi), 7.46-7.25 (7H, m, Naph, OCH2Ph), 5.38 (2H, 
s, H -l’), 5.16-5.08 (2H, m, OC//2Ph), 4.20-4.17 (2H, m, H-5’), 3.71-3.69 (2H, m, 
H-4’), 1.52, 1.50 (6H, 2s, NHC(C//3)2).
I3C-NMR (MeOD, 125 MHz): 6 27.45 (d, Jc p = 4.6, CH3), 27.72 (d, JC-/> = 6.8, 
CH3), 58.10 (C(CH3)2), 67.21 (d, JC-/> = 5.7, C-5’), 68.25 (OCH2Ph), 69.48 (d, Jr 
P = 7.5, C-4’), 73.61 (C -l’), 116.34, 117.55, 122.97, 125.76, 126.50, 127.30, 
127.68, 127.93, 128.78, 129.26, 129.31, 129.54 (C-5, C-2 Naph, C-3 Naph, C-4 
Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, OCH2/7i), 136.26, 
137.32 (C-4a Naph, ‘ipso’ OCH2P/i), 139.69 (C-8), 148.09, 148.15 (‘ipso’ Naph, 
C-4), 155.62 (C-2), 159.36 (C-6), 176.59 (d, JC-/> = 3.6, COOCH2Ph).
El MS= 607.2048 (M+Na).
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Anal. Calcd for C29H31N6O7P H 2O: C, 55.77; H, 5.33; N, 13.46. Found: C, 55.83; 
H, 5.15; N, 12.92.
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9.14 Synthesis of ganciclovir ProTides
Synthesis of N2-DMF ganciclovir (AP-(9-[(l,3-dihydroxypropan-2-yloxy)me- 
thyl]-6-oxo-6,9-dihydro-l//-purin-2-yl)-AyV-diinethylforinimidamide). [208]
dimethylformamide dimethyl acetal (1.30 mL, 9.79 mmol) and the reaction 
mixture was stirred at room temperature for 22 h. After this period was added 
N,N-dimethylformamide dimethyl acetal (0.65 mL, 4.90 mmol) and the 
suspension was stirred at room temperature for 7 h. The suspension was then 
filtered, and the solid was washed with diethyl ether to give a white solid (84%,
(4H, m, H-4’, H-5’), 3.16, 3.04 (6H, 2s, N(CH3)2).
Synthesis of N2-DMF ganciclovir-[l-phenyl(benzoxy-L-alaninyl)] di­
phosphate [209a]
lBuMgCl (1.0 M THF solution, 1.50 mL, 1.50 mmol), 131d (0.78 g, 2.22 mmol) 
in anhydrous THF (6 mL) and the reaction mixture was stirred at room 
temperature overnight. After this period were added: ‘BuMgCl (1.0 M THF
O C12H18N6O3
Mol Wt.: 310.3091
To a suspension of 10 (0.50 g, 1.96 mmol) in 
anhydrous DMF (10 mL) was added N,N-
0.51 g).
H-NMR (DMSO 500 MHz): 6 11.31 (1H, s, NH), 8.57 (1H, s, 1H), 7.93 (1H, s, 
H-8), 5.54 (2H, s, H -l’), 4.64 (2H, bs, 2xOH), 3.66-3.60 (1H, m, H-3’), 3.49-3.43
O C 4 4 H 5 0 N 8 O 1 2 P 2  
Mol Wt.: 944.8617
Prepared according to Standard 
Procedure C, from 208 (0.23 g, 0.74 
mmol) in anhydrous THF (15 mL) 
and anhydrous pyridine (5 mL)
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solution, 0.75 mL, 0.75 mmol) and 131d (1.31 g, 3.70 mmol) in anhydrous THF 
(6 mL) and the reaction mixture was stirred at room temperature for 24h. Then the 
residue was purified by column chromatography gradient elution of DCM/MeOH 
= 98/2, then 95/5, to give a white product: (80%, 0.60 g).
3IP-NMR (MeOD, 202 MHz): 5 3.91, 3.52, 3.39.
Synthesis of ganciclovir-|l-phenyl(benzoxy-L-alaninyl)] diphosphate. [210a|
o  C41H45N7O l2P2
//n '~ ||^N H  Mol Wt.: 889.7832
9  H £ h3 A s°luti°n of 209a (0.60 g, 0.64 mmol) in
O - P - N —(
O V-OBn 2-propanol (20 mL) was stirred under
O reflux for 40 h. After this period the
O - P - O
solvent was removed and the residue 
purified by column chromatography gradient elution of DCM/MeOH = 98/2, then 
96/4, then 95/5, and then further purified by preparative reverse phase HPLC 
(gradient elution of H20/CH3CN= from 100/0 to 0/100 in 35 min) to give a white 
solid (7%, 0.040 g).
3IP-NMR (MeOD, 202 MHz): 6 3.86, 3.85,3.80, 3.73, 3.52, 3.49, 3.41.
’H-NMR (MeOD, 500 MHz): 6 7.80-7.72 (1H, m, H-8), 7.41-7.26 (12H, m, PhO, 
OCHjPA), 7.22-7.09 (8H, m, PhO, OCH2P/i), 5.51-5.36 (2H, m, H -l’), 5.18-5.10 
(4H, m, 2xOC//2Ph), 4.24-3.90 (7H, m, H-3’, H-4’, H-5’, 2xC//CH3>), 1.38-1.30 
(6H, m, 2xCHCH,).
I3C-NMR (MeOD, 125 MHz): 6 20.38, 20.43, 20.49 (CHCHj), 51.60, 51.63, 
51.75 (CHCH3), 66.32, 66.36, 66.40, 66.44, 68.01, 68.03, (C-4’, C-5’), 72.74, 
72.85, 72.98 (C -l’), 76.94, 77.00, 77.07 (C-3’), 117.62, 121.40, 121.43, 121.46, 
121.51, 121.55, 126.15, 126.20, 128.01, 128.28, 129.25, 129.28, 129.33, 129.36, 
129.38, 129.60, 129.62, 129.64, 130.79, 130.83, 137.26 (C-5, PhO, OCH2P/0, 
139.61, 139.66 (C-8), 152.09, 153.29 (‘ipso’ Ph and OCH2Ph, C-4), 155.82 (C-2),
159.55 (C-6), 174.67, 174.75, 174.93 (COOCH2Ph).
El MS= 912.25 (M+Na).
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Anal. Calcd for C4 1 H4 5N 7O 12P2 H2O: C, 54.25; H, 5.22; N, 10.80. Found: C, 
54.10; H, 4.97; N, 10.53.
Synthesis of N2-DMF-ganciclovir-[l-naphthyl(benzoxy-L-aIaninyl)] di­
phosphate [209b]
O C 5 2 H 5 4 N 8 O 1 2 P 2  
Mol Wt.: 1044.9791
Prepared according to Standard 
Procedure C, from 208 (0.30 g, 
0.97 mmol) in anhydrous THF 
(15 mL), ‘BuMgCl (1.0 M THF
solution, 1.93 mL, 1.93 mmol), 193a (1.17 g, 2.90 mmol) in anhydrous THF (10 
mL) and the reaction mixture was stirred at room temperature for 20 h. Then the 
residue was purified by column chromatography gradient elution of DCM/MeOH 
= 98/2, then 95/5, to give a white product: (46%, 0.47 g).
3 IP-NMR (MeOD, 202 MHz): 5 4.30, 4.23,4.04, 4.00, 3.93.
'H-NMR (MeOD, 500 MHz): 6  8.63-8.40 (1H, m, NC«N(CH3)2), 8.16-8.03 (2H, 
m, H- 8  Naph), 7.90-7.74 (3H, m, H-8 , Naph), 7.71-7.60 (2H, m, Naph), 7.55-7.17 
(18H, m, Naph, Ph), 5.50-5.31 (2H, m, H -l’), 5.16-4.99 (4H, m, 2xC//2 Ph), 4.35- 
3.97 (7H, m, H-3’, H-4’, H-5’, 2xC//CH3), 3.34-3.32 (6 H, m, N(CH3)2), 1.34-
1.26 (6 H, m, 2xCHC//3).
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Synthesis of ganciclovir-[l-naphthyl(benzoxy~L-alaninyl)] di-phosphate 
[210b]
O - P - O
C49H49N 7O 12P2 
Mol Wt.: 989.9006
N NHct f i H°vj
^  V_oBn *n 2-propanol (15 mL) was stirred under 
O reflux for 70 h. After this period the
A solution of 209b (0.40 g, 0.38 mmol)
solvent was removed and the residue 
purified by column chromatography gradient elution o f DCM/MeOH = 95/5, then 
93/7, and then further purified by preparative TLC (gradient elution of 
DCM/MeOH= 98/2 then 96/4 then 95/5) to give a white solid (3%, 0.010 g).
31P-NMR (MeOD, 202 MHz): 6 4.23, 4.08, 3.96, 3.93.
'H-NMR (MeOD, 500 MHz): 6 8.17-8.00 (2H, m, H-8 Naph), 7.93-7.79 (2H, m, 
Naph), 7.75-7.60 (3H, m, H-8, Naph), 7.54-7.16 (18H, m, Naph, Ph), 5.46-5.17 
(2H, m, H -l’), 5.14-4.95 (4H, m, 2xC//2Ph), 4.31-3.94 (7H, m, H-3’, H-4’, H-5’, 
2xC//CH3), 1.41-1.22 (6H, m, 2xCHC//3).
13C-NMR (MeOD, 125 MHz): 6 20.33 (d, JC-p = 7.4, CHCH3), 20.45 (d, JC-p = 
7 2 ,  CHCH3), 51.76, 51.84 (CHCH3), 65.24, 66.46, 66.50, 66.55, 66.59 (C-4’, C- 
5’), 67.98, 68.01, 68.03 (CH2Ph), 72.63, 72.77, 72.91 (C -l’), 76.73, 76.80, 76.84 
76.90 (C-3’), 116.35, 116.38, 116.42, 116.44, 116.49, 116.52, 117.61, 122.63, 
122.66, 122.80, 126.03, 126.06, 126.55, 127.56, 127.79, 127.89, 128.00, 128.84, 
128.86, 129.18, 129.21, 129.26, 129.28, 129.31, 129.33, 129.52, 129.58 (C-5, C-2 
Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a 
Naph, OCU2Ph), 136.26, 137.15, 137.20 (C-4aNaph, ‘ipso’ OCH2P/2), 139.53 (C- 
8), 147.88, 147.94 ( ‘ipso’ Naph, C-4), 153.19 (C-2), 159.25, 159.85 (C-6),
174.64, 174.93 (2s, COOCH2Ph).
El MS= 990.3035 (M+H).
HPLC = H20/M eOH 40/60 isocratic = retention time 4.71 min.
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Synthesis of N2-DMF-ganciclovir-[l-naphthyl(isopropoxy-L-alaninyI)] di­
phosphate [209c] and N2-DMF-ganciclovir-[l-naphthyl(isopropoxy-L- 
alaninyl)] di-phosphate. [209d]
h3c ^ . o
o  ,, qh3o - p - o
c h 3 o
C 4 4 H 5 4 N 8 0 1 2 P 2  
Mol Wt.: 948.8935
O - P - O
CH3 o
N N N
CHq
h3c ^ .O
C28H36N7O8P 
Mol Wt.: 629.6013
Prepared according to Standard 
Procedure C, from 208 (0.25 g, 
0.81 mmol) in anhydrous THF 
(15 mL), ‘BuMgCl (1.0 M THF solution, 1.61 mL, 1.61 mmol), 193f (0.86 g, 2.42 
mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred at room 
temperature overnight. After this period were added: pyridine (5 mL), ^uMgCl 
(1.0 M THF solution, 1.61 mL, 1.61 mmol) and 193f (1.60 g, 4.49 mmol) in 
anhydrous THF (10 mL) and the reaction mixture was stirred at room temperature 
for 3 days. Then the residue was purified by column chromatography gradient 
elution of DCM/MeOH = 98/2, then 95/5, to give two products: [209c] (44%, 0.34 
g), [209d] (14%, 0.071 g).
DiProTide: [209c]
3IP-NMR (MeOD, 202 MHz): 5 4.04 (bs).
MonoProTide: [209d]
3IP-NMR (MeOD, 202 MHz): 6 4.19 (bs).
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'H-NMR (MeOD, 500 MHz): 6 8.74-8.68 (1H, m, NC//N(CH3)2), 8.17-7.36 (8H, 
m, H-8, Naph), 5.73-5.70 (2H, m, H -l’), 4.99-4.80 (1H, bs, COOC//(CH3)2), 
4.39-4.05 (3H, m, H-3’, H-5’), 3.97-3.88 (1H, m, C//CH3), 3.70-3.56 (2H, m, H- 
4’), 3.20, 3.12 (6H, s, N(CH3)2), 1.33-1.28 (3H, m, CHC//3), 1.22-1.16 (6H, m, 
COOCH(C//3)2).
Synthesis of ganciclovir-[l-naphthyl(isopropoxy-L-aIaninyl)] diphosphate. 
[210c]
c h 3 o
h3c .  .0
C41H49N7O j2P 2 
Mol Wt.: 893.8150
A solution of 209c (0.33 g, 0.35 
mmol) in 2-propanol (10 mL) was 
stirred under reflux for 80 h. After 
this period the solvent was 
removed and the residue purified by column chromatography gradient elution of 
DCM/MeOH = 95/5, then 94/6, then 93/7, to give a white solid (8%, 0.025 g).
3,P-NMR (MeOD, 202 MHz): 6 4.29, 4.25, 4.23, 4.17.
'H-NMR (MeOD, 500 MHz): 6 8.17-8.05 (2H, m, H-8 Naph), 7.85 (2H, m, H-6 
Naph), 7.75-7.71 (1H, m, H-8), 7.68-7.34 (10H, m, Naph), 5.41-5.37 (2H, m, H- 
1’), 4.99-4.87 (2H, m, 2xC//(CH3)2), 4.27-4.14 (5H, m, H-3’, H-4’, H-5’), 4.01-
3.91 (2H, m, 2xC//CH3), 1.36-1.26 (6H, m, 2xCHC//3), 1.21-1.11 (12H, m, 
2xCOOCH(C//3)2).
13C-NMR (MeOD, 125 MHz): 6 20.49, 20.56, 20.61, 20.64, 20.69 (CHCH3), 
21.90, 22.00, 22.02 (CH(CH3)2), 51.87 (CHCH3), 66.51, 66.55, 66.66, 66.70 (C- 
4’, C-5’), 70.23, 70.30, 70.32 (COOCH(CH3)2), 72.91 (C -l’), 76.94 (C-3’), 
116.13, 116.42, 122.67,122.70, 122.79, 126.03, 126.55, 127.54, 127.80, 127.86, 
128.87 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-l Naph, C- 
8 Naph, C-8a Naph), 136.26 (C-4a Naph), 138.42 (C-8), 147.92, 147.98, 150.02 
(‘ipso’ Naph, C-4), 155.64 (C-2), 159.44 (C-6), 174.72 (COOCH2Ph).
El MS= 916.3 (M+Na).
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Anal. Calcd for C41H49N7O12P2: C, 55.09; H, 5.53; N, 10.97. Found: C, 54.62; H, 
5.56; N, 10.60.
Synthesis of ganciclovir-[l-naphthyl(isopropoxy-L-alaninyl)] diphosphate. 
[210d]
O C25H31N6O8P
//N' y xNH Mol Wt.: 574.5228
0 vj* n ^ n h 2
A solution of 209d (0.070 g, 0.11
I OH mmol) in 2-propanol (4 mL) wasT T
CH3 O stirred under reflux for 24 h. After this
period the solvent was removed and the residue purified by preparative reverse 
phase HPLC (gradient elution of H20/CH3CN= from 100/0 to 0/100 in 35 min) to 
give a white solid (33%, 0.021 g).
3,P-NMR (MeOD, 202 MHz): 5 4.40, 4.36,4.34, 4.27.
'H-NMR (MeOD, 500 MHz): 6 8.20-8.06 (1H, m, Naph), 7.90-7.85 (1H, m, 
Naph), 7.83-7.79 (1H, m, H-8), 7.75-7.66 (1H, m, Naph), 7.59-7.49 (2H, m, 
Naph), 7.49-7.36 (2H, m, Naph), 5.51-5.45 (2H, m, H -l’), 5.03-4.94 (1H, m, 
Ctf(CH3)2), 4.39-4.11 (2H, m, H-5’), 4.05-3.91 (2H, m, H-3’, C/7CH3,), 3.65- 
3.47 (2H, m, H-4’), 1.40-1.29 (3H, m, CHC//3), 1.26-1.14 (6H, m, 
COOCH(C//3)2).
I3C-NMR (MeOD, 125 MHz): 6 20.46 (d, J c-p = 6.7, CHCH3), 20.57 (d, JC-p = 
6.7, CHCH3), 20.68 (d, JC-p = 6.6, CHCH3), 21.90 (d, 3C-P = 2.3, CH(CH3)2), 
21.99 (d, J c-p = 2.9, CH(CH3)2), 51.83 (CHCH3), 61.78, 61.92 (2s, C-4’), 67.36 
(d, J c-p = 5.4, C-5’), 67.45 (d, 3C-p = 5.7, C-5’), 70.17 (COOCH(CH3)2), 70.26 (d, 
Jcw> = 5.6, COOCH(CH3)2), 72.89, 73.06, (C -l’), 78.95 (d, Jc-r = 7.3, C-3’), 
79.21 (d, 3C-r = 7-6, C-3’), 116.31, 116.34, 116.37, 116.40, 117.48, 117.56,
122.70, 122.74, 122.83, 125.98, 126.55, 127.50, 127.78, 127.80, 127.88, 127.93,
128.85 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C- 
8 Naph, C-8a Naph), 136.27 (C-4a Naph), 139.70, 139.75 (C-8), 147.97, 148.05 
(‘ipso’ Naph, C-4), 155.72 (C-2), 159.46 (C-6), 174.52 (COOCH2Ph).
El MS= 597.1832 (M+Na).
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Anal. Calcd for C, 50.68; H, 5.61; N, 14.18. Found: C, 50.75;
H, 5.44; N, 13.89.
Synthesis of N2-DMF-ganciclovir-[ethoxy-L-aIaninyl)] cyclic phosphate. [212]
°  C I7H26N707P
//N' l |  y H Mol Wt.: 471.4048
NA NA N ^ N 'CH°I
0.97 mmol) in anhydrous THF (10 mL)
O y  CH
°cp  J 3 To a stirring solution of 208 (0.30 g,
EtCL ,  u
ch3 and anhydrous pyridine (5 mL) was
added ‘BuMgCl (1.0 M THF solution, 
2.00 mL, 2.00 mmol) and the reaction mixture was stirred at room temperature for 
30 min. After this period, a solution of 211 (0.45 g, 1.93 mmol) in anhydrous THF 
(5 mL) was added and the reaction mixture was stirred at room temperature for 24 
h. After this period, anhydrous pyridine (5 mL) and lBuMgCl (1.0 M THF 
solution, 2.00 mL, 2.00 mmol) were added and the reaction mixture was stirred at 
room temperature for 16 h. After this period the solvent was removed and the 
residue purified by column chromatography gradient elution of DCM, then 
DCM/MeOH = 98/2, 92/8 then 80/20, to give a white product: (93%, 0.43 g).
3IP-NMR (MeOD, 202 MHz): 6 3.53, 2.44.
Synthesis of ganciclovir-(ethoxy-L-alaninyl)] cyclic phosphate. (213]
O C l4H2iN60 7P
>N"Ti NH Mol Wt.: 416.3263
U - A
OvJN ^ N  n h 2
0 ,9  J A solution of 212 (0.43 g, 0.91 mmol) in 2-
ivONH propanol (20 mL) was stirred at reflux for 9 h.
E t O ^ c H 3 After this period the solvent was removed and
^  the residue purified by column chromatography
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gradient elution of DCM/MeOH = 97/3, 94/6, 90/10 then 85/15 to give a white 
solid, which was further purified by preparative TLC (gradient elution of 
DCM/MeOH = 97/3 then 95/5) to give a white solid (11%, 0.040 g).
31P-NMR (MeOD, 202 MHz): 6 3.73, 2.89.
‘H-NMR (MeOD, 500 MHz): 6 7.91 (1H, s, H-8), 5.70-5.55 (2H, m, H -l’), 4.63- 
4.30 (5H, m, H-3’, H-4’, H-5’), 4.26-4.10 (2H, m, CH2CH3), 3.93-3.76 (1H, m, 
C//CH3), 1.45-1.32 (3H, m, CH2C//3), 1.31-1.24 (3H, m, CHC//3).
13C-NMR (MeOD, 125 MHz): 6 14.46, 14.49 (CH2CH3), 20.43 (d, JC-p = 6.4, 
CHCH3), 20.51 (d, J c-p = 6.6, CHCH3), 50.93, 51.34 (CHCH3), 62.29, 62.38 
(CH2CH3), 69.89, 69.92, 69.94, 69.97, 70.26, 70.31, 70.42, 70.46, 70.51, 70.85, 
70.90 (C-3’, C-4’, C-5’), 71.26, 71.42 (C -l’), 117.49 (C-5), 139.69 (C-8) 155.82 
(C-2), 159.40 (C-6), 175.02 (d, JC-p = 5.8, COOCH2CH3), 175.11 (d, JC-p = 5.5, 
COOCH2CH3).
El MS= 417.12 (M+H) and 439.11 (M+Na).
HPLC = H20/AcCN 95/5 to 0/100 in 30 min = retention time 7.75 min.
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B < /
NH1
HO
5' 2' N ' T ' N4 ' N^ N ' CH3
• ^ ^ l 9 3 'V OH3
Mol Wt.: 308.3363
HO
To a suspension of 11 (3.00 g, 11.85 mmol) 
anhydrous DMF (40 mL) was added N 
dimethylformamidedimethylacetal (7.90 mL, 59.23 mmol) and the reaction mixture 1 
stirred at room temperature for 6 h. After this period, the solvent was removed and 
residue was triturated with Et20 and filtered. The solid was washed with Et20 to gi\ 
white solid (95%, 3.45 g).
'H-NMR (DMSO, 500 MHz): 6 11.17 (1H, bs, NH), 8.56 (1H, s, N=C#N), 7.81 (IE 
H-8), 4.09 (2H, t, J = 7.3, H-L), 3.49-3.35 (4H, m, H -4\ H-5’), 3.16, 3.04 (6H, 
2xCH3), 1.76 (2H, dd, J = 14.1, 7.0, H-2’), 1.46 (1H, dt, J = 12.0, 5.9, H-3’).
Synthesis of N2-DMF-penciclovir-[l-phenyl-(benzoxy-L-alaninyI)] diphosph; 
[215a]
BnO
O - P - O
N N N 3 
CH ,
n  , C H : 
O - P - N —(
O OBn
V
C 45H 52N 8011P 2 
Mol Wt.: 942.8889
Prepared according to Standard Procec 
C, from 214 (0.40 g, 1.30 mmol) 
anhydrous THF (15 mL), 'BuMgCl (l.C 
THF solution, 2.60 mL, 2.60 mmol), 1,
(0.92 g, 2.60 mmol) in anhydrous THF (8 mL) and the reaction mixture was stirre* 
room temperature for 8 h. Then the solvent was removed and the residue purified
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column chromatography gradient elution of DCM/MeOH = 98/2, then 96/4 then 94/6 
then 90/10 then 80/20 to give a white solid (54%, 0.67 g). A sample was further purified 
by preparative TLC gradient elution of DCM/MeOH = 98/2 then 95/5 to give a white 
solid.
31P-NMR (MeOD, 202 MHz): 6 4.01, 3.96, 3.46, 3.43, 3.37.
'H NMR (MeOD, 500 MHz): 6 8.67 (1H, s, N=C//N), 7.78 (1H, m, H-8), 7.37-7.24 
(14H, m, PhO, P/iCH2), 7.24-7.11 (6H, m, PhO, P/*CH2), 5.15-5.07 (4H, m, 2xC//2Ph), 
4.21-3.92 (8H, m, H -l’, H-4’, H-5’, 2xC//CH3), 3.09, 3.06 (6H, 2s, N(C//3)2), 1.91-1.74 
(3H, m, H-2’, H-3’), 1.39-1.28 (6H, m, 2xCHC//3).
I3C NMR (MeOD, 126 MHz): 6 20.34 (d, JC-p = 3.2, CH3), 20.39 (d, JC-p = 3.6, CH3),
28.94, 29.02, 29.10 (C-2’), 35.34 (NCH3), 38.36 (C-3’), 41.51, 41.52 (NCH3), 41.76,
41.85 (2s, C -l’), 51.66, 51.81 (2s, CHCH3), 66.85, 66.90, 66.98, 67.02 (C-4’, C-5’),
67.94, 67.96 (2s, CH2Ph), 121.42, 121.46, 121.49, 121.54, 121.58, 121.62, 126.20, 
129.23, 129.24, 129.27, 129.28, 129.30, 129.31, 129.34, 129.36, 129.38, 129.54, 129.60, 
129.63, 130.13, 130.81, 130.82 (PhO, CH2Ph), 137.26 (‘ipso’ OCH2P/z), 140.38 (C-8), 
152.17, 155.23 (C-2, C-4), 158.94 (C-6), 159.84 (N=CHN), 174.68 (d, JC-/> = 4.5, 
COOCH2Ph), 174.96 (d, JC-p = 3.7, COOCH2Ph).
El MS = 943.3314 (M+H), 965.3083 (M+Na)
HPLC = H20/AcCN from 95/5 to 0/100 in 30 min = retention time 23.09 min.
= H20/MeOH 30/70 isocratic = retention time 12.68 min.
Synthesis of penciclovir-[l-phenyl-(benzoxy-L-alaninyl)] diphosphate. [216a]
C42H47N70nP2
Mol Wt.: 887.8104
A suspension of 215a (0.60 g, 0.64 mmol) in 2- 
propanol (30 mL) was stirred at 95 °C for 39 h. 
After this period the solvent was removed and the 
residue purified by column chromatography
O
NH
NH
O - P - O
NH CH
BnO. OBn'CH
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gradient elution of DCM/MeOH = 98/2, then 96/4, then 94/6 to give a white solid which 
was further purified by preparative TLC (gradient elution of DCM/MeOH = 98/2, then 
96/4, then 95/5) to give a white solid (0.026 g) corresponding to the desired compound 
and (4%, 0.020 g) corresponding to the pure starting material.
31P-NMR (MeOD, 202 MHz): 6 3.90, 3.86, 3.43, 3.34.
‘H NMR (MeOD, 500 MHz): 6 7.67 (1H, m, H-8), 7.40-7.25 (14H, m, PhO, P/*CH2),
7.23-7.11 (6H, m, PhO, P/*CH2), 5.17-5.08 (4H, m, 2xC//2Ph), 4.20-3.93 (8H, m, H -l’, 
H-4\ H-5\ 2xC//CH3), 1.91-1.69 (3H, m, H-2’, H-3’), 1.36 (3H, t, J = 2.2 Hz, CHC//3) 
1.35 (3H, t, J = 2.6 Hz, CHC//3).
13C NMR (MeOD, 126 MHz): 6 20.37, 20.42 (2s, CHCH3), 28.99, 29.05 (2s, C-2’), 38.42 
(C-3’), 41.79, 41.87 (C-T), 51.68, 51.81 (2s, CHCH3), 66.97, 67.02 (C-4\ C-5’), 67.58, 
67.97 (2s, CH2Ph), 121.45, 121.51, 121.55, 121.59, 121.63, 126.15, 129.21, 129.26, 
129.30, 129.33, 129.34, 129.37, 129.51, 129.59, 129.61, 130.05, 130.80 (PhO, CH2Ph), 
137.26 (‘ipso’ OCH2Ph), 152.16, 155.24 (C-2, C-4), 174.73, 174.99 (2s, COOCH2Ph).
El MS = 888.2908 (M+H), 910.2741 (M+Na).
HPLC = H20/AcCN from 95/5 to 0/100 in 30 min = retention time 24.68 min.
= H20/MeOH 30/70 isocratic = retention time 4.55 min.
Synthesis of N2-DMF-pencicIovir-[l-naphthyl(benzoxy-L-alaninyl)] diphosphate.
lBuMgCl (1.0 M THF solution, 2.60 mL, 
2.60 mmol), 193a (1.05 g, 2.60 mmol) in anhydrous THF (8 mL) and the reaction 
mixture was stirred at room temperature for 8 h. Then the solvent was removed and the
[215b]
O C53H56N80nP2
Mol Wt.: 1043.0063
Prepared according to Standard 
Procedure C, from 214 (0.40 g, 1.30 
mmol) in anhydrous THF (15 mL),
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residue purified by column chromatography gradient elution of DCM/MeOH = 98/2, then 
97/3 then 96/4 to give a white solid (20%, 0.28 g). A sample was further purified by 
preparative TLC gradient elution of DCM/MeOH = 98/2 then 95/5 to give a white solid.
3IP-NMR (MeOD, 202 MHz): 6 4.43, 4.42,4.37,4.34,4.06, 3.97, 3.95, 3.88.
'H NMR (MeOD, 500 MHz): 6 8.52-8.44 (1H, m, N=C«N), 8.16-8.06 (2H, m, H-8 
Naph), 7.90-7.77 (2H, m, H-6 Naph), 7.70-7.57 (3H, m, H-8, Naph), 7.52-7.19 (18H, m, 
NaphO, Ph), 5.11-5.00 (4H, m, 2xC//2Ph), 4.20-3.87 (8H, m, H -l’, H-4’, H-5\ 
2xC//CH3), 3.02-2.92 (6H, m, N(C//3)2), 1.90-1.48 (3H, m, H-2’, H-3’), 1.37-1.29 (6H, 
m, 2xCHC//3).
I3C NMR (MeOD, 126 MHz): 5 20.34, 20.40 (2s, CHCH3), 28.83, 28.99, 29.08 (C-2’),
35.25 (NCH3), 38.37 (C-3’), 41.39, 41.44 (NCH3), 41.64, 41.72 (2s, C -l’), 51.80, 51.88 
(2s, CHCH3), 66.92, 67.10, 67.26 (C-4\ C-5’), 67.96 (CH2Ph), 116.48, 116.60, 116.71,
122.68, 122.86, 126.05, 126.09, 126.51, 127.48, 127.52, 127.79, 128.89, 128.92, 129.18, 
129.27, 129.33, 129.58 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 
Naph, C-8 Naph, C-8a Naph, OCHiPh), 136.23, 137.16 (C-4a Naph, ‘ipso’ OCH2P/z), 
140.12 (C-8), 147.95 (‘ipso’ Naph, C-4), 152.06 (C-2), 158.83 (C-6), 159.72 (N=CHN),
174.68, 175.00 (2s, COOCH2Ph).
El MS = 1043.3613 (M+).
HPLC = H20/AcCN from 95/5 to 0/100 in 30 min = retention time 26.35 min.
= H20/MeOH 20/80 isocratic = retention time 9.23 min.
Synthesis of pencicIovir-[l-naphthyl(benzoxy-L-alaninyl)] diphosphate. [216b]
C5oH5,N70 „ P 2 
Mol Wt.: 987.9278
A suspension of 215b (0.23 g, 0.22 mmol) in 2- 
propanol (15 mL) was stirred at 95 °C for 72 h. 
After this period the solvent was removed and
O - P - O 9 H , c h 3
O - P —N— (
y~OBn 
O
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the residue purified by column chromatography gradient elution of DCM/MeOH = 99/1, 
then 98/2, then 96/4 to give a white solid which was further purified by preparative TLC 
(gradient elution of DCM/MeOH = 98/2, then 96/4, then 95/5) to give a white solid (7%,
0.015 g).
3IP-NMR (MeOD, 202 MHz): 6 4.32, 4.26,4.24, 3.98, 3.94, 3.85.
'H NMR (MeOD, 500 MHz): 6 8.18-8.06 (2H, m, H-8 Naph), 7.88-7.78 (2H, m, H-6 
Naph), 7.72-7.59 (2H, m, Naph), 7.53-7.16 (19H, m, H-8, NaphO, Ph), 5.10-5.04 (4H, m, 
2xC//2Ph), 4.16-3.99 (6H, m, H -l’, H-4’, H-5’), 3.91-3.76 (2H, 2xC//CH3), 1.67-1.41 
(3H, m, H -2\ H-3’), 1.33-1.30 (6H, m, 2xCHC//3).
I3C NMR (MeOD, 126 MHz): 5 20.34, 20.39 (2s, CHCH3), 28.98 (C-2’), 38.45 (C-3’),
41.60, 41.65, 41.73 (C-P), 51.81, 51.89 (2s, CHCH3), 67.07, 67.16 (C-4’, C-5’), 67.97 
(CH2Ph), 116.41, 116.50, 116.64, 116.75, 117.54, 122.65, 122.70, 122.73, 122.85, 
126.02, 126.52, 127.50, 127.74, 127.77, 127.94, 128.86, 128.88, 129.21, 129.29, 129.32,
129.52, 129.54, 129.57 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 
Naph, C-8 Naph, C-8a Naph, OCH2P/i), 136.25, 137.16 (C-4a Naph, ‘ipso’ OCH2P/j),
139.29 (C-8), 147.97, 148.03 (‘ipso’ Naph, C-4), 155.16 (C-2), 159.39 (C-6), 174.77, 
175.02 (2s, COOCH2Ph).
HPLC = H2O/ACCN from 95/5 to 0/100 in 30 min = retention time 25.35 min.
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9.16 Synthesis of thio-ganciclovir ProTides
Synthesis of (l,3-di-0-benzyl-2-0-/Moluenesulfonyl)glyceroI. [218]
OBn C 24H 26O 5S
TosO-
■OBn Mol Wt.: 426.5252 
To a solution of 217 (25.78 g, 93.63 mmol) in anhydrous pyridine (90 mL) was addedp- 
toluenesulfonyl chloride (22.31 g, 117.03 mmol) and the reaction mixture was stirred at 
room temperature overnight. After this period the solvent was removed and the residue 
dissolved in DCM. The organic phase was washed with water (twice), with a saturated 
solution of Na2CC>3 (twice), dried over MgSC>4, filtered and concentrated to give a clear 
oil (99%, 39.90 g).
*H NMR (CDCI3, 500 MHz): 6 7.80 (2H, d, J = 8.3, tosylate), 7.39-7.27 (10H, m, Ph), 
7.26-7.20 (2H, m, Ph), 4.78 (1H, p, J = 5.1, CH), 4.46 (4H, q, J = 11.9, C//2Ph), 3.73-3.64 
(4H, m, 2xCH2), 2.41 (3H, s, CH3).
Synthesis of l,3-bis(benzyloxy)-2-(acetylthio)propane. [219]
OBn C19H22O3S
AcS-
■OBn Mol Wt.: 330.4412
To a solution of 218 (39.90 g, 93.55 mmol) in anhydrous DMF (70 mL) was added 
potassium acetate (14.42 g, 126.29 mmol) and the reaction mixture was stirred at 90 °C 
for 2 h. After this period, the reaction mixture was allowed to cool down and it was 
dilueted with DCM. The organic phase was washed with water (5 times), saturated 
solution of Na2CC>3 (3 times), and 10% aqueous solution of HC1 (3 times), then dried 
over MgSC>4. After filtration, the solvent was removed to give a dark/brown oil (99%, 
30.50 g).
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'H NMR (CDCI3, 500 MHz): 6 7.42-7.26 (10H, m, Ph), 4.56 (4H, s, 2xC//2Ph), 4.02-3.96 
(1H, m, CH), 3.74 (2H, dd, J = 9.8, 4.9, CH2CH), 3.69 (2H, dd, J = 9.7, 6.4, CH2CH), 
2.37 (3H, s, CH3).
Synthesis of l,3-bis(benzyloxy)-2-propanethiol. [220J
OBn C n H zo O zS
HS-
■OBn Mol Wt.: 288.4045
Procedure A: A solution of 219 (10.33 g, 31.26 mmol) in methanolic ammonia (70 mL) 
was stirred at room temperature for 16 h. After this period, the solvent was removed and 
the residue filtered through silica gel eluting with DCM to give a red/brown oil (72%, 
6.52 g).
Procedure B: to a solution of 219 (30.90 g, 93.51 mmol) in anhydrous MeOH (350 mL) 
was added sodium methoxide (6.06 g, 112.21 mmol) and the reaction mixture was stirred 
at room temperature for 1.5 h. After this period, the solution was neutralised with 
amberlite, filtered and concentrated to give a brown/red oil, which was filtered through 
silica gel eluting with DCM to give a red/brown oil (73%, 19.58 g).
‘H NMR (CDCh, 500 MHz): 5 7.44-7.29 (10H, m, Ph), 4.58 (4H, s, 2xC//2Ph), 3.69 (4H, 
d, J = 5.8, 2xC/72CH), 3.27-3.19 (1H, m, CH), 1.97 (1H, d, J = 8.2, SH).
Synthesis of diacetylguanine. [222]
O C9H9N5O3
Mol Wt.: 235.1995
NHAc
H3C O A suspension of guanine 221 (15.00 g, 99.25 mmol) in
dimethylacetamide (120 mL) and acetic anhydride (25 mL) and the reaction mixture was 
stirred at 160 °C for 7 h. Then the reaction mixture was allowed to cool down and the 
precipitate formed was filtered and washed with ethanol. A second precipitate was
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formed and it was filtered and washed with ethanol to give a pale brown solid (90%,
21.01 g).
'H NMR (DMSO, 500 MHz): 8 11.98 (2H, bs, 2xNH), 8.45 (1H, s, H-8), 2.82 (3H, s, 
CH3), 2.22 (3H, s, CH3).
Synthesis of N2-acetyl-9-{[l,3-bis(benzyloxy)-2-propylthio]methyl}guanine. [223]
O C25H27N504S
NH Mol Wt.: 493.5780
AN NHAc
HC1 gas (generated in situ) was bubbled into a stirred
mixture of 220 (19.50, 67.61 mmol) and
paraformaldehyde (4.06 g, 135.25 mmol) in 1,2-dichloroethane at 0 °C for 2 h. Then, the
reaction mixture was dried over MgSC>4 and then concentrated.
The resulting oil was dissolved in anhydrous DMF (40 mL) and sodium acetate (11.09 g,
135.25 mmol) was added and the reaction mixture was stirred at room temperature for 2 
h. The suspension was filtered and washed with DCM. The filtrate was further diluted 
with DCM and washed with water (3 times), saturated solution of Na2C 03 (3 times) and 
10% aqueous solution of HC1 (3 times), then dried over MgSC>4 and concentrated.
The resulting oil was dissolved in sulfolane (100 mL) and were added 222 (15.90 g, 
67.61 mmol) and bis(4-nitrophenyl) phosphate (0.30 g) and the reaction mixture was 
stirred at 100 °C for 6 h then at room temperature for 17 h. After this period, the resulting 
mixture was diluted with DCM and filtered through celite and the resulting solution was 
filtered through silica gel gradient elution of DCM then DCM/MeOH = 98/2 then 95/5. 
The residue was further purified by column chromatography eluting with DCM/MeOH = 
97/3 to give a mixture of N-7 and N-9 isomer as an oil. This mixture was further purify 
by column chromatography gradient elution of DCM then DCM/MeOH = 98/2 then 96/4 
to obtain a mixture of N-7 and N-9 isomer as an oil. This crude was dissolved in a 
minimum amount of DCM and triturated with Et20  and filtered. The solid was washed 
with Et20  (3 times) to give N-9 isomer as a white solid (7%, 2.20 g).
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'HNMR (DMSO, 500 MHz): 8 12.04 (1H, bs, NH), 11.70 (1H, bs, NH), 8.09 (1H, s, H- 
8), 7.40-7.17 (10H, m, Ph), 5.31 (s, 2H, H -l’), 4.56-4.30 (4H, m, 2xC//2Ph), 3.64-3.46 
(4H, m, H-4\ H-5’), 3.39-3.29 (1H, m, H-3’), 2.17 (3H, s, CH3).
UC NMR (DMSO, 126 MHz): 6 23.75 (CH3), 44.13 (C -l’), 45.36 (C-3’), 69.86 (C-4’, C- 
5’), 72.07 (CH2Ph), 120.21 (C-5), 127.30, 127.40, 128.17 (Ph), 138.10 (ipso-Ph), 139.31 
(C-8), 147.85 (C-2), 148.37 (C-4), 154.77 (C-6), 173.51 (COOCH3).
Synthesis of N -acetyl-9-[(l,3-diacetoxy-2-propylthio)methyl]guanine. [224)
o  C ,5H ,9N 50 6S
aN' Y VNH Mol Wt.: 397.4063
S-J HAc
To a suspension of 223 (1.40 g, 2.84 mmol) in acetic 
anhydride (30 mL) was added drop wise at 0 °C boron 
trifluoride etherate (1.00 mL, 7.94 mmol) and the reaction mixture was stirred at room 
temperature for 2.5 h. After this period, the solvent was removed and the residue 
dissolved in a small amount of DCM and triturated with Et20 and filtered. The solid was 
purified by column chromatography gradient elution of DCM then DCM/MeOH = 97/3 
then 95/5 to give a pink solid (50%, 0.57 g).
'H NMR (DMSO, 500 MHz): 5 12.06 (1H, bs, NH), 11.69 (1H, bs, NH), 8.11 (1H, s, H- 
8), 5.33 (2H, s, H -l’), 4.18-4.06 (4H, m, H-4\ H-5’), 3.46 (1H, p, J = 6.0, H-3’), 2.20 
(3H, s, NHCOOC//3), 1.96 (6H, s, 2xCOOCH}).
,3C NMR (DMSO, 126 MHz): 6 20.39 (COOCH3), 23.78 (NHCOOCH3), 43.19 (C-3’), 
43.79 (C -l’), 63.12 (C-4’, C-5’), 120.25 (C-5), 139.26 (C-8), 147.92 (C-2), 148.36 (C-4), 
154.78 (C-6), 169.99 (COOCH3), 173.51 (NHCOOCH3).
AcO' 
AcO'
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Synthesis of 9-[(l,3-dihydroxy-2-propylthio)methyl)guanine. [205]
o  C9H,3N503S
</N'll NH Mcl W t " 21X2962  
SvJN N NH2
A suspension of 224 (0.52 g, 1.31 mmol) in methanolic 
ammonia (15 mL) was stirred at room temperature for 18 h. 
After this period the solvent was removed under reduced pressure and the residue 
triturated with DCM to give a white solid (90%, 0.32 g).
]H NMR (DMSO, 500 MHz): 8 10.56 (1H, bs, NH), 7.78 (1H, s, H-8), 6.47 (2H, bs, 
NH2), 5.15 (2H, s, H -l’), 4.76 (2H, t, J = 5.4, OH), 3.52 (4H, t, J = 5.5, H-4’, H-5’), 2.89 
(1H, p, J = 5.7, H-3’).
13C NMR (DMSO, 126 MHz): 8 42.87 (C-l’), 49.71 (C-3’), 61.21 (C-4’, C-5’), 116.52 
(C-5), 136.98 (C-8), 150.92 (C-2), 153.62 (C-4), 156.71 (C-6).
El MS = 271.0737 (M+), 272.0813 (M+H).
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9.17 Synthesis of 6-methoxy and 6-chloro penciclovir derivatives
Synthesis of 9-(4-acetoxy-3-acetoxymethyIbut-l-yl)guanine. [225]
o  C ,4H 19N 5 0 5
Mol Wt.: 337.3312
AcO
AcO
A mixture of 11 (2.00, 7.90 mmol) in anhydrous DMF (15 
mL) was added to a mixture of DMAP (0.05 g, 0.40 mmol) 
in acetic anhydride (1.70 mL, 18.16 mmol) and the reaction mixture was stirred at 45 °C 
for 1.5 h. After this period, the mixture was allowed to cool down and 2-propanol (30 
mL) was added and the reaction mixture was stirred at 0 °C for 1.5 h. The suspension was 
filtered and the solid was washed 2-propanol (2 x 5mL). The wet crystals were added to 
ethyl acetate (20 mL), heated at 70 °C and cooled to room temperature. The solid formed 
was filtered and washed with ethyl acetate to give a white solid (83%, 2.20 g).
'H NMR (DMSO, 500 MHz): 6 10.52 (1H, bs, NH), 7.71 (1H, s, H-8), 6.40 (2H, bs, 
NH2), 4.11-3.92 (6H, m, H-L, H-4\ H-5’), 2.00 (6H, s, CH3), 1.97-1.88 (1H, m, H-3’), 
1.85-1.75 (2H, m, H-2’).
Synthesis of 9-(4-acetoxy-3-acetoxymethyIbut-l-yl)-2-amino-6-chloropurine. [226]
Cl C,4H,8C1N504
Mol Wt.: 355.7768
NH2
A mixture of 225 (2.12 g, 6.28 mmol) and
benzyltriethylammonium chloride (2.86 g, 12.57 mmol) in 
acetonitrile (15 mL) was cooled to 0 °C and added to a mixture of A,A-dimethylaniline 
(0.40 mL, 3.14 mmol) and POCI3 (2.60 mL, 28.28 mmol) and the reaction mixture was 
stirred at 70 °C 1 h. After this period, the solvent was removed and the residue dissolved 
in DCM. The organic phase was washed with saturated solution of NaHCQ3 (twice) and
269
Marco Derudas Chapter 9
water (once), dried over MgSC>4 and concentrated. To the residue was added methanol (4 
mL) and water (2 mL) and the mixture was stirred at 0 °C for 1.5 h. The suspension was 
filtered and the solid washed with 75% aqueous methanol to give a white solid (46%, 
1.04 g).
'H NMR (DMSO, 500 MHz:) 6 8.16 (1H, s, H-8), 6.87 (2H, bs, NH2), 4.14 (2H, t, J =
7.1, H -l’), 4.02 (4H, d, J = 5.6, H -4\ H-5’), 1.99 (6H, s, COOCH3), 1.96-1.90 (1H, m, H- 
3’), 1.90-1.83 (2H, m, H-2’).
Synthesis of 9-(4-hydroxy-3-hydroxymethylbut-l-yl)-2-amino-6-methoxypurine. 
[206]
i C11H17N5O3
Mol Wt.: 267.2844
NH2
To a suspension of 226 (0.35 g, 1.04 mmol) in anhydrous 
methanol (10 mL) was added sodium methoxide (0.30 g, 
4.16 mmol) and the reaction mixture was stirred at 40 °C for 6 h. After this period, the 
reaction mixture was neutralized with amberlite, filtered and concentrated. The crude was 
purified by column chromatography eluting with DCM/MeOH = 9/1 to give a white solid 
(71%, 0.20 g).
'H NMR (DMSO, 500 MHz): 5 7.86 (1H, s, H-8), 6.37 (2H, bs, NH2), 4.42 (2H, t, J =
5.1, OH), 4.07 (2H, t, J = 7.4, H -l’), 3.96 (3H, s, OCH3), 3.47-3.40, 3.39-3.34 (4H, 2m, 
H-4’, H-5’), 1.80-1.69 (2H, m, H-2’), 1.51-1.39 (1H, m, H-3’).
I3C NMR (DMSO, 126 MHz): 6 28.56 (C-2’), 40.75 (C-3’), 41.04 (C -l’), 53.05 (OCH3),
61.29 (C-4’, C-5’), 113.78 (C-5), 139.66 (C-8), 154.08 (C-2), 159.68 (C-4), 160.57 (C-6). 
El MS= 268.14 (M+H).
HPLC = H20/AcCN from 95/5-to 0/100 in 30 min = retention time 6.52 min.
= H20/MeOH from 95/5 to 0/100 in 40 min = retention time 12.79 min.
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Synthesis of 9-(4-hydroxy-3-hydroxymethylbut-l-yI)-2-amino-6-chIoropurine. [207]
Cl C ioH h C IN sO z
Mol Wt.: 271.7035
NH2
A solution of 226 (0.18 g, 0.51 mmol) in methanolic 
ammonia (10 mL) was stirred at room temperature for 6 h. 
After this period the solvent was removed and the residue purity by column 
chromatography eluting with DCM/MeOH = 90/10 to give a white solid (85%, 0.12 g).
'H NMR (DMSO, 500 MHz): 8 8.16 (1H, s, H-8), 6.88 (2H, bs, NH2), 4.43 (2H, t, J =
5.2, OH), 4.12 (2H, t, J = 7.4, H -l’), 3.47-3.41, 3.38-3.33 (4H, 2m, H-4’, H-5’), 1.82-1.74 
(2H, m, H-2’), 1.51-1.41 (1H, m, H-3’).
I3CNMR (DMSO, 126 MHz): 8 28.33 (C-2’), 40.77 (C-3’), 41.45 (C -l’), 61.29 (C-4’, C- 
5’), 123.33 (C-5), 143.18 (C-8), 149.23 (C-2), 154.04 (C-4), 159.69 (C-6).
El MS= 271.08 (M+).
HPLC = H2O/ACCN from 95/5 to 0/100 in 30 min = retention time 10.71 min.
= H20/MeOH from 95/5 to 0/100 in 40 min = retention time 12.33 min.
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9.18 Synthesis of 6-methoxy penciclovir ProTides
Synthesis of 9-(4-hydroxy-3-hydroxymethyIbut-l-yl)-2-amino-6-methoxypurine-[l- 
phenyl(benzaxy-L-alaninyl)] diphosphate [227a] and 9-(4-hydroxy-3- 
hydroxymethylbut-l-yl)-2-amino-6-niethoxypurine-[l-phenyl(benzoxy-L-alaninyI)] 
phosphate. [227b]
Prepared according to Standard Procedure C, from 206 (0.13 g, 0.49 mmol) in anhydrous 
THF (10 mL), lBuMgCl (1.0 M THF solution, 0.58 mL, 0.58 mmol), 131d (0.20 g, 0.58 
mmol) in anhydrous THF (5 mL) and the reaction mixture was stirred at room 
temperature overnight. Then were added ‘BuMgCl (1M solution in THF, 0.50 mL, 0.50 
mmol) and 131d (0.20 g, 0.58 mmol) in anhydrous THF (5 mL) and the reaction mixture 
was stirred at room temperature for further 24 h. After this period the solvent was 
removed and the residue was purified by column chromatography gradient elution of 
DCM, then DCM/MeOH = 98/2, 96/4 to give compound 227a as a white solid (2%, 0.01 
g). An impure fraction was further purified by preparative TLC to give 227b as a white 
solid (3%, 0.01 g).
OCH 3 C43H49N7O11P2
Mol Wt.: 901.8370
O C H 3 C 27H 33N 6O 7P
N Mol Wt.: 584.5607
O
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227a
31P-NMR (MeOD, 202 MHz): 6 3.91, 3.86, 3.83, 3.44, 3.41, 3.40, 3.32.
'H NMR (MeOD, 500 MHz): 6 7.84-7.71 (1H, m, H-8), 7.40-7.24 (14H, m, PhO, 
P/7CH2), 7.23-7.08 (6H, m, PhO, P/2CH2), 5.14-5.09 (4H, m, 2xC//2Ph), 4.20-3.97 (8H, 
m, H - l\  H-4\ H-5’, 2xC//CH3), 3.37 (3H, s, OCH3), 2.05-1.67 (3H, m, H-2’, H-3’),
1.39-1.27 (6H, m, 2xCHC//3).
13C NMR (MeOD, 126 MHz): 5 20.34 (d, JC-p = 3.7, CHCH3), 20.40 (d, JC-p = 3.5, 
CHCH3), 28.83, 28.86 (2s, C-2’), 38.48 (d, JC-p = 6.2, C-3’), 38.57 (d, JC-p = 7.8, H-3’), 
41.91, 41.97 (C -l’), 49.87 (OCH3), 51.65, 51.68 (CHCH3), 66.92, 66.98, 67.02, 67.11 
(4s, C-4’, C-5’), 67.90, 67.96 (CH2Ph), 115.25 (C-5), 121.45, 121.50, 121.51, 121.55, 
121.58, 121.59, 121.64, 126.13, 126.17, 129.16, 129.27, 129.32, 129.33, 129.35, 129.58,
129.60, 130.79, 131.11 (PhO, CH2Ph), 137.25 (‘ipso’ OCH2P/0, 140.96 (C-8), 152.15, 
152.21, 155.05 (C-2, C-4), 161.82 (C-6), 174.73, 174.99 (2s, COOCH2Ph).
HPLC = H20/AcCN from 95/5 to 0/100 in 30 min = retention time 23.49 min.
227b
3,P-NMR (MeOD, 202 MHz): 6 4.06, 4.00, 3.59.
'H NMR (MeOD, 500 MHz): 5 7.85-7.79 (1H, m, H-8), 7.38-7.27 (7H, m, PhO, P/zCH2),
7.23-7.13 (3H, m, PhO, P/?CH2), 5.15-5.12 (2H, m, C//2Ph), 4.24-3.99 (5H, m, H -l’, H- 
5’, C//CH3), 3.60-3.48 (2H, m, H-4’), 3.37 (3H, s, OCH3), 1.92-1.73 (3H, m, H-2’, H-3’),
1.40-1.33 (3H, m, CHC//3).
13C NMR (MeOD, 126 MHz): 5 20.36 (d, JC-p = 4.4, CHCH3), 20.43 (d, JC-p = 2.8, 
CHCH3), 29.34, 29.36 (2s, C-2’), 40.32 (d, JC-p = 3.0, C-3’), 40.42 (d, JC-p = 7.4, C-3’), 
42.37, 42.39 (C -l’), 48.96 (OCH3), 51.65, 51.68 (CHCH3), 62.27, 62.32 (C-4’), 67.80, 
67.84, 67.86, 67.91 (C-5’, CH2Ph), 115.27 (C-5), 121.48, 121.51, 121.54, 121.57, 121.61, 
126.09, 126.12, 129.28, 129.31, 129.34, 129.57, 130.74 (PhO, CH2Ph), 137.25 (‘ipso’ 
OCH2P/*), 141.04 (C-8), 152.22, 152.25, 152.28, 152.31 (C-2, C-4), 161.82, 162.72 (C- 
6), 174.72 (d, J c-p = 5.0, COOCH2Ph), 175.00 (d, J C-p = 4.6, COOCH2Ph).
HPLC = H20/AcCN from 95/5 to 0/100 in 30 min = retention time 16.41 min.
= H20/MeOH 40/60 isocratic = retention time 9.60 min, 10.44 min.
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Synthesis of 9-(4-hydroxy-3-hydroxymethylbut-l-yI)-2-amino-6-methoxypurine-[l- 
naphthyl(benzoxy-L-alaninyl)] phosphate. [227c]
mL, 0.58 mmol), 193a (0.23 g, 0.58 mmol) in anhydrous THF (5 mL) and the reaction 
mixture was stirred at room temperature overnight. Then were added ‘BuMgCl (1M 
solution in THF, 0.50 mL, 0.50 mmol) and 193a (0.23 g, 0.58 mmol) in anhydrous THF 
(5 mL) and the reaction mixture was stirred at room temperature for further 24 h. After 
this period the solvent was removed and the residue was purified by column 
chromatography gradient elution of DCM, then DCM/MeOH = 98/2, 96/4 to give a white 
solid which was further purified by preparative TLC to give DM1739 as a white solid 
(3%, 0.01 g).
3IP-NMR (MeOD, 202 MHz): 5 4.15, 4.44,4.50.
'H-NMR (MeOD, 500 MHz): 8 8.19-8.12 (1H, m, H-8 Naph), 7.90-7.81 (1H, m, H-6 
Naph), 7.81-7.62 (2H, m, H-8, Naph), 7.56-7.23 (9H, m, PhO, P/tCH2), 5.16-5.03 (2H, m, 
Ctf2Ph), 4.29-3.98 (5H, m, H -l’, H-5’, CHCH}), 3.53-3.42 (2H, m, H-4’), 3.37 (3H, s, 
OCH3), 1.81-1.58 (3H, m, H-2’, H-3’), 1.47-1.34 (3H, ra, CHCHj).
13C NMR (126 MHz, MeOD) 6 20.37 (d, JC-r = 3.0, CHCH3), 20.45 (d, JC-r = 3.8, 
CHCH3), 29.29, 29.35 (2s, C-2’), 40.38 (d, iC P = 4.2, C-3’), 40.44 (d, JC-p = 5.8, C-3’), 
42.28, 42.32, 42.36 (C -l’), 49.86 (OCH3), 51.82, 51.87 (CHCH3), 62.24, 62.31 (C-4’), 
67.90, 67.97, 68.03, 68.08 (C-5’, CH2Ph), 115.23 116.49, 116.29, 116.35, 122.69, 
122.80, 125.92, 126.51, 127.20, 127.42, 127.45, 127.73, 128.85, 129.26, 129.30, 129.32,
129.53, 129.56, 130.79 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-l 
Naph, C-8 Naph, C-8a Naph; OCH2/>/i), 136.26, 137.20 (C-4a Naph, ‘ipso’ OCH2P/i),
OCH3 C3,H35N607P
N Mol Wt.: 634.6194
O
Prepared according to Standard Procedure C, 
from 206 (0.13 g, 0.49 mmol) in anhydrous THF 
(10 mL), 'BuMgCl (1.0 M THF solution, 0.58
274
Marco Derudas Chapter 9
140.89 (C-8), 148.11 (‘ipso’ Naph, C-4),) 152.92 (C-2, C-4), 161.78, 162.73 (C-6), 
174.76, 174.80 (COOCH2Ph).
HPLC = H20/AcCN from 95/5 to 0/100 in 30 min = retention time 18.43 min.
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Herpes simplex virus infection is often well managed by the use 
f acyclovir, (ACV, 1), its prodrug valacyclovir, or related com- 
wnds. The widespread use of (1 ) has led to the emergence of 
SV strains that are resistant to this drug.
Resistance appears uncommon in immunocompetent patients; 
lorfin1 reports a prevalence below 1%. A more recent study in 
le Netherlands reports a prevalence of 0.27% in this population.2 
owever, resistance is significantly more common in immunocom- 
omised patients. Stranska et al.2 report 7% and Morfin cites 5%. 
otably, the proportion of resistant isolates rises to 30% in patients 
ceiving allogeneic bone marrow transplants. Three separate 
echanisms of resistance to (1) have been considered to occur; a 
ss of viral thymidine kinase (TK) activity, an altered TK substrate 
lecificity and an alteration of viral DNA polymerase.3 Given the 
m-essential nature of the viral TK and the importance of the viral 
ilymerase, it is unsurprising that the great majority of resistant 
)lates correspond to deletion/inactivation of the TK gene.4 One 
iproach to manage TK-related resistance is to use agents not 
quiring HSV TK for activation, such as cidofovir or foscarnet. 
iwever, they may carry a risk of increased toxicity. Another ap- 
oach would be to bypass the dependence of (1) on HSV TK by 
ing a suitable phosphate prodrug, or ProTide. Several such meth- 
Is now exist, such as the cyclosal approach,5 ester-based methods 
SATE6 and phosphoramidate diesters.7 Our group has developed 
i aryloxy phosphoramidate triester approach,8 which has been
Corresponding author. Tel./fax: +44 2920 874537. 
E-mail address: mcguigan@cardiff.ac.uk (C. McGuigan).
recently successfully applied to abacavir for HIV9 and ^-substi­
tuted nucleosides for Hepatitis C Virus (HCV).10
W e have previously reported the application of this method to 
ACV (1 ) and the results indicated that the approach failed.11 Thus, 
the ProTide (2) derived from (1) was found to be poorly active ver­
sus HSV2 (EC50 ^  100 pM ) unlike (1) itself. Compound (2) was 
roughly equi-active as (1 ) versus VZV and slightly more active ver­
sus human cytomegalovirus (HCMV) but there was no clear thera­
peutic advantage. However we have recently reported a new 
generation of phosphoramidate protides in which the aryl moiety 
is a bicyclic system such as 1-naphthyl.12
W e were keen to explore the application of the naphthyl 
ProTide methodology to (1) for tw o reasons. Firstly the observation 
that naphthyl for phenyl can give a potency boost and secondly 
that these compounds may have a significant lipophilicity enhance­
ment over prior structures. This may be particularly important in 
the case of (1) where the inherent lipophilicity is rather low, and 
first generation protides may be insufficiently lipophilic for effi­
cient passive diffusion into cells. Indeed, ClogP13 estimates on (2) 
indicate a figure of ca. -0 .8 ; although significantly more lipophilic 
than (1) this is somewhat lower than what may be viewed as opti­
mal. Thus, in addition to examining naphthyl phosphates we also 
sought more lipophilic esters than the methyl ester (2) previously 
reported.
Compounds were prepared from (1) as shown in Scheme 1.
In order to improve the solubility of ACV we protected the 
guanine base using N,N-dimethylformamide dimethyl acetal, to 
give (7). The coupling w ith  the appropriate phosphorochloridate
50-894X/J - see front m atter Crown Copyright © 2008 Published by Elsevier Ltd. All rights reserved. 
:10.1016/j.bmd.2008.06.069
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Scheme 1.
was performed using tert-butyl magnesium chloride as a hydroxyl 
activator, to give blocked compounds of type (8 ).14 The DMF- 
protecting group was then removed by refluxing in 2-propanol 
(40-72 h). Owing to the chirality of the phosphorus, all of these 
compounds have been isolated and tested as a mixture of two dia- 
stereoisomers. Their structures have been demonstrated by NMR 
(3,P, *H and 13C), mass spectroscopy and elemental analysis.15
The target compounds were first evaluated by plaque assay for 
their ability to inhibit the replication of ACV-sensitive and 
ACV-resistant HSV2 in Vero cells (Table I ) . 16
As can be seen from Table 1, while the previously reported phe­
nyl methylalanine phosphate (2 ) is poorly active, being ca 7-fold 
less active than (1), in marked contrast to (1) it does retain full po­
tency versus the resistant strain. This implies that (2) does function 
as a monophosphate prodrug as intended, but w ith  low efficiency, 
particularly in the nucleoside-sensitive assay. By comparison, the 
naphthyl phosphate (3) is roughly equi-active w ith (1) versus 
TK-competent virus and notably retains full potency versus 
ACV-resistant HSV-2. The simplest explanation of this is that the 
ACV-resistant HSV-2 mutant is TK deficient and that (3) is TK-inde- 
pendent, strongly implying a successful thymidine kinase bypass. 
Notably, ClogP calculations on (3) indicate a significant enhance­
ment over (1) to a figure of ca. 2 which may be regarded as near 
optimal. Indeed the ‘mixed’ compounds (4) and (5) have lower 
ClogP values and are less active in the HSV-2 TK+ assay, but retain 
good activity in the HSV-2 TK-  assay. In a further assay in HEL cells 
we evaluated the samples against both TIC and TK-  HSV-1 and 
HSV-2 with data shown in Table 2.
Similar data emerge here, w ith (3) being particularly active and 
retaining significant activity in the TK“assay. In this case com­
pound (4) shows a similar profile, while (5) is less active. This im ­
plies that the ester moiety (benzyl in (3) and (4), versus methyl in 
(2) and (5)) is more important than the aryl moiety. Notably, the 
amino acid-modified compound (6 ) which has Phe in place of 
Ala, is poorly active in this assay, particularly versus the resistant 
virus. This is despite what might be regarded as a near-optimal 
lipophilicity for (6 ) (Table 1) and points to the importance of the 
amino acid moiety for activity.
One concern w ith  bypassing the HSV-TK might be of enhanced 
cytotoxicity and loss of antiviral selectivity. However, the MCC 
data on this series (Table 2) do not reveal a significant toxicity. If, 
as appears likely, the viral TK is being bypassed, there must still 
be some element of viral specificity at another stage, most likely 
at the polymerase level.
In another assay we examined this family of prodrugs against 
kinase-competent and kinase deficient VZV (in HEL cells) w ith  data 
shown in Table 3. As noted in this table, unlike ACV (1) several of 
the agents retain good potency in the TK-  VZV assays, notably 
compound (4) which essentially retains full potency. Interestingly 
(4) is also non-toxic while (3) does have some toxicity here.
Thus, compound (4) emerges as particularly active in a range of 
assays. It retains full activity versus all resistant viral strains, HSV- 
1, -2 and VZV, being low or sub-pM in most cases, and non-toxic.
In conclusion, we report the successful application of the Pro­
Tide approach to acyclovir. The naphthyl and phenyl benzyl ala­
nine ProTides are fully active in vitro against ACV—resistant
Table 1
Anti-HSV-2 activity of ProTides
Compound At R Amino acid ClogP
HSV2-HG32 (ECACC 158)
ECsoa (pM)
HSV2-ACVR (ECACC 513)
1 _ _ _ -2 .42 6±1.3 >100
2 Ph Me Ala -0.82 43.1 ±10.6 18.7+7.2
3 1-Nap Bn Ala 2.06 9.8±2.2 14.5±6.6
4 Ph Bn Ala 0.89 20.3±6.6 15.5±7.4
5 1-Nap Me Ala 0.35 40.4±13.4 15+6.2
6 Ph Bn Phe 2.31 20.3±6.6 33.2±3.9
1 Values are means of three experiments, with standard deviations given, in Vero cells.
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fable 2
Anti-HSV-1 and -2 activity of ProTides
Compound Ar R Amino acid
HSV-1 (Kos)
ECsoa/pM 
HSV-2 (G) HSV-1 TK-Kos ACVR
MCC b (pM)
I — — — 0.4 0.2 50 >250
1 Ph Me Ala 20 15 80 >100
i 1-Nap Bn Ala 2 1.4 11 >100
I Ph Bn Ala 0.9 1.4 8 >100
i 1-Nap Me Ala 16 10.4 80 >100
i Ph Bn Phe 17 8 >100 >100
EC5o. 50% effective concentration that inhibits virus-induced cytopathicity by 50%, in HEL cells.
’ MCC, minimal cytotoxic concentration that causes a microscopically visible alteration of cell morphology.
fable 3
Anti-VZV activity of ProTides
Compound EC50a (pM) MCCb (pM) CC50C (pM)
OKA TK* YS TK+ 07/1TK- YS/RTK-
2.5 2.9 61 43 >500 1350
1 19 20 24 16 >100 162
l 7.2 3.3 6.9 ND >50 20
1 0.72 1.0 1.8 0.59 >50 >100
i 7.6 10.9 22 6.1 >50 >100
i 5.2 6.6 8.4 10.0 >50 86.9
‘ EC50, 50% effective concentration that inhibits virus-induced cytopathicity by 50%, in HEL cells. 
b MCC, minimal cytotoxic concentration tha t causes a microscopically visible alteration of cell morphology. 
c CC5o, 50% cytostatic concentration that inhibits cell proliferation by 50%.
yiruses and appear to represent successful thymidine kinase by- 
oass. Notably the ProTides do not in general suffer from significant 
cytotoxicity.
The phenyl benzyl alanine compound (4 )  appears a particularly 
yromising lead for further development.
These data strongly support the notion that ProTide derivatives 
ire successful in the intracellular delivery of the monophosphate of 
\CV and bypass the dependence of the nucleoside analogue on 
viral) thymidine kinase. Interestingly, the naphthyl phosphate is 
iot a pre-requisite for activity, and some phenyl phosphates dis­
play good potency, particularly in kinase-deficient cells. Modifica- 
ion of the ester moiety or the aryl, or both, seems to be beneficial 
0 tune the ProTide for optimal activity. Although the overall lipo- 
ihilicity may be an important feature for activity, it is not the only 
leterminant.
We are exploring further the lim its of the technology on acyclic 
mdeoside analogues and the opportunities that by-passing the 
riral kinase may bring.
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SUMMARY
For most viruses, there is a need for antimicrobials 
that target unique viral molecular properties. Acyclo­
vir (ACV) is one such drug. It is activated into a human 
herpesvirus (HHV) DNA polymerase inhibitor exclu­
sively by HHV kinases and, thus, does not suppress 
other viruses. Here, we show that ACV suppresses 
HIV-1 in HHV-coinfected human tissues, but not in 
HHV-free tissue or cell cultures. However, addition 
of HHV-6-infected cells renders these cultures sensi­
tive to anti-HIV ACV activity. We hypothesized that 
such HIV suppression requires ACV phosphorylation 
by HHV kinases. Indeed, an ACV monophosphory- 
lated prodrug bypasses the HHV requirement for 
HIV suppression. Furthermore, phosphorylated ACV 
directly inhibits HIV-1 reverse transcriptase (RT), ter­
minating DNA chain elongation, and can trap RT at 
the termination site. These data suggest that ACV 
anti-HIV-1 activity may contribute to the response 
of HIV/HHV-coinfected patients to ACV treatment 
and could guide strategies for the development of 
new HIV-1 RT inhibitors.
INTRODUCTION
HIV-1 in fection  is u su a lly  a c c o m p a n ie d  b y  in fectio n  w ith  o th er  
m icro b es , HIV-1 c o p a t h o g e n s ,  w h ic h  e ith er  p r e -e x is t  in th e  hu ­
m an b o d y  or in v a d e  it d e  n o v o . T h e  rep lica tio n  o f  HIV-1 c o p a th ­
o g e n s  is freq u en tly  p r o m o te d  in H IV -1 -in fected  h o s t s ,  a n d  their  
su p p r e s s io n  is o fte n  b e n e fic ia l for th e  clin ica l c o u r s e  o f  HIV d is ­
e a s e  (C orey, 2 0 0 7 ;  J a c o b s o n  a n d  M ills, 1 9 8 8 ). H um an h e r p e sv i­
rus (HHV) in fe c tio n s  a re  c o m m o n ly  a s s o c ia t e d  w ith HIV-1. In par­
ticular, h e r p e s  s im p le x  v iru s 2  (H SV -2) in fectio n  is a s s o c ia t e d
with an  in c r e a s e  in HIV-1 tr a n sm iss io n  (C o h en , 2 0 0 4 ;  F reem a n  
e t  a l., 2 0 0 6 )  a n d  w o r s e n s  th e  clin ical c o u r s e  o f  HIV d is e a s e .  
H SV -2 rea ctiv a tio n  m a y  le a d  to  in c r e a se d  p la sm a  HIV-1 le v e ls ,  
th e r e b y  a d v e r s e ly  a f fe c tin g  survival r a te s  (C orey e t  al., 2 0 0 4 ;  
S c h a c k e r  e t  a l., 2 0 0 2 ) .
A cyclov ir  (ACV) is a  g u a n o s in e  n u c le o s id e  a n a lo g  particularly  
a c t iv e  a g a in s t  H S V -2  a s  w ell a s  a g a in st  th e  o th e r  a -H H V s  
(HSV-1 a n d  VZV) (Elion, 1 9 8 3 ). It a lso  inh ibits, a lth o u g h  w ith  
lo w er  p o te n c y , th e  rep lica tio n  o f  th e  p-H H V s (CMV, H H V -6, 
an d  HHV-7) a n d  o f  th e  y -H H V s (EBV a n d  HHV-8) (D e C lercq  
e t  a l., 2 0 0 1 ) .
T h e  m e c h a n ism  o f  HHV s u p p r e s s io n  b y  ACV is w ell u n d er­
s t o o d . ACV is p h o sp h o r y la te d  in H H V -in fected  c e l ls  by viral- 
e n c o d e d  k in a se s . T h e  resu ltin g  m o n o p h o s p h a te  d eriv a tiv e  
(ACV-M P) is th e n  c o n v e r te d  into ACV tr ip h o sp h a te  (ACV-TP) 
by  cellu lar  e n z y m e s  a n d  is s u b s e q u e n tly  in co rp orated  b y  th e  
viral D N A  p o ly m e r a se  in to  th e  n a sc e n t  viral DNA ch a in , c a u s ­
ing its o b lig a te  term in ation  (R eard on  a n d  S p e c to r , 1 9 8 9 ). G e n ­
erally, th e  se n s itiv ity  o f  d ifferen t HHVs to  ACV is d e te r m in e d  
b y  th e  e x te n t  o f  its p h o sp h o ry la tio n  b y  HHV k in a se  a n d  b y  
th e  ra te  o f in corp o ra tio n  o f  A C V -TP into th e  viral DNA ch a in  
(D e C lercq  e t  a l., 2 0 0 1 ) . T h e  m e c h a n ism  d e sc r ib e d  a b o v e  e x ­
p la in s w h y  ACV d o e s  n o t d irectly  a ffe c t  v ir u se s  o th er  th a n  
H H V s, in clu d in g  HIV-1. N e v e r th e le s s , early  clin ical trials ind i­
c a te d  th a t AC V  tr e a tm e n t m a y  resu lt in survival b e n e f its  in c o ­
horts o f  HI V -1 -in fe c te d  p a tie n ts  w ith a  h igh  in c id e n c e  o f  c lin ­
ically  id en tifiab le  HHV (lo a n n id is  e t  a l., 19 9 8 ). In a g r e e m e n t  
w ith t h e s e  d a ta , r e c e n t  trials sh o w e d  that, in H S V -2 -c o in -  
f e c t e d  in d iv id u als , th e  s u p p r e s s io n  o f  H SV -2 by ACV is  a c ­
c o m p a n ie d  b y  r ed u ctio n  o f  th e  p la sm a tic , gen ita l, a n d  rec ta l  
HIV-1 lo a d  (B a e te n  e t  a l., 2 0 0 7 ;  D elan y  e t  a l., 2 0 0 7 ;  D u n n e  
e t  a l., 2 0 0 8 ;  N a g o t  e t  a l., 2 0 0 7 ;  Z u ck erm a n  e t  a l., 2 0 0 7 ) .  
T h is d e c r e a s e  w a s  attrib u ted  to  th e  su p p r e s s io n  o f  H S V -2 -  
m e d ia te d  in flam m ation  ind irectly  red u cin g  HIV-1 load .
H ere, w e  rep ort o n  th e  d irect activ ity  o f  ACV o n  HIV-1 a n d , 
sp e c ific a lly , o n  th e  inhibition o f  HIV-1 r e v e r se  tr a n sc r ip ta se
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(RT) by ACV-TP. W e  d e m o n s tr a te  th a t, c o n se q u e n t ly , ACV is  an  
anti-HIV-1 a g e n t  in h u m an  ly m p h o id , recta l, a n d  g en ita l t i s s u e s ,  
w hich are w id ely  in fe c te d  w ith  o n e  or m o re  H H Vs tha t a re  a b le  to  
p h osp h ory la te  ACV.
RESULTS
ACV Suppresses HIV Replication in Human Lymphoid 
Tissue Coinfected Ex Vivo with HSV-2
In th is s tu d y , w e  u s e d  an  e x  v iv o  s y s t e m  th a t p r e s e r v e s  th e  c y -  
toarch itectu re o f  h u m an  t i s s u e s  a n d  su p p o r ts  rep lica tio n  o f  var­
ious v iru se s  w ithou t e x o g e n o u s  st im u la tio n  (G lu sh a k o v a  e t  a l., 
1995).
Initially, w e  in o c u la te d  t i s s u e s  w ith  HIV-1 lau*  a n d  H SV -2  
(strain G). B oth  v ir u se s  read ily  r e p lic a te d  in t i s s u e s .  A s  e x p e c t e d ,  
ACV at a  co n cen tra tio n  o f  3 0  pM  s u p p r e s s e d  H S V -2  rep lica tio n  in 
both H SV -2 sin g ly  in fe c te d  a n d  HIV-1 c o in fe c te d  t i s s u e s  (by  9 7  ±  
1.8%  an d  9 3  ±  5 .8 % , r e s p e c t iv e ly , p  =  3  x  1 0 - 5 , p  =  5  x  1 0 ~ 4, 
n =  4). H ow ever, in t h e s e  H S V -2 -c o in o c u la te d  t i s s u e s ,  ACV  
a lso  s u p p r e s s e d  HIV-1 rep lica tio n  b y  6 2  ±  4 .2 %  (p =  2  x  1 0 - 3 , 
n = 4) (Figure 1A).
ACV Suppresses HIV Replication in Singly Infected 
Human Lymphoid Tissue Ex Vivo
Surprisingly, ACV w a s  a ls o  fo u n d  to  s u p p r e s s  HIV-1 rep lica tion  
in tonsillar t i s s u e s  from  3 8  d o n o r s  th a t w e r e  n o t c o in o c u la te d  
with H SV -2 (F igures 1 B -1 D ).
In HIV-1 sin g ly  in fe c te d  t i s s u e s ,  th e  s u p p r e s s io n  o f  HIV-1 r ep ­
lication, m e a su r e d  a s  p 2 4 gag a c c u m u la tio n  in cu ltu re  m ed iu m ,  
w a s d o s e  d e p e n d e n t  w ith  a  5 0 %  e f fe c t iv e  c o n c e n tr a t io n  (EC50) 
of 3.1 (95%  c o n f id e n c e  interval: 1 .8 5 - 5 .2 4 )  (F igure 1B).
HIV-1 rep lication , e v a lu a te d  b y  th e  m e a s u r e m e n t  o f  HIV-1 p rovi-  
ral DNA in t is s u e  b lo c k s  a t d a y  1 2  p o s t in fe c t io n , w a s  r e d u c e d  by  
94 .8%  (interquartile r a n g e  [IQR] 6 5 .9 % -9 9 .8 % )  in b lo c k s  o f  to n ­
sillar t i s s u e s  trea ted  w ith  A C V  at th e  c o n c e n tr a t io n  o f  3 0  *iM 
co m p a red  w ith d o n o r -m a tc h e d  u n tr e a te d  b lo c k s . T h e  m e d ia n  v i­
ral load  w a s  r e d u c e d  b y  ~ 1 . 3  lo g 10, from  3 1 0 8  g a g  DN A  c o p ie s  
per 1 0 4 c e lls  in u n tre a ted  t i s s u e s  (3 .4 9  lo g 10; IQR 2 .9 9 - 4 .0 1 )  to  
162 g a g  DNA c o p ie s  p er  1 0 4 c e l l s  in A C V -trea ted  t i s s u e s  (2 .2 7  
lo g 10; IQR 0 .0 9 - 3 .0 7 ,  p  < 1 0 - 4 , n =  2 7 )  (F igure 1C ). C o n s is te n tly , 
ACV sign ifican tly  d e c r e a s e d  th e  a m o u n t  o f  p 2 4 gag r e le a s e d  into  
the  culture m ed iu m  o n  a v e r a g e  b y  8 0  ±  4 %  (p <  7  x  1 0 - 7 , n =  38)  
in hum an tonsillar t i s s u e s  (F igu re 1 D). T h e  a v e r a g e  cu m u la tiv e  
production  o f  p 2 4 gag in th e  cu ltu r e  m e d iu m  o f  tonsillar  t i s s u e s  
w a s 4 6 .4  ±  8  n g /m l a n d  1 6 .6  ±  4 .6  n g /m l, r e s p e c t iv e ly , in t i s s u e s  
untreated  an d  tr e a te d  w ith  3 0  pM  ACV.
T o avo id  th e  p o s s ib le  c o n fo u n d in g  e f f e c t s  o f  co n ta m in a tin g  
p ro d u cts in c o m m e r c ia l A C V , w e  u s e d  A C V  from  th r e e  s o u r c e s  
and foun d  th a t all o f  th e m  sim ilarly  s u p p r e s s e d  HIV (p >  0 .4 5 ,  
n = 4). S u p p r e ss io n  o f  HIV-1 rep lica tio n  b y  AC V  w a s  n o t a s s o c i ­
a ted  with T c e ll d e p le t io n , a s  e v id e n c e d  from  th e  sim ilar n u m b ers  
of total T c e l ls  (C D 4+C D 3 + a n d  C D 8 +C D 3 +, p  >  0 .5 , n =  3) an d  
their s u b s e t s  o f  a c t iv a te d  (C D 2 5 +, H LA -D R +, or C D 38), n a iv e  
(CD45RA+C D 62L +), or n o n n a iv e  (C D 45R A " C D 6 2 L +/- )  (p >  
0 .1 6 , n =  3) c e lls . M o reo v e r , A C V  antiviral activ ity  w a s  res tr ic ted  
to  H SV -2 an d  HIV-1 s in c e ,  a s  e x p e c t e d ,  ACV d id  n o t r e d u c e  v a c ­
cinia virus rep lica tion  in to n s illa r  t i s s u e  e x  v iv o  (d a ta  n o t sh o w n ).
ACV Suppresses Replication of CCR5- and CXCR4- 
Tropic HIV-1 Variants in Various Human Tissues
T o  t e s t  w h e th e r  AC V  s u p p r e s s e d  HIV-1 rep lica tion  in t i s s u e s  
o th e r  th a n  to n s ils , w e  u s e d  e x p la n ts  o f  t i s s u e s  that a ls o  p lay  
an  im p ortan t ro le  in HIV tr a n sm iss io n  an d  p a th o g e n e s is  in vivo: 
lym ph  n o d e s  a n d  c e r v ic o v a g in a l a n d  c o lo r e c ta l t i s s u e s .  ACV  
s u p p r e s s e d  HIV-1 rep lica tio n , m e a su r e d  b y  p 2 4 gag a c c u m u la ­
tion  in cu ltu re  m e d iu m , in lym ph  n o d e s  by 7 0  ±  1 3 .9 %  (p =  2  x  
1 0 ~ 3, n =  7), in c o lo r e c ta l  t i s s u e s  b y  7 2 .6  ±  9%  (p =  2  x  1 0 ~ 2 , 
n =  3), a n d  in c e r v ic a l t i s s u e s  b y  6 0 .1  ±  3 .5 %  (p =  7  x  1 0 ~ 3, 
n =  3). AC V  tr e a tm e n t o f  e x  v iv o  h u m an  lym ph  n o d e s  r e d u c e d  
th e  a v e r a g e  c u m u la t iv e  p ro d u ctio n  o f  p 2 4 gag in cu lture m ed iu m  
from  6 7 .3  ±  2 8 .1  n g /m l to  1 5 .4  ±  6 .6  n g /m l, in e x  v ivo  hu m an  c o ­
lorecta l t i s s u e s  from  7 .2  ±  6 .8  n g /m l to  1 .3  ±  1 .2  n g /m l (n = 3), an d  
in e x  v ivo  h u m an  cerv ico v a g in a l t i s s u e s  from  3 .8  ±  1 .7  ng /m l to  
1 .4  ±  0 .5  n g /m l (n =  3) (F igure 2A).
F urtherm ore, w e  e v a lu a te d  th e  e ff ic ie n c y  o f  ACV in s u p p r e s s ­
ing d ifferen t HIV-1 v a r ia n ts. W e  in o c u la te d  e x  v ivo  lym ph oid  t is ­
s u e s  w ith  C C R 5 - a n d  C X C R 4-trop ic  HIV-1 varian ts X 4 lai.o4, 
R 5Sf i62> R 5 BaL. a n d  R 5Ad8- A s  s h o w n  in F igure 2 B , ACV s u p ­
p r e s s e d  rep lica tio n  o f  all o f  t h e s e  is o la te s  in tonsillar t i s s u e s  
w ith sim ilar e f f ic ie n c y  (by  8 8 % , 9 5 % , 8 9 % , an d  9 4 % , 
r e sp e c t iv e ly , a s  a s s e s s e d  from  p 2 4 gag prod u ction ).
Coinfection with Different Endogenous Human 
Herpesviruses is Associated with the Anti-HIV Effect 
of ACV
T o  t e s t  w h e th e r  s u p p r e s s io n  o f  HIV b y  ACV is re la ted  to  th e  anti- 
h erp etic  activ ity  o f  th is  d ru g , w e  m e a su r e d  th e  p r e s e n c e  o f  var­
io u s  H H Vs in th e  ton silla r  t i s s u e s  u s e d  in th e  p r e se n t  w ork  
(Figure 2C ). R e a l-tim e  P C R  a n a ly s is  r e v e a le d  th at all 2 7  tonsillar  
t i s s u e s  th a t w e r e  t e s t e d  for th e  p r e s e n c e  o f  HHVs w e r e  n e g a tiv e  
for H S V -1 , H S V -2 , H H V -3 (VZV), a n d  H H V-8 but w e r e  in fe c ted  
w ith H H V-4 (EBV), -5  (CMV), -6 , a n d  -7  in v a r io u s co m b in a tio n s  
(F igure 2C ). CM V  w a s  p r e s e n t  in 15%  o f t is su e s ;  EBV, in 52% ;  
H H V -7, in 89% ; a n d  H H V -6, in all bu t o n e  t is s u e  (96% ).
Sim ilar to  w h a t w a s  o b s e r v e d  in im m u n o c o m p r o m ise d  p a ­
t ie n ts  (L u sso  a n d  G allo , 1 9 9 4 ), HHV load  w a s  in c r e a se d  in t is ­
s u e s  e x  v iv o . T h er e  w a s  a  5 -fo ld  in c r e a s e  in th e  m ed ia n  HHV- 
6  lo a d  a t d a y  1 2  in cu ltu re , from  2 2 .4  DN A  c o p ie s  p er 1 0 4 
c e l ls  a t th e  t im e  o f  su r g e r y  (IQR 1 .8 -5 7 .7 )  to  1 1 6 .6  DNA c o p ­
ie s  p er  1 0 4 c e l ls  (IQR 3 3 .7 - 8 0 8 ,  p  =  3  x  1 0 ~ 4, n =  26). After 
ACV trea tm en t, th e  m e d ia n  H H V -6 load  at d a y  12  w a s  re­
d u c e d  to  5 5 .1  D N A  c o p ie s  p er  1 0 4 c e l ls  (IQR 2 1 .3 - 3 3 4 .6 ,  
p =  1 0 - 2 , n =  2 6 ), d e m o n str a tin g  th at ACV sign ifican tly  s u p ­
p r e s s e d  H H V -6 rep lica tio n . T h e  se n s itiv ity  o f  H H V-6 to  ACV  
w a s  further e v a lu a te d  in s e p a r a te  e x p e r im e n ts  in w h ich  
e x  v ivo  tonsillar  t i s s u e s  w e r e  in o c u la te d  w ith  H H V -6B (PL-1 
strain). In t h e s e  e x p e r im e n ts , ACV s u p p r e s s e d  H H V -6B repli­
c a t io n  in a  d o s e - d e p e n d e n t  m a n n er  w ith an  EC50 o f  ~ 2 7  |iM . 
W e fo u n d  th a t AC V  r e d u c e d  th e  to ta l p ro d u ctio n  o f  H H V-6B  
in cu ltu re  m ed iu m  o n  a v e r a g e  b y  5 6 .2  ±  1 1 .4 %  (5 2 .2  ±  1 2 .4  
x  1 0 8 D N A  c o p ie s  p er  ml v e r s u s  2 2 .5  ±  9 .4  x  1 0 8 DNA c o p ­
ie s  p er  ml in co n tro l a n d  A C V -trea ted  t i s s u e s ,  r e sp ec tiv e ly ;  
p =  3  x  1 0 " 3, n =  3).
H H V -7, H H V -4, a n d  H H V -5 m ed ia n  lo a d s  in tonsillar t i s s u e s  
w e r e , r e sp e c t iv e ly , 9 .2 3  (IQR 0 .5 1 - 5 6 .8 1 ) ,  4 .7 1  (IQR 0 .0 6 -  
4 4 8 .3 ) , a n d  0 .1  (IQR 0 .0 6 - 0 .1 )  D N A  c o p ie s  p er  1 0 4 c e lls  at 
th e  t im e  o f  su rg e ry  a n d  2 1 .8 7  (IQR 0 .9 - 2 1 9 .7 ,  n =  24 ), 3 1 .1 6
Cell Host & Microbe 4 , 260-270, Septem ber 11, 2008 ©2008 Elsevier Inc. 261
Cell Host & Microbe
Acyclovir Inhibits HIV-1 Reverse Transcriptase
2 5  l O  HIV-1
HIV-1 +  H S V -2  
► HIV-1 + H S V -2  + A C V
:=  ?  1 5
E C 50: 3 .1 1pM
1 10 100 
[ACV] pM
105<
g ?  10*LJ <t>
2 £  103r-
> 1/5
o . |  102
Q . O  
T  »  101
>  &  .  
T  ^  1 0 °
10
• • •
untreated ACV
co _  ■z: -j 
16 E0 B) 
—  cQl X ® ?
> “1
2 5
20
% 1 5
10
^  u n tr e a te d  
- * •  A C V
6  9  1 2
d a y s
Figure 1. ACV S uppresses HIV Infection in Human Tonsillar Tissues
(A) Blocks of hum an tonsillar tis su e  w ere  co inocu lated  ex vivo with HSV-2 strain G and  X4 lai.o4  and  tre a ted  or not with ACV (30 nM). HIV-1 replication w as m on­
itored by m easuring p24gag accu m u la ted  in culture m edia over 3 day  periods. P resen ted  are  m eans  ± SEM of the  results with tissues  from 4 to  17 donors. For each  
donor, e ach  da ta  point re p re sen ts  poo led  viral re lease  from 27 tissu e  blocks. Note that ACV su p p re ss e s  HIV-1 in HSV -2-coinfected tissues.
(B) HIV-1 replication w as m ea su re d  in tonsillar b locks infected with X4lai 0 4  a s  in (A). ACV w as ad d ed  a t the  concen tra tions  of 0 .3 ,3 ,1 0 ,3 0 , and  100 nM, and  its 
anti-HIV activity w as evaluated  from the  sup p ress io n  of viral replication com pared  with d o no r-m atched  HIV-infected tissu es  not trea ted  with ACV. The 50%  ef­
fective concentration  (EC5 0 ) w a s  e stim ated  by fitting the  d a ta  to four-param eter logistic regression  an d  w as estim ated  to  be  3.1 pM (95% confidence interval: 
1.85-5.24). P resen ted  a re  m ean s ± SEM of the  resu lts  with tis su e s  from th ree  to  seven  donors. N ote tha t ACV su p p re ss e s  HIV-1 replication in the  tonsillar tissues 
in a  d o se-d ep en d en t m anner.
(C) HIV-1 proviral DNA load in tis su e  b locks a t day  12 postinfection w as m easu red  by real-tim e PCR. P resen ted  a re  m edians and  interquartile ranges of the  results 
(n = 27). Note tha t ACV efficiently re d u c e s  HIV-1 proviral DNA load in b locks of tonsillar tissue.
(D) HIV-1 replication w as m onitored  a s  in (A). P rese n ted  are  m eans ± SEM of the  results (n = 38). N ote th a t ACV efficiently su p p re sse s  HIV-1 replication in the 
tonsillar tissues te sted .
(IQR 3 .63-260 .9 , n = 14), and 388 (IQR 175 .9 -2416, n = 4) copies 
per 104 cells after 12 days of culture.
In all tissues infected with different combinations of HHVs, 
ACV suppressed HIV-1 replication with a similar efficiency (Fig­
ure 2C). HHV-6 was the only HHV that was present in all com bi­
nations. Moreover, it seem s that the suppression of HIV-1 by 
ACV is related to the amount of HH V-6. In tissue blocks in which 
ACV inhibited HIV-1 replication by more than 50% , the median 
HHV-6 load on day 12 in culture was significantly higher than 
in the tissues in which ACV suppressed HIV-1 replication by 
less than 50% : 131.1 DNA copies per 104 cells (IQR 3 6 .1 -  
1154, n = 23) versus 21 .6  DNA copies per 104 cells (IQR 0 .6 -  
77.4, n = 4; p = 4 x  10~2), respectively. Furthermore, we docu­
mented a correlation between the ACV-m ediated suppression
of HIV-1 replication, as measured by p24gag release, and the 
level of H H V -6 in tissues where the HIV-1 inhibition was 
suboptimal (between 0 and 99% ; r = 0.43, p = 0.03, n = 25).
Although several HHVs, such as HHV-6, are ubiquitous and 
transmitted early in childhood, we identified a tissue in which 
there was no detectable HHV. In agreement with our hypothesis, 
in this tissue, ACV suppression of HIV-1 (at the concentration of 
30 fiM) was negligible (16% ) (Figure 2C).
C o in f e c t io n  w ith  H H V s Is  N e c e s s a r y  a n d  S u f f ic ie n t  
fo r  t h e  A n ti-H IV  E f f e c t  o f  A C V
To prove this claim, we performed experiments with MT4 cells, 
an HHV-uninfected T cell line that efficiently supports the rep­
lication of HIV-1 l a i . 04- W e found that ACV did not suppress
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Figure 2. ACV Suppresses Replication of Different HIV-1 Variants in Human T issues Coinfected with Various HHVs
(A) HIV-1 replication in b locks of hum an  lymph n o d es  and  colorectal and  cervicovaginal tis su e s  w as m onitored  a s  in Figure 1A. For e ac h  type of tissue , th e  g raph  
represents a  typical result of th ree  to  sev en  experim ents  perform ed with tis su e s  from different donors. N ote th a t ACV efficiently s u p p re ss e s  replication of HIV-1 in 
lymph nodes and colorectal a n d  cervicovaginal tissues.
(B) Examples of ACV su p p re ss io n  of different HIV-1 variants (X4lai.(m. R5b3l. R5sfi62. and  R5ad8)- Each d a ta  point rep re sen ts  pooled  viral re lease  from 27 tis su e  
tonsillar blocks. Note th a t ACV efficiently s u p p re ss e s  replication of all four HIV-1 variants.
(C) P resence of HHV-1, -2, -3, -4, -5, -6 , -7, an d  - 8  by real-tim e PCR in blocks of tonsillar tissue. All tis su e s  w ere  negative for HHV-1, -2, -3, and  -8 . P re se n ted  are  
m eans ± SEM of the  results with tonsils  from n donors. N ote th a t th e re  are  no significant differences in th e  level of ACV supp ress io n  of HIV-1 replication in tis su e s  
infected with various HHVs.
HIV-1 lai . 0 4  (ECso > 250 pM) in these cultures, in agreement with 
earlier observations (Barral et al., 2003). To test whether HHV in­
fection is sufficient for the anti HIV-1 effect of ACV, we added  
various amounts of H H V -6B -infected  M T4 cells to HHV-free  
MT4 cultures infected with HIV-1 l a i .04- A s  expected, AC V sup­
pressed HHV-6. After 3 days of culture, the fraction of HHV- 
6B-infected cells was reduced in a dose-dependent manner, 
as measured by flow cytom etry (Figure 3A). Importantly, in these 
cultures, ACV suppressed HIV replication as well, as evaluated 
by the number of p24gag+ T  cells and p24gag release into the culture 
medium (EC50 of ~ 5 0  pM) (Figures 3A and 3B). In these experi­
ments, 9%  of H HV-6B-infected cells were sufficient to suppress 
HIV-1 la i . 0 4  replication by ~ 7 0 %  (Figure 3A). W e found that, in 
agreement with earlier publications (De Clercq et al., 2001), the con­
centration that corresponds to the EC50 in these experiments did 
not affect cell viability (50%  cytotoxic concentration > 250 pM).
To further prove that ACV phosphorylation is required for HIV- 
1 inhibition, we synthesized the monophosphorylated ACV  
prodrug acyclovir-(1 -naphthyl [methoxy-L-alaninyl]) phosphora­
midate (Cf2649) (Figure 3C). This com pound bypasses the re­
quirement of HHVs for the activation of ACV since it is already 
monophosphorylated. Indeed, when applied to (HHV-free) MT- 
4 cells, Cf2649, in contrast to nonphosphorylated ACV (EC50 > 
250 pM), suppressed HIV-1 replication with an EC50 of ~ 3  pM
(Figures 3D  and 3E). Similar results were obtained with another 
HHV-free T  cell line (CEM) (data not shown).
In conclusion, w e dem onstrated that neither in HHV-free tissue 
nor in HHV-free cell lines does ACV suppress HIV-1 infection. 
Reconstitution of the cell line system with HHV-6-infected cells 
or bypassing the HHV-kinases requirement by applying an 
ACV monophosphate derivative makes HHV-free systems 
susceptible to HIV suppression by ACV.
ACV-TP Inhibits HIV-1 RT
Since we dem onstrated that the anti-HIV-1 activity of A C V  re­
quires HHV-m ediated activation and that phosphorylated deriv­
atives of ACV are produced in HHV-infected tissues (see Supple­
mental Data and Figure S1 available online), we hypothesized  
that ACV-TP, into which ACV is ultimately converted (Elion, 
1983), interferes with the activity of the HIV-1 RT and directly 
suppresses HIV-1 replication.
W e tested whether ACV-TP suppresses RT by measuring the 
polymerizing activity of RT from lysed HIV-1 using an exoge­
nously added HIV-1 tem plate. W e observed a dose-dependent 
inhibition of HIV-1 RT activity by ACV-TP, while we noted no sup­
pression of HIV-1 RT activity by ACV itself, even at high concen­
trations (Figure 4A).
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Figure 3. ACV Suppresses HIV-1 in HHV-Free MT-4 Cell Cultures Either in the Presence of HHV-6-lnfected Cells or as Monophosphorylated 
Prodrug
(A)HIV-1 |_Aio4 -inf©cted MT4 ce lls  w e re  co cu ltu re d  w ith HHV-6 B -in fec ted  MT4 cells in a  ratio of 10:1. P re se n ted  a re  th e  d istributions of HHV-6 B (upper panel) a n d  
HIV-1 lai 0 4 -in fec ted  cells  (low er panel), a s  m e a su re d  by  flow cy to m etry  a t day  3 post-HIV-1 infection, in cu ltu res  u n trea ted  o r tre a te d  with various co n cen tra tio n s  
of ACV. N ote  th a t th e  frac tion  of b o th  HHV-6 B- a n d  H IV -1-infected cells is red u ced  in a  d o s e -d e p e n d e n t m an n er by ACV trea tm en t.
(B) HIV-1 LAi.o<»-infe c te d  MT4 ce lls  w e re  c o cu ltu re d  w ith HHV-6 B -infec ted  MT4 cells. HIV-1 replication w a s  m onito red  a s  in Figure 1 A. N ote th a t th e  replication of 
HIV-1 in H H V -6B -/H IV -1-infected c o c u l tu re s  is s u p p re s s e d  by ACV trea tm en t in a  d o s e -d e p e n d e n t m anner.
(C) The c o m p o u n d  acy c lov ir-(1 -naph thy l [m ethoxy-L-alaninyl]) p h o sp h o ram id a te  (Cf2649) h a s  b e en  sy n th esized  a s  d e sc rib e d  in the  S u pp lem en ta l D ata.
(D) HIV-1 lai 0 4 -in fec ted  HHV -free MT4 ce lls  w e re  t re a te d  w ith various c o n cen tra tio n s  of th e  ACV m o n o p h o sp h o ry la ted  p rod rug  Cf2649. P re sen ted  a re  th e  kinetics 
of HIV-1 lai 0 4  rep lication , m o n ito red  by  m e asu rin g  p 2 4 oao a cc u m u la te d  in culture  m edia  a t d ay s  2, 3 ,4 ,  a n d  6  postin fection . P rese n ted  d a ta  a re  rep re sen ta tiv e  of 
two experim en ts . N ote  th a t c o m p o u n d  C f2649  s u p p r e s s e s  th e  replication of HIV-1 lai cm in a  d o s e -d e p e n d e n t m anner.
(E) HIV-1 lai cM-inf©ctecl MT4 cells  n o t in fe c te d  w ith an y  HHVs w ere  tre a te d  with various co n cen tra tio n s  of th e  co m p o u n d  Cf2649. The cum ulative  re lease  of p24aag 
into culture  m ed ia  over 6  d a y s  of cu ltu re  tre a te d  w ith va rious  c o n c en tra tio n s  of the  com pound  Cf2649 is p re s e n te d  a s  a  fraction  of th e  p24flao p roduction  in the  
untreated cu ltu res . P re s e n te d  d a ta  a re  re p re s e n ta tiv e  of tw o  in d e p e n d en t experim ents. N ote th a t co m p o u n d  Cf2649 s u p p re s s e s  th e  replication of HIV-1 la, 0 4  in 
a d o se -d ep e n d e n t m anner.
S in c e  A C V -T P  is  a  g u a n o s in e - 5 ' - t r ip h o s p h a te  a n a lo g , w e  
in v e st ig a te d  w h e th e r  it a c t s  a s  a  n u c le o t id e  RT inh ib itor  
by t e s t in g  w h e th e r  d G T P  p r e v e n t s  A C V -T P  inh ib ition  o f  RT. 
We fo u n d  that, a t A C V -T P  c o n c e n t r a t io n s  o f  3 .3 8  nM or 
33.8 pM , HIV-1 RT inh ib ition  w a s  in v e r s e ly  d e p e n d e n t  o n  
the d G T P  c o n c e n tr a t io n s . At th e  h ig h e s t  c o n c e n tr a t io n  o f  
ACV-TP t e s t e d ,  n o  c o m p e tit io n  w ith  d G T P  w a s  o b s e r v e d  
(Figure 4B ). S in c e  A C V -T P  la c k s  a n  a d d itio n a l h yd ro x y l g ro u p  
(present in d G T P  a n d  e s s e n t ia l  for D N A  c h a in  p o ly m e r iza tio n ), 
we further h y p o th e s iz e d  th a t th e  a b o v e - d e s c r ib e d  s u p p r e s ­
sion o f HIV-1 RT b y  A C V -T P  is  sim ila r  t o  its s u p p r e s s io n  o f  
HSV D N A  p o ly m e r a s e , n a m e ly  b y  in c o r p o r a tio n  in to  th e  
n ascent HIV D N A  resu ltin g  in its c h a in  te r m in a tio n  (R ea rd o n  
and S p e c to r , 1 9 8 9 ).
To p r o v e  th is  h y p o th e s is ,  w e  u s e d  a  g e l - b a s e d  a s s a y  (M arch- 
and a n d  G o tte , 2 0 0 3 ;  M arch a n d  e t  a l., 2 0 0 7 )  a n d  fo u n d  th a t HIV-
1 RT in co rp o ra ted  A C V -T P in to  th e  D N A  prim er a s  e ffic ien tly  a s  
th e  natural s u b s tr a te  dG T P . T h e  e f f ic ie n c y  o f s in g le -n u c le o t id e  
in corp oration  e v e n t s  (kcat/K m) u n d er  s t e a d y - s t a te  c o n d it io n s  
for dG T P  a n d  A C V -T P  w a s  1 4 .7  p M - 1 m in ~ 1 a n d  1 4 .0  
p |y r 1m in ~ 1, r e s p e c t iv e ly  (T ab le  S 1 ). F urth erm ore, A C V -T P in­
c o rp o ra tio n  r e su lte d  in c o m p le t e  D N A  ch a in  term in ation , a s  
sh o w n  in F ig u res 5A  a n d  5 B . A prim er th a t c o n ta in e d  th e  natural 
dG M P  at its 3' e n d  w a s  s u c c e s s fu l ly  e x te n d e d  in th e  p r e s e n c e  o f  
dTT P, w h ich  is  th e  s u b s tr a te  for th e  fo llo w in g  th r e e  c o n s e c u t iv e  
t e m p la te  p o s it io n s  (F igure 5 B , left p an el). In c o n tr a st , D N A  s y n ­
t h e s is  w a s  e f fe c t iv e ly  b lo c k e d  w h e n  th e  prim er w a s  term in a ted  
w ith A C V -M P. E ven  th e  re la tively  h igh  c o n c e n tr a t io n  o f  5 0  nM  
o f  dTTP d id  n o t perm it its in co rp o ra tio n  (Figure 5 B , right pan el). 
T h e s e  d a ta  s u g g e s t  th a t th e  m e c h a n ism  o f  a c tio n  o f  ACV is  
sim ilar to  th e  currently  a p p r o v e d  anti-H IV n u c le o s id e  r e v e r se  
t r a n sc r ip ta se  inh ib itors (NRTIs).
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Figure 4. ACV-TP Inhibits HIV-1 RT in Exogenous Template Reverse 
Transcriptase Assays
(A) E xogenous tem p la te  rev e rse  tra n s c r ip ta se  a s s a y s  w ere  perform ed in the  
p resence  of various co n ce n tra tio n s  of ACV or ACV-TP a s  d e sc rib ed  in the  
Experimental P ro ced u res . P re s e n ted  a re  m ea n s  ± SEM of the  resu lts  of two 
experim ents perfo rm ed  in d u p lic a tes . N ote th a t ACV-TP inhibits HIV-1 RT 
in a d o s e -d ep e n d e n t m anner.
(B) The d e p en d e n c e  of th e  RT inhibition by ACV-TP on the  concen tra tion  of 
dGTP w as evaluated  using a n  e x o g en o u s  tem p la te  reverse  transcrip tase  a s ­
say. dG TP w as u sed  a t th e  ind ica ted  co n cen tra tio n s . The reactions w ere p e r­
formed in th e  p re s en c e  of th e  in d ica ted  co n cen tra tio n s  of ACV-TP. P resen ted  
are m ean s ± SEM of th e  re su lts  of tw o  experim en ts  perform ed in duplicate. 
Note tha t inhibition of HIV-1 RT activity by ACV-TP is inversely d ep en d en t 
on the  concen tra tion  of dGTP.
DNA chain termination by NRTIs is not irreversible but can be 
subjected to phosphorolytic excision of the incorporated drug by 
HIV RT (Meyer et al., 1998). Binding of the next complementary 
nucleotide following the DNA chain terminator can lead to the 
formation of a dead-end complex (DEC). In this complex, HIV 
RT is trapped in a conformation that blocks the excision reaction. 
Thus, to test whether ACV-MP-terminated DNA is accompanied 
with the formation of a dead-end complex, we evaluated the in­
hibition of ACV-MP phosphorolytic excision from the 3' end of 
the primer by HIV-1 RT. The excision of a DNA chain terminator 
requires the presence of pyrophosphate (PPi) or pyrophosphate 
donor molecules (such as ATP). W e found that HIV-1 RT is capa­
ble of excising the incorporated ACV-MP in the presence of 
physiologically relevant concentrations of ATP (data not shown)
Figure 5. Chain Termination with ACV-MP
(A) The reaction  s ch e m e  sh o w s  the  relevant region of th e  prim er an d  tem plate  
an d  tw o possib le  o u tco m es  of the  prim er elongation. Elongation of the  prim er 
in the  p re sen c e  of dG TP or ACV-TP is indicated  by the  “Z ” in red, which refers 
to  the  incorpora ted  m o n o p h o sp h a te  dGM P or ACV-MP, respectively. 
Incorporation ev en ts  following position Z with dTTP are  in blue a n d  underlined.
(B) The prim er (S, lane C) w as  initially e longated  to  incorporate  dG M P or ACV- 
MP, respectively, a t the  3' en d  referred to  a s  Z. Incubation with increasing  c o n ­
cen tra tions of the  next nucleotide dTTP resu lted  in th ree  nucleo tide  incorpora­
tion even ts  with the  dG M P -term inated  primer, w hich a re  labeled  a s  p ro d u c ts  
(P). Note th a t the  A CV-M P-term inated prim er is not ex ten d ed , w hich sh o w s 
th a t the  inhibitor a c ts  a s  a  chain  term inator.
as demonstrated for certain NRTIs. However, to analyze whether 
the ACV-terminated primer permits formation of a dead-end 
complex, the ATP-dependent excision reaction was assayed in 
the presence of increasing concentrations of the next comple­
mentary nucleotide. We found that the next complementary nu­
cleotide caused 50%  inhibition of ACV-MP excision (IC50) at 
a concentration of ~ 26  pM (Figures 6A and 6B). These data 
strongly suggest the formation of a dead-end complex in ACV- 
MP-incorporated templates. The higher IC50 (26 pM versus 
3.1 pM) in comparison to reactions conducted with the control 
DNA chain terminator ddGMP was probably due to the acyclic 
nature of ACV-MP. In general, the excision reaction was ineffi­
cient; only 10% —15% of the terminated primer strands were res­
cued for continuation of DNA synthesis at low concentrations of 
the next complementary nucleotide.
To provide additional direct evidence of dead-end complex 
formation, we employed site-specific footprinting that allowed 
us to determine the position of HIV-1 RT on its primer/template 
at single-nucleotide resolution (Marchand and Gotte, 2003; 
Marchand et al., 2007). Nucleotide binding and formation of 
a dead-end complex can only occur in the posttranslocated con­
formation in which the nucleotide-binding site of HIV-1 RT has
Z = d G M P  Z = ACV-MP
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Figure 6. Inhibition of ATP-Dependent Excision in the Presence of the Next Nucleotide Substrate
A T P -dependen t excision w a s  m onito red  in a  co m b in ed  ex cision /rescue  a ssay  a s  previously d e sc rib ed  in the  Supp lem en ta l Experim ental P rocedures.
(A) The reaction  s ch e m e  s h o w s  th e  re levant region of the  prim er and  tem plate . Extension of the  prim er in th e  p re s en c e  of ddG T P or ACV-TP is ind icated  by the  "Z” 
in red. The excision of a  DNA chain  te rm ina to r requ ires th e  p re sen c e  of ATP a s  py rophosphate  donor. The 3 '-u ltim ate  nucleotide  (Z) w a s  ex c ised  with ATP, a n d  the 
sim ultaneous p re s e n c e  of dG TP an d  ddTT P (in blue) allow ed the  re scu e  of DNA synthesis.
(B) The com bined  e x c is io n /rescu e  reaction  w as  s tud ied  with ddG M P and ACV-M P-terminated prim ers. Z refers to  th e  te rm inated  prim er and  P to  the  re scu ed  
p roduct. The aste risk  in d ica tes  dG M P m isincorporation  in th e  a b se n c e  of the  correct ddTTP su b stra te . Q uantification of ex c isio n /rescu e  reactions for ddG M P 
and  ACV-MP are  p lo tted . The co n ce n tra tio n  of th e  next com plem entary  nucleotide required to  inhibit 50%  of the  reaction  is ca lcu la ted  on the  b a s is  of th e se  two 
curves. Note tha t A C V -M P-term inated prim er exc isio n /rescu e  reaction  is inhibited due  to  d ead -en d  com plex  form ation.
(C) Incorporation of ACV-TP p ro d u c e s  a  d e a d -e n d  com plex  with HIV-1 RT. P resen ted  is s ite-specific footprinting of HIV-1 RT with ddG M P- and  ACV-M P-ter­
m inated prim ers in th e  p re s e n c e  of increasing  co n cen tra tio n s  of the  next com plem entary nucleotide. L anes -F e  an d  +Fe show  control reactions in the  a b se n c e  
and p re sen c e  of divalent Fe2+ ions th a t c a u s e  site -spec ific  c leavage  on the  labeled tem plate. The arrow s a n d  the  s e q u e n c e  u n d ern ea th  th e  gel show  th e  position 
of the  oxidative c leav ag e  on th e  tem p la te  s tran d  a t positions - 1 7  and  -1 8 , which are  indicative for p o st- a n d  p re tran slo ca ted  com plexes, respectively. N ote that, 
for A CV-M P-term inated prim er, no  c leav ag e  o c cu rs  a t low next com plem entary nucleotide concen tra tions , indicating th a t th e  com plex  be tw een  RT an d  term i­
na ted  prim er is fragile, w h e reas , a t h igher co n cen tra tio n s  of the  next com plem entary nucleotide, RT is b locked  in a d e a d -e n d  com plex.
been cleared. In this conformation, the RT has moved a single 
nucleotide further downstream relative to the pretranslocated 
state. Our footprints are based on oxidative cleavage on the tem­
plate strand at positions - 1 7  and -1 8 ,  which are indicative of 
post and pretranslocated complexes, respectively. We com­
pared footprints of complexes with ddGM P- and ACV-MP-termi­
nated primers in the presence of increasing concentrations of the 
next complementary nucleotide (Figure 6C). bow concentrations 
of the next complementary nucleotide are sufficient to stabilize 
the posttranslocated complex when the primer was terminated 
with ddGMP, proving the formation of a dead-end complex. A 
similar pattern is seen with ACV-MP, although the concentration 
of the next nucleotide required to stabilize the complex is higher. 
Oxidative cleavage in case of ACV-MP did not occur in the ab­
sence of or at low concentrations of the next complementary 
nucleotide. These findings suggest that, at the low next comple­
mentary nucleotide concentration, the complex between RT and 
terminated primer formed at the site of the ACV-MP termination 
is relatively fragile—perhaps prone to dissociation. In contrast, at 
high concentration of the next complementary nucleotide, RT 
can be trapped in a dead-end complex. The dissociation con­
stant for ACV-terminated primers in the presence of a high con­
centration of the next nucleotide (111 nM) is increased ~3-fold  
(Figure S2).
Thus, these data explain why the excision of ACV-MP is gen­
erally inefficient at both low and high concentrations of the next 
complementary nucleotide. At low concentrations, the complex 
between RT and ACV-MP is relatively unstable, while, at higher 
concentrations, a DEC is formed.
To prove that ACV targets HIV-1 RT in human tissues as in cell- 
free assays, we tested two pairs of HIV isogenic strains that are 
resistant to some of the currently approved NRTIs. The isolate
266 Cell Host & Microbe 4, 260-270, Septem ber 11, 2008 ©2008 Elsevier Inc.
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AZT.4x containing the mutations at D67N, K70R, T215Y, and 
K219Q express complete resistance to AZT and resulted to be 
as sensitive to ACV in infected tissues as its parental HIV-1 var­
iant (Figure S3A). However, an HIV-1 isolate carrying the M184V  
mutation (that confers resistance to Lamivudine) was less sensi­
tive to ACV than its parental strain (Figure S3B). The EC50 for the 
M184V isolate was approximately four times higher than that for 
the parental HIV-1 isolate. Thus, the evidence that a specific iso­
lated mutation of one amino acid in RT can reduce the sensitivity 
of an HIV-1 isolate to ACV further proves that HIV-1 RT is tar­
geted and suppressed by ACV in human tissues, in agreement 
with the data on ACV suppression of HIV-1 RT in cell-free sys­
tems.
DISCUSSION
Growing epidemics of HIV-1 infection, especially in countries 
with limited resources, and the emergence of drug-resistant 
viruses make it necessary to find ever new safe, efficient, and 
inexpensive strategies against this virus. Strategies as effective 
and safe as those developed against several other human path­
ogens such as HSV, which can be efficiently treated with ACV, 
have yet to be developed against HIV. The antiherpetic specific­
ity of ACV is primarily based on the unique ability of HHV- 
encoded kinases to phosphorylate ACV to its monophosphate 
derivative, which is subsequently converted into the antivirally 
active ACV-TP (Reardon and Spector, 1989). Consistent with 
its highly restricted antiherpetic activity, ACV is not currently 
used as a direct HIV-1 inhibitor.
Our findings demonstrate (1) the direct inhibitory effect of 
ACV-TP, but not of ACV itself, on isolated HIV-1 RT in a cell- 
free system, (2) the suppression of HIV-1 replication by ACV in 
human tissues and in T cell lines if and only if they carry HHV 
that phosphorylate ACV, and (3) the ability of a phosphorylated 
ACV prodrug to bypass the requirement of HHV to suppress 
HIV. Thus, we provide definitive experimental evidence of inhibi­
tion of HIV-1 RT activity by phosphorylated ACV and demon­
strate that ACV phosphorylation occurring in HHV-infected hu­
man tissues transforms this widely used antiherpetic drug into 
an HIV-1 inhibitor.
The direct suppression of HIV-1 RT activity by ACV-TP was 
demonstrated in two different cell-free assays, one using re­
combinant HIV-1 RT and the other using RT extracted from lysed 
HIV-1 virions. We showed that ACV-TP is incorporated into the 
nascent viral DNA chain with a level of efficiency similar to that 
of its natural equivalent dGTP. Incorporation of ACV-TP results 
in the termination of reverse transcription, while the excision of 
the incorporated ACV-MP from the DNA chain is partially in­
hibited because of the fragility of the complex between HIV-1 
RT and the terminated DNA chain or because of the formation 
of a dead-end complex. These properties of ACV resemble those 
of certain approved anti-HIV NRTIs (Marchand and Gotte, 2003; 
Meyer et al., 1999), and we showed here that ACV-TP, a non- 
phosphonate acyclic nucleoside analog, inhibits HIV-1 RT.
To further confirm that, in HIV-1-infected cells, ACV-triggered 
HIV-1 suppression is mediated by RT, we identified a pair of iso­
genic HIV-1 strains differing only by one amino acid (M184V) in 
RT but having different sensitivities to ACV in ex vivo human tis­
sues. Future studies on selection of ACV-resistant HIV-1 isolates
and testing of various multidrug-resistant HIV-1 isolates for ACV 
sensitivity will reveal the exact set of RT mutations associated 
with reduced sensitivity to ACV and the rate of their evolution. 
Identification of ACV-resistant mutants does not, in general, ex­
clude the use of ACV against HIV-1 variants resistant to other 
NRTIs; for instance, ACV efficiently suppresses the replication 
of AZT-resistant H IV-1.
As demonstrated in a cell-free system, to inhibit HIV-1 RT, ACV  
has to be converted into ACV-TP. In human tissues, such con­
version requires HHV infection. Accordingly, we found that, in 
the presence of HHVs that are capable of phosphorylating 
ACV, HIV-1 was inhibited in ACV-treated tonsils, lymph nodes, 
and cervico-vaginal and colorectal tissues, where the critical 
events of HIV-1 pathogenesis and transmission occur in vivo.
Various HHVs, including the ubiquitous HHV-6 detected in all 
but one tissue ex vivo, may mediate HIV-1 suppression by 
ACV. The level of HHV-6 replication may be essential. In tonsillar 
tissues, in which ACV inhibited HIV replication by more than 
50% , the median HHV-6 load was significantly higher than in 
the tissues in which ACV suppressed HIV replication by less 
than 50% . Moreover, in tissues where the HIV-1 inhibition was 
suboptimal, there was a correlation between the ACV-mediated 
suppression of HIV-1 replication and the level of HHV-6. These 
results demonstrate again the critical role of HHVs in ACV-medi­
ated suppression of HIV-1 and indicate the importance of HHV-6  
in mediating HIV-1 suppression by ACV in our ex vivo tissue 
system.
HHV-6 and HHV-7 are ubiquitous viruses, and, therefore, the 
probability of finding an HHV-free tissue is very low. Neverthe­
less, by testing tissues from multiple donors, we identified one 
tonsillar tissue that was not infected by any HHV. ACV did not 
inhibit HIV-1 replication in this tissue.
However, to further demonstrate that HHVs are necessary and 
sufficient for the anti-HIV effect of ACV, we used the HHV-unin- 
fected MT4 cell line. Consistent with the proposed mechanism 
based on HHV-mediated activation, ACV did not inhibit HIV rep­
lication in this HHV-free cell line. However, when HHV-6-infected 
cells were added to the HIV-1 -infected cultures, ACV became an 
HIV-1 suppressor. This effect was dependent on both the con­
centration of ACV and the fraction of HHV-6-infected cells. 
Apparently, in HHV reconstituted MT4 cultures, ACV that is 
phosphorylated in HHV-6-infected cells is transferred to HIV-1- 
infected cells, since the majority of these cells were not coin­
fected with HHV-6. These results are in full agreement with the 
published data on the transfer of phosphorylated ACV between 
cells (Burrows et al., 2002; Degreve et al., 1999). In tissues, trans­
fer of phosphorylated ACV between cells is facilitated by special­
ized contacts (Nicholas et al., 2003). These and probably other 
factors (e.g., rapid proliferation and large endogenous dNTP  
pools, as well as a high level of HIV-1 replication) may contribute 
to a lower sensitivity of HIV-infected cell lines to ACV compared 
with integral tissues.
To further demonstrate the necessity of ACV activation for HIV 
suppression, we synthesized an already monophosphorylated 
(activated) ACV in which the phosphate is masked by liphophilic 
groups In contrast to nonphosphorylated ACV, this prodrug 
suppressed HIV-1 in HHV-free cultures of MT4 or CEM cells. Al­
though enzymatic reactions mediating ACV prodrug conversion 
into its active form have been described (Congiatu et al., 2007),
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the entire process of this conversion remains to be elucidated. 
Nevertheless, our results provide strong evidence that, upon 
phosphorylation, ACV suppresses HIV-1 replication in cells. Im­
portantly, these experiments also demonstrate the feasibility of 
designing a new class of anti-HIV compounds. However, unlike 
ACV (with a proven safety record and exhaustively studied phar­
macokinetics), ACV prodrug effects in various systems have to 
be evaluated in order to form conclusions on their potential 
clinical use.
In summary, the following mechanism seems to be responsi­
ble for ACV suppression of HIV-1 in human tissues ex vivo, the 
majority of which carry one or several HHVs, including HHV-6: 
ACV is monophosphorylated by herpesviral enzymes in HHV-in- 
fected cells and then further converted to ACV-TP, which sup­
presses HIV by inhibiting HIV-1 RT, similarly to other NRTIs.
Our results suggest that ACV may be therapeutically beneficial 
for various HIV-1 -infected patients, since the majority of humans 
are already infected with HHV-6, often together with other HHVs 
that activate ACV at least during reactivation. In particular, in im­
munocompromised patients for whom HHV replication is fre­
quent, those HHVs that are not completely suppressed by ACV 
(e.g., HHV-6) can continuously generate phosphorylated ACV 
derivatives. The incomplete inhibition of HHV-6 by ACV con­
firmed in our experiments is consistent with the much higher 
Kj of ACV-TP for HHV-6 DNA polymerase (UL69) compared 
with that of HSV-2 or HSV-1 DNA polymerase (Bapat et al., 1989).
However, clinical trials are needed to test whether replication 
of HHVs—in particular of HHV-6, which is typically maintained in 
various organs, including the intestines and the vagina, even in 
immunocompetent individuals (De Bolle et al., 2005)—would 
be sufficient to suppress HIV-1 in ACV-treated individuals. 
Also, clinical trials should reveal whether the range of ACV con­
centrations used in our study to suppress HIV-1 is clinically rele­
vant. Although ACV penetration efficiency and drug clearance 
were unknown for ex vivo tissues, the calculated EC50 of 3.1 pM 
was in the range of what was reported in vivo: a dose of 1 g of 
oral valacyclovir per day results in a plasma peak concentration 
of 29.5 pM, a minimum concentration in serum of 3 pM, and 
a plasma concentration time curve of 89 pM/h ACV (Lycke 
et al., 2003; Soul-Lawton et al., 1995). Moreover, the therapeutic 
dose of the orally administered ACV prodrug valacyclovir, de­
pending on clinical indications, can be increased to as much 
as 3 g per day.
Recent clinical trials performed so far are in agreement with 
our ex vivo results and demonstrated that ACV is efficient in sup­
pressing HIV in HSV-2-coinfected individuals (Baeten et al., 
2007; Delany et al., 2007; Dunne et al., 2008; Nagot et al., 
2007; Zuckerman et al., 2007). Valacyclovir treatment, at the 
dose of 1 g per day, reduced the HIV-1 plasma load in these in­
dividuals by 50 % -7 0% , an effect comparable to that reported 
here for human tissues infected with other HHVs. This HIV-1 viral 
load reduction was clinically beneficial (Corey, 2007) and similar 
to that reported for AZT or stavudine monotherapy (~70% ) (Delta 
Coordinating Committee and Delta Virology Committee, 1999; 
Katzenstein et al., 2000; Rey et al., 1998). In contrast to the es­
tablished ACV activity in reducing HIV load in HSV-2 coinfected 
patients, recent trials failed to demonstrate that HSV-2 suppres­
sive therapy prevents acquisition of HIV-1 (Celum et al., 2008; 
Cohen, 2007; Lisco and Vanpouille, 2008; Watson-Jones et al.,
2008). However, none of the approved NTRIs widely used for 
therapy was yet developed into an efficient preventive drug 
when used alone.
Our results provide new insights into the effect of ACV in HIV- 
1-infected patients. In all previous trials, the effect of ACV on 
HIV-1 was considered to be indirect and due to the suppression 
of HSV-2-mediated inflammation. Here, we demonstrate that 
ACV directly suppresses HIV-1 RT in HHV-coinfected tissue. 
This effect depends on the levels of HHVs, which were not eval­
uated in these clinical trials or in previous in vitro studies (Resnick 
et al., 1986). Obviously, the results obtained in tissues ex vivo 
should be extrapolated to the in vivo situation with caution. How­
ever, the reliance on lymphotropic HHVs to create the active HIV 
suppressor at the site of HIV replication may, in principle, solve 
the critical pharmacological problem of drug delivery.
In conclusion, our data on HIV-infected tissues coinfected with 
various HHVs suggest that ACV may be used to decrease the 
HIV load in both the peripheral blood and the genital compart­
ments of patients infected with one or several HHVs, including 
the highly prevalent HHV-6 (Campadelli-Fiume et al„ 1999). Al­
though the magnitude of HIV-1 suppression by ACV as well as 
by the currently approved NRTIs is too low to be used in mono­
therapy, it is sufficient to be an important part of drug cocktails.
In general, the combination of ACV with an endogenous HHV 
infection to suppress HIV may constitute a new principle of anti- 
HIV therapy—a “binary weapon” in which one inert component 
is converted by another endogenous component into an active 
therapeutic compound. In the case of ACV, its exceptionally 
low toxicity and the low cost of ACV and related drugs that 
have been safely used in humans for more than 30 years, as 
well as their existing formulations as pills and creams, make 
them potentially applicable for HIV treatment, possibly in combi­
nation with other drugs. New targeted clinical trails will test 
whether ACV and its derivatives can be used for this new pur­
pose in line with a popular trend to identify new uses for old drugs 
(Chong and Sullivan, 2007).
EXPERIMENTAL PROCEDURES 
Tissue and Cell Culture
Tonsillar tis su e s  from  routine su rg e ry  w ere  o b ta in ed  from th e  C hildren’s  Na­
tional M edical C en ter (W ashington , DC). Lymph n o d e s  an d  co lo rec tal a n d  cer- 
vicovaginal tis su e s  w ere  o b ta in e d  e ithe r from routine su rgery  o r from  c a d av e rs  
th rough th e  National D isease  R es e a rc h  In terchange (Philadelphia, PA). All tis­
s u e s  w ere  ob ta ined  a cco rd in g  to  IR B -approved pro toco ls . T issu es  w ere  d is­
s e c te d  into 2 m m 3 b locks a n d  cu ltu red  a s  d e sc rib e d  earlier (F letcher e t al., 
2006; G lushakova e t al., 1995; Grivel e t  al., 2007). MT4 cells w ere  ob ta ined  
from th e  Am erican T ype C ulture  C ollection (M anassas, VA) an d  cu ltu red  in 
RPM 11640 m edium  with 10%  h ea t-in ac tiv a ted  FCS.
Viral Infections
T issue inoculation with HIV-1 a n d  HHV-6B w as pe rfo rm ed  a s  d e sc rib e d  earlier 
(Grivel e t al., 2007). For further d e ta ils, s e e  the  S upp lem ental Experim ental 
P rocedu res .
ACV and ACV Monophosphorylated Prodrug Treatment
ACV pharm aceu tica l form ulations for intravenous infusion (B edford L abora to ­
ries, Bedford, OH; NDC 55390-612-10 ) w ere  diluted in distilled w a te r a n d  u sed  
a t th e  ind ica ted  co n ce n tra tio n s . A d ifferent pharm aceu tica l form ulation for in­
travenous infusion (Am erican P h a rm aceu tica l P artners , S chaum burg , IL; NDC 
63323-325-10) a n d  a  co m m erc ia l p repara tion  of ACV (Sigm a-Aldrich, St. 
Louis, MO) w ere  te s te d  for HIV-1 su p p re ss io n  in m a tch ed  tonsillar tis su e s
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from four donors , w ith sim ilar resu lts. S yn thesis  of the  m onophosphory lated  
ACV prodrug-acyclovir-(1-naphthyl [methoxy-L-alaninyi]) phosphoram idate  
(Cf2649) is d e sc rib e d  in th e  S upp lem en ta l Experim ental P rocedures. C om ­
pounds w ere  a d d e d  to  th e  cu ltu re  m edium  12 hr prior to  HIV-1 infection and  
again a t e ac h  culture  m edium  ch an g e .
Real-Time PCR
The HHV load a n d  th e  HIV-1 proviral load  in tis su e s  w ere  de term ined  by m ea­
surem ent of the  num ber of viral DNA co p ies. DNA from  tw o blocks of tissue  
w as ex trac ted  with the  Q IAam p kit (QIAGEN G m bH , Hilden, Germany) a cc o rd ­
ing to  the  m anufactu rer’s  instruc tions. For further deta ils  on  real-tim e PCR 
TaqM an assay , prim ers, a n d  p ro b e s  s e q u e n c e s ,  s e e  th e  S upplem ental Exper­
imental P rocedures.
Exogenous Template RT Assay
Exogenous tem p la te  HIV-1 RT a s s a y s  w ere  pe rfo rm ed  a s  d esc rib ed  previ­
ously (Gorelick e t al., 1990), w ith m odifications spec ified  in the  Supplem ental 
Experimental P rocedu res .
Steady-State Kinetics, ATP-Dependent Excision, and Site-Specific 
Footprinting
T hese a ssa y s  w ere  pe rfo rm ed  a s  d e sc r ib e d  previously (G otte e t al., 1998; 
M archand and  G otte, 2003; M arch an d  e t  al., 2007) with m odifications sp ec i­
fied in the  Supplem ental E xperim ental P ro ced u res .
Statistical Analysis
Each datum  point is th e  resu lt o f analy sis  of s e ts  of 9 to  27 tissu e  b locks d e ­
rived from each  of n d o n o rs , w h e re  n is ind ica ted  in th e  tex t. S ince th e  abso lu te  
level of HIV-1 replication varied  from  d o n o r to  donor, for every experim ent, w e 
com pared  th e se  levels using  d a ta  from  m a tc h e d  contro l b locks a s  th e  b a sis  of 
normalization. This allow ed u s  to  pool re su lts  o b ta in ed  from tis su e s  from differ­
en t donors. W e analyzed th e s e  d a ta  using  a  tw o-ta iled  paired  S tu d en t’s  t test. 
B ecause  the  distribution of th e  n u m b e rs  of HHV-6 a n d  HIV-1 (proviral) DNA 
equivalents failed th e  K olm ogorov-Sm irnov norm ality te st, w e u sed  d istribu­
tion-free nonparam etric  m e th o d s  (W ilcoxon M atch-P airs, S igned-R anks 
Test, and  M ann-W hitney U te st) to  ev a lu a te  th e  significance of th e  differences 
betw een various experim ental g ro u p s . H ow ever, w hen  th e se  d a ta  w ere  log10 
transform ed, th e  normality w a s  ach iev e d  a n d  w e  app lied  param etric  m e th o d s  
(paired or unpaired S tu d e n t’s  t  test). T he s ta tistica l significance of d ifferences 
betw een d a ta  from various ex perim en tal g ro u p s  ev a lu a ted  a fte r transfo rm a­
tion w as similar to  tha t e v a lu a ted  w ith non p aram etric  m e th o d s  app lied  to  non­
transform ed results. D epend ing  o n  th e  ty p e  of statistica l analysis, th e  pooled  
da ta  a re  p re sen ted  e ither a s  m e a n s  ± s ta n d a rd  error of th e  m ean  (SEM) or a s  
m edian and  interquartile ran g e  (IQR). All of th e  h y po thesis  te s ts  w ere  tw o- 
tailed, and  a  p  value of <  0 .05  de fin ed  s ta tis tica l significance.
SUPPLEMENTAL DATA
The Supplem ental Data include S u p p lem en ta l Experim ental P rocedu res , th ree  
figures, and  o n e  tab le  a n d  c an  b e  found  with th is  article online a t h ttp ://w w w . 
cellhostandm icrobe .eom /cg i/con ten t/fu ll/4 /3 /260 /D C 1/.
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It has recently been demonstrated that the anti-herpetic drug 
acyclovir (ACV) also displays antiviral activity against the human 
immunodeficiency virus type 1 (HIV-1). The triphosphate form of 
ACV is accepted by HIV-1 reverse transcriptase (RT), and subse­
quent incorporation leads to classical chain termination. Like all 
approved nucleoside analogue RT inhibitors (NRTIs), the selective 
pressure of ACV is associated with the emergence of resistance. 
The V75I mutation in HIV-1 RT appears to be dominant in this 
regard. By itself, this mutation is usually not associated with resist­
ance to currently approved NRTIs. Here we studied the underlying 
biochemical mechanism. We demonstrate that V75I is also 
selected under the selective pressure of a monophosphorylated 
prodrug that was designed to bypass the bottleneck in drug activa­
tion to the triphosphate form (ACV-TP). Pre-steady-state kinetics 
reveal that V75I discriminates against the inhibitor at the level of 
catalysis, whereas binding of the inhibitor remains largely unaf­
fected. The incorporated ACV-monophosphate (ACV-MP) is vul­
nerable to excision in the presence of the pyrophosphate donor 
ATP. V75I compromises binding of the next nucleotide that can 
otherwise provide a certain degree of protection from excision. 
Collectively, the results of this study suggest that ACV is sensitive 
to two different resistance pathways, which warrants further inves­
tigation regarding the detailed resistance profile of ACV. Such 
studies will be crucial in assessing the potential clinical utility of 
ACV and its derivatives in combination with established NRTIs.
Acyclovir (ACV)4 (Fig. 1, right) was developed decades ago as 
one of the first selective antiviral agents, and it is still used in the
* This w o rk  w as  s u p p o r te d ,  in w h o le  o r  in p a r t ,  b y  N a tio n a l In s titu te s  o f  H ealth  
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AIDS R esearch ; to  R. F. S.) a n d  b y  th e  NICHD In tra m u ra l P ro g ra m  (to  A. L.,
C. V., B. B., a n d  L. M.). This s tu d y  w a s  a lso  s u p p o r te d  b y  th e  C an a d ia n  Insti­
tu te s  fo r H ealth  R esea rch .
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clinic to treat infections caused by herpes simplex virus 1 and 2 
(HSV-1 and HSV-2) (1-3). As its valyl prodrug, and to a lesser 
extent as parent ACV, it is also used in treating varicella zoster 
infections. The drug is an acyclic guanosine analogue that needs 
to be selectively converted to its triphosphate form (ACV-TP) 
that is accepted by the viral polymerase and acts as a chain 
terminator. The herpesviruses provide the kinases that gener­
ate the monophosphate (ACV-MP), whereas cellular enzymes 
are required to synthesize the triphosphate form (4 -6 ). 
ACV-TP competes with intracellular dGTP pools for incorpo­
ration. Once incorporated, it acts as a chain terminator because 
of the lack of a structural equivalent of the 3 '-hydroxyl group of 
the sugar moiety of a natural nucleotide (7, 8). The next com­
plementary nucleotide, immediately downstream of the ACV- 
terminated 3 '-end of the primer, can still bind to the HSV DNA  
polymerase and triggers formation of a stable dead-end com ­
plex (DEC) (9).
It has recently been demonstrated that under certain condi­
tions ACV also exhibits antiviral activity against the human 
immunodeficiency virus type 1 (HIV-1) (10, 11). ACV was 
shown to suppress HIV-1 replication in human tissues co-in- 
fected with HIV-1 and human herpesviruses (10). The latter 
provide the viral kinase that facilitates production of ACV-MP. 
This bottleneck in the production of the active antiviral agent 
can also be bypassed with a monophosphorylated prodrug 
(CF2648) (Fig. 1, left), that shows anti-HIV activity in herpesvi­
rus-free cells (4,12,13). Cell-free assays revealed HIV-1 reverse 
transcriptase (RT) as the target (10, 11). ACV-TP binds to the 
nucleotide binding site, and the incorporated ACV-MP causes 
DNA chain termination after the release of pyrophosphate 
(PPi). Like most other nucleoside analogues (14-16), the incor­
porated ACV-MP can be excised from the 3 '-end of the primer 
in the presence of PPi or the PPi-donor ATP (10). This reaction 
can reduce the overall inhibitory effect; however, the removal of 
the chain terminator can be blocked through formation of a 
DEC (17). DEC formation depends critically on the chemical 
nature of the inhibitor (18). High concentrations (>100 /lim) of 
the next nucleotide are required to form a DEC with a primer
o s id e  a n a lo g u e  RT in h ib ito r ; DEC, d e a d - e n d  co m p le x ; PPi, p y ro p h o s p h a te ;  
AZT, z id o v u d in e ; TAM, th y m id in e  a n a lo g u e -a s s o c ia te d  m u ta tio n ; PFA, fos- 
c a rn e t ;  DTT, d ith io th re i to l;  WT, w ild  ty p e .
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FIGURE 1. Structures of ACV and the monophosphorylated prodrug 
CF2648.
terminated with zidovudine (AZT), whereas submicromolar 
concentrations are often sufficient to form a DEC with ddNTPs 
(16). ACV-MP shows a behavior in the middle of the spectrum; 
~25 /am concentrations o f the next nucleotide inhibits excision 
by 50% (10).
In vitro selection experiments revealed that ACV drug pres­
sure is linked to the emergence o f mutation V75I in the RT gene 
(11). A similar change, i.e. V75T, has earlier been associated 
with resistance to stavudine (19). Mutations M184V and T69N  
are other previously known resistance-conferring mutations 
that emerged under the selective pressure of ACV; however, 
V75I outgrew the culture over protracted periods of time, sug­
gesting that this mutation is strongly associated with ACV 
resistance. HIV variants containing V75I showed marked 
increases in 50% effective antiviral concentrations (EC50), 
which confirms the selection experiments (11).
Here we studied the underlying biochemical mechanism of 
HIV resistance to ACV associated with V75I. Two major mech­
anisms of resistance to nucleoside analogue RT inhibitors 
(NRTIs) have been described (20-24). The first mechanism is 
based on substrate discrimination. In this case the mutant 
enzyme can selectively diminish binding and/or incorporation 
of the nucleotide analogue, whereas the properties of the natu­
ral counterpart remain largely unaffected. M l84V  that confers 
high level resistance to 2',3'-dideoxy-3'-thiacytidine is a prom­
inent example in this regard. The second major resistance 
mechanism associated with NRTIs is based on excision. In this 
case, the mutant enzyme can increase the rate of excision of the 
incorporated inhibitor. Thymidine analogue-associated muta­
tions (TAMs) were shown to be able to recruit ATP as a PPi 
donor and increase excision o f incorporated AZT-MP (17). In 
this study we demonstrate that V75I discriminates against 
ACV-TP at the level of incorporation. Excision of the incorpo­
rated nucleotide is also increased when compared with wild 
type RT; however, the effect is less pronounced, as seen with the 
excision of ACV-MP against a background of TAMs. V75I does 
not provide further protection from excision through DEC for­
mation. Collectively, the data suggest that ACV is vulnerable to 
both major resistance mechanisms.
EXPERIMENTAL PR O C E D U R ES
Enzymes and Nucleic Acids—Heterodimeric reverse tran­
scriptase p66/p51 was expressed and purified as described (25). 
Mutant enzymes were generated through site-directed 
mutagenesis using the Stratagene QuikChange kit according to 
the manufacturer’s protocol. TAM2 refers to HIV1-RT con­
taining the following substitutions: D67N, K70R, T215F, and 
K219Q. Oligodeoxynucleotides used in this study were chemi­
cally synthesized and purchased from Invitrogen and from 
Integrated DNA Technologies. The following sequence was 
used as template T50A6: 5'-CCAATATTCACCATCAAGGC- 
TT G ATG AAACTT C ACT CC ACT AT ACC ACT C. The under­
lined nucleotides are the portion of the templates annealed to 
the primer. The following primer was used in this study: PI, 
5' -G AGTGGTATAGTGG AGTG AA.
Synthesis of ACV-TP—ACV (1.5 mmol) was dissolved in 200 
ix 1 of dry l,3-dimethyl-2-oxohexahydropyrimidine N,N'-dim- 
ethylpropylene urea with 12-15 molecular sieves under nitro­
gen and stirred for 24 h. The mixture was chilled with an ice- 
water bath and stirred for 1 h followed by slow addition of 3 eq 
of phosphorus oxychloride and stirring for an additional 25 
min. A solution of tributylammonium pyrophosphate (4 eq) in 
200 ix 1 of NUV'-dimethylpropylene urea and tributylamine (15 
eq) was simultaneously added to the reaction. After 45 min the 
reaction was quenched with ice-cold water, and then it was 
slowly brought to the room temperature. The reaction was 
washed with chloroform, and the aqueous layer was collected 
and co-evaporated with deionized water three times. The resi­
due was resuspended in 100 (xl of deionized water and purified 
on an ion-exchange column by high performance liquid chro­
matography A(max) =  253. To reduce the amount of excess salt, 
the final product was co-evaporated with water 5 times, giving 
total yield of ACV-TP (NH3)4 of 18% with purity ^95%. The 
molecular weight of the ACV-TP was confirmed by liquid chro­
matography-tandem mass spectrometry; m /z (M + 1) 466—>152 
(26).
Synthesis of CF2648—The ACV prodrug CF2648 was pre­
pared by the coupling o f suitably base-protected ACV with the 
appropriate phosphorochloridate reagent under anhydrous 
conditions followed by base deprotection, according to proce­
dures we have previously reported (27).
Competition between ACV-TP and dGTP—DNA synthesis 
was monitored with 5 '-end-labeled primers unless otherwise 
indicated. 150 nM DNA/DNA (T50A6/P1) was incubated with 
30 nM HIV-1 RT in a buffer containing 50 mM Tris-HCl, pH 7.8, 
50 mM NaCl, constant concentrations of dGTP (1 /a m ) and 
ddTTP (2 /a m )  or dNTP mix (1 /a m ) and increasing concentra­
tions of ACV-TP. Nucleotide incorporation was initiated by the 
addition of MgCl2 to a final concentration of 10 m M , and the 
reactions were allowed to proceed for 5 min. The reactions 
were stopped by the addition of 3 reaction volumes of formam- 
ide containing traces of bromphenol blue and xylene cyanol. 
The samples were then subjected to 15% denaturing PAGE fol­
lowed by phosphorimaging. Inhibitory concentrations of 
ACT-TP required to inhibit DNA synthesis at position + 2  by 
50% (IC50) was determined by normalizing the product fraction 
formed at position + 2  in the presence of ACV-TP to the cor­
responding value in the absence of inhibitor. Data points were 
fit to a sigmoidal dose response (variable slope) function using 
GraphPad Prism (Version 5.0).
ATP-dependent Excision—The T50A6/P1 DNA/DNA sub­
strate was extended by a single nucleotide to generate an oligo­
nucleotide with ACV-MP at the 3 '-end. The extended primer 
was gel-purified and annealed with template T50A6.50 nM sub­
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strate was then incubated w ith  500 nM H IV -1  R T  in a buffer 
containing 50 mM T ris -H C l, p H  7.8, 50 mM N aC l, 10 mM  
M gCl2, and 3.5 mM A T P  (pyrophosphatase-treated). A liquots  
were taken at d ifferent tim e points and analyzed as described.
Site-specific  F o o tp r in tin g — In  preparation o f the footprinting  
experiments, tem plate T 5 0 A 6  was 5 '-end-labeled  and heat-an­
nealed w ith  p rim er P I .  50 nM D N A /D N A  hybrid was incubated  
with 750 nM H IV -R T  fo r 10 m in  in a reaction m ixtu re contain­
ing sodium cacodylate, p H  7 (120  m M ), N a C l (20 mM), D T T  (0.5 
mM), M g C l2 (10 mM), and 25 fxM d d G T P  o r 5 /xm A C V -T P  in  a 
final volume o f 15 /x\. In  con tro l reactions d dG T P  and A C V -T P  
were either om itted  or substituted w ith  100 p \  phosphonofor- 
mic acid (PFA or foscarnet). A fte r  com plete com plex form ation  
and/or nucleotide incorporation , increasing concentrations o f 
dTTP were added to the reactions follow ed by an incubation o f 
5 min at 37 °C. For the actual footprin ting , complexes were  
treated w ith  0.1 mM am m o n iu m  iron  ( I I)  sulfate hexahydrate  
(28). The reactions w ere allow ed to proceed fo r 5 m in  and were  
processed and analyzed as described.
D E C  F o rm a tio n — D N A  synthesis at tem plate position + 1  
was conducted in a s im ilar fashion as described above except 
that a chain term ina tor (d d G T P , 25 jxm or A C V -T P , 2.5 jam) 
was incorporated at this position. A  tim e  course o f incorpora­
tion o f the chain te rm in a to r at position + 1  in the absence or in 
the presence o f increasing concentrations o f the nucleotide at 
the following position, + 2 ,  was m onitored. T h e  reactions were  
processed and analyzed as described. Slopes o f the linear p or­
tion o f product fo rm ation  illustrate the velocities o f the reac­
tion, which when norm alized  to  the enzym e concentration, 
determine the turnover n um ber (k cat). In h ib itio n  o f D N A  syn­
thesis by D E C  fo rm ation  is illustrated by a decrease in  k caV
P re-s teady-s ta te  K in e tic s  f o r  N u c le o t id e  In c o rp o ra tio n — N u ­
cleotide incorporation u nder single-turnover conditions was 
monitored using a rapid  quench-flow  instrum ent (K in T ek  
RQF-3). Reactions involved rapid  m ix ing  o f a solution contain­
ing preincubated 100 nM D N A /D N A  tem p la te /p rim er hybrid  
with 500 nM H IV -1  R T  in  a b u ffe r consisting o f 50 mM T ris -H C l, 
pH 7 .8 ,50  mM N aC l, and 10 m M  M g C l2 at 37 °C w ith  a solution  
of the same buffer com position  except th at tem pla te /p rim er  
and R T  were substituted w ith  a given concentration o f d G T P  or 
A C V -TP . Nucleotide incorporation  was m onitored  at tim e  
points o f 0 .0 1 5 ,0 .0 2 5 ,0 .0 5 ,0 .0 7 5 ,0 .1 ,0 .2 ,0 .3 ,0 .5 , and 1 s. T he  
reactions were processed and  analyzed as described. Data  
points from  tim e courses w ere fit by nonlinear regression 
(GraphPad Prism (Version 5 .0 )) to  a single exponential equa­
tion, [product] =  A (1  — e x p (—A:observedt)), w here A  represents 
the am plitude, and £observed is the first o rder rate constant for 
dGTP or A C V -T P  incorporation . k observed w ere replotted ver­
sus increasing concentrations o f d G T P  or A C V -T P  to deter­
mine the respective £observed. D ata  points w ere fit to  a hyper­
bolic function, k observed =  £ p o i[d N T P ]/(/rrfidNTp +  [d N T P ]), 
where k pol is the m axim u m  firs t-o rd er rate constant for d G M P  
or A C V -M P  incorporation , and K d>dNTp *s equ ilibrium  dis­
sociation constant for the in terac tion  o f d G T P  or A C V -T P  w ith  
the R T -tem p la te /p rim er com plex.
Selection  o f  R es is ta n ce— M T - 4  cells w ere obtained from  the 
N IH  A ID S  Research and Reference Reagent Program  and 
infected w ith  H IV -  1LAI in the absence o r presence o f CF2648.
21498 JOURNAL OF BIOLOGICAL CHEMISTRY
TABLE 1
Inhibitory activity of ACV ProTide CF2648 against HIV-1 ^  04 in MT-4 
cells
 ____________________ W T  CF2648-selected virus -Fold increase
ECsq ±  S.E. (hm )“ 3.4 ±  2.8__________ 51 ±  2.3________________ 15_________
a ECS0, e ffe c tiv e  c o n c e n t r a t i o n  th a t  in h ib i ts  50% o f  HIV-1LAI 04 re p l ic a t io n  ±  S.E.
Every 3 - 5  days, 3% o f the culture supernatant was used to infect 
fresh cells. Cultures w ere m aintained in the absence or pres­
ence o f gradually escalating concentrations o f CF2648. H IV -1  
replication in  infected cultures was assessed by measuring 
p24gag from  cu lture supernatants, as previously described (10). 
Phenotypic resistance o f viruses serially passed in the absence 
or in the presence o f the CF2648 was evaluated in M T -4  cell 
cultures using drug concentrations ranging from  0 to 150 ju,M. 
T he effective concentration that inhibits 50% replication was 
calculated by fittin g  the data points to a sigmoidal dose-re- 
sponse curve using G raphPad Prism (Version 4.0).
G en o typ in g  o f  th e  D ru g -exp o sed  H IV -1  S tr a in s— V ira l R N A  
was extracted from  plasma using the Q IA a m p  V ira l R N A  M in i 
K it (Q iagen, H ilden , G erm any). H IV -1  R N A  was reverse-tran­
scribed into  c D N A , and a 2878-bp  nucleotide fragm ent encom ­
passing protease and reverse transcriptase was am plified in an 
outer PCR using S uperscript I I I  O ne-Step R T -P C R  System 
w ith  P latinum  T aq  H ig h  Fidelity  (lnvitrogen) and outer primers 
A V 1 90 -1  and CR1 (29). A  2853-bp  nucleotide fragm ent was 
am plified using Expand H ig h  Fidelity PCR System (Roche D iag­
nostics) and the inn er prim ers A V 1 9 0 -2  and CR2. A m plifica­
tion products w ere separated on a 1% agarose gel and visualized 
by eth id ium  brom ide staining. PCR products were purified w ith  
M icrosp in  S -400 (G E Healthcare). Sequencing was perform ed  
using the A B I P R IS M  BigDye T erm in a to r v3.1 Ready Reaction 
Cycle Sequencing k it as described before (29). T he  reactions 
w ere run  on an A B I3 10 0  G enetic Analyzer, and analysis was 
perform ed using Sequence Analysis Version 3.7 and SeqScape 
version 2.0 (A pplied  Biosystems, N ieuw erkerk a/d  Ijssel, The  
Netherlands).
RESULTS
S elec tion  o f  R esis ta n ce  w ith  C F 2648— The V 7 5 I m utation in 
H IV -1  R T  was shown to emerge rapidly under the selective 
pressure o f A C V  (11). T h e  poor production o f A C V -M P  and, in 
turn , the poor production  o f A C V -T P  is a possible factor that 
dim inishes the efficacy o f A C V  and facilitates the selection o f 
resistance. I t  is curren tly  unknow n w hether m onophosphoryl­
ated prodrugs can prevent o r significantly delay the develop­
m ent o f resistance. T o  address this problem , we attem pted to 
select for resistance w ith  the monophosphorylated prodrug  
CF2648. H IV -1  was propagated in M T - 4  cells in the presence 
of increasing concentrations o f CF2648. T he antiviral activity o f 
C F2648 after 39 serial passages (—120 days) in  the presence o f  
the com pound was reduced relative to  the control propagated 
in the absence o f the drug. Sequencing o f H IV -1  R T  revealed 
the emergence o f V 7 5 I, and phenotypic resistance measure­
ments revealed a 15-fold  increase in the EC50 value (Table 1). 
Overall, the data suggest that the selection o f V 7 5 I in the R T  
enzym e m ay not be prevented w ith  prodrugs that bypass the 
first phosphorylation step. G iven the potential relevance o f this
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+1
I
5 ' *GAGTGGTATAGTGGAGTGAA 
3 '  CTCACCATATCACCTCACTTCAAAGTA..
dG T P /ddT T P  
A A C V -T P
+ 1 
I
5 '  *...GAAGT 
3 '  ...CTTCAAAGTA...
+ 1
5 '  *...GAAX 
3 '  ...CTTCAAAGTA.,
B
+To2
d G T P , 1 p M  and  ddT T P , 2 nM
W T V 75I
ACV-TP. pM A C V -T P , pM
2 ^ ^.2 'O (N
g  O  ©  — • (N u-> 2 o  o  o<N 'I- 00 o  <n *n o © <N o  ©  ©  ©— fN Tl- 00
+2 »
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■ W T  
□  V75I
1 10 
A C V -T P , pM
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FIGURE 2. C o m p e ti t io n  b e tw e e n  ACV-TP a n d  dG T P . A, reac tio n  sch em e . 
Nucleotide in co rp o ra tio n  w as m o n ito re d  a t p o s itio n s  + 1  a n d  + 2 . Letters in 
bold italic  illustrate th e  in c o rp o ra te d  nu c leo tid e(s) . X  illu stra tes  an  in c o rp o ­
rated ACV-MP. The asterisk p o in ts  to  th e  5 '- e n d  ra d io la b e led  prim er. B, tw o  
nucleotide inco rp o ra tio n  e v e n ts  in th e  p re s e n c e  o f c o n s ta n t c o n ce n tra tio n s  
of dGTP a n d  ddTTP a n d  in c re a s in g  c o n c e n tr a tio n s  o f ACV-TP. A C V -m ediated 
inhibition of DNA sy n th esis  is m o n ito re d  a t p o s itio n  + 2 ,  a n d  co rre sp o n d in g  
arrows illustrate th e  m ig ra tio n  p a t te rn  o f n o n -e x te n d e d  s u b s tra te  an d  
extended prim ers. C, g ra p h  o f d a ta  sh o w n  u n d e r  B. Dotted lines illu stra te  a 
shift in IC50.
mutation in clinical settings, we studied the underlying bio­
chemical mechanisms.
D iscrim ination aga in s t A C V -T P — W e initially studied sub­
strate discrimination as a possible mechanism for resistance. 
Classic protocols that address this problem include steady-state 
kinetics that measure efficiencies o f incorporation of the inhib­
itor and its natural counterpart in separate experiments. H ow ­
ever, with this approach we were unable to detect significant 
differences between purified w ild  type (W T ) R T  and the 
mutant enzyme containing V 7 5 I (data not shown). W e consid­
ered two potential problems associated w ith  this assay. First, 
incorporation of the inh ibitor was measured in the absence of 
the natural counterpart dG TP. Therefore, we devised an assay 
that monitors incorporation o f A C V -M P  in the presence of 
both A C V -T P  and dG TP  (Fig. 2A ). The prim er/tem plate was 
designed to m onitor incorporation o f A C V -M P  at the next
V +7I
5 ' *A TTC TG A C TA A A A G G G TC TG A G G G A  
3 '  T A A G A C TG A TTTTC C C A G A C TC C C TA G A G A TC A A TG
B dNTP mix, lp M
f l *
+ 7
W T V751
^  A C V -T P , p M A C V -T P , p M
c  m
'* 5  o  o  o o  O  -  fN m  — M -to o ™ ‘O o  o o  ©  o  -  (N < n r- rs ^  oc
c
1001 ►
>
< 50-
■ W T  
□  V 75 I
1000 1 10
A C V -T P , p M
FIGURE 3. C o m p e ti t io n  b e tw e e n  ACV-TP a n d  dG TP d u r in g  la te r  s ta g e s  o f 
DNA s y n th e s is .  A, DNA/DNA p rim er /te m p la te  s u b s tra te  u sed  in th e  experi­
m en t. ACV-MP in c o rp o ra tio n  w as m o n ito red  a t position  + 7 . The asterisk 
p o in ts  to  th e  5 '- e n d  rad io lab e led  p rim er. B, m ultip le  n u c leo tid e  inco rpo ra ­
tio n  e v en ts  in th e  p re sen c e  o f c o n s ta n t c o n ce n tra tio n  o f dNTP mix an d  
inc reasing  c o n c e n tra tio n s  o f ACV-TP. Arrows illustra te  th e  m ig ration  p a tte rn  
o f n o n -e x te n d e d  s u b s tra te , e x te n d e d  p rim ers by sev en  nuc leo tides , an d  full- 
le n g th  (fD p ro d u c t. C, g ra p h  o f d a ta  sh o w n  u n d e r  B. Dotted lines p o in t to  50% 
p ro d u c t fo rm atio n ; h o w ever, w e  w e re  u n ab le  to  accu ra te ly  d e te rm in e  IC50 
va lues u n d e r  th e s e  co n d itio n s . In co rpo ration  o f ACV-MP is generally  d im in ­
ished  w h e n  c o m p a re d  w ith  th e  s e q u e n c e  u sed  in Fig. 2.
template position (n +  1) after the 3'-end o f the primer («). 
Incorporation o f A C V -M P  causes chain termination, whereas 
incorporation o f d G M P  allows the addition of a second nucle­
otide that is provided as a "stop nucleotide,” which limits D N A  
synthesis and reduces complexity of the assay. The natural 
dG TP was provided at a constant concentration of 1 p,M, and 
A C V -T P  was provided at varying concentrations (Fig. 2B). W e  
found that the concentrations required to diminish dinucle­
otide extensions by 50% were significantly higher w ith the 
mutant enzyme, which suggests that the V 75 I mutant increases 
discrimination against the inhibitor (Fig. 2Q . W e obtained 
essentially the same result w ith  a different primer/template  
sequence that allowed us to m onitor A C V -M P  incorporation at 
template position + 7  (Fig. 3).
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TABLE 2
P re - s te a d y  s t a t e  p a r a m e te r s  f o r  n u c l e o t id e  in c o r p o r a t io n  b y  W T a n d  V 75I m u t a n t  RT
Substrate
Enzyme dGTP ACV-TP SELa RES*
pol /C
WT
V75I
66 ±  3.(7 
114 ±  2.9
1.3 ±  0.16 
3.7 ±  0.18
51
31
14 ± 0.39 
1.5 ±  0.071
2.2 ±  0.18 
3.8 ±  0.43
6.4
0.40
8.0
78
1.0
9.8
“ SEL, selectiv ity , is  c a lc u la te d  as  a r a t io  o f  k pn{IKd fo r  d G T P  o v e r  k poi/ K d  fo r  A C V -T P .
h RES, res is tan ce , is c a lc u la te d  as  a r a t io  o f  se le c tiv ity  o f  W T  o v e r th e  se lec tiv ity  o f  V 75I m u ta n t  RT.
r E rro rs  re p o r te d  re p re s e n t  th e  d e v ia t io n  o f  p o in ts  fro m  th e  c u rv e  fit g e n e ra te d  by G ra p h P a d  P r ism  (V e rs io n  5.0).
A second common problem  associated w ith classic steady- 
state kinetics is that the m ultip le turnovers can mask differ­
ences in substrate binding or catalysis (30). T o  address this 
problem we measured kinetic parameters under pre-steady- 
state conditions, which provides at the same tim e mechanistic 
insight (Table 2). W T  R T  binds A C V -T P  and dG TP w ith  simi­
lar affinity as evidenced by K d  values o f 2.2 and 1.3 /um, respec­
tively. However, the rate o f incorporation is significantly higher 
for dG M P (/rpo, =  66 s" *) as compared w ith  A C V -T P  (/rpo, =  14 
s-1 ), which translates to an 8-fo ld selective advantage o f the 
natural nucleotide over the inh ib itor w ith  regard to the effi­
ciency of nucleotide incorporation {k poXIK d ).
The efficiency o f incorporation o f the natural nucleotide is 
not largely affected by the V 7 5 I m utation. The subtle increase in 
the K d  value is neutralized by a subtle increase in the k poi value, 
and these variations are not considered to be relevant. H o w ­
ever, we measured a marked decline in the rate o f incorporation  
for A C V -M P  when V 7 5 I is compared w ith  W T  R T (Arpo, =  1.5 
s-1 v ersu s  k po, =  14 s_1), whereas the K d  value is not signifi­
cantly increased. The selective effect on the rate constant sug­
gests that V 75 I affects the catalytic step. Nucleotide binding o f 
A C V -TP  is not significantly changed. Overall, the data point to 
a 10-fold increase in discrim ination against the inhibitor at sin­
gle nucleotide resolution.
E x c is io n  o f  A C V - M P — A n  increased rate o f excision is yet 
another possible mechanism that could help to explain the 
resistance phenotype associated w ith  V 75 I. W e  devised a 
primer that was term inated w ith  A C V -M P  and studied the effi­
ciency of the A TP-dependent excision reaction w ith  W T  RT, 
V75I, and a m utant enzyme that contains four T A M s  (D 67N , 
K70R, T215F, and K219Q ). This particular combination repre­
sents the T A M 2  pathway. Like other combinations of TA M s, 
this cluster facilitates the recruitm ent o f A T P  as a PPi donor. In  
agreement w ith previous reports, excision w ith  W T  R T is inef­
ficient (Fig. 4). However, V 7 5 I appears to increase the efficiency 
of A C V -M P  excision over tim e, and the T A M -conta in ing  
enzyme shows further significant increases. Thus, increases in 
excision of the incorporated A C V -M P  may be considered as 
another possible factor that contributes to A C V  resistance.
P o s it io n in g  o f  R T  o n  A C V - t e r m i n a t e d  P r im e r s — The precise 
positioning of R T on its prim er/tem plate  and, in turn, enzy­
matic function can be influenced by the chemical nature o f the 
3'-end of the prim er (31, 32). Before nucleotide incorporation, 
the enzyme needs to translocate a single position farther down­
stream, which liberates the nucleotide binding site from the 
3'-end of the prim er (28, 33, 34). In  contrast, excision can only 
take place when the 3 '-end  o f the prim er occupies the nucleo-
Substrate: A CV -M P term inated prim er / tem plate 
A TP, 3.5 mM
W T V751 TAM2
Tim e, m in Tim e, min Time, min
f-<
O ^O'AiO © in © *0 © ©mom© 5-r^vo — <N ro m 'O —« — N N n  -  — N N m  I
s>
FIGURE 4. A T P -d e p e n d e n t  e x c is io n  o f  A C V -M P -co n ta in in g  p r im e rs .  Time 
co u rse  o f A T P -d e p en d e n t excision  of ACV-MP from  th e  3 ' -en d  of th e  p rim er is 
show n . The m ig ra tio n  p a t te rn  o f th e  5 '- e n d  rad ioac tively -labeled  p rim er (s) 
a n d  reac tio n  p ro d u c t (p) is illu s tra te d  by th e  c o rre sp o n d in g  arrows.
tide binding site (15, 21, 33). The two conformations are 
referred to as post- and pre-translocational states, and the RT  
enzyme is able to shuttle between the two conformations. W e  
have recently developed site-specific footprinting techniques 
that allow us to distinguish between the two complexes (28,32). 
Incubation o f R T -D N A /D N A  prim er/tem plate complexes with  
Fe2+ generates specific cuts on the template strand. These cuts 
are mediated through the RT-associated ribonuclease H  active 
site at the C -term inal dom ain o f the enzyme. Cleavage at posi­
tion - 1 7  is indicative for post-translocated complexes, whereas 
cleavage at position —18 is indicative for pre-translocated com­
plexes. Here we compared footprints obtained with W T  R T and 
V 7 5 I in complex w ith  either ddG M P - or AC V-term inated  
primers (Fig. 5). Complexes w ith  the bound nucleotide can only 
exist in the post-translocational state, whereas complexes w ith  
the PPi-analogue PFA exist pre-translocation (see controls). In 
an attem pt to gradually stabilize the complex (DEC formation), 
we increased concentrations o f the next complementary nucle­
otide, i.e. dTT P , which correlated w ith an increase in signal 
intensity. Complexes w ith  W T  RT and ddG M P-term inated  
primers exist predom inantly in the post-translocated state even 
in the absence o f nucleotide substrate. The signal is increased 
in the presence of increasing concentrations of the next nucleo­
tide, which confirms form ation o f a DEC in the post-transloca­
tional state. In  contrast, corresponding complexes w ith  A C V -  
term inated  prim ers are difficult to identify. M uch higher 
concentrations o f the next nucleotide are required to trap the 
complex in the post-translocational state. W e obtained very 
similar results w ith  the V 75 I mutant. The trend is the same, 
although the overall band intensity appears slightly diminished 
when compared w ith  W T  RT. Overall, these findings suggest 
that D E C  form ation is compromised with A C V -M P , and the
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A  .1 7
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5 ' GAGTGGTATAGTGGAGTGAA
3 ' CTCA CCA TA TCACCTCACTTCAAAGTAGTTCGGAACTACCACTTATAACC *
f t F e 2+/R N a se H  “ p o s t” 
I Fe27 R N a s e H  “ p r e ”
A d T T P
d d G T P  o r A C V -T P
+ 1
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3 '  CTCA CCA TA TCA CCTCACTTCA AA G TA GTTCGG AA CTA CCA CTTATA ACC *  
f t  F e2+/R N a se H  “ p o s t+ 1 ” 
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FIGURE 5. Site-specific fo o tp r in tin g  o f HIV1 RT-DNA s u b s tra te  com p lex es . A, reac tio n  sch e m e . C o m p lex es  
were tre a te d  w ith  Fe2+ a f te r  in c o rp o ra tio n  o f ACV-MP o r ddGM P. T he ad d itio n a l p re s e n c e  o f PFA o r dTTP 
provides co n d itio n s  to  tra p  th e  p re - o r p o s t- tra n s lo c a te d  c o m p lex , respec tive ly . The asterisk illu s tra te s  a 5 '- e n d  
radioactively lab e led  te m p la te .  B, fo o tp r in tin g  p a t te rn s  w ith  ddG M P- o r A C V -M P-term inated p rim ers, minus 
Fe2+ rep re sen ts  a c o n tro l e x p e r im e n t in th e  a b s e n c e  o f Fe2+. plus Fe2+ re p re s e n ts  tre a tm e n t  o f  b in a ry  c o m ­
plexes w ith  Fe2+ b e fo re  n u c le o tid e  in c o rp o ra tio n . PFA 100 pM re p re s e n ts  th e  fo o tp r in t in th e  p re s e n c e  o f  100 
jxM PFA th a t trap s  th e  p re - tra n s lo c a te d  c o m p lex .
V75I m u ta tio n  m ay  fu r th e r  c o n tr ib u te  to  th is  effect. T h e  d im in ­
ished signal p o in ts  to  in c rea sed  c o m p lex  d issoc ia tion .
DEC Form ation— T o  c o m p a re  an d  q u an tify  th e  ab ility  o f  W T  
RT and  V75I to  fo rm  a D EC , w e m e a su re d  th e  tu rn o v e r  after 
incorporation  o f  A C V -M P  an d  d dG M P , respectively . T he 
sim ultaneous in c lu sion  o f  th e  n e x t n u c leo tid e  a t d iffe ren t c o n ­
cen trations allow s fo rm a tio n  o f  th e  te rn a ry  D EC  (Fig. 6). In  th is  
set-up, increases in  th e  tu rn o v e r  n u m b e r  (A:cat) co rre la te  
inversely w ith  D EC  fo rm a tio n  (T ab le  3). W T  R T show s a 
decline in the  tu rn o v e r  w ith  d d G M P -te rm in a te d  p rim ers  and  
increasing c o n c e n tra tio n  o f  th e  n ex t nu c leo tid e . D EC fo rm a­
tion is ~ 8 -fo ld  e n h a n c e d  a t c o n c e n tra tio n s  o f  100 pM d T T P
w h en  co m p ared  w ith  th e  con tro l 
in  th e  absence  o f th e  nucleo tide  
su b s tra te . U n d e r th e  sam e co n d i­
tio n s  D EC fo rm atio n  is co m p ro ­
m ised  w ith  A C V -te rm in a ted  p rim ­
ers  (only  2-fold increases w ith  100 
)um d T T P ), and  V75I fu r th e r 
e n h an ces  th is effect. T hese findings 
suggest th a t DEC form ation  is likely 
to  be insignificant under physiologi­
cally relevant conditions w ith  dN T P 
concen tra tions below  100 pM. Thus, 
the  A C V -term inated  p rim er is u n ­
likely to  be pro tec ted  from  excision in 
the  m utational con tex t o f V75I.
DISCUSSION
T h e  p o ten tia l clinical benefit o f  
A C V  o r th e  p ro d ru g  version  valacy­
clov ir in tre a tin g  H IV /H SV -2 co -in ­
fec tion  has been  te s ted  in large clin ­
ical tria ls  (3 5 -3 7 ). H IV  co-in fec tion  
w ith  H SV -2 can exacerba te  disease 
p ro g ressio n  (38, 39). In su p p o rt o f 
th is  n o tio n , several tria ls have been 
show n  th a t  A C V -m ed ia ted  su p ­
p ressio n  o f H SV -2 is associated  w ith  
red u c tio n s  in H IV  viral load  (36,40). 
In  c o n tra s t, o th e r  tria ls failed to  
show  th a t  an ti-h e rp e tic  th erap y  
p rev en ts  in fec tion  w ith  H IV-1 (41, 
42). T w o su b seq u en t stud ies d em ­
o n s tra te d  th a t  A C V  can  also directly  
in h ib it H IV -1 rep lica tion  by ta rg e t­
ing  th e  R T  enzym e (10, 11). H ow ­
ever, th e  d ev e lo p m en t o f resistance  
can  co m p ro m ise  th e  an tiv ira l activ­
ity  in c lin ical se ttings. T h ree  differ­
e n t m u ta tio n s  in H IV-1 RT w ere 
show n to  em erge  u n d e r  th e  selective 
p re ssu re  o f A CV  in vitro, M l8 4 V , 
T 69N , an d  V 75I (11). E xperim en ts 
w ith  c o n s tru c ts  th a t  w ere g enera ted  
by  s ite -d irec ted  m u tagenesis  co n ­
firm ed  th e  se lec tion  experim en ts 
an d  revealed  th a t each  o f th e  th ree  
m u ta tio n s  can  red u ce  su scep tib ility  to  ACV. V75I show s by far 
th e  s tro n g e s t effect in  th is  regard . M oreover, h e re  we d e m o n ­
s tra te  th a t  V 75I is likew ise se lec ted  in  th e  p resen ce  o f a m o n o ­
p h o sp h o ry la ted  p ro d ru g  derivative o f A C V  th a t was developed  
to  bypass th e  b o ttle n e c k  in  th e  m etabo lic  c onvers ion  o f  A CV  to  
A C V -T P. A lth o u g h  o th e r  m u ta tio n s  in d e p e n d e n t o f o r  in co n ­
ju n c tio n  w ith  V 75I m ay  also c o n tr ib u te  to  H IV -1 resistance  to  
A C V  o r  its p ro d ru g s , h e re  w e focused  o n  th e  c h a rac te riza tio n  o f 
th e  effect o f  V 75I o n  th e  fu n c tio n  o f  RT.
R esidue V al-75  is loca ted  in close p ro x im ity  to  tem p la te  posi­
tion  n + 1 o p p o site  th e  in co m in g  n u c leo tid e  (Fig. 7) (43). T hus, 
a d irec t effect o f a m u ta tio n  a t th is  p o sitio n  on  b in d in g  a n d /o r
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FIGURE 6. DEC fo rm a t io n . G raph ical re p re s e n ta tio n s  o f tim e  co u rse  o f incor­
poration  o f ddGTP (A) or ACV-TP (8) ch a in  te rm in a to rs  a t position  +1 in th e  
absence  (closed squares) o r in th e  p re s e n c e  o f increasing  co n ce n tra tio n s  of 
the  nucleo tide  (dTTP) fo r th e  b in d in g  a t p o sitio n  + 2  (open symbols) are  
shown. Left an d  right graphs o f th e  p an e l re p re s e n t ddGTP in co rp o ra tio n  by 
WT RT an d  V75I, respectively . S lopes o f th e  linear p o rtio n  o f th e  no rm alized  
p roduct fo rm ation  illustra te  th e  tu rn o v e r  n u m b e r  (kcax) (Table 3).
TABLE 3
In h ib itio n  o f  DNA s y n th e s is  b y  W T RT a n d  V75I m u ta n t  RT th r o u g h  
DEC fo rm a t io n
Enzyme
W T V75I
^cal DEC"
-Fold
change* ^cat DEC
-Fold
change
ddGTP1 
dTTP^O^M 
dTTP 10 jam
m in~‘
0.46 ±  0.057* 
0.16 ± 0.014 2.9 1.0
m in~ ‘
0.77 ±  0.078 
0.51 ±  0.021 1.5 1.9
dTTP 100 fiM 0.060 ± 0.0057 7.7 1.0 0.23 ±  0.014 3.3 2.0
ACV-MP 
dTTP*0 mm 
dTTP 10 mm
0.63 ± 0.028 
0.54 ± 0.0071 1.2 1.0
0.64 ±  0.15 
0.65 ±  0.078 1.0 1.2
dTTP 100 mm 0.27 *  0.014 2.3 1.0 0.55 ± 0.021 1.2 1.9
“ DEC fo rm a tio n  is ca lc u la te d  as a r a t io  o f  kcat in  th e  ab sen c e  o f  d T T P  o v e r£ cat in  th e  
p resen ce  o f  dT T P .
h -Fold ch a n g e  reflec ts  d iffe re n c e s  in  D E C  fo rm a tio n  by  W T  R T o v e r  V 75I m u ta n t  
RT.
c T h e  3 '-e n d  o f  th e  p r im e r  w as te rm in a te d  in th e  p re s e n c e  o f  d d G T P  o r  A C V -T P  to  
p rev en t in c o rp o ra tio n  o f  th e  n e x t  n u c le o tid e  d u r in g  D E C  fo rm a tio n .
* N ex t c o m p le m e n ta ry  n u c leo tid e .
* S.D. w ere d e te rm in e d  on  th e  b a s is  o f  a t  lea s t th re e  in d e p e n d e n t e x p e rim e n ts .
incorporation  o f nucleoside  analogues is n o t evident. V75I is 
part o f the  “Q 151M  c lu s te r” th a t  is associa ted  w ith  m ultip le  
resistance to  N R T Is (44, 45). H ow ever, in  th is con tex t, V75I 
does n o t appear to  co n tr ib u te  to  th e  resistance  phenotype; the  
m utation  ra th e r com p en sa te s  for enzym atic  deficits th a t are 
in troduced by Q 151M  (46). A  re la ted  m u ta tio n , i.e. V 75T, has 
been associated  w ith  low  level ( 3 -  4 - fold) resistance  to  stavu- 
dine, w hich is a 2 ',3 '-u n s a tu ra te d  th y m id in e  analogue and, 
therefore, stru c tu ra lly  d is tin c t from  A C V  (19,46). T h e  increase 
of approxim ately  1 -2  o rd e rs  o f  m ag n itu d e  in  resistance  to  ACV  
is by far the s tro n g est effect th a t has been  rep o rted  fo r changes 
at this position  (Ref. 11 and  th is  study). W e consider th ree  co m ­
plem entary m echan ism s th a t  he lp  to  explain  the  res istan t 
phenotype.
FIGURE 7. R e la tiv e  lo c a tio n  o f  V al-75  a n d  c ritic a l o th e r  a m in o  a c id  re s i­
d u e s  in HIV-1 RT. The crystal s tru c tu re  o f HIV-1 RTin com plex  w ith tenofov ir 
a n d  p rim e r /te m p la te  (PDB c o d e  1105) (62). Tenofovir is show n  in cyan, p rim er 
position  is in red, a n d  te m p la te  p o sitions  n a n d  n +  1 are  highlighted in green. 
R esidues im p lica ted  in re s is ta n ce  a re  labe led  (see "Discussion").
D iscrim ination against A C V -TP —C om petition  experim en ts 
u n d e r s tead y -s ta te  co n d itio n s and  p re-steady-sta te  kinetics 
suggest th a t V 75I fu r th e r  d iscrim inates against the inhibitor. 
T he  selective advan tage  for th e  n a tu ra l nucleo tide over the 
inh ib ito r th a t is seen  w ith  W T  RT is 10-fold increased  w ith  the 
V75I m u tan t. T h e  d ifference can  be assigned to  equivalent 
changes in /rpo, values. T hus, th e  V75I m u ta tio n  appears to  co m ­
prom ise  th e  chem ical step , w hereas affinities to  substra te  and 
in h ib ito r rem ain  largely unchanged . T h is resu lt is unexpected  
given th e  considerab le  d is tance  betw een  V al-75 and  the active 
site o r th e  in co m in g  n u c leo tide  (Fig. 7). T he V75I change may, 
therefo re , in d irec tly  affect th e  catalytic step. Specific decreases 
in A;po, values have been  rep o rted  for o th e r N RTI resistance- 
associated  m u ta tio n s  (47 ,48). K65R and  Q 151M  are im p o rtan t 
exam ples in th is  regard  (4 7 -50 ). Lys-65 is located  in close p ro x ­
im ity  to  th e  y -p h o sp h a te  o f the  incom ing  nucleotide, w hich 
ind icates th a t changes a t th is  position  m ay affect its p roper 
a lignm en t w ith  th e  a ttack in g  3 '-e n d  o f the  prim er. T he side 
chains o f G in -151 an d  also A rg-72 are  seen in the vicinity  o f the 
a -p h o sp h a te  o f th e  incom ing  nucleo tide, w hich  suggests a 
d irec t role in th e  cata ly tic  step  (51,52). By extension , changes at 
th is position  can  d irec tly  com prom ise  catalysis a t the cen te r o f 
th e  reaction . It is, th ere fo re , conceivable th a t changes at posi­
tion  V al-75 can  affect th e  precise  position ing  o f one o f the tw o 
residues o r b o th , w h ich  cou ld  help  explain the  observed 
decreases in /rpol values. T h e  backbone o f V al-75 is in con tac t 
d is tance  w ith  th e  backbone o f G in -151, and  subtle s truc tu ra l 
a lte ra tio n s a t V al-75, i.e. V75I, can  im pact on  the  position ing  of 
A rg-72, b o th  p a rt o f  th e  flexible j33-/34 ha irp in  loop th a t traps 
th e  incom ing  nucleo tide . R egardless o f th e  precise m echanism , 
th e  effect o f V 75I o n  A C V -M P in co rp o ra tio n  appears to  be 
ind irec tly  m ed ia ted  th ro u g h  o th e r  am ino  acids. In  con trast, 
classic N R T I-associa ted  m u ta tions, such  as M l84V , K65R, and 
Q 151M , d isc rim in a te  against the  inh ib ito r d irectly  a t the active 
site.
P revious o th e r  s tud ies  have show n th a t changes a t V al-75 can 
also affect th e  affinity  to  th e  substra te . V 75T  show ed increases 
in /^ v a lu e s  fo r stavud ine  w ith o u t affected /rpol (46). M oreover, 
m ispair ex tens ion  ex p erim en ts  w ith  th e  V75I m u tan t enzym e 
show ed likewise sign ifican t increases in Kd values w ithou t 
affecting Zrpol (53). T o g e th e r th e  resu lts suggest th a t changes at 
position  V al-75 can  affect nucleo tide  inco rp o ra tio n  th rough
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different mechanisms. M u ta tio n s  at this position can affect 
substrate b inding or the catalytic step. W h e th e r the effects o f 
V 75 I on the catalytic step o f A C V -M P  incorporation can be 
ascribed to the acyclic nature o f the inh ib ito r remains to be 
seen. However, in this context it is interesting to note that the  
acyclic phosphonate tenofovir, w hich  is an im portan t com po­
nent in currently used drug regimens, is sensitive against the  
Q 151M  cluster that includes V 7 5 I (54).
E xcision  o f  A C V -M P — Excision o f incorporated N R T Is  is a 
second m ajor m echanism  fo r N R T I resistance. T A M s  increase 
the excision o f A Z T -M P  w hen  com pared w ith  W T  R T  (15 ,16);  
however, the reaction is not restricted to  thym id ine analogues. 
The efficiency o f the A T P -d ep en d e n t excision reaction is rela- 
; tively high w ith  A Z T -M P  at the 3 ' -end  o f the prim er. In  con­
trast, ddN M P s and 2 ',3 '-d id e o x y -3 '-th ia c y tid in e -M P  te rm i­
nated prim er strands are poor substrates for the reaction, 
although these nucleotides analogues are n ot com pletely resist­
ant to excision (55). H e re  we dem onstrate that a m utant 
enzyme containing four T A M s  can also m arked ly increase exci­
sion o f A C V -M P . O f  note, p urin e  analogues are usually poorly  
excised when com pared w ith  th e ir p yrim id in e  counterparts, 
which indicates that the base m o iety  is an im p ortan t d eterm i­
nant for the reaction (56). H ow ever, the acyclic purine ana­
logues tenofovir (32) and A C V -M P  are both  efficiently  
removed from  the p rim e r term inus, suggesting th at the 
increased flexib ility o f the acyclic lin ke r between the base and 
the phosphate or phosphonate o f these com pounds can facili­
tate the reaction.
The V 7 5 I m utation  shows an in term ediate  phenotype when  
the excision o f A C V -M P  is com pared w ith  W T  R T  and T A M s . 
However, the m echanism  associated w ith  such an increase in 
efficiency o f the excision reaction is likely to be d ifferent as 
described for T A M s . T A M s  w ere shown to facilitate b ind ing  o f 
A TP  in a catalytically com petent fashion (15). T h e  arom atic  
side chains o f T 2 1 5 Y  or T 215 F , i.e. the h allm ark fo r A Z T  resist­
ance, are im plicated in stacking in teraction  w ith  the base m o i­
ety o f A T P , w hich facilitates its b ind ing  in  an orien tation  that 
allows its use as a PPi donor (Fig. 7). In  contrast, the position o f  
Val-75 in close p ro x im ity  to  tem plate  position n  +  1 and the  
nature o f the am ino acid substitution do n o t support such in te r­
action. T he m utation m ay ind irec tly  affect the excision reaction  
in a sim ilar m anner as proposed fo r the incorporation  o f A C V -  
MP; however, such an in te rac tion  w ou ld  be counterproductive. 
Thus, we also consider an alternative  interpreta tion . Excision o f 
A C V -M P  w ith  A T P  generates the A C V -(5 ')-te tra p h o sp h o - 
(5 ')-A  (A C V p 4 A ) that is eventually released from  the complex. 
The tetraphosphate can be used as a substrate (16 ,5 7 ), resulting  
in re-incorporation o f A C V -M P . A t  this level, the V 7 5 I m utant 
has a disadvantage over W T  R T , w h ich  leads to  an accum ula­
tion o f the excised product. In  contrast, T A M -c o n ta in in g  
enzymes do not significantly affect the efficiency o f incorpora­
tion o f nucleotide analogues (5 8 - 6 0 ) .
D E C  F o rm a tio n — T h e fo rm atio n  o f a D E C  w ith  the next 
complementary nucleotide after the chain term ina tor at the 
3'-end o f the p rim er has tw o m ajor consequences. First, the 
bound nucleotide stabilizes the com plex, w hich  translates in a 
diminished tu rnover o f the reaction under steady-state condi­
tions (61). Th is  experim ental set-up allowed us to com pare and
AUGUST 7 ,2 0 0 9 ’VOLUME 284-NUMBER 32
to  quantify  D E C  fo rm atio n  o f W T  R T  w ith  m utant V 7 5 I RT. 
A C V -M P  generally dim inishes D E C  form ation w hen compared  
w ith  d dG T P , and V 7 5 I increased this effect. A  sim ilar effect has 
been observed w hen com paring tenofovir w ith  d dA TP , sug­
gesting that the acyclic lin ker can negatively influence nucleo­
tide b inding (32). V 7 5 I m ay fu rth er affect D E C  form ation  
through structural alterations at tem plate position n  +  1 that is 
com plem entary to  the next nucleotide. O f  note, our data show 
at the same tim e  th at neither the A C V -term in ate d  prim er nor 
the V 7 5 I m u tatio n  affect the distribution o f pre- and post­
translocated complexes.
T h e  second m ajor consequence o f a stable D E C  is that the 
3 '-en d  o f the p rim e r is protected from  excision (16). The nucle­
otide traps the com plex in  its post-translocational state, w hich  
prevents excision to occur (33). Th is observation is o f potential 
biological relevance considering that W T  R T  can excise A C V -  
M P , although the reaction is inefficient.
C o n c lu s io n — T h e  results o f this study suggest that d iscrim i­
nation against the in h ib ito r at the level o f incorporation is the 
dom inant m echanism  associated w ith  A C V  resistance con­
ferred by V 7 5 I. Protection against excision is compromised  
through d im inished fo rm ation  o f a ternary D EC , and T A M s  can 
directly increase efficiency o f excision o f A C V -M P . Thus, A C V  
appears to be vulnerable to  both m ajor N RTI-associated resist­
ance pathways. I t  is, therefore, essential to characterize the 
detailed resistance profile o f this com pound to better assess its 
potential clinical u tility  in com bination w ith  established an ti­
retrovirals. T h e  use o f A C V  m ight be com prom ised in persons 
w ho w ere recently infected w ith  resistant H IV  variants. In  addi­
tion, the clinical use o f A C V  may cause the emergence o f resist­
ance m utations th at can decrease susceptibility to established 
antiretroviral agents.
A cknow ledgm ent— W e th a n k  Suzanne M cC orm ickfor excellent tech­
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The Application of Phosphoramidate Protide Technology to Acyclovir Confers Anti-HIV Inhibition
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R ecently, it has been repo rted  th a t phosphorylated  acyc lovir ( A C V )  inh ib its  h um an  im m unodeficiency  
virus type 1 ( H IV - 1 )  reverse transcriptase in a cell-free system. T o  d e liver p ho sp horylated  A C V  inside 
cells, we designed A C V  m o n op h osph ory la ted  derivatives using P ro T id e  technology. W e  found th at the  
L-alanine d erived  P ro T id es  show  a n t i - H IV  ac tiv ity  a t n o n cy to to x ic  concentrations; ester and aryl 
varia tio n  was to le ra te d . A C V  P ro T id es  w ith  o ther am in o  acids, o th e r th an  L -phenylalan ine, showed no  
detectable ac tiv ity  against H I V  in cell cu lture. T h e  in h ib ito ry  ac tiv ity  o f  the prodrugs against herpes 
simplex virus ( H S V )  types -1 and  -2  and th ym id in e  k inase-defic ient H S V -1  revealed d iffe ren t structure— 
activ ity  re la tionsh ips b u t was again  consistent w ith  successful nucleoside kinase bypass. E n zym atic  and  
m olecu lar m o d e lin g  studies have been p erfo rm ed  in o rder to  b etter understand  the a n tiv ira l behavio r o f  
these com pounds. P ro T id es  show ing d im in ished  carboxypeptidase la b ility  trans la ted  to  p o o r a n t i -H IV  
agents and vice versa, so the assay becam e predictive.
Introduction
Hum an immunodeficiency virus (H IV " )  belongs to the 
retroviradae fam ily and causes the acquired im m unodefi­
ciency syndrome (A ID S ) . A  variety o f different compounds 
have been developed for the treatm ent o f  H IV ,  and currently 
25 drugs have been approved for clinical use including nucleo­
side reverse transcriptase inhibitors (N R T Is ) ,  non-nucleoside 
reverse transcriptase inhibitors (N N R T Is ) ,  protease inhibi­
tors (P I), a viral fusion inh ib itor (F I) ,  a C C R -5  coreceptor 
inhibitor, and a viral integrase ( IN )  inh ib ito r.1
Because o f the rapid development o f  drug resistance as well 
as to the toxicity shown by these drugs,2 novel a n t i-H IV  
agents are needed. Diverse structures are sought to  address 
the constant threat o f  v ira l resistance.
In  this context, recently it has been reported how the 
antiherpetic drug acyclovir (A C V , 1, Figure 2) inhibits H IV  
upon human herpesvirus ( H H V )  coinfection in tissue cul­
tures.3 This activity was found to be correlated w ith the 
phosphorylation o f the parent drug to the monophosphate 
form mediated by H H V -en co ded  kinase(s). H IV  does not 
encode an enzyme that recognizes A C V  as a substrate for this 
activation (phosphorylation) step, hence the need for the 
H H V  coinfection for activity. T he  subsequent phosphoryla­
tions to the di- and triphosphate derivatives m ay be mediated 
by cellular guanosine monophosphate kinase and nucleoside 
diphosphate kinase, respectively.4,5 In  its triphosphate form ,
*To w hom  co rre sp o n d en ce  sh o u ld  be add ressed . P hone: + 4 4  29 
20874537. Fax: + 4 4  29 20874537. E -m ail: m cguigan@ card ifT .ac.uk .
"A bbrev ia tions: A C V , acyclov ir; H IV , h u m a n  im m unodeficiency 
virus; HSV, herpes sim plex v irus; N N R T Is , non -nucleoside  reverse 
transcrip tase inh ib ito rs; P I, p ro te a se  in h ib ito r; F I, fusion  inh ib ito r; 
H H V , h um an  herpes v irus; A C V M P , acyclov ir 5 '-m o n o p h o sp h a te ; 
D M F, N ,N -d im eth y lfo rm am id e .
A C V  inhibits H IV  R T  acting as a chain term inator.3 Follow ­
ing these results, it is evident that the a n ti-H IV  activity can 
only occur upon A C V  monophosphate (A C V -M P ) formation  
which requires H H V  coinfection. A C V -M P  itself can not be 
used as efficient a n t i-H IV  chemotherapeutic agent to bypass 
the first lim iting phosphorylation step because o f its instability 
in biological media and its poor efficiency o f diffusion through 
intact cell membranes. A  suitable strategy to overcome these 
lim itations would consist o f masking the negative charges o f 
the monophosphate w ith lipophilic groups. In  this regard, the 
phosphoramidate ProTide technology has been developed 
and successfully applied to  a range o f nucleosides o f antiviral 
and anticancer interest.6-9 The structural m o tif o f this app­
roach consists o f  masking the nucleoside monophosphate 
w ith  an aryl m oiety and an amino acid ester. Cell entry then 
apparently occurs by passive diffusion. Once inside the cell, 
the phosphoramidate prodrug is activated and converted to 
the monophosphorylated A C V  (Figure l ) . 10 The first step 
involves an enzymatic hydrolysis o f  the amino acid ester 
moiety mediated by an esterase- or carboxypeptidase-type 
enzyme followed by spontaneous cyclization and subsequent 
spontaneous displacement o f the aryl group and opening o f 
the unstable ring mediated by water. The last step before 
release o f the A C V  monophosphate involves a hydrolysis o f 
the P - N  bond mediated by a phosphoramidase-type enzyme. 
T he phosphoramidate ProTide approach has been already 
successfully applied to A C V , demonstrating its ability to 
bypass the thym idine kinase deficiency o f HSV-1 and -2 and 
varicella zoster virus strains resistant to A C V .11
In  this paper, we present the synthesis and in itia l b io lo ­
gical evaluation  o f a novel series o f A C V  ProTides  
(F igure 2). The P ro T id e  m oiety has three different change­
able parts: the ary l m oiety, the am ino acid, and the ester. In  
the first p art o f  this study, we have chosen L-alanine as the
pubs.acs.org/jmc Published on Web 07/31/2009 ©  2009 American Chemical Society
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Figure 2. AC V and its ProTides.
am ino acid, as it has shown previously an optim al b io log i­
cal p ro file ,12 varying the other tw o com ponents. F o r the  
aryl moiety we considered phenol, naphtho l, and /7-fluoro- 
phenol and as the ester m o iety  m ethyl, ethyl, 77-p ro py l, iso­
p ro p y l, ter t-butyl, and benzyl and com binations thereof. 
A ll o f these com binations allow ed us to  extensively vary  
the LogP for these com pounds and to study how this 
variation can influence the an tiv ira l activ ity . M o reo ver, it 
has been previously reported how  the substitutions can 
influence the b ioactivation  o f the P roT ide; fo r exam ple, 
naphthol has shown an enhancem ent o f activ ity  against a 
panel o f cancer cell lines fo r phosphoram idates6 and the 
tert-bnXyl ester showed a lack o f  bio logical activ ity  due to 
the poor bioactivation o f  the b u lky  m oiety. F o llow ing  the 
results for these derivatives, d iffe ren t am ino  acids have been 
considered including L-valine, L-leucine, L-isoleucine, l- 
proline, glycine, and the n o n -n a tu ra l D-alanine, D-valine, 
and dim ethylglycine. M o re o v e r, some interm ediate-prote­
cted (N 2- D M F ) - A C V  ProT ides have been biologically  
evaluated.
Chemistry
The compounds have been synthesized following the pro­
cedure reported by U ch iyam a13 using /er7-butylmagnesium  
chloride ( ‘B u M g C l) as a coupling reagent and using T H F  as a 
solvent in most o f  the cases.
Aryl phosphorodichlorophosphates 26 and 27 have been 
synthesized, coupling respectively 1 -naphthol (24) or p-fluor- 
ophenol (25) w ith  P O C l3 in the presence o f  E t3N  (lequ iv) 
(Scheme 1), while phenyl dichlorophosphate (28) was com­
mercially available. The coupling w ith  the appropriate amino  
acid ester salt (29—44) has been perform ed in the presence o f  
E t3N  (2 equiv) (Scheme 2), giving the final product (45—65) as 
an oil which was, in most o f the cases, purified by column 
chromatography.
Scheme \ a
or ( f j  _  1 ^  a J L c i  2 6 ' J-N aphtoy
V  A, 27, p-F-pheny!
oh  Cl
 7A  —   - ..................................................
" R eagen ts and  cond itions: (i) PO C l3, an h y d ro u s T E A , anhydrous 
E t20 ,  —78 °C , 1 h th en  r t, overn igh t.
Scheme 2"
Ft b 1 o
Ar O Ft. nR‘ . Ar O V —tf'1 1 V* <-» 1 1 1 / \
D - P - C I  + X - H g N ^ V ^ R ------------------   O - P - N H  O - R
Cl o Cl
26-28 29-44 45-65
A r  =  Ph. N aph , p -fluoro-P h
R , R ' =  L -A la , D -A la, Gly, DMG, L -V al,
D -V aJ, L -L eu, L -ile , L -Phe, L -P ro  
___________ R "  =  Mfi. F t .  nP r  ip r  tR ll  R n ____________________
"R e a g e n ts  and  cond itions: (i) an h y d ro u s T E A , anh y d ro u s D C M , 
—78 °C, 30 m in to  1 h , then  rt, 30 min to  4 h.
T o  improve the solubility o f A C V  in T H F ,  used as ideal 
solvent for the coupling reaction, the 2-amino was protected 
using dim ethylform am ide dimethyl acetal (Scheme 3). H o w ­
ever, compound 66 is not completely soluble in T H F  but the 
solubility was improved sufficiently to carry out the reaction. 
The final coupling o f  the nucleoside was performed using an 
excess o f  the appropriate phosphorochloridate (1 .50—4.00 
equiv) in the presence o f lB u M g C l (2 equiv). Because o f the 
reactivity problem , the use o f V-m ethylim idazole (N M I) ,  
following the V an  Boom procedure,14 was used for the 
synthesis o f the L-proline (22) and glycine (23) derivatives. 
M oreover, a m ixture o f T H F /p yrid in e  (3 /2) was used as a 
solvent to im prove the solubility o f  N 2-D M F -A C V .
The deprotection o f the dim ethylformyl D M F  derivative 
was initially carried out by refluxing the compound in
1-propanol (Scheme 3). However, because o f a transesterifica- 
tion during the synthesis o f  2, obtaining compound 3, the 
solvent was changed to 2-propanol, obtaining the desired 
compounds (2, 4—23).
A ll the compounds were obtained as a mixture of 
two diastereoisomers confirmed by the presence o f two peaks 
in the 31P N M R ,  w ith the exception o f the glycine and
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“ R eagen ts an d  cond itions: (i) d im e th y lfo rm am id e  d im eth y l ace ta l, an hydrous D M F , rt, 1 day; (ii) 'B u M g C l, T H F , rt, overn igh t o r N M I, T H F / 
pyridine = 3/2, rt, overn igh t; (iii) 1-p ro p a n o l, reflux , fo r  18 h o r  2 -p ro p an o l, reflux, 2 4 -9 6  h.
Table 1. A nti-H SV  A ctiv ity  fo r A C V  a n d  Its P ro tid e s
com pds aryl a m in o  acid ester C L o g P
antiv ira l activity E C 50° («M ) cy to to x ic /cy to sta tic  activ ity  (mM)
HSV-1 HSV-2 HSV-1 T K ~ M C C * (H el) 1C50‘ (H el)
2 N ap h L-Ala Bn 2.06 2 ±  0 1.4 ± 0 .8 10 ±  2.1 > 20 20
3 N a p h L-Ala nPr 1.41 5.5 ±  2.1 1.9 ±  1.6 16 ±  5.7 > 5 0 68
4 N ap h L-Ala M e 0.35 16 ±  5.7 10 ±  2.1 79 ±  29 > 5 0 > 100
5 N ap h L-Ala Et 0.88 32 ±  25 9.5 ± 0 .7 32 ±  18 > 150 > 100
6 N ap h i.-A la ’Bu 1.59 > 100 50 > 100 > 5 0 > 100
7 N ap h L-Ala ‘Pr 1.19 15 ±  7.1 10 ±  0 > 45 > 5 0 > 100
8 Ph L-Ala M e - 0 .8 2 20 ± 0 16 ±  5.7 79 ±  29 > 100 N D
9 Ph L-Ala Bn 0.89 8 ±  5.7 4 ±  0 15 ±  7.1 > 5 0 91
10 Ph L-Ala 'P r 0.02 1 0 ± 0 8.5 ± 0 .7 27 ±  25 > 5 0 > 100
11 p -F -P h L-Ala Bn 1 .11 0.9 ± 0 .1 0.5 ± 0 1.5 ± 0 .7 > 100 N D
12 Ph D-AIa Bn 0.89 2 ± 0 1.4 ± 0 .8 23 ±  16 > 100 N D
13 N ap h D M G Bn 2.37 2.4 ± 0 1.6 ±  1.1 3.2 ±  1.1 > 5 0 > 100
14 Ph D M G Bn 1.20 1.4 ± 0 .8 5 0.8 ±  0.0 5.5 ±  2.1 > 100 N D
15 Ph P h e Bn 2.31 17 ± 4 .2 8 ±  5.7 > 100 > 5 0 87
16 Ph L-Val Bn 1.82 2 ±  0 0.85 ±  0.2 7.5 ± 6 .4 > 100 N D
17 N a p h L-Val M e 1.28 > 100 > 1 0 0 > 100 > 100 N D
18 N a p h L-Val E t 1.81 51 ± 9 .2 32 ±  18 42 ±  3.5 > 100 N D
19 N a p h D-Val M e 1.28 > 100 > 100 > 100 > 100 N D
20 Ph L-Leu Bn 2.35 0.8 ±  0.07 0.7 ± 0 1.4 ± 0 .8 > 100 N D
21 Ph L-lle Bn 2.35 1.1 ± 0 .4 1.1 ±  0.4 1.4 ± 0 .8 > 100 N D
22 Ph L-Pro Bn 2.82 > 100 > 100 > 100 > 100 > 100
23 Ph G ly Bn 0.58 3 0.8 9 > 100 N D
ACV (1) - 2 .4 2 0.4 0.2 50 > 100 N D
“ 50%  E ffective c o n c e n tra tio n , o r  c o m p o u n d  c o n c e n tra tio n  requ ired  to inhib it v irus-induced cy top a th ic ity  by 
tion, o r  co m p o u n d  c o n c e n tra tio n  req u ired  to  cause  a m icroscopically  visible a lte ra tio n  o f  cell m orpho logy , 
com pound co n cen tra tio n  req u ired  to  in h ib it cell p ro life ra tio n  by 50% . N D  -  no t determ ined
50% . h M inim a] cy to tox ic  co ncen tra- 
' 50%  In h ib ito ry  co n cen tra tio n , o r
dimethylglycine derivatives, due to  the absence o f a chiral 
center, and L-proline, for which we were able to isolate only 
one diastereoisomer.
Biological R esults
A nti-H SV  A ctivity. The activ ity  o f  the compounds were 
evaluated against three d ifferent strains o f  H S V  including  
HSV-1 (K O S ), H S V -2  (G ), and th ym id ine kinase-deficient 
HSV-1 (A C V r ).
N ative A C V  showed subm icrom olar (E C s0: 0.4 and 
0.2 / /M )  activity against respectively H S V -1  and H S V -2  
(Table 1) but was inactive against T K -d e fic ie n t HSV-1  
(EC50: 50 fxM ). The A C V  ProTides did n ot show increased 
activity against H S V -1 and H S V -2  com pared to the parent 
compound. O nly  tw o compounds (11 and 2 0 ), respectively 
the /?-fluorophenyl-L-A la-O Bn and the phenyl-L -Leu -O B n
derivatives, showed a n ti-H S V  activity in the subm icrom olar 
range, while the m ajo rity  o f the compounds showed an 
activity in the range o f  ca. 1—30 / /M .  Com pound 6 having  
the bulky /-bu ty l group as ester m oiety did not show any 
marked activity (>  5 0 ^ M )  against the H S V  strains. A C V  has 
been evaluated against thym idine kinase-deficient HSV-1  
showing a dram atic loss o f  activity ( >  100-fo ld ) (E C 50: 
50 / /M ) .  Interestingly, several o f  the ProTides showed sig­
nificant retention o f  activity, dem onstrating a successful 
bypass o f  the first phosphorylation step (i.e., compounds 
11, 13, 2 0 , 2 1 ). N o tab ly , none o f the A C V  ProTides showed 
appreciable cytostatic/cytotoxic activ ity despite the potential 
loss o f an tiv ira l selectivity that could fo llow  from  viral 
nucleoside kinase bypass.
A nti-H IV  A activity. The A C V  ProTides have also been 
evaluated against H IV -1  and H IV -2  in C E M  and against
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Table 2. A nti-H IV  A ctivity o f  the A C V  P roT ides and  ACV
compels aryl am ino  acid ester
an tiv ira l activity  E C 5 0 " (wM) cy tosta tic  activity  (aM )
HIV-1 C E M H IV -2 C E M HIV-1 M T-4 ICso^CEM CC50r (M T-4) IC 5 0 6  (M T-4)
2 N ap h L-Ala Bn 15 ±  14 8.9 ± 6 .3 0.8 17 N D > 150
3 N aph L-Ala nP r 6.6 ±  5.6 24 ±  30 10 22 N D N D
4 N aph L-Ala M e 10 ± 7 .9 13 ±  6.4 4.7 ±  2.1 57 > 150 18.7 ±  3.2
5 N aph L-Ala Et 12 ± 9 .8 42 ±  13 1.7 ± 0 .8 32 ±  7.8 > 150 12 ±  5.3
6 N aph L-Ala 'B u > 100 > 100 > 150 > 100 > 150 > 150
7 N aph L-Ala ’Pr 6.2 ±  5.4 12 ± 0 .7 1 5.4 36 ±  15 > 150 72.5
8 Ph L-Ala M e 17 ± 4 .6 26 ± 8 .5 15 67 ±  7.8 N D N D
9 Ph L-Ala Bn 16 ±  14 11 ± 4 .9 5.7 ±  1.6 42 ±  11 > 150 33.8 ±  10.6
10 Ph L-Ala 'P r > 100 > 100 > 150 > 100 > 150 > 150
II p -F -P h L-Ala Bn > 2 0 > 2 0 N D 76 ±  13 N D N D
12 Ph D-Ala Bn > 2 5 0 > 250 N D > 250 N D N D
13 N aph D M G Bn >100 79 ± 3 0 N D > 100 N D N D
14 Ph D M G Bn > 100 > 100 7 > 100 > 150 > 150
15 Ph Phe Bn 26 ±  11 34 ± 2 4 16 42 N D N D
16 Ph L-Val Bn > 5 0 > 5 0 N D > 100 N D N D
17 N aph L-Val M e > 100 > 100 N D > 100 N D N D
18 N aph L-Val E t > 100 > 100 N D > 100 N D N D
19 N aph D-Val M e > 100 > 100 N D > 100 N D N D
20 Ph L-Leu Bn > 2 0 > 2 0 0.8 > 2 0 17 > 150
21 Ph L-Ile Bn > 2 0 > 2 0 N D N D N D N D
22 Ph L-Pro Bn > 2 0 > 2 0 N D > 100 N D N D
23 Ph G ly Bn > 100 > 100 N D > 100 N D N D
I T ' N aph D M G Bn > 2 0 > 2 0 15 40 ±  2.8 45 140
l% d Ph D M G Bn > 100 > 100 70 > 100 > 150 > 150
% \d N aph L-Val M e > 100 > 100 > 150 > 100 > 150 > 150
M d Ph L-Pro Bn > 2 0 > 2 0 30 45 ±  0.0 90 > 150
ACV (1) > 2 5 0 > 2 5 0 > 2 5 0 > 2 5 0 > 2 5 0 > 2 5 0
" 50%  Effective c o n cen tra tio n , o r c o m p o u n d  co n cen tra tio n  required  to  inhib it virus-induced 
or co m pound  concen tra tio n  requ ired  to  decrease the viability  o f  the cell cu ltures by 50% . ‘ 50%  
required  to inhib it cell p ro life ra tio n  by 50% . N D  =  n o t determ ined. rfN 2-D M F -A C V .
cy to p a th ic ity  by 50% . h 50%  
In h ib ito ry  co n cen tra tio n , or
C ytotoxic  concen tra tion , 
com pound  concen tration
H IV -1  in M T -4  cell cultures and in H IV -in fec ted  tonsillar 
tissues ex vivo (Table 2).
W hile  parent A C V  was inactive, in most o f the L-alanine 
derivatives (2 —11), w ith the exception o f 6, 10, and 11, 
showed activity (E C 50) in a range o f 6 .2—17 /uM  against 
H IV -1  (C E M ) and in a range o f 8 .9—4 2 / /M  against H IV -2  
(C E M ) (Table 2). S im ilar results were obtained when these 
compounds were applied to the H IV -l- in fe c te d  M T -4  cell 
cultures. In  these cells, parental A C V  was inactive whereas 
H IV  was suppressed by all the tested compounds with E C 50’s 
in the range o f 0 .8—30 f i M ,  w ith  the exception o f  6, 10, 78, 
and 81 (Table 2). The an tiv ira l activity o f the A C V  ProTides 
was confirmed in H IV -in fe c ted  tonsillar tissue ex vivo. The 
compounds 4, 5, and 9 suppressed H IV  replication with  
E C 50’s in a range o f 0 .1 —0.6 juM  (data not shown). These 
findings indicate that the A C V  ProTide approach can also be 
successfully applied to H IV -in fec ted  tissue.
N o  clear-cut structure—activ ity relationship could be ob­
served with regard to the nature o f the aryl moiety nor the 
alaninyl ester moiety in terms o f eventual antiviral activity o f 
the ProTide derivatives. The lack o f  activity-obtained for the 
/-butyl analogue (6) is in agreement w ith the previous report 
and w ith the enzymatic experim ent to be discussed later. A ll 
of these compounds showed an antiproliferative effect (on 
C E M  or M T -4  cell cultures) in a range between 17 and 
76 f iM .
W ith  regard to the am ino acid m odifications, we found 
that, besides the L-alanine ProTides, only the phenylalanine 
derivative (15) had activity against H IV -1  (2 6 / /M )  and H IV -  
2 (34 / /M ) .  A ll other derivatives, including D-alanine (12), 
dimethylglycine (13 and 14), L-valine (1 6 —18), D-valine (19), 
L-leucine (20), L-isoleucine (21), L-proline (22), and glycine
(23), did not show appreciable activity in C E M . These results 
are in agreement w ith previous reports for other nucleosides, 
in which the substitution o f the L-alanine w ith different 
natural L-amino acids gave loss (~ 1 0 - to 100-fold) o f anti­
viral ac tiv ity .15 How ever, in the case o f dimethylglycine, this 
result is quite surprising as this variation led usually to a 
retention o f a n t i-H IV  activity compared to the L-alanine 
derivatives.16
Interestingly, in M T -4  cell cultures, the am ino acid m od­
ification seems to be tolerated, in fact compounds 14 (D M G )  
and 20 (L-Leu), showed respectively an a n t i -H IV -1 activity o f 
7 and 0.8 / /M .
M oreover, in M T -4 , the N 2-D M F -p ro tec ted  A C V  Pro­
Tides (77 ,78 , and 86) showed activity against H I V - 1 (E C 50’s: 
15, 70, and 30, respectively), indicating that this kind o f 
substitution may be tolerated. However, in the case o f C E M ,  
these compounds did not show any inhibitory activity.
From  these results, it is possible to conclude that the 
am ino acid L-alanine is optim al for the a n ti-H IV  activity o f 
the A C V  ProTides. N e ither D-alanine nor glycine can effi­
ciently substitute for L-alanine nor can bulkier am ino acids.
In  contrast to the structural requirement for a n ti-H IV  
activities, the a n ti-H S V  activity tolerates liberal am ino acid 
variation. This m ay reflect different substrate specificities 
and/or different intracellu lar levels o f the necessary activat­
ing enzymes. I t  should indeed be noticed that the H IV  
assays are performed in rapid proliferating lymphocyte cell 
cultures (generation time ~  24 h), whereas the antiherpetic 
assays are carried out in confluent fibroblast monolayer 
(nonproliferating) cell cultures. Thus, the different cell-type 
and cell-cycle conditions between both assay models can 
result in different prodrug activation modalities that may
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explain the differential an tiv ira l activities o f  the A C V  Pro­
Tides.
Enzym atic Studies. The mechanism o f activation o f the 
ProTides involves a first enzym atic activation step mediated 
by carboxypeptidase-type enzyme(s), which hydrolyze the 
ester o f the am ino acid m oiety (F igure 1).
T o  probe the activation o f the A C V  ProTides to the 
monophosphorylated form  inside cells, we perform ed an
enzymatic study using carboxypeptidase Y  following the 
conversion by 3IP N M R .  O f  three different L-alanine deri­
vatives (9, 6, and 10), the first one is active vs H IV  and the 
second and third compounds are inactive against H IV ,  as 
well as the inactive L-valine 17 and D-valine derivatives 19 
that have been considered for these experiments. The assay 
has been carried out by dissolving the compounds in acetone- 
d(, and trizm a buffer (p H  =  7.6), incubating with the enzyme
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Figure 5. Carboxypeptidase-mediated cleavage of compound 6, monitored by 31P NM R.
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Figure 6. Carboxypeptidase-mediated cleavage of compound 17, monitored by 31P NM R.
and recording a blank for each sample before the addition o f 
the enzyme.
In the case o f the phenyl benzylalanine compound 9 
(Figure 3), the experiment showed a fast hydrolysis o f the 
starting material (<5P =  3.65 and 3.60) to the intermediate type 
88 (Figure 1) (<5P=4.85  and 4.70), noting the presence o f the two 
diastereoisomers. This intermediate is then processed to a 
compound o f type 90 (dP =  7.10) through the putative inter­
mediate 89, which is not detected by 3IP N M R . The half-life for 9 
is 17 min. In the case o f the isopropyl ester analogue 10 
(Figure 4), the experiment showed a slow conversion o f the 
starting material to 90 with a half-life of 46 h. This is ca. 150 times 
slower than 9. This result is in accordance with the inactivity of 
10 against H IV  (Table 2). Notably one o f the two diastereo­
isomers seems to be faster converted compared to the other one.
Compound 6, the naphthyl /-butyl alanine analogue 
(Figure 5), showed no conversion at all presumably due to 
the presence o f the /er/-buty l ester, which is too bulky to be 
processed by the enzyme. This observation is in agreement 
with the lack o f antiviral activity for this compound.
In  the case o f the L-valine derivative 17 (Figure 6), the 
experiment showed, as already demonstrated for compound 
10, a slow conversion to the compound o f  type 90, w ith  a 
half-life o f 72 h. The D-valine derivative 19 (F igure 7) was not 
processed due to the presence o f the non-natural am ino acid, 
which seems not to be recognized by the enzyme.
Also, C E M  cell extracts have been prepared to examine 
the rate o f hydrolysis o f the antivira lly active 9 and 4 and the 
inactive 6 derivatives. Whereas 9 and 4 were efficiently 
hydrolyzed within a short time period ( >  95%  conversion 
o f 9 and 65%  conversion o f 4 w ithin 1 h o f incubation), 6 
proved entirely stable after a 120 min incubation period 
(Figure 8). These observations are in agreement w ith the 
antiviral data and demonstrate that C E M  cell-associated 
enzymes can efficiently convert methyl and benzyl esters o f 
the A C V  ProTides but not Ze/7-butyl esters. Tonsil extracts 
were also found to efficiently hydrolyze 9 and 4, with the 
same preference profile o f 9 over 4 as found for the C E M  cell 
extracts (data not shown).
These experiments support the need o f activation o f A C V  
ProTide in order to deliver the A C V  monophosphate meta­
bolite. The enzym atic data correlate well with the in vitro  
a n ti-H IV  data and m ay support the role o f carboxypeptidase 
Y  in the ProTide activation in the lymphocyte cell cultures.
Stability  Studies o f  A C V  ProTide. T w o  different stability 
studies o f compound 9 using human serum and p H  1.0 buffer 
have been conducted. In  the case o f human serum, 9 was 
dissolved in D M S O  and D 20  and human serum was added. 
The experiment was conducted at 37 °C  and monitored by 
31P N M R .  In  Figure 9 are reported 3lP N M R  spectra 10 min 
after the addition o f the serum and after 12 h. F or a better 
resolution, both original spectra and deconvoluted ones have
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been reported. The spectra show that the A C V  ProTide is 
stable under these conditions. In  fact, after 12 h, 56%  o f the 
compound is still present. The spectra also show the form a­
tion o f the compound type 90 and the form ation o f a peak at 
(5P =  1.90, which may correspond to the monophosphate 
form. The peak at d P =  2.25 corresponds to the human serum 
that in the first experiment is overlapping w ith the peak at at 
<5P =  1.90.
In  the case o f the stability in acid, a p H  o f 1.0 was used. 
Com pound 9 was dissolved in M e O D , and the buffer was
added. The experiment was conducted at 37 °C  and m oni­
tored by 31P N M R . The experiment showed a good stability 
o f the compound (see Figure 12 in the Supporting In ­
form ation) having an half-life o f 11 h. Notably, the form a­
tion after 5 h o f a peak at <3P =  —0.25, which should 
correspond to the monophosphate form was observed.
M olecular M odeling-1: Carboxypeptidase Y Enzyme. 
T o  better understand the enzymatic results obtained using 
carboxypeptidase Y , molecular modeling studies using a 
crystal structure o f the enzyme have been perform ed.17 The
Article
Figure 10. (a) D o ck in g  o f  c o m p o u n d  9 w ith in  the  ca ta ly tic  site o f  
ca rb o x y p ep tid ase  Y enzym e, (b ) D o ck in g  o f  co m p o u n d  6 w ith in  the 
c a ta ly tic  site o f  c a rb o x y p e p tid a se  Y enzym e.
pu ta tive  m echanism  o f  ac tion  involves an  a tta ck  from  the 
Ser 146 to  the carbony l o f  the  ester, w hich is co o rd in a ted  with 
the N H  from  G ly52 and  G ly 5 3 .18
T he processed co m p o u n d  9 show ed a positive in terac tion  
w ith the active site o f  th e  enzym e for bo th  phospha te  
d iastereo isom ers (show n on ly  the RP d iastereo isom er) 
(F igure  10a). In p a rticu la r, th e  carbony l m oiety is in a 
su itab le  position  fo r the nucleoph ilic  a ttack  from  the c a ta ­
lytic Ser 146, w ith the  N H  from  G ly52 and  G ly53 correctly  
placed to  stabilize the te trah ed ra l in term ediate . T his result is 
in accordance  w ith the enzym atic  resu lt for this com pound . 
In the case o f  the inactive co m p o u n d  6, the carbonyl is no t 
in a favorab le  position , p o in tin g  aw ay from  G ly52 and 
G ly53, p robab ly  due to  the presence o f  the  bulky te/7-butyl, 
w hich m ay influence the in te rac tio n  w ith  enzym e resulting in 
a p o o r ac tiva tion  (repo rted  on ly  th e  S P-diastereo isom er, 
F igure 10b). T he dock ing  o f  co m p o u n d  10, w hich show ed 
a faster hydrolysis o f  one d ias te reo iso m er com pared  to  the 
o th e r one, show ed in teresting  results . In  fact, th e  tw o d ia ­
stereoisom ers docked  in a d ifferen t way. T he /?-diastereo- 
isom er show ed a preferab le  position  fo r the carbony l m oiety, 
while in the case o f  the ^ -d ias te reo iso m er the position  o f 
carbony l g ro u p  is d ifferen t and  it is n o t ab le  to  co o rd in a te
Journal o f  Medicinal Chemistry, 2009, Vol. 52, No. 17 5527
' 1<*U ■
His
His
o*
Figure 11. (a) In te ra c tio n s  o f  90 (L-Ala) w ith the  active site o f  
h u m an  H in t-1 , (b) D o ck in g  o f  co m p o u n d  90 (L-Ala) A C V -M P  
p h o sp h o ra m id a te  w ith in  the  ca ta ly tic  site o f  h u m an  H IN T  (I) 
enzym e.
with the G ly52 and  G ly53. T his result su p p o rts  the fact th a t 
one o f  them  is faster m etabolized , p resum ably  the RP, th an  
the o th e r one, and  th is is due  to  a d ifferen t b ind ing  in the 
ca ta ly tic  site o f  the enzym e. In the case o f  the valine 
derivatives, none o f  them  show ed a  suitab le  pose in the active 
site o f  the enzym e.
Molecular Modeling-2: Human H int Enzyme. As show n in 
the enzym atic  experim en t on  9, the  first step o f ac tivation  
proceeds well and  leads to  co m p o u n d  90, w hich needs to  be 
fu rther converted  in o rd er to  release the m o n o p h o sp h a te  
form  91. T he last step o f  the  ac tiv a tio n  o f  the P roT ide 
involving the cleavage o f  the  P —N  bond  is n o t w ell-know n, 
and  it is considered  to  be m ed ia ted  by a phosphoram idase- 
type enzym e called H in t, be longing  to  the H IT  superfam ­
ily .19 A m olecu lar m odeling  s tudy  using hum an  hint enzym e 
1, cocrystallized  w ith adenosine  m onophospha te , has been 
perfo rm ed  in o rd e r to  investigate th is last step o f  activation . 
T he ca ta ly tic  activ ity  o f  th is enzym e is due to  the presence o f 
th ree  h istid ines, w hich in te rac t w ith the substra te , and  to  the 
presence o f  a serine, w hich b inds the nitrogen o f  the am ino  
acid, p ro to n a tin g  the n itrogen , and  favoring P - N  bond 
cleavage (F igure  11a). F ro m  F igure l i b ,  it is clear to  see 
how  the com pound  b inds correctly  in the active site o f  the
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enzym e p o s itio n in g  th e  p h o sp h a te  m o ie ty  (p in k ) in a su itab le  
p o sitio n  fo r th e  cleavage o f  th e  P —N  b o n d . T h is  ex p e rim en t 
suggests th a t  th e  last s tep  o f  th e  a c tiv a tio n  to  re lease A C V - 
M P  m ay  p ro ceed  well in th e  case  o f  A C V  a lan in y l p h o sp h a te  
in v ivo, s u p p o r tin g  th e  b io log ica l d a ta .
Conclusion
A series o f  22 acyclov ir P ro T id es  h as  been  rep o rted . These 
c o m p o u n d s  as well as th e  p a re n t A C V  h av e  been  biologically 
eva lu a ted  ag a in s t HSV-1 an d  -2 a n d  ag a in s t H IV -1 an d  -2.
In  th e  case  o f  HSV-1 a n d  -2, th e  c o m p o u n d s  d id  n o t show  
any  im p ro v em en t o f  ac tiv ity  c o m p a re d  to  th e  p aren t. H ow ­
ever, these c o m p o u n d s  re ta in ed  ac tiv ity  ag a in s t the T K - 
deficient HSV-1 s tra in  w hile A C V  sh o w ed  a loss on  activity. 
T hese resu lts  show ed a successful th y m id in e —kinase bypass.
In th e  case o f  HIV-1 a n d  -2, A C V  d id  n o t show  any  ac ti­
vity, w hile the  P ro T id es show  a g o o d  ac tiv ity  in a  range o f
6 .2 —17/^M  (H IV -1 , C E M ), 8 . 9 - 4 2 p M  (H IV -2 , C E M ), and 
0 .8 - 3 0  ^ M  (H IV -1 , M T -4).
T h e  v a ria tio n  o f  th e  a m in o  acid  m o ie ty  seem s to  be 
to le ra ted  in th e  case o f  H SV . In  th e  case  o f  H IV , th is varia tion  
is less to le ra ted , show ing  g o o d  resu lts  o n ly  in the  case o f  the l- 
a lan in e  derivatives an d  p h en y la lan in e  derivative . In  the  M T -4 
cell cu ltu res , d im ethy lg lycine , a n d  L-leucine a re  to lerated . 
T hese  d ifferences on  ac tiv ity  m ay  be d u e  to  d iffe ren t substra te  
specificities a n d /o r  d iffe ren t in tra c e llu la r  levels o f  enzym e 
necessary  fo r the  ac tiv a tio n  o f  these  c o m p o u n d s .
Experim ental Section
General. A nhydrous so lvents were b o u g h t from  A ldrich and 
used w ithou t fu rther pu rifica tion . All reac tions were carried  out 
under an argon  a tm osphere . R eactions were m onito red  with 
analytical T L C  on silica gel 60-F254 p recoated  a lum inum  plates 
and visualized under U V  (254 nm ) a n d /o r  w ith 31P N M R  
spectra. C olum n c h ro m a to g rap h y  w as perform ed on silica gel 
( 3 5 - 7 0 /^M). P ro to n  ( ’H ), ca rb o n  ( l3C), and p hospho rus (3 P) 
N M R  spectra  were reco rded  on  a  B ruker A vance 500 spec tro ­
m eter a t 25 °C. Spectra  w ere au to ca lib ra ted  to  the deu tera ted  
solvent peak and  all 13C  N M R  an d  31P N M R  were p ro to n - 
decoupled. H igh reso lu tion  m ass spectra was perfo rm ed  as a 
service by B irm ingham  U niversity  using elec trospray  (ES). 
C H N  m icroanalysis were p e rfo rm ed  as a service by the School 
o f  P harm acy  at the U niversity  o f  L ondon . Purity  (> 9 5 % ) o f  all 
final p roduc ts  was assured  by a com bination  o f  m icroanalysis, 
and H P L C , w ith add itional charac te riza tion  in every case by: H, 
C, and P N M R , and H R M S .
Standard Procedure A: Synthesis o f Dichlorophosphates (26, 
27). T o a solution o f  phosphorus oxychloride (1.00 mol/equiv) 
and the appropria te  substituted phenol o r naphthol (1.00 m ol/eq) 
in anhydrous diethyl ether, stirred under an argon atm osphere, 
and added dropw ise at —78 °C  under an argon atm osphere 
anhydrous T E A  (1.00 m ol/equiv). Follow ing the addition, the 
reaction m ixture was stirred a t —78 °C for 30 min and then at 
room  tem perature overnight. F o rm atio n  o f  the desired com ­
pound was m onitored by 3IP N M R . T he m ixture was filtered 
under nitrogen and the corresponding  filtrate reduced to dryness 
to give the crude product as an oil.
Standard Procedure B: Synthesis o f Phosphorochloridates 
(45—65). T o a stirred solu tion  o f  the a p p ro p r ia te  aryl dichlor- 
o p h ospha te  2 6 -2 8  (1.00 m ol/equiv) and  the ap p ro p ria te  am ino 
acid ester salt 29—44 (1.00 m ol/equ iv) in an h y d ro u s D C M  was 
added dropw ise a t —78 °C under an  a rg o n  a tm osphere , anhy­
d rous T E A  (2.00 m ol/equiv). Follow ing the ad d itio n  the reac­
tion m ix ture w as stirred  at —78 °C for 30 m in to 1 h and then at 
room  tem peratu re  for 30 m in to 3.5 h. F o rm atio n  o f  the desired 
com pound  was m onito red  by 3IP N M R . A fter this period, the
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solvent w as rem oved u nder reduced pressure and the residue 
tr itu ra ted  w ith anh y d ro u s diethyl ether. T he precipitate was 
filtered u nder n itrogen  and the so lu tion  was concentrated  to give 
an oil. M ost o f  the aryl p hospho roch lo rida tes  synthesized were 
purified by flash colum n ch rom atog raphy  (eluting with ethyl 
ace ta te /petro leum  e ther in d ifferent p roportions).
Standard Procedure C: Synthesis o f Phosphoramidates (67— 
85). T o a stirring  suspension o f  N 2-D M F -A C V  (1.00 m ol/equiv) 
in an hyd rous T H F  w as added  dropw ise under an argon  a tm o ­
sphere ‘B uM gC l (2.00 m ol/equiv), and  the reaction  m ixture was 
stirred  a t room  tem peratu re  fo r 30 min. Then w as added 
dropw ise a so lu tion  o f  the ap p ro p ria te  phospho roch lo ridate  
(1.50 to 4.00 m ol/equiv) in an hyd rous T H F . T he reaction 
m ixture w as stirred  a t room  tem pera tu re  overnight. T he solvent 
was rem oved under reduced pressure, and  the residue was 
purified by colum n ch ro m ato g rap h y  elu ting  w ith D C M /M eO H  
in d ifferent p ropo rtions .
Standard Procedure D: Deprotection of N 2-DM F-Phosphor- 
amidates (2—23). A so lu tion  o f  67—87 in 1-propano l or
2-p ropanol w as stirred  u n d er reflux for 24—96 h. T he solvent 
w as then rem oved u n d er reduced pressure, and the residue was 
purified by co lum n ch ro m ato g rap h y  eluting w ith D C M /M eO H  
in different p ro p o rtio n s . T he p ro d u c t was usually fu rther p u r­
ified by p repara tive  T L C  or sem ipreparative H PL C  to give a 
w hite solid.
Synthesis o f A^-DM F Acyclovir (A'-(9-((2-Hydroxyethoxy)- 
m ethyl)-6-oxo-6,9-dihydro-1 //-purin-2-yl)-N,  A'-dimethylformi- 
midamide) (66). T o a suspension  o f  1 (1 .00 g, 4.44 m m ol) in dry  
D M F  (20 m L) w as added  A^Af-dim ethylform amide dim ethyl 
acetal (2.96 m L , 22.20 m m ol) and  the reaction  m ixture was 
stirred a t room  tem pera tu re  fo r 1 day. A fter this period , the 
solvent was rem oved and  the residue tritu ra ted  w ith diethyl 
ether and  filtered. T he solid w as w ashed w ith diethyl ether to 
give a w hite solid (97% , 1.20 g). 'H  N M R  (D M SO , 500 M H z): <3 
11.30 (1H , s, N H ), 8.58 (1H , s, C //N (C H 3)2), 7.94 (1H , s, H-8), 
5.45 (2H , s, H -T ), 4.65 (1H , t, O H ), 3 .5 2 -3 .4 9  (4H , m , H -4', H- 
5'), 3.17, 3.04 (6H , 2s, N (C H 3)2).
Synthesis of 1-Naphthyl Dichlorophosphate (26). Prepared 
accord ing  to stan d ard  p rocedure A, using 24 (4.00 g, 27.74 
m m ol) in anhydrous diethyl e ther (60 m L), PO C l3 (2.59 m L, 
27.74 m m ol), and  anhyd rous T E A  (3.87 m L, 27.74 mm ol). A fter 
3IP N M R , the solvent w as rem oved u nder reduced pressure and 
the residue w as tr itu ra ted  w ith anhyd rous diethyl ether. T he 
precip itate was filtered, and the organic phase was rem oved 
under reduced pressure to  give an  oil (95% , 6.91 g). 3IP N M R  
(CDC13, 202 M H z): d 3.72. 'H  N M R  (CDC13, 500 M H z): <5
8 .0 2 -8 .0 0  (1H , m, H-8), 7 .8 1 -7 .8 0  (1H , m , H-5), 7 .7 2 -7 .7 0  
(IH , m, H-4), 7 .5 4 -7 .4 5  (4H , m , H-2, H-3, H-6, H-7).
Synthesis of l-Naphthyl(benzoxy-L-alaninyl)-phosphorochlor- 
idate (45). Prepared accord ing  to s tandard  procedure B, 26 
(6.91 g, 26.48 m m ol), t.-alanine benzyl ester tosylate 29 (9.30 g, 
26.48 m m ol), and  an hyd rous T E A  (7.40 m L, 52.96 m m ol) in 
anhyd rous D C M  (100 m L). T he reaction  m ixture w as stirred at 
—78 °C for 1 h, then  at room  tem pera tu re  for 2 h. The crude was 
purified by colum n ch ro m ato g rap h y  elu ting  w ith ethyl acetate/ 
hexane =  5/5 to give an  oil (72% , 7.68 g). 3IP N M R  (CDC13, 202 
M H z): 6 8.14, 7.88. 'H  N M R  (CD C13, 500 M H z): 6 7 .9 9 -7 .2 5  
(12H , m, N ap h , O C / /2Ph), 5 .1 5 -5 .0 7  (2H , m , C / /2Ph), 4 .3 0 -  
4.23 (1H , m , C T /C H 3), 1 .4 9 -1 .4 6  (3H , m , C H C //3).
Synthesis of N 2-DM F-acyclovir-[l-naphthyl(benzoxy-L-alani- 
nyl)] Phosphate (67). P repared  accord ing  to s tandard  procedure 
C, from  66 (0.30 g, 1.07 m m ol) in anhyd rous T H F  (10 mL), 
‘B uM gC l (1.0 M T H F  so lu tion , 2.14 m L, 2.14 mm ol), 45 (1.31 g, 
3.25 m m ol) in anh y d ro u s T H F  (10 m L), and the reaction 
m ix ture  w as stirred  at room  tem peratu re  overnight. T he residue 
was purified by colum n ch rom atog raphy , eluting w ith D C M / 
M eO H  =  95/5, to give a w hite solid (17% , 0.12 g). 3,P N M R  
(M eO D , 202 M H z): d 4.18, 3.92. 'H  N M R  (M eO D , 500 M Hz): 
d 8.47, 8.46 (1H , 2s, N C //N (C H 3)2), 8 .0 1 -7 .9 8  (1H , m, H-8 
N aph), 7 .7 8 -7 .7 4  (2H , m , H -8, H -6 N aph), 7.56, 7.55 (1H , m,
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H-2 N aph), 7 .4 1 -7 .1 2  (9H , m, N aph , O C / / 2 Ph), 5 .3 7 -5 .3 6  
(2H, 2s, H -l ') , 5 .00 -4 .93  (2H , m, O C / / 2 Ph), 4 .1 4 -4 .0 6  (2H, m, 
H -5'), 3 .9 6 -3 .8 8  (1H , m, C //C H 3), 3 .8 8 -3 .5 9  (2H , m, H-4'), 
2 .9 5 -2 .9 3  (6 H, m, N (C //3)2), 1 .20 -1 .17  (3H , m, C H C //3).
Synthesis o f Acyclovir-[l-naphthyl(benzoxy-L-alaninyI)] Phos­
phate (2). A solution o f  67 (0.10 g, 0.16 m m ol) in 2-propanol 
(5 m L) was stirred under reflux for 2 days. T he solvent was then 
rem oved under reduced pressure, and  the residue was purified 
by colum n ch rom atography  elu ting  w ith D C M /M eO H  = 96/4. 
The product was purified by prepara tive  T L C  (gradient elution 
o f D C M /M eO H  =  99/1, then 98/2, then 96/4) to give a white 
solid (35% , 0.032 g). 3fP N M R  (M eO D , 202 M Hz): <5 4.13,3.96. 
‘H N M R  (M eO D , 500 M H z): <5 8 .0 1 -7 .9 9  (1H, m, H - 8  N aph), 
7 .7 7 -7 .7 5  (1H , m, H - 6  N aph ), 7.67, 7.64 (1H , 2s, H -8 ), 7.58— 
7.13 (10H, m, N aph , O C H 2Ph), 5.28, 5.25 (2H , 2s, H -l') , 4 .9 9 -  
4.94 (2H , m , O C // 2 Ph), 4 .1 2 -4 .0 6  (2H , m , H -5'), 3 .97 -3 .93  
(1H, m, C //C H 3), 3 .6 4 -3 .5 9  (2H , m , H -4 '), 1 .24-1 .20  (3H , m, 
C H C //3). , 3C N M R (M e O D , 125 M H z): d 20 .32 ( d , / C- p = 7.63, 
C H C //3), 20.43 (d, 7C-p  =  6.61, C H C //3), 51.76, 51.81 (2s, 
C H C H 3), 67.20 (d, yC-p  =  5.58, C -5 '), 67.28 (d, 7C-p  = 4.91, C- 
5'), 67.95,67.98 (2s, O C H 2 Ph), 69.34 (d, J C-p  =  7.72, C-4'), 69.40 
(d, / c - p  =  8.14, C-4'), 73.65 (C -1'), 116.26, 116.29, 116.35, 
122.69, 122.80, 125.92, 126.51, 127.20, 127.42, 127.46, 127.74, 
128.81, 128.83, 129.27, 129.33, 129.52, 129.57 (C-5, C-2 N aph, 
C-3 N aph , C-4 N aph , C-5 N aph, C - 6  N aph , C-7 N aph, C - 8  
N aph , C -8 a N aph, O C H 2Ph), 136.26, 137.23 (C-4a N aph, 
“ ipso” O C H 2Ph), 139.69 (C -8 ), 147.98, 148.04 (“ ipso” N aph, 
C-4), 152.44 (C-2), 159.39 (C -6 ), 174.61, 174.88 (2s,
C O O C H 2 Ph). El M S =  615.1735 (M  +  N a). A nal. C alcd for 
C 2 8 H 2 9 N 6 O 7 P -0 .5 H 2 O: C, 55.91; H , 5.03; N , 13.97. Found: C, 
55.81; H , 4.91; N , 13.78.
Antiviral Activity Assays. The com pounds were evaluated 
against the follow ing viruses: HSV-1 stra in  K O S, thym idine 
kinase-deficient (T K ~) HSV-1 K O S strain  resistan t to  ACV 
(A C V r), HSV-2 stra in  G , HIV-1 stra in  IIIB /L ai, and  HIV-2 
strain  R O D . The an tiv iral, o ther than an ti-H IV , assays were 
based on inhibition o f  virus-induced cy topath ic ity  o r plaque 
form ation  in hum an em bryonic lung (H E L ) fib rob lasts. C on ­
fluent cell cultures in m icro tite r 96-well plates w ere inoculated 
w ith 100 C C ID 50 o f  virus (1C C ID 50 being the virus dose 
required to infect 50%  o f  the cell cultures). A fter a 1—2 h 
adso rp tion  period , residual virus was rem oved and the cell 
cultures were incubated  in the presence o f  varying concen tra ­
tions o f  the test com pounds. V iral cytopath icity  w as recorded as 
soon as it reached com pletion  in the contro l virus-infected cell 
cu ltures th a t were no t trea ted  w ith the test com pounds. A n ti­
viral activity was expressed as the E C 50  or effective com pound 
concen tration  required to  reduce virus-induced cytopath icity  by 
50% .
H um an C EM  cell cultures (~ 3 x  10s cells m L ‘) were infected 
with 100 C C ID 50 H IV -I(I I Ib) o r H IV -2(R O D ) per m L and 
seeded in 20 0 //L  well m icro tite r p lates, containing appropria te  
dilu tions o f the test com pounds. A fter 4 days o f incubation  at 
37 °C, C EM  giant cell fo rm ation  w as exam ined m icroscopically.
M T-4 cells (1 x 104  cells per m L ) were suspended in fresh 
culture m edium  and infected w ith 10 fiL  (0.7 ng o f p24) of 
X 4LA] 0 4  viral stock per m L  o f  cell suspension. Infected cell 
suspensions were then transferred  to  m icroplate wells, mixed 
w ith 1 m L o f  m edium  con ta in ing  the test com pound a t an 
app rop ria te  d ilu tion  and fu rth er incubated  a t 37 °C. A fter 3 
days, p24 production  was m easured  in the M T-4 cell culture 
supernatan ts. The E C 5 0  co rresponded  to the com pound con­
cen tra tion  required to suppress the p ro d u c tio n  o f  p24 in the 
virus-infected M T-4 cell cu ltures by 50% . V iability  in M T-4 cell 
cu ltures were evaluated using a nucleocoun ter au tom ated  cell 
counting  system (C hem om etec, D enm ark). T o ta l num ber o f 
cells and  num ber o f  dead cells in the cultures un trea ted  and 
treated  w ith A CV  ProT ides were enum erated  using a prop id ium  
iodide-based assay according to  the m an u fac tu re rs’ pro tocol.
D ata  were collected and  analyzed using N ucleoview softw are 
(C hem om etec, D enm ark).
H um an tonsils ob ta ined  under an IR B -approved protocol 
were dissected in to  ~ 2  m m  blocks and cultured  on collagen rafts 
a t the m edium —air interface. Tissues were inoculated ex vivo 
w ith X 4 LAi .o4 (~ 0 .5  fig  o f  p24gag per block) and treated with 
ACV  ProT ides at concen tra tions ranging from  0.1 to 10 fiM.  
T he culture m edium  was changed every 3 days, and ACV 
ProTides were replenished. F o r each com pounds’ concentration  
HIV-1 release was quantified  by m easurem ents o f p24gag accu­
m ulated  over 3-day periods in the culture m edia bath ing  18 
tissue blocks. T he E C 5 0  corresponded  to the com pound con ­
cen tra tion  required to suppress by 50%  the p roduction  o f p24.
Preparation of CEM  and Tonsil Cell Extracts and Analysis of 
ProTide Conversion. E xponentially  grow ing C EM  cells o r tonsil 
tissues were w ashed twice w ith PBS. T hen, cells and tissues were 
suspended in PBS, and  ex tracts were m ade in a Precellys-24 
hom ogenizator (Berlin Technologies, M ontigny-en-B reton- 
neux, F rance) (tonsils) o r by a H ielscher-U ltrasound T echnol­
ogy (C EM  cells) (G erm any). T he extracts were cleared by 
centrifugation  (10 m in, 15000 rpm ) and frozen at - 2 0  °C before 
use. Ten m icrom olar so lu tions o f 9, 4, and 6 were added to the 
crude cell and  tissue ex tracts (100/iL ) and incubated for 30, 60, 
and 120 min at 37 °C. A t each tim e poin t, 20fiL  o f  the incubation 
m ixtures were w ithdraw n  and added to 30 f iL  cold m ethanol to 
precipitate the p ro teins. A fter centrifugation , the supernatan ts 
were subjected to  H P L C  analysis on a reverse phase C l 8  colum n 
(M erck) to separa te  the p aren t ACV ProTides from  their 
hydrolysis p roduc ts th a t m ay be form ed during the incubation 
process. D a ta  were p lo tted  as percent o f d isappearance o f  the 
intact paren t A CV  P roT ide from  the incubation  mixture.
Acknowledgm ent. M a rc o  D e ru d as  ded ica tes th is w ork  to  
the  m em ory  o f  A n to n ie tta  D eru d as. W e th an k  F ried a  D e 
M eyer, Leentje P erso o n s, V icky B roeckx, Leen Ingels, and  
R ia  V an B erw aer fo r excellent technical assistance w ith the 
an tiv ira l and  enzym atic  assays. W e acknow ledge th e  excellent 
adm in is tra tiv e  su p p o r t o f  H elen M u rphy . F inanc ia l su p p o rt 
by a  g ra n t o f  the  K U  Leuven (G O A  no. 05/19) w as prov ided . 
T he w ork  o f  A .L ., C .V ., an d  L .M . w as su p p o rted  by the 
N IC H D  In tram u ra l P ro g ram .
Supporting Information Available: Preparative m ethods,
spectroscopic and analytical d a ta  on target com pounds. This 
m aterial is available free o f  charge via the In ternet at h ttp :// 
pubs.acs.org.
R eferences
(1) D ru g s  U s e d  in th e  T r e a tm e n t o f  H I V  Infection ', U.S Food and drug 
Administration: Silver Spring, MD, 2008; http://www.fda.gov/oashi/ 
aids/virals.html (accessed 5 March 2009).
(2) C lavel, F.; H ance, A. J. H IV  d ru g  resistance. N . E n g l. J . M e d . 2004, 
3 5 0 , 1023-1035.
(3) Lisco, A.; V anpouille, C .; T chesnokov , E. P.; G rivel, J.-C .; Bian- 
c o tto , A.; B richacek, B.; E llio tt, J.; F rom en tin , E.; S hattock , R.; 
A n to n , P.; G orelick , R.; B alzarin i, J.; M cG uigan , C.; D erudas, M.; 
G o tte , M .; Schinazi, R. F .; M argo lis, L. A cyclovir is activated  into 
a HIV-1 reverse tran scrip tase  in h ib ito r in herpesvirus-infected 
h u m an  tissues. C e l l  H o s t  M ic r o b e  2008, 4 , 260-270.
(4) M iller, W . H .; M iller, R. L. P hosph o ry la tio n  o f  acyclovir m o n o ­
p h o sp h a te  by G M P  kinase. J . B io l. C h em . 1980, 2 5 5 , 7204-7207.
(5) M iller, W. H .; M iller, R. L. P h osphory la tion  o f  acyclovir d ip h o ­
spha te  by cellu lar enzym e. B io c h e m . P h a m a c o l. 1982, 3 1 , 3879- 
3884.
(6) C o n g ia tu , C .; M cG uigan , C.; Jiang , W. G .; Davies, G .; M ason, M. 
D . N aph thy l p h o sp h o ram id a te  derivatives o f  BVdU as potential 
an ticancer agents: design, synthesis and  biological evaluation . 
N u c le o s id e s , N u c le o t id e s  N u c le ic  A c id s  2005, 2 4 , 485-489.
(7) M cG uigan, C.; C ahard , D.; Sheeka, H. M.; De Clercq, E.; Balzarini, 
J. Aryl phosphoram idate  derivatives o f  d4T  have im proved anti-H IV
5530 Journal o f  Medicinal Chemistry, 2009, Vol. 52, No. 17 Derudas el al.
efficacy in tissue culture and m ay act by the generation o f  a novel 
intracellular m etabolite. J . M e d . C h em . 1996, 39 , 1748-1753.
(8) M cG uigan , C.; H arris, S. A .; D aluge, S. M .; G ud m u n d sso n , K. S.; 
M cL ean , E. W.; B u rn e tte ,T . C.; M arr, H .; H azen, R .;C o n d rea y , L.
D.; Joh n so n , L.; De C lercq, E.; Balzarini, J. A pplication  o f  
p h o sp h o ram id a te  p ronucleo tide  technology to  abacav ir leads to 
a significant enhancem ent o f  an tiv ira l potency. J . M e d . C h em . 
2005 , 4 8 ,  3504-3515.
(9) Perrone, P.; L uoni, G . M .; K elleher, M . R .; D averio , F.; Angell, A.; 
M ulready , S.; C ong ia tu , C.; R a jyaguru , S.; M a rtin , J. A.; Leveque, 
V.; Le Pogam , S.; N ajera , 1.; K lum pp , K .; Sm ith, D. B.; M cG uigan,
C. A pplication  o f  the p h o sp h o ram id a te  P roT ide  ap p roach  to 4 ’- 
azidourid ine confers subm icro m o lar po tency  versus hepatitis C 
virus on  an inactive nucleoside. J . M e d . C h e m .lW X l, 5 0 , 1840-1849.
(10) S abou lard , D.; N aesens, L.; C a h a rd , D .; Salgado , A.; P ath irana , 
R.; Velazquez, S.; M cG uigan , C .; D e C lercq , E.; Balzarini, J. 
C h a racteriza tion  o f  the ac tiv a tio n  p a th w ay  o f  phosphoram idate  
triester p ro d ru g s o f  s tavud ine  (d4T ) and  Z idovudine (A ZT). M o l. 
P h a r m a c o l . 1999, 5 6 , 693-704.
(11) M cG uigan , C.; D erudas, M .; B ugert, J. J.; A ndrei, G .; Snoeck, R.; 
B alzarini, J. Successful k inase bypass w ith  new acyclovir phos­
pho ram id a te  p rod rugs. B io o r g . M e d . C h e m . L e t t .  2008, 18, 4364- 
4367.
(12) M cG uigan , C.; T sang , H . -W .; C a h a rd , D .; T u rn er, K .; Velazquez, 
S.; S algado, A.; Bidois, L.; N aesens, L.; D e C lercq , E.; Balzarini, J.
P h o sp h o ram id a te  derivatives o f  d4T  as in h ib ito rs o f  HIV: the effect 
o f  am ino  acid v aria tio n . A n tiv ir a l  R es . 1997, 3 5 , 195-204.
(13) U chiyam a, M .; A so, Y.; N oyori, R.; H ayakaw a, Y. O-Selective 
p h o sp h o ry la tio n  o f  nucleosides w ith o u t N -p ro tec tion . J. O rg . 
C h e m . 1993, 5 8 , 373-379.
(14) Van Boom , J. H .; B urgers, P. M . J.; C rea , R.; Luyten, W . C. M. M .; 
V ink, A. B. J .; Reese, C. B. P hosph o ry la tio n  o f  nucleoside deriva­
tives w ith aryl p h o sp h o ram id o ch lo rid a tes. T e tr a h e d ro n  1975, 3 1 ,  
2953-2959.
(15) M cG uigan , C.; T sang , H .-W .; C a h a rd , D.; T urner, K .; Velazquez, 
S.; S algado, A .; Bidois, L.; N aesens, L.; De C lercq, E.; B alzarini, J. 
P h o sp h o ram id a te  derivatives o f  d4T  as inh ib ito rs  o f  HIV : the effect 
o f  am ino  acid v aria tion . A n tiv ir a l  R e s . 1997, 3 5 ,  195-204.
(16) C a h ard , D.; M cG uigan , C.; B alzarini, J. A ryloxy P h o sp h o ram i­
date  T riesters as P ro-T ides. M in i-R e v . M e d . C h e m . 2004, 4, 371 — 
382.
(17) Endrizzi, J. A .; B reddam , K .; R em ington , S. J. 2.8 A S truc tu re  o f  
yeast serine carboxypep tidase . B io c h e m is tr y  1994, 3 3 , 11106-11120.
(18) Jung , G .; U eno , H.; H ayash i, R.; C a rboxypeptidase, Y structu ra l 
basis for p ro te in  so rtin g  and ca taly tic  triad . J. B io c h e m . 1999, 126 , 
1- 6 .
(19) B renner, C. H in t, F h it, and  G a lT : function , s truc tu re , evolution , 
and  m echanism  o f th ree  b ranches o f  the  histidine triad superfam ily 
o f  nucleo tide  hydro lases and  transferase. B io c h e m is tr y  2002, 4 1 ,  
9003-9014.
Bioorganic & Medicinal Chemistry Letters 19 (2009) 6264-6267
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
j o u r n a l  h o m e p a g e :  w w w . e l s e v i e r . c o m / l o c a t e / b m c l
2'-Fluorosugar analogues of the highly potent anti-varicella-zoster virus 
bicydic nucleoside analogue (BCNA) Cf 1743
Christopher McGuigana'*, Marco Derudas4, Maurizio Quintiliania, Graciela Andreib, Robert Snoeckb, 
Geoffrey Henson c, Jan Balzarinib
a Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK 
bRega Institute for Medical Research, Minderbroedersstraat 10, Leuven B-3000, Belgium 
c Inhibitex, 9005 Westside Parkway, Alpharetta, CA 30004, USA
A R T I C L E  I N F O A B S T R A C T
Article history:
Received 4 September 2009 
Revised 29 September 2009 
Accepted 29 September 2009 
Available online 3 October 2009
Keywords:
VZV 
BCNAs 
C f1743
Thymidine kinase
Zoster
Shingles
Nucleosides
Herpes
Fluorosugars
W e re p o rt th e  p rep ara tio n  o f 2'-oc-F, 2 '-0-F  and  2 ',2 '-d iflu o ro  analogues o f th e  lead ing  an ti-varice lla  zoster 
v irus (VZV) pen ty lphenyl BCNA Cf 1743. VZV th y m id in e  k inase  sh o w ed  th e  h ighest p hosphory la ting  
capac ity  for th e  p-fluoro derivative, th a t  re ta in ed  equal an tiv ira l po ten cy  as th e  p a re n t com pound . In con­
tra s t, th e  a -flu o ro - and  2 ',2 '-d ifluoro  BCNA d e riv a tiv es w e re  m arked ly  less (~ 1 0 0 -fo ld ) an tiv ira lly  active.
© 2009  E lsevier Ltd. Ail righ ts reserved.
In 1999 we first reported the anti-VZV activity of the bicyclic 
nucleoside analogue family now known as the BCNAs.1 W e subse­
quently reported nanomolar activity and exclusive anti-VZV selec­
tivity for the pentylphenyl BCNA (Fig. 1, l ) . 2
As its 5'-valyl Pro-Drug FV100 (Fig. 1,2)  human phase 2 clinical 
trials for VZV shingles have recently commenced.3
We have reported extensively on the structure-activity rela­
tionships surrounding this fam ily of potent antivirals.4 In general, 
there is little tolerance for structural modifications; indeed we re­
cently reported that the corresponding carbocycle, a modification 
often tolerated amongst antiviral nucleosides, is very poorly active 
in this case.5 Also, the arabinosyl BCNA was considerably less 
inhibitory than its parental 2'-deoxyribosyl BCNA.6
There have been a number of cases where 2'-modification, in 
particular 2'-fluorination of bioactive nucleosides leads to 
enhancements in the biological activity profile, notably, the 
anti-cancer agent gemcitabine w ith  a 2',2'-difluoro pattern7 and 
Pharmasset's anti-HCV agent PSI6130 (2'-deoxy-2'-a-fluoro-2/-p- 
C-methyl cytidine).8 Therefore, w e were interested to prepare var­
ious 2'-fluorinated analogues of the parent BCNA (1) (Fig. 2).
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The desired 2'-fluoro-substituted BCNAs were prepared via su­
gar base coupling of protected 5-iodouracil to the appropriate flu- 
oro sugar followed by construction of the BCNA base.
Thus, as shown in Scheme 1, 5-iodouracil (3) was silylated to 
give (4) and l,3,5-tri-0-benzoyl-2-deoxy-2-p-fluororibose (5) was 
converted to its 1-bromo analogue (6) using HBr/AcOH,9 and these 
reagents were allowed to couple using HMDS and ammonium sul­
fate to give mixed anomers of the protected nucleoside (7).9
The two isomers were separated by filtration to give the pure 
p-anomer as a white solid 7 in a yield of 51%. The deprotection 
of the benzoyl groups was performed using sodium methoxide 
and the corresponding unprotected compound 8 converted to its 
p-pentylphenyl BCNA (9) by standard methods1,2 in a yield of 
45% from (7). Compound (9) showed spectroscopic ( 1H NMR and 
13C NMR) and analytical data entirely as expected including a 19F 
NMR peak at -1 9 8  ppm and other data (high resolution mass spec­
tra and HPLC) confirmed its structure and purity.10 Similarly pre­
pared by analogous methods were the a-fluoro analogue (10) 
and the 2',2'-difluoro BCNA derivative (11). Compound (10) was 
prepared starting from the commercial available 2'-a-F-2'-deoxy- 
uridine which was iodinated at the 5-position and then coupled 
with the phenyl acetylene under standard method. Compound 
(11) was prepared starting from commercially available 2-deoxy-
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2,2-difluoro-D -eo/thro-pen tafuranos-l-u lose-3 ,5-d ibenzoate  w hich 
was reduced to  benzoylated  lactol using LiAI(0-tBu)3H and then 
m esylated. The crude m esylate  w as coupled w ith  sily l-protected  
5-iodouracil in d ich loroethane and the  p-anom er w as obtained 
by precip itation  from th e  organic solvent after the  w ork-up. Depro­
tection of the  benzoyl g roups by sodium  m ethoxide in m ethanol 
provided the  desired nucleoside.
Given th e  crucial requ irem en t for the BCNAs to be 5 '-phosphor- 
ylated by VZV thym id ine kinase (TK) for the ir antiviral activ ity11 w e 
first probed the ir in teraction  w ith  VZV TK.12 Thus, in Table 1 w e 
show  th e  50% inhibitory concentrations (1C50) of (1) and (9-11) for
Table 1
Compound 2'-Fluoro position VZVTK lCso/pM
1 _ 3.3
9 P-Fluoro 38
10 a-Fluoro 2.7
11 Difluoro -1 3
the phosphorylation  o f 1 pM [CH3 -3H ]thym idine by purified recom ­
binant VZV TK.
It is notable from  Table 1 th a t th e  a-fluoro  analogue (10) retains 
low pM potency as an inh ib ito r of VZV TK-catalysed dThd phos­
phorylation. The p-fluoro derivative 9 w as at least 10-fold less 
inhibitory. The 2 ',2 '-d ifluoro  analogue 11 show ed an IC50 value in 
betw een 9 and 10 (Table 1).
W e then  m easured  su b stra te  activity  of th e  BCNA derivative for 
VZV TK a t d ifferent com pound concentrations by determ in ing  both 
Km and Vmax values for each com pound (Table 2, SI).
Compared w ith  th e  pa ren t com pound 1 (Cf 1743), the  th ree  flu- 
oro derivatives w ere endow ed w ith  Km values th a t w ere som ew hat 
(up to threefold for com pound 10) low er than  for com pound 1. 
W hereas the  Vmax value for 9 w as ~2.5-fold h igher and for 11 
w as 1.5-fold low er than  noticed for 1, the Vmax for the  a-fluoro  
derivative 10 w as m arkedly low er than  observed for the  paren t 
com pound (6-7-fold). As a result, the  phosphorylating capacity 
(Vmax/Km) of the  enzym e proved h ighest for the  p-fluoro derivative 
9 and low est for th e  a-fluo ro  derivative 10 (Table 2).
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Scheme 1. Reagents and conditions: (i) HBr in acetic acid, DCM, rt, 22 h; (ii) hexamethyldisilazane, ammonium sulfate, acetonitrile, 70 °C, 5 h; (iii) Nal, DCM, acetonitrile, rt. 
1 week; (iv) MeONa, MeOH, 1 h, rt; (v) 4-n-pentylphenylacetylene, tetrakis (triphenylphosphine)Pd(O), Cul, DIPEA, DMF, rt, overnight, then Cul, TEA, 85 °C, 8 h.
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Table 2
Kinetic values of the 2'-f1uoro-substituted test compounds
Compound Km (pM) Vmax (pmol/pg protein/h) Vmax/Km
1 1.58 22 14
9 1.11 50 45
10 0.47 3.4 7.2
11 0.95 14 14
The kinetic values shown in Table 2 were derived from the Lineweaver-Burk dia­
grams based on the data shown in Supplementary data.
Table 3
Compound VZV ECsoa (pM) MCC1* (pM)
OKA YS TK" 07-1
1 0.0097 _ >20 >50
9 0.007 0.011 >50 >50
10 0.75 - >20 >50
11 1.5 6.7 >50 >50
a 50% Effective concentration, or compound concentration required to reduce 
viral plaque formation by 50% in the VZV-infected human embryonic (HEL) cell 
cultures.
b Minimal cytotoxic concentration, or compound concentration that results in a 
microscopical alteration of HEL cell morphology.
W hen te s ted  in v itro  against tw o  strains o f TK -com petent VZV13 
(Table 3) w e  found th a t (10) w as m oderately  antivirally  active, being 
ca. 100 tim es less active th an  (1), The 2 \2 /-difluoro BCNA (11) w as 
also m arkedly  less active than  th e  paren t d rug  1. By contrast, th e  p 
fluoro derivative (9) w as highly active, being com parable to  (1) in 
its anti-VZV activity. As previously show n,1-2 all com pounds lost 
activity versus VZVTK- deficient virus strains, confirm ing th e ir need 
for VZV TK -m ediated activation (phosphorylation).
As noticed before for o th e r BCNA derivatives,11 phosphorylation  
by VZV TK proved necessary, b u t no t sufficient to  display p o ten t 
antiviral efficacy. In fact, th e  pa ren t com pound 1 show ed an equal 
capacity for phosphory lation  to  th a t of com pound 11 (difluoro- 
derivative) b u t proved ^ 1 0 0 -fo ld  m ore antivirally active than  11 . 
Instead, th e  p-fluoro derivative 9  could be ~3.5-fold b e tte r phos- 
phorylated th a n  1, bu t w as found equally antivirally active as 1. 
Thus, th e re  is no  correlation betw een  antiviral po tency and VZV 
TK affinity (substra te ) p roperties indicating th a t o th e r factors are 
im portan t for eventual antiviral action .11
Thus, in conclusion, w e report th e  synthesis o f th e  a -  and p- 
m ono-2 '-fluoro analogues 10 and 9 of the po ten t anti-VZV BCNA 
(1) and also th e  2 ',2 '-difluoro BCNA 11. Only the 2 '-p-fluoro an a ­
logue re ta in s full low -nanom olar potency versus VZV in cell 
culture.
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